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Abstract 
Pairing of cancer genome and transcriptome data has revealed that heterozygous mutations 
aren’t always expressed in cells. The potential for point mutation or genomic rearrangement to 
alter tumour allelic expression has implications for understanding cellular heterogeneity and 
application of treatments. Mutation of SPOP, PTEN and IDH-1 was assessed in 51 primary prostate 
cancer cultures to establish allelic heterozygosity and ascertain whether oncogenic change to 
coding regions altered allelic expression. No mutations were detected in the three genes, 
although 18% of tested cultures had loss of heterozygosity in PTEN. The TMPRSS2-ERG fusion, 
present in half of all prostate cancers, is selectively expressed at an allelic level by cancer stem 
cells. Monoallelic expression didn’t correlate with TMPRSS2 promoter hypermethylation. Prostate 
cultures expressed fusion transcript, however epigenetic features of monoallelically expressed 
genes were not investigated in the epithelial subpopulations. Understanding of allelic chromatin 
states may inform treatment strategies that permit tumour suppressor expression or oncogenic 
protein repression. 
Inability to predict indolent or aggressive progression of organ-confined prostate cancers has 
created the problem of surgical overtreatment. Focal therapies targeting the tumour core are 
being met with increasing rates of recurrence, necessitating development of novel treatments. 
The anti-cancer properties of Low Temperature Plasma (LTP) are being explored in prostate 
models where it produces autophagy and necrosis through generation of reactive species. Initial 
gene expression response to LTP and the activation of upstream transcription factors were 
analysed. LTP activated Nrf2, AP-1 and Notch signalling in patient matched prostate normal and 
cancer cultures. The progenitor-containing cell fraction was more responsive to LTP than 
differentiated epithelial cells in both transcription of response genes and nuclear accumulation of 
active Notch1. When linked to cell-fate outcomes, these immediate molecular responses of 
prostate cancer to LTP could be used as hallmarks of resistance or treatment efficacy in patients. 
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1.1 - The Prostate; Anatomy and Cellular Hierarchy  
1.1.1 – Prostate Anatomy 
Situated below the bladder, the prostate is a walnut sized organ that surrounds the descending 
urethra (Figure 1). In the adult male, the prostate is an accessory sex organ that secretes 
proteolytic fluid into the ejaculatory duct. This exocrine exudation contains classical markers of 
the luminal epithelial cell population such as prostatic acid phosphatase (PAP) and prostate 
specific antigen (PSA), alongside proteases and nutrients that afford sperm greater motility. The 
alkaline nature of the fluid neutralises the acidic environment of the vaginal canal to increase 
sperm viability (1).  
The prostate itself is made up of distinct heterogeneous tissues surrounded by a vascularised 
stromal capsule. Four separate prostatic zones have been classified (Figure 1); 
• Peripheral Zone (PZ) – makes up ~70% of the glandular prostate and is situated at the 
posterior of the gland. This is the region where prostatic intraepithelial neoplasia (PIN), 
(the supposed precursor to cancer) and the majority of adenocarcinomas form. 
• Central Zone (CZ) – ~25% of the glandular prostate tissue. The CZ surrounds the vesicular 
seminalis ductal tube to where it meets the urethra (verumontanum). This section of the 
prostate is rarely implicated in disease with ~3% of tumours originating in the CZ (2). 
• Transitional Zone (TZ) – constitutes ~5% of the glandular prostate and is found at the 
anterior of the gland. It surrounds the transitional urethra, immediately below the 
bladder. This region continually grows in a hormone dependent manner and is the tissue 
in which benign prostatic hyperplasia (BPH) arises. Population studies have indicated that 
~25% of prostate cancers initiate in this zone of tissue (3). 
• Anterior Zone (AZ) - lacks any glandular structure and consists of fibromuscular stroma (1, 
4). 
1.1.2 – Prostate Development 
The generation of this anatomically complex organ begins with coordinated tissue development 
from the urogenital sinus (UGS) in a process called branching morphogenesis. Here, epithelial 
buds from the UGS invade the surrounding mesenchyme with subsequent elongation and 
branching, forming the epithelial ducts and acini of the adult prostate (5). 
  
16 
 
FIGURE 1 – Zonal anatomy and situation of the prostate 
The prostate is situated directly below the male bladder, and surrounds both the descending 
urethra and the junction with the ejaculatory duct from the seminal vesicles. The human prostate 
can be divided into four zones; peripheral (PZ), central (CZ), transitional (TZ) and anterior (AZ). 
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Morphogenesis proceeds through paired differentiation of the UGM (mesenchyme) and UGE 
(epithelia). This occurs upon contact and in conjunction with the seminal vesicle epithelia and 
mesenchyme (6). 
Initial development of the prostate is hormone dependent (7). Transduction of proliferative 
signalling through binding of androgens to the androgen receptor (AR) is well characterised in the 
somatic luminal cells of the prostate, however AR also plays a role in early prostatic development. 
Both the UGM and UGE are AR+ yet only the mesenchymal component requires the nuclear 
receptor for synchronous development of both tissues into the characteristic acinar structure. 
This suggests that an enforced paracrine signalling loop is established which transmits the 
downstream proliferative effects of AR from the mesenchyme to the epithelium (8, 9). The UGE 
progresses into the hierarchal basal and luminal epithelia whilst the UGM forms the surrounding 
stromal capsule of smooth muscle cells and fibroblasts (10). It would be reasonable to 
hypothesise that due to the distinct nature and phenotype of the UGM and UGE, both tissues 
have separate stem cell populations which are heavily involved in the early stages of branching 
morphogenesis.  
The initial surge of androgens in the neonatal prostate mirrors that of pubescent hormone levels 
in the organ, and has the effect of “imprinting” a proliferative response to androgens. 
Consequently this may explain the androgen-dependence of early cancers in the adult prostate. 
Imprinting effects have also been shown with estrogens. In the early prostate; variance in 
estrogen levels have long term consequences on both adult organ size and function (5). Estrogen 
receptor (ER) expression in the early prostate follows after the initial spike in AR levels. This 
transient ER peak temporally coincides with a rise in the levels of progesterone (PR) and retinoid 
receptors (RAR/RXR) hinting at a hormonal switch in development. Exposure of rat prostate to 
estrogen caused down-regulation of genes that promote epithelial differentiation. Among these 
were the homeobox genes; NKX3.1 and HOXB13, as well as SHH (sonic hedgehog) and FGF-10 
(fibroblast growth factor). Elevated neonatal estrogen also maintained anti-proliferative BMP4 
levels. Typically, expression of BMP4 becomes reduced in the post-natal prostate to allow for 
branching morphogenesis (11). Hormonal control of organ development is thus extremely 
important, with imprinting of the tissue influencing latter malignancy.  
To understand prostate cancer aetiology and development it is first necessary to understand the 
cellular components and the hierarchical organisation of the glandular prostate epithelium. 
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1.1.3 - Cells of the Prostate 
The glandular prostate of transitional, peripheral and central zones is further organised into 
bundles of exocrine acini. These structures are composed of stroma and epithelium separated by 
the basement membrane (BM). This is a complex mesh of cellular adhesion molecules (CAMs) and 
structural proteins including; collagen IV, laminin and heparin sulphate proteoglycans (12, 13). 
The stroma originates from the UGM and is composed of smooth muscle cells, myo-fibroblasts 
and fibroblasts (Figure 2F). These cells aid epithelial growth and differentiation through androgen-
dependent expression of a range of growth factors (GFs) including; epidermal (EGF), insulin-like 
(IGF1), platelet-derived (PDGF) and vascular endothelial (VEGF) (14). The composition of stromal 
cell-types is altered in malignancy, with almost complete loss of smooth muscle (15). In prostate 
cancer, the stroma exhibits genetic instability alongside aberrant epigenetic regulation of genes 
involved in stress response and cellular growth (16-18).  
The prostate epithelium itself contains 3 cell types; neuroendocrine, secretory luminal and 
undifferentiated basal cells. The latter two are organised into distinct luminal and basal layers 
(Figure 2A-D). These cells are classically characterised by immunophenotypic markers such as 
cytokeratins (CK), with the normal prostate showing a 60:40 luminal to basal cell ratio (Figure 
2G)(19). 
Luminal cells are the largest cellular population in the prostate and are terminally differentiated, 
existing in a state of senescence. They function as secretory cells that exocytose PSA and PAP into 
the prostatic ducts. Classic luminal cytokeratin markers are CK8 and CK18, and these cells also 
express AR, CD24, CD57 and ALOX15B (Figure 2D)(20, 21). Luminal hyperplasia results in the 
precursor lesion PIN, and a continued expansion of this epithelial layer in cancer skews the 
epithelial hierarchy to a stage where the tumour cell population is typically ~99% luminal (22). 
These cells are dependent upon androgens for survival. 
Neuroendocrine cells are the other terminally differentiated cell-type in the adult prostate and 
exist scattered throughout the epithelium. Cellular function is unclear but they canonically lack AR 
and are identified through staining for chromogranin A (23). Expression of another marker; 
neuropeptide Y, which is thought to promote angiogenesis through mitogen activated protein 
kinases (MAPKs), has been used to show increased numbers of neuroendocrine cells in tumours. 
The enrichment of this cell-type suggests a role in cancer progression, supported by findings that 
the cells also secrete VEGF, another angiogenic protein (24, 25). These neuroendrocrine or 
anaplastic prostate cancers arise in late-stage disease. They are innately castrate resistant due to 
the cells lacking AR, and are therefore androgen-independent pre-ablation therapy (Figure 
2E)(26). Androgen blockade may therefore select for the neuroendocrine lineage or development 
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of this neuroendocrine phenotype from the resistant cells could be a reflexive adaptation 
following treatment (27). 
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FIGURE 2 - Organisation of the normal prostate epithelium 
A-F) The cell populations of the prostate, with identifying immunophenotypic markers (13, 20, 21, 
23, 28). G) Constituent representation of the prostate epithelial cells in a normal gland. H) 
Diagrammatic schematic of a normal acinus with epithelial bilayer surrounded by fibromuscular 
stroma.   
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The basal cellular compartment is heterogeneous and contains several distinct populations 
(Figure 2A-C). Canonical basal cell markers include; CK5, CK14, p63, CD44 and Bcl-2 (29). These 
cells adhere to the BM as their name suggests and contain ~70% of total proliferating cells in the 
prostate (30). This, along with other compelling evidence, suggests that the adult epithelial stem 
cells reside in the basal layer of the human prostate. Prospective populations of these stem cells 
(SC) (CD133+ α2β1hi AR-), alongside transit amplifying (TA) (CD133- α2β1hi AR+) and committed basal 
(CB) cells (CD44+ α2β1lo ARlo) have been identified within this monolayer (13, 20, 28). Low levels of 
AR protein have been observed in the CD133+ population (31), yet this report conflicts with work 
in which no AR transcript or protein were detectable in the epithelial stem cells (13). Basal 
populations can focally express other hormonal nuclear receptors such as ER and PR that aid the 
androgen independence of the epithelial layer (32). 
Other groups have also identified markers that define prostate epithelial stem cells and cancerous 
equivalents. CD166/ALCAM is found to enrich for murine progenitors (33) and enhances 
metastatic potential in end-stage disease (34). Like CD166, ALDH1 was initially identified as a 
marker for murine prostate stem populations (both normal and cancerous) (35) and has been 
significantly associated with human prostate cancer through large patient cohort studies (36, 37). 
1.1.4 - Prostate Epithelial Stem Cells 
Stem cells are defined by both their ability to produce cells that are committed to separate 
lineages of differentiation and their enhanced self-renewal capacity. A single adult stem cell thus 
has the innate ability to reconstitute and populate its originating organ or cellular lineage. 
Self-renewal is the maintenance of stem cell population number whilst also generating non-stem 
daughter cells that are committed to a differentiation path, a phenomenon that occurs by 
asymmetric mitosis. Stem cells can also commit to symmetrical division to produce either two 
stem daughter or two non-stem daughter cells, (Figure 3) (38) allowing for expansion or deletion 
of the stem cell pool respectively.  
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FIGURE 3 – The stem cell niche and the role it can play in division choice 
The prostate epithelial stem cell niche is likely to reside on the basement membrane in close 
proximity to the stromal compartment. Heterotypic signalling in this environment is likely to 
determine self-renewal decisions.   
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Replication choice is dependent upon both intrinsic and niche-related factors. Intrinsic effectors 
that govern stem cell asymmetric division include transcription factors (such as Notch, Hedgehog 
and Wnt) and other cellular proteins/nucleic acids within the progenitors themselves that 
produce asymmetric accumulation of fate determining polypeptides and mRNA transcripts that 
subsequently promote asymmetric division (38, 39). 
The niche or microenvironment is the cocktail of GFs and cellular contacts that surround a stem 
cell (Figure 3). In the prostate, the niche is probably situated on the basement membrane of acini 
due to high stem cell expression of α2β1 integrin that binds collagen (40, 41). This positions the 
stem cells in close proximity to the underlying stromal compartment that through heterotypic 
signalling may play an important role in stem cell self-renewal choices. TGFβ and Wnt are 
examples of ligands that are consistently present in niches that self-renew tissues through stem 
cell asymmetric division and are seen to be dysregulated in prostate cancer to promote 
tumourigenesis (38, 42). Cell surface molecules are the other determining extrinsic factor that 
governs division choice. An example of this would be Notch signalling; Numb regulation of Notch 
receptors facilitates exclusive formation of asymmetric contacts to promote self-renewal of the 
stem cell (43).  
Adult or somatic stem cells are found in all tissues where they have an important role in 
population homeostasis and in situations of wound healing or tissue replacement (38). 
Haematopoietic stem cells are the most studied of these somatic populations and are well 
characterised, (CD34+ Lin- CD38+) giving rise to the myeloid and lymphoid lineages of the blood 
(44, 45). Adult stem cells have a number of defining features. They exist as a minute 
subpopulation in the tissue, situated in a specific niche. They have a large nuclear to cytoplasmic 
ratio, are structurally unspecialised with few organelles, are slow cycling yet have a rapid (and 
inducible) proliferative ability and give rise to a population of TA cells that proliferate clonally to 
ultimately yield a terminally differentiated cell population (46). Stem cells of epithelial tissues, 
such as the prostate, are characterised by a heightened in vitro and in vivo proliferative capacity 
and exist within a well-protected niche that is in contact with a mesenchymal compartment (46). 
 The case for a basally situated prostate epithelial stem cell pool began with the androgen 
depletion and replacement experiments in the rat prostate performed in the 1980s. Here, 
castration caused apoptosis of the androgen-dependent luminal cells whilst leaving an intact basal 
layer. Re-introduction of androgen at a later stage caused regeneration of the luminal cell layer 
(47). This lead to the hypothesis of a basal stem cell that produces an androgen-responsive TA 
population capable of self-expansion and reproduction of the terminally differentiated secretory 
layer (48). The relapse of human prostate cancer after hormonal castration by androgen 
deprivation therapy (ADT) mirrors this response, and highlights the phenotypic plasticity of the 
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progenitor basal compartment. Prospective prostate epithelial stem cells were isolated from 
within the total CD44+ basal population (49) on the basis of high α2β1 integrin expression. (21, 41). 
This α2β1hi population was later found to contain both stem and TA cell subpopulations, with 
further enrichment of stem cells achieved by selection using the CD133 marker (28, 50). 
Biochemical evidence, further supporting the initial hypothesis proposed by Isaacs and Coffey in 
1989, (48) was obtained by interrogating AR expression in these fractionated cell populations. 
Prostate epithelial stem cells were found to be AR- or ARlo, TA cells had relatively high amounts of 
the nuclear receptor whilst CB cells had low to undetectable protein levels (13). This molecular 
evidence highlights the plausibility of the original hypothesis and strongly suggests that the 
somatic stem cells of the prostate may play a more sinister role in cancer development. 
In vitro cell growth experiments also suggest a basal stem cell. Spheroid culture of prostate 
epithelial cells only permitted clonal growth from cells of a basal phenotype, characterised by 
CK5, integrin α6, CD44 and p63 expression (51). These prostaspheres lacked AR and PSA luminal 
markers and could be formed from either CD133+ or CD133- fractions. Basal epithelia are also 
easier to grow in organoid culture systems. Organoids generated from single basal cells have a 
70% growth efficiency compared to those of luminal origin. Luminal cells could only successfully 
generate organoids in 1-2% of cases (52). The stark difference in clonogenicity of the epithelial 
populations in the normal prostate is clear. However, current work does suggest that a rare 
luminal progenitor also exists in the prostate, but that its contribution to the normal epithelial 
hierarchy and, by association, the initiation of cancer is comparably negligible to that of the basal 
stem cell (52, 53). 
Lineage analysis of these cells has further supported their status at the root of the epithelial 
hierarchy in the prostate (Figure 2). One study used lineage-tracking lentiviral vectors to 
incorporate fluorescent PSA reporter genes into basal epithelial cells. These cultures were then 
stimulated to differentiate and fluorescence was observed, as expected, as the cells developed 
into secretory luminal cells (54). Other studies have used mitochondrial DNA mutations to map 
cytochrome c oxidase (COX) deficiency in prostatic acini. These mutations are reasoned to 
accumulate in stem cells and become observable through lateral clonal propagation throughout 
the acinus. This can be tracked by immunohistochemical staining of COX deficient cells through 
sequential tissue sections. Deficiency presented in all three cell types; basal, luminal and 
neuroendocrine, dictating that a common originating cell must exist within the epithelium (55). 
Further in-depth tissue sectioning of COX deficiency in prostates located multipotent basal 
progenitor cells (53). These were situated in a niche proximal to the urethra and gave rise to 
bipotent basal cells from which the mitochondrial mutation could be simultaneously inherited; 
laterally, by the basal epithelia and through differentiation, by the luminal monolayer. These 
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multipotent basal progenitors expressed high levels of Delta homolog 1, DLK, integrin α6 and 
Notch1 and could generate differentiated spheroids. Like the generation of organoid cultures 
(52), this lineage tracing approach also identified a minor population of luminal epithelial stem 
cells (53).  
Telomeres are extended sequences of hexanucleotide repeats found at the end of the 
chromosomes and buffer the loss of genetic material caused by the end-replication problem after 
every mitotic S-phase. Telomeric regions get shorter as the cell ages, causing genomic instability 
and eventually replicative cell senescence (56, 57). These repeats are maintained in the germline 
by the telomerase enzyme (TERT) which is later silenced in development. Analysis of telomere 
lengths and congruent activation of telomerase allows for tracking of cell population progression. 
In BPH, the basal stem cell population may be either bipotent or produce an early progenitor that 
can resolve down both the basal or luminal lineages. Here only the SC and TA populations have 
telomerase activation yet luminal cells have longer telomere lengths than CB cells. Progression 
down a linear route of epithelial differentiation of SC to TA, TA to CB and CB to luminal cell in this 
model does not account for this sequential loss and gain of telomere length, therefore the luminal 
cells must be produced directly from the SC or TA populations (58). 
TERT is silenced in the normal prostate epithelial subpopulations (59) including the stem cells, but 
becomes active during PIN and in the luminal cells of prostate cancers with both RNA and protein 
levels increasing in primary to metastatic disease (60, 61). The telomere lengths of cancer cells 
however are lower than that of surrounding normal tissue epithelium, (60-63) suggesting that an 
expansion of the TERT- stem cell pool occurred during tumorigenesis that resulted in telomere 
reduction of its more differentiated progeny (59). By extrapolating the findings in BPH there may 
be a root for the aberrant differentiation seen in prostate cancer. The burst of stem cell 
differentiation may “exhaust” the basal cell lineage as TERT reactivation doesn’t occur, however 
the telomere length can be maintained in the cancerous luminal cells that have active telomerase 
and thus the imbalance observed in luminal to basal epithelial populations is created (58). 
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1.2 - Disorders of the Prostate 
1.2.1 - Benign Prostatic Hyperplasia 
Normal postnatal prostatic growth occurs due to a rise in circulating testosterone levels during 
puberty, however the organ can also undergo abnormal growth later in life due to BPH; a chronic 
disease that affects the TZ of the prostate. Here hormone-dependent micronodular hyperplasia of 
the glandular and stromal tissue enlarges the TZ to constrict the descending urethra, resulting in 
lower urinary tract symptoms such as acute urinary retention. The restriction of urinary flow and 
obvious discomfort can be alleviated by transurethral resection of the prostate (TURP) where the 
tissue overgrowth is surgically removed. An increase in prostate volume due to BPH has been 
linked to elevated PSA levels, which may contribute to false positive cancer diagnoses through use 
of the canonical diagnostic test (discussed further in Section 1.4) (64). Future growth of the 
prostate in BPH can be predicted using baseline prostate volume and assessing internal prostatic 
architecture. For example; if a patient has a clearly defined TZ with an obvious stromal border, a 
larger endpoint prostatic volume can be expected (65).  
Microarray data has highlighted the divergence of BPH and cancer at the transcriptional level (66). 
The diseases are also phenotypically distinct in the fact that BPH has hyperproliferation of both 
layers of prostate epithelium rather than an exclusively luminal expansion (58, 67). 
1.2.2 - Prostatitis 
Tissue inflammation is the most common disorder of the prostate and occurs at a higher 
incidence than both BPH and cancer (68). Bacterial and viral infection, along with chemical 
exposure all cause prostatitis (69, 70). The disease can be split into four separate classes; I – acute 
bacterial prostatitis, II – chronic bacterial prostatitis, III – chronic pelvic pain syndrome, and IV – 
asymptomatic prostatitis (70). It is estimated that ~16% of US males will suffer symptomatic 
prostatitis (I-III) during their lifetime. Surprisingly, asymptomatic prostatitis is much more 
prevalent in the population and high percentages of both BPH and cancer biopsies show signs of 
surrounding tissue inflammation (70). Prostatitis, like BPH, can raise serum PSA levels - thought to 
be linked to destruction of tissue architecture causing “leakage” of the protein into the 
circulation, with levels of the antigen decreasing concordantly upon application of antibiotics (71).  
1.2.3 - Inflammatory Aetiology of Prostate Cancer 
Inflammation has been postulated as a triggering event or accelerating factor for prostate cancer 
development for many years (68, 72, 73). Inflammation, produced by an initial infection, can then 
trigger immune cell infiltration of the tissue; creating a disruptive chemical environment that can 
result in prolonged exposure of epithelial cells to a cocktail of transforming cyto- and chemokines. 
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Our lab has identified that prostate cancers do exhibit a reliance on inflammatory pathways 
centred about NF-kB, IFNGR and IL-6 signalling (66) which may have been cultivated in a situation 
not dissimilar to that described above.  
The initial (or combination of) infectious or chemical insult that triggers the cascade of 
inflammation and immune activation can come from a wide array of sources. 
Inflammation; Infectious Agents 
Many infectious organisms that produce prostatic inflammation are sexually transmitted, owing 
to the close proximity of the gland to the male genitalia. Sexually transmitted infections (STI) of 
Chlamydia trachomatis (Chlamydia), (74) Neisseria gonorrhoeae (Gonorrhoea), (75) Treponema 
pallidum (Syphilis), Herpes Simplex Virus, Human Papillomaviruses (HPV), Human Herpes Virus 
and Cytomegalovirus (76) have all been detected in prostate tissue.  
Meta-analysis linking STI data to prostate cancer has shown that past history of any STI increases 
later disease incidence. In particular, gonorrhoea infection heightens risk of malignancy 
development by 20% (77). 
Propionibacterium acnes, as the name suggests, is more commonly associated with the skin 
condition acne, (78) yet is recurrently discovered in inflamed prostate tissue (79, 80). Studies, 
both in vitro and in vivo, that position the bacterium in this prostatic niche have identified similar 
molecular activations and defects seen in human prostate tumours. Culturing the bacterium with 
the prostate epithelial cell line RPWE-1, caused activation of STAT3 and NF-kB with secretion of 
the IL-6 cytokine (81) and in a mouse model; infection stimulated epithelial hyperproliferation, 
inflammation and downregulation of  the tumour suppressor, NKX3.1 (82)(Figure 4A). 
HPV infection has been correlated with increased Gleason grading of tumours and also with lower 
survival rates (83, 84). However, several studies have also found no correlation with infection and 
many tumour tissues display absence of any genetic material attributable to the virus (85-87). This 
suggests that further studies with larger patient cohorts and sequencing depth would be required 
to ascertain the involvement of HPV in prostate cancer development.  
Another virus that has been recurrently found in the prostate is Epstein-Barr virus (EBV). This 
pathogen has historical ties to epithelial and blood cancers (88) and is proposed to collaborate 
with HPV infection to initiate prostate carcinogenesis (89). 
Human BK polyomavirus has been detected in cancer and associated proliferative inflammatory 
atrophy (PIA) lesions, suggesting a role for the virus in disease development. Interestingly the 
virulent BK T antigen can abrogate both p53 and Rb protein function (both usually intact in early 
prostate cancers (90), marking a path for non-mutagenic removal of two key tumour suppressing 
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genes by the virus (91, 92). Conversely, BK sero-positivity in patients with prostate cancer is linked 
to a reduction in rates of biochemical recurrence – meaning that presence of the virus may be a 
good prognostic factor – yet again, studies with larger sample sizes will hopefully ascertain if the 
virus plays a role in the development of prostate cancer (93)(Figure 4B). 
Deep sequencing of homogenised tissue can now identify the presence of bacterial and viral 
genetic information in prostate samples, (79) a feat only previously achievable through targeted 
PCRs – a sensitive yet blinkered approach (94-96). This opens a gateway leading to possible 
identification of new pathogenic species, that previously couldn’t be sustained in ex vivo culture, 
and any subsequent involvement in prostate carcinogenesis that they may have. 
Inflammation; Dietary Compounds 
Epidemiology has linked the increase of prostate cancer incidence in a population with high intake 
of animal fat and red meats (97, 98). The active chemicals cited to trigger carcinogenesis are 
heterocyclic amines (HCA). Supplementing the diet of rats with an HCA; 2-amino 1-methyl-6-
phenylimidazo[4,5-b]pyridine (PhIP) caused spontaneous cancer formation in the breast, 
intestinal and prostate tissue of the animals (99). This HCA also increased the mutation rate in the 
rodent prostate cancers and was observed to have lobe-specific effects – similar to the high zonal 
specificity seen in human disease. The rats also had a marked progression of disease; with stages 
of PIA and PIN existing prior to full adenocarcinoma (72, 100, 101). Dietary PhIP has also been 
observed to enhance bacterial prostatitis with congruent IL-6 signalling activation and 
development of prostate cancer (102, 103). 
Dietary compounds have also been linked to a reduced risk of prostate cancer development and 
progression. These have mainly been associated through large cohort studies and include; green 
tea, (104) tomatoes (lycopenes), (105) cruciferous vegetables, (106) soy, (107) and pomegranates 
(108). Specific chemicals in these foodstuffs have been shown in isolation to halt cancer cell 
growth in vitro and protect against oxidative stress – a key mediator of inflammatory damage in 
this early stage of disease (Figure 4C). 
Inflammation; Immune Cell Infiltration 
There is also considerable evidence suggesting that tissue infiltrates of immune cells contribute 
towards BPH and cancer (68-70, 109). 
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FIGURE 4 – Factors influencing prostate inflammation in carcinogenesis.  
A) Bacterial and B) viral infections, alongside C) diet and the individual’s immune D) response all 
affect prostate inflammation and the outcome of disease initiation and progression. 
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Against initial thought, an increased number of intratumoural immune cells can, in fact, promote 
disease progression (110). T cell infiltrates of prostate tumours are regularly found to be 
“exhausted” (non-active) due to expression of the PD-1 receptor and cognate ligand PD-L1 (111). 
These infiltrates also contain a high percentage of Treg cells, suggesting further dampening of the 
T-cell directed immune response against the tumour (111, 112). Other immune cells also have 
correlative incidences with prostate tumours. An increase in tumour associated macrophages and 
B cells (113, 114) can promote disease whilst the reverse is true of Natural Killer (NK) cell numbers 
(115). B cells also contribute towards cancer cell self-renewal processes through heterotypic 
signalling; something that may be harnessed, and misappropriated, by the stem cell compartment 
of the organ in disease (116)(Figure 4D). 
Inflammation; Further Aetiological Evidence 
Suppression, by pharmacological “dampening”, of a patient’s immune system following organ 
transplant, increases the risk of prostate adenocarcinoma developing, suggesting that infectious 
agents or a lack of immune surveillance plays a role in the initiation of disease (117). Several 
studies have found that a recurrent dose of non-steroidal anti-inflammatories reduces prostate 
cancer incidence (72, 118-120) and that higher grade cancers often have inflammation in the 
surrounding normal tissue. This also provides further evidence in favour of inflammation playing a 
role in disease initiation and progression (121). 
1.2.4 - Proliferative Inflammatory Atrophy 
PIA is thought to occur as a precursor to PIN, manifesting as regenerative hyperproliferation of 
the epithelia in response to an initiating inflammatory insult. PIA is most commonly found in the 
PZ and has been seen here to merge with PIN and cancerous epithelial tissue (72, 122) – providing 
correlative evidence towards a hierarchical progression of disease (Figure 5A). Interestingly, 
similar molecular defects can be tracked across these overlaying lesions. Loss and gain of genetic 
material, commonly observed in prostate cancer, doesn’t occur in PIA lesions (123) yet there are 
several notable changes in gene expression. GSTπ1, a protector against oxidative stress, and Bcl-2, 
an apoptosis suppressor, are both upregulated whilst tumour suppressor genes commonly 
deleted in prostate cancers are downregulated (70, 124, 125). Progression of PIA to PIN is likely, 
however there is also evidence that disputes this hypothesis; a study that processed over 1000 
biopsies from 98 patients suggests that PIA has links to prostatitis yet it is unlikely the lesion 
develops into PIN based on tissue architecture and proximity (126). Further evidence is therefore 
required to ascertain if there is a true development of PIN from PIA. 
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1.2.5 - Prostatic Intraepithelial Neoplasia 
PIN is suspected to be a precancerous lesion, characterised by hyperplasia of the luminal cell 
population into the acinar lumen. It is biochemically, genetically and phenotypically similar to 
prostate adenocarcinoma, however there is no disruption of the basement membrane 
(127)(Figure 5B). Other key differences include the reduction of basal cells (still present in PIN, 
whereas in cancer the basal population is proportionally negligible) and the surrounding stromal 
tissue isn’t completely reactive (128). In PIN the relative mitotic rates of cells in the bilayer switch 
and the luminal cells become more proliferative, causing the observed hyperplasia. This 
overgrowth can present as tufting, micropapillary projection, cribiform or flat growth into the 
lumen (127). PIN is a chronic disease that has been identified in men as early as in their twenties. 
Prostate cancer foci can be detected within a decade later, with percentages of both diseases 
increasing as population cohorts grow older. This implies that prostate cancer initiates relatively 
early in men yet doesn’t present clinically until much later in life (129). Anatomically PIN, like 
cancer, occurs dominantly in the PZ and is thought to give rise to the malignant phenotype via a 
“field” effect, a hypothesis supported by common reports of high-grade PIN (hgPIN) and cancer 
tissue merging (127, 130). 
In terms of their expression profiles, PIN and cancer are significantly similar. The ETV and ERG 
gene fusions specific to prostate adenocarcinomas are foreshadowed in PIN, where the neoplasia 
presents with active transcriptional networks reliant upon the very same ETS transcription factors 
(123). A recent study exposing clonal dynamics in tissue by means of unique TMPRSS2-ERG fusion 
breakpoints observed that some hgPIN lesions were actually retrograde carcinomas that also 
harboured PTEN deletions (131). These presented, in tissue pathology, as PIN yet were actually 
cancers. In similar cases, hgPIN has been shown to harbour primary genetic defects of prostate 
cancer such as the TMPRSS2-ERG fusion, (132) SPOP mutation (133) and NKX3.1 loss (127), 
highlighting a possible hierarchy of multi-step carcinogenic development through neoplasia or 
cancer mimicry of PIN tissue patterns. 
Development of adenocarcinoma from PIN has also been assessed using temporally separated 
biopsies taken from the same patient’s prostate (134). A study of just under 800 patients that 
were diagnosed with PIN at first biopsy and then re-biopsied within a year of initial diagnosis, 
found that there was an increase in the amount of cancers sampled. However, the authors 
attributed this to the poor initial sampling of the patients i.e. the cancer was present yet 
undetected the first time, rather than a progression of PIN into carcinoma. 
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FIGURE 5 – Proposed staged progression of prostatic disease into prostate cancer. 
Disease progression, highlighting the cellular and molecular changes through A) PIA, B) PIN and C) 
Cancer.   
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1.2.6 - General Attributes of Prostate Cancer 
Prostate cancer is the most commonly diagnosed cancer in men of the United Kingdom (135). The 
prevailing risk factor for disease seems to be age, with diet and infection also thought to play 
important roles in disease aetiology. The most striking phenotypic feature of ductal carcinoma is 
the apparent breakdown of acinar tissue architecture. The skewing of epithelial cell populations 
seen in hgPIN is further exaggerated in cancer with luminal expansion, twinned with loss of basal 
cells, causing a >99% to <1% luminal-basal split (22). The BM is degraded and cells migrate into 
the reactive stroma where heterotypic signalling facilitates further invasion of the tissue (14). The 
disruption of normal acinar morphology is thought to be what leads to higher circulating levels of 
PSA, the canonical diagnostic marker of the cancer (136). 
Tissue architecture is histopathologically defined by the Gleason grading system, upon which 
patient disease can be stratified and prognostic severity estimated (128). Prostate cancer is also 
classified by the TNM (tumour, nodes, metastases) scale. T1-4 stratifies the local primary tumour 
growth and invasion, N0-3 infers level of lymph node metastases, and finally M0-1 signifying the 
presence of any distant metastases (137). Localised disease can be treated by surgical removal of 
prostate tissue, an array of focal therapies and, in advanced cases, ADT. ADT is used to target the 
AR-dependent luminal cells of the tumour to result in initial remission of the cancer (136). As 
prostate cancer is distinctly heterogeneous, treating tumours as a homogeneous collection of 
cells (as ADT does) ultimately fails as the reduced basal compartment, and possibly a small 
percentage of luminal cells that have escaped androgen dependence, can regenerate the tumour. 
Relapse of castration-resistant prostate cancer (CRPC) typically presents 12-24 months following 
hormone therapy (26). Advanced prostate cancer either rapidly metastasises following treatment 
or may have spread to secondary sites prior to hormonal therapy. This catastrophic stage of 
disease leads rapidly to patient mortality.  This end-stage disease is currently inefficiently treated 
with broad-spectrum cytotoxic chemotherapeutic drugs or second generation anti-androgens that 
extend life by a few months. All therapies at this point are palliative (26). 
1.2.7 - Prostate Cancer Epidemiology  
In the United Kingdom and United States, prostate cancer has the greatest annual incidence of 
diagnosis in males, accounting for approximately 1 in 4 male cancer cases (138). The most up to 
date figures in the UK state that there were around 47,000 new diagnoses of disease in 2014 
(138). It is also the second most common cause of male cancer death in both countries with just 
over 11,000 mortalities in the UK and 30,000 in the USA (139). Age is the major obvious risk 
factor; over 50% of cases are diagnosed after the age of 70 (138)(Figure 6). 
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FIGURE 6 – Age as a disease risk-factor in prostate cancer 
Data from 2012-2014 compiled by CRUK indicating peak incidence of disease in 65-70yr old men 
and >50% diagnoses coming after 70yrs of age. http://www.cancerresearchuk.org/health-
professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence#heading-One  
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Familial prostate cancer accounts for 10-20% of population cases. It is defined in a family that has 
disease incidence in two first-degree relatives (father, brother or son) or in one first-degree and at 
least 2 second-degree relatives (uncle, cousin, nephew, half-brother) (140). 
Hereditary prostate cancer has stricter criteria than that of familial cases; 
1. Prostate cancer in three or more first-degree relatives  
2. Prostate cancer in three consecutive generations 
3. Early diagnosis of prostate cancer (~50 years old) in two siblings (140) 
It is notable that, whilst not fully understood, there is a racial predisposition to prostate cancer 
with Asian men having the lowest rick of mortality from disease and African-Americans, the 
highest (141-143). 
Aside from genetic factors, other compelling epidemiological evidence highlights that 
environmental factors also significantly contribute towards disease. As previously mentioned, the 
incidence of prostate cancer in the Asian population is lower than that observed in Westerners. 
However, in Japanese who migrated to Hawaii it was observed that previously low rates of 
prostate cancer development in the population rose to match that of the American indigenous 
(144). This suggests that a change in diet, or habit, (145) or possibly an endemic infection may 
have caused the rise in incidence and also infers there may be an underlying connection of 
prostate cancer to an environmental influence that supersedes any current observation of racial 
predisposition to the disease. 
Recent statistics show the extent of the impact that prostate cancer has in the male population. 
With current treatments unable to combat advanced prostate cancers that have become castrate 
resistant, better understanding of cancer cell type of origin and the development of the disease is 
required to produce new and effective therapies. 
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1.3 - Tumour Heterogeneity and Cancer Stem Cells 
Tumours present a complex microenvironment due to heterogeneity of constituent and recruited 
cells. Tumour cell phenotypic variance can be observed both histopathologically and within 
proliferation and differentiation states (146-148). Unfortunately, most cancer treatments assume 
that tumours are close to a homogeneous cellular mass which can be killed within the spectrum 
of singular agent or combination therapies. These treatments can cause initial regression of 
tumour bulk yet the cancer often relapses in a more advanced form, suggesting selection of a 
more aggressive phenotype. This raises several questions. Is resistance adaptive or pre-existing? 
How is tumour heterogeneity generated presuming a clonal origin of cancer, and, do all cells have 
an equal capacity for tumour regeneration?  
Heterogeneity observed in blood malignancies (149) and solid tumours (150) has shown that 
cancers consist of genetically and phenotypically diverse cells. This variance within tumours can 
be accounted for, and generated by two theories which are not entirely mutually exclusive (19, 
151). 
1.3.1 - Clonal Evolution Model 
In this model, all cells have an equal propensity to become tumourigenic, with transformation 
occurring through a stochastic mutational or epigenetic event. This transformed cell then gives 
rise to other like-cells via mitosis, which have similar tumour forming ability. The tumour cells can 
then acquire subsequent mutation/s, giving them a selective advantage that allows for disease 
progression (19, 151).  
The first cell (and the clonal expansion of cells it produces) to incur the epigenetic or genetic 
change can be thought of as the “trunk” of the cancer (tree), with all further sub-clones branching 
off as the tumour develops (Figure 7A). Initiating genetic events, so called trunk mutations, have 
been classically modelled, by transformation of cell lines through introduction or removal of single 
genes that are altered across human cancers (152-156). Assimilation of cancer genomic data has 
allowed around 150  carcinogenic “driver” genes which operate in 12 central signalling pathways 
to be identified (157). 
A driver is a gene that, when “favourably” altered, gives the cell a proliferative edge over its 
neighbours, causing the cell to behave selfishly. The transformed cell abandons its role in the 
tissue and competes to survive and divide. Drivers can be further subclassified as tumour 
suppressors (when disease is promoted by gene loss or inactivation) and oncogenes (when 
disease is promoted by gene gain or activation). However, cancers usually harbour many more 
mutations than would be required to transform a single cell. These additional mutations are called 
37 
 
passengers. They accumulate in the clone with the advantageous driver mutation/s and are 
selected alongside during clonal evolution. In a very small fraction of cancers, these passenger 
mutations may become adaptive in a different microenvironment (such as that encountered in a 
new treatment regime or secondary metastatic site) and aid tumour survival. The majority of 
current sequencing studies use late stage tumours loaded with an overwhelming amount of 
mutational changes. From this end-point it is difficult to decipher which order the mutations 
occurred in, and also which alterations are critical to cancer initiation, development and 
progression (157). 
Epigenetic events can also drive cancer progression. Epigenetically altered tumour progenitor cells 
do not have inflexible fixed mutations but instead, and more elegantly, fluctuate the expression of 
critical genes. Control of transcript levels through methylation of the DNA or histone tails allows 
the cell a heightened plasticity over that of a mutational change, as it can adapt within a mitotic 
cycle to microenvironmental alteration (158). 
A study that highlights the feasibility of the clonal evolution model in prostate cancer was 
conducted by Goldstein et al. Sequential lentiviral introduction of the oncogenes ERG and AKT 
(mimicking TMPRSS2-ERG fusion and PTEN loss respectively) into basal cells caused formation of 
PIN-like disease in mice. Addition of AR into these activated cells then produced various tumours; 
some of which presented with outgrowth of an AR+ population and “loss” of the basal cells that 
were initially transformed, a situation not dissimilar to the presentation of human prostate 
cancers in situ (159). This challenges current thought that prostate tumours at diagnosis are the 
same at initiation, progression and presentation. The same group has repeated this study of serial 
gene alteration in human cell derived organoid cultures that were subsequently transplanted into 
mice. Transformation of basal cells produced a more aggressive disease phenotype than that of a 
luminal origin. Formation of luminal cell derived tumours show that these secretory cells can 
initiate cancer in this specific context with the study also observing divergent histology and 
heterogeneity of cancers (that were representative of human disease) stemmed by cells of the 
different epithelial populations (160). However, the study failed to address which particular 
subpopulation in the broad basal and luminal epithelial classes was the cell of origin. The 
organoids were also not serially transplanted in mice, only cultured in vitro, meaning that further 
interrogation of cell of origin is required for human prostate cancer. 
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FIGURE 7 – Linear step, clonal evolution and field cancerisation. 
A) A schematic of a fictional tumour, the dark blue line traces the route of a linear progression 
with mutation gained step by step, the dark grey line shows the network of clonal evolution in the 
tumour with continuation of route lineages and branching of less “successful” sub clones. B) The 
associated diagram showing the field cancerisation effect of the tumour schematic in A – here any 
cell in the field can gain a mutational change that allows for development of successful sub-
clones.  
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1.3.2 - Linear step carcinogenesis 
Proposed by Fearon & Vogelstein in 1990, (152) step-wise carcinogenesis implies the sequential 
accumulation of driver mutations in a single cell (Figure 7A). The mutational burden, upon 
reaching a certain number, transforms the cell into the initiating clone. The number of mutations 
required to create a cancer cell appears to be tissue specific with initial estimates placing the 
number of specific aberrations to be around 7 (161). However, recent analytical modelling 
suggests that this number is more likely to be ~3 specific mutations in the majority of solid 
tumours (162). Leukaemias usually present in childhood, where the early onset is thought to be 
driven by the minimal requirement of a single transformative event such as well characterised 
BCR-ABL and RUNX1-ETV5 gene fusions (146, 163). In the case of prostate cancer, sequential 
mutagenesis in mouse models suggests that 1-3 mutational events are needed to form the 
initiating cell (128). 
Linear step carcinogenesis however has two main criticisms; 
• Metastatic potential 
The original model places cellular acquisition of metastatic potential as a final step 
immediately prior to patient death, however metastasis is now known to occur early in 
cancer development yet remain undetectable. This is due to inefficiency in secondary-site 
seeding and the variable latency of micro-metastases (164-166). 
 
• Immune surveillance and apoptosis evasion 
Step-wise accrual of mutations that drastically affect cell growth pathways would usually 
cause cell death or elimination by the immune system; the body’s quality control 
mechanisms. There would need to be a mutational protection from self-initiated cell 
death before other proliferative mutations could occur. The HPV oncogenes; E6 and E7, 
give a perfect example of this. E7 binds cellular Rb and causes cell cycle dysregulation yet 
requires E6 to bind p53 the prevent the destruction of the transformed cell. Both are 
needed for survival and growth advantage. Therefore, the step-wise gain of mutation has 
to be coordinated and well timed to transform a cell without simultaneously inducing 
apoptosis (167-169). 
1.3.3 - Field Cancerisation 
Field cancerisation (FC) is similar to the linear-step model but considers that the entire tissue or 
“field”, rather than just a single cell, is pre-disposed to carcinogenesis (Figure 7B). It was proposed 
due to the multi-focal nature of primary oral cancers that formed in extreme proximity to one 
another, yet were entirely separate (170). Here, in the “activated” field, a cell can incur an 
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epi/genetic change and then divide; producing a sub-field of clonal cells in which further change 
can accumulate until a tumourigenic profile is achieved and cancer forms (171). 
There is evidence of this effect, both epigenetically and genetically, in prostate cancer; that exists 
commonly as multi-focal disease (172). Methylation ratios of two genes; APC and RARβ2, across 
both tumour and surrounding benign prostate tissue, highlighted a previously undetected 
underlying field of heritable epigenetic defect (173). Similarly, deep-sequencing of sectioned 
tissue from three prostates and their associated cancers found an unexpectedly (due to previously 
reported low mutation rates in prostate cancer (90, 174)) high incidence of background somatic 
mutations in “normal” tissue. The authors themselves proposed that this was representative of an 
activated mutational field that then stemmed the multifocal prostate tumours they were studying 
(175). 
1.3.4 - Cancer Stem Cell Model 
The Cancer Stem Cell (CSC) theory stipulates that only some cells have an ability to initiate and 
regenerate a cancer. They are thought to arise from somatic stem cells or a transformational 
event in a near progenitor that affords the cell stem-like attributes. Heterogeneity is then 
generated through aberrant differentiation from the clonal CSC origin which produces the 
dysfunctional lineage (28, 176-178)(Figure 8A). Accumulation of mutations and epigenetic defects 
in the stem cell is thought to occur in pre-tumour development (179). 
CSCs were predicted long before their eventual discovery. In 1938, Furth & Kahn discovered that a 
single cell was sufficient to transmit leukaemia between mice from a common genetic background 
(180). Twenty years later, Chury and Tobiska described a leukaemia observed in a human patient 
as a stem cell disease (181). John Cairns then discussed the potential role of stem cells in human 
cancers, as tumours arise primarily in epithelial tissues sustained by a somatic progenitor 
population (182). Culture of extracted human patient tumour stem cells in vitro was then 
pioneered and suggested that it would, in future, permit assessment of metastatic potential and 
allow for targeted personalised medicine to be applied against the individual’s cancer (183). In 
1988, Pierce & Speers proposed that tumours mirrored dysfunctional tissues and were therefore 
sustained by a small population of, in this instance, malignant stem cells (147).  
Once technology had advanced sufficiently to allow isolation of cells by expression of surface 
molecules, the first tumour progenitors to be identified were the leukaemic stem cells of the 
acute myeloid leukaemia (AML) initiating population by Bonnet and Dick in 1997 (184). These cells 
shared the immunophenotype of Haematopoietic Stem Cells (HSCs), possessed an enhanced self-
renewal capability and were able to generate the entirety of the leukaemic blast lineage. 
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Fractionation of tumour cells has now allowed for the identification of many tumour initiating 
populations in solid cancers, listed in Table 1.  
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FIGURE 8 – CSC model and metastatic relapse 
A) The CSC model of heterogeneity generation. A mutated (X1) progenitor or CSC can both give 
rise to a more differentiated lineage and create stem cell clones by asymmetric division. The CSC 
clones can then incur further mutation (X2) to produce another CSC derived mutated lineage and 
generate the heterogeneity observed in tumours. B) Following ADT the basal CSCs, which are 
innately resistant to castration, can trigger relapse and metastatic spread of the cancer.  
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Tissue Phenotype Reference 
Haematopoietic System CD34+ CD38- (Bonnet & Dick 1997)(184) 
Breast CD44+ CD24-/lo (Al-Hajj 2003)(185) 
Brain CD133+ (Singh 2003)(186) 
Multiple Myeloma CD138- (Matsui 2004)(187) 
Prostate CD44+ CD133+ α2β1hi (Collins 2005, Patrawala 
2007)(21, 28) 
Melanoma CD20+ (Fang 2005)(188) 
Pancreas CD44+ CD24+ ESA+ (Li 2009)(189) 
Liver CD133+ (Ma 2007)(190) 
Colon CD133+ (Ricci-Vitiani 2007)(191) 
Head and Neck Squamous 
Carcinoma 
CD44+ BMI1+ (Prince 2007)(192) 
Lung CD133+ (Eramo 2008)(193) 
Ovary CD44+ CD117+ (Zhang 2008)(194) 
Endometrium CD133+ (Rutella 2009)(195) 
Bladder 67LR+ CEACAM6+ CK17+ (He 2009)(196) 
Cervix CD44+ CK17+ (Feng 2009)(197) 
TABLE 1 – Cancer Stem Cells of solid tumours.  
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The CSC fraction is characterised much in the same way as adult stem cells. They must be able to 
self-renew, to maintain the CSC pool, and have differentiation capacity to produce the more 
differentiated tumour cell lineage. They also display similar cell surface markers (or 
immunophenotype) to that of their normal tissue counterparts (19). The exact origin of CSCs in a 
tumour’s natural history isn’t definitively known, yet current thought is that they arise from a 
transformative event in a tissue stem cell or near progenitor. The best evidence of this is from 
colorectal cancers. Here adenocarcinomas were induced in mice only upon stem cell 
transformation and not in the case of attempted initiation by transformed TA cells (176). 
The gold standard for CSC validation remains the initiation of cancer by xenotransplantation of 
enriched cells (preferably a single cell) into immunocompromised mice  (151). However, the 
degree to which each recipient mice strain’s immune system is deficient can complicate the 
interpretation; some may permit CSC growth whilst others may not, based solely on the 
complement of endogenous immune cells left intact in the mouse (198). Existence of a rare CSC 
population (apart from in melanomas, where all cells have CSC properties (198)) has huge 
implications for existing therapies that target tumour bulk, yet leave this resistant fraction 
unscathed to act as minimal residual disease (44, 199). CSCs can be selected and expanded by 
chemotherapy (200, 201) as depletion of tumour bulk causes CSC activation; the root of the 
cancerous lineage dividing to replace differentiated tumour cells lost to treatment. This could 
make tumour progenitors susceptible to correctly timed therapies and gives a possible 
explanation to immediate relapse of cancer following “successful” treatment.  
1.3.5 - Pre-tumour development 
Pre-tumour development describes a period that occurs well before visible emergence of cancer. 
The adult or somatic stem cell pool of the prostate isn’t depleted by differentiation, development 
or apoptosis and is maintained throughout the course of an individual’s life-span. The long-life 
and constancy of this cell pool is afforded by the relative quiescence and slow-turnover of the 
stem cells. This means that, in the case of the prostate, pre-tumour development can take place 
over decades. The increased emergence of disease in older men does suggest that the stem cell 
population has a role in disease (146, 179). 
However, this is perhaps an oversimplification of the many factors that contribute to 
carcinogenesis. Recently, the number of life-long stem cell divisions was correlated with cancer 
incidence in several tissues (202). This analysis however drew widespread criticism as the authors; 
neglected to use data from major cancers including breast and prostate, (203) didn’t account for 
known environmental influences which aid tumourigenesis, (204) only used data from the USA 
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and suggested that cancer is “bad luck” (205-207) which flies in the face of current evidence that 
lifestyle choices play a critical deterministic factor in disease initiation and progression (208). 
The vast number of mutations harboured by late-stage solid tumours cannot be plausibly accrued 
using random multi-hit mutational modelling (209, 210) without the early development of a 
mutator phenotype (68, 179, 211). This is more suggestive of microevolutionary processes that 
select for advantageous mutation in the stem cells (212). Mathematical modelling implementing 
cancer genome deep sequencing data has been used to support this theory; identifying that the 
necessary drivers are present in the first cell with heterogeneity then being derived after initiating 
events to create the passenger mutation noise that then masks the foundational signature. Here 
lineages can develop neutrally with passenger mutations becoming adaptive later in progression 
(213). 
1.3.6 - The stem cell niche 
Adult and cancer stem cells are maintained by, and contribute to, a niche. The niche is a 
protective microenvironment that surrounds the stem cell population in the tissue and is 
constituted by the necessary cell-cell, cell-structure contacts alongside immersion in growth 
factors and other soluble compounds that can alter stem cell fate and division choice (38, 214). 
The best evidence for an independent CSC niche is from glioblastoma. Here a hypoxic 
microenvironment maintains the stem cells (215) yet there also exists a sub-clone that can act 
through trans-differentiation as an endothelial progenitor if the niche requires oxygen (216, 217). 
The prostate epithelial stem cell niche is most likely located at the basement membrane of acini 
due to high expression of the collagen-binding integrin α2β1 (CD49b) (28, 41). More research is 
required into establishing the exact location (218) and determining what factors separate the 
normal and cancerous niches, as specific disruption of the CSC niche would likely amount to an 
efficacious treatment of prostate cancer. This may also extend to treatments of metastatic 
disease as niche-mimicry and secondary site seeding by CSCs remain a distinct possibility in 
prostate cancer (219). 
1.3.7 - The immortal strand hypothesis 
Stem cell asymmetric division may also protect the population from fixing mutations. The 
immortal strand hypothesis stipulates that, in mitosis, the stem cell non-randomly retains its 
template genetic material so that any mutation incurred in DNA replication is segregated to the 
non-stem daughter. This facilitates both the survival of the stem cell and the serial creation of 
mutated and differentiated progeny through asymmetric division (19, 44, 148, 220, 221). Initial 
evidence suggested that the hypothesis may be founded in truth, with selective retention of 
template strands observed in embryonic fibroblasts (222) and by the stem cells of skeletal muscle 
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(223) and mouse intestine (224). Recent observations however dispute existence of an immortal 
strand as both HSCs (225) and mouse intestinal stem cells (226) randomly segregate DNA upon 
asymmetric division, experiments that are in agreement with current modelling of somatic stem 
cell mutational accumulation (227). This meta-analysis does have shortcomings in that it 
compares normal stem cell divisions with cancer genome data and also fails to take into account 
that CSCs may purposefully disrupt strand segregation mechanisms (228) to create an 
environment more favourable to mutational accumulation. 
1.3.8 - Cancer relapse; a stem cell triggered event? 
A CSC does not have to increase its proliferative capabilities to be “successful”, indeed the ability 
to enter and re-emerge from a quiescent state is far more advantageous to a cancerous 
progenitor. This renders treatments such as radio- and chemotherapy ineffective as both rely on 
cell division to have a toxic effect. Indeed, normal somatic HSCs evade DNA damage through this 
mechanism (229). 
In prostate cancer, targeted treatment of androgen deprivation therapy causes tumour volume to 
decrease as cells dependent on the hormone develop regressive morphology, stop growing and in 
some instances, undergo apoptosis (230-233). However, in the following 36 months, the cancer 
usually reappears and often does so in the advanced and catastrophic spread of metastasis. 
Dormant CSCs coming out of their quiescent state are a likely perpetrator for the sudden 
emergence of disease, however little is known about successful metastatic founder clones of 
prostate cancers (165, 178, 234)(Figure 8B). The targeting of dormant cells with therapy is a 
difficult challenge in which there are two possible treatment options. The first, and most risky due 
to the possibility of cellular evasion over time, is enforcing the dormancy of the CSC 
subpopulation so that they can’t re-enter mitosis and bring about relapsed disease. The other acts 
upon the opposite end of the same signalling axis and actively triggers the CSCs into a cycling 
state. This would be tailored so that the CSCs have a preference for symmetrical division to 
produce non-stem daughters, allowing depletion of the cell pool. This so-called differentiation 
therapy hopes to shift the cancerous cells to a phenotype that then also becomes targetable by 
the spectrum of conventional chemotherapies (235-237). Differentiation therapy does have one 
major challenge to overcome, that is; the selective nature of inducing CSC-specific mitotic entry 
and not that of normal tissue somatic stem cells. This off-target effect in treatment of prostate 
cancer would result in drastic loss of glandular and acinar architecture – and may also affect other 
somatic stem cell pools.  
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1.3.9 - Prostate Cancer Stem Cells 
Prostate cancer is slow growing and has been observed histologically in men as young as forty, in 
whom the disease becomes clinically apparent in later life (129). This suggests a model of 
accumulated mutations in the stem cell population, rather than cancer arising in the senescent 
luminal cells. The dominant luminal phenotype in prostate adenocarcinoma (22) also hints at an 
aberrant differentiation program produced by the CSC. 
Mouse models have evidence for both basal (33, 238) and luminal (239, 240) CSCs whereas in the 
human prostate, overwhelming current evidence points towards a prostate epithelial and 
cancerous stem cell of basal phenotype (21, 28, 49, 52, 160, 241-243). Isaacs & Coffey predicted 
existence of these malignant progenitors (48) before Collins et al. identified the CD44+ CD133+ 
α2β1hi CSC population (28). Subsequent studies using similar basal molecular markers as a base for 
fractionation and enrichment of this prostate CSCs have independently verified existence of this 
rare cell type (21, 244). Interestingly, experiments attempting to initiate cancer from benign 
human basal epithelial subpopulations found that the CD133+ cells were protected from 
tumourigenesis and it was the CD133- α2β1hi TA population that was susceptible to transformation 
(245). This suggests that prostate cancers may initiate in a CD133- basal cell that then adapts into 
a CD133+ cell to sustain tumour growth. 
The biochemistry of this CD133+ CSC population has been further investigated. These cells express 
the basal epithelial markers; p63, CK5 and CK14, and lack canonical luminal markers; AR, PSA and 
PAP. The invasive nature noted by Collins et al. was further confirmed in microarray data, by 
identification of an epithelial to mesenchymal transition (EMT) signature, with loss of E-cadherin 
and gain of both vimentin and osteonectin (13, 28). Common genetic alterations in prostate 
cancer, such as the TMPRRS2-ERG fusion and PTEN deletions, are confirmed to be present in this 
tumourigenic population (66, 246, 247). 
Notch signalling, classically observed in epithelial cell fate decision making and in the maintenance 
of the stem cell compartment, is active in prostate epithelial stem cells and their cancerous 
equivalents (Rachel Adamson, unpublished data). Notch is context dependent; invoking varying 
responses in different cell types and disease stages (248). Active signalling is maintained by cell-
cell contact in which a ligand receptor; Jagged 1 (JAG1), JAG2 or Delta-like 1 (DLL1), DLL2 or DLL3, 
binds the Notch receptor, of which there are four isoforms (NOTCH1-4). Notch receptors are 
comprised of an extracellular and an intracellular domain (NICD). Binding of ligand receptor to 
NOTCH begins a series of proteolytic cleavage events, releasing the NICD into the cytosol 
whereupon it acts as a transcription factor (alongside RBPJ) for a number of canonical 
downstream genes such as the HES1 and HEY1 transcriptional repressors, MYC and CCND1 (248). 
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This maintains a dedifferentiated state and facilitates asymmetrical divisions through the 
polarisation of cell-cell contacts (249). 
 
FIGURE 9 – Molecular markers of prostate cancer stem cells.  
Combination of basal epithelial, stem cell, epithelial to mesenchymal transition and inflammatory 
proteins can be used to identify and isolate the cancer stem cells of prostate cancer.   
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The suspected inflammatory aetiology of prostate cancer may also have roots in the CSC pool. 
Microarray data distinguished a CSC expression signature with an enrichment in JAK-STAT 
signalling and NF-kB activation with involvement of IL-6 (66). IL-6 is highly expressed in prostate 
cancers and serum concentration of the cytokine becomes elevated in metastatic disease (250-
252). CSCs have also been shown to express high levels of IL-6 and its cognate receptor (IL-6R), 
reinforcing an autocrine signalling loop to promote JAK-STAT activation. Disruption of this 
pathway by STAT3 phosphorylation inhibitor LLL12 resulted in reduced CSC colony forming 
efficiency and viability as a result of differentiation (253). IL-6 positive feedback via NF-kB has also 
been shown to act as a transforming and cancer-sustaining event in a breast epithelial cell line, 
enhancing sphere forming ability and induction of a breast CSC phenotype (254). Activation of 
STAT3 signalling also affords prostate cancers an androgen independence mechanism in castrate-
disease, (255) and has been implicated in maintenance of glioblastoma stem cell self-renewal 
ability (256). The pervasive nature of the STAT3 pathway throughout prostate cancers has led to 
the development of phosphorylation (253, 255, 257) and DNA-binding inhibitors as future 
treatments of advanced disease (258)(Figure 9). 
As alluded to at the beginning of this section, both CSC and clonal evolution theories are likely to 
co-exist in cancers. For prostate cancer, the slow progression and almost inevitable relapse after 
hormone therapy can readily be attributed to the CSC pool, whilst the runaway nature of 
metastatic castrate disease looks to be a CSC-derived dominant clonal expansion of cells (259). 
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1.4 - Prostate Cancer Diagnosis 
1.4.1 - Prostate Specific Antigen Testing 
Screening and diagnosis of prostate cancer is currently centred upon serum levels of PSA, a serine 
protease that aids seminal fluid liquification. PSA in the blood is indicative of cancer, where higher 
levels correlate with more advanced disease (260). In disease, characteristic degradation of the 
basement membrane allows escape of this protein into the vasculature, (136) increasing 
circulating concentrations by up to 105 fold. The normal adult male blood concentration of PSA is 
~0.6ng/ml (261) and the threshold value for prostate cancer diagnosis has been set at 4ng/ml. The 
Prostate Cancer Prevention Trial required all 5519 participants in the placebo group to undergo 
prostate biopsy after PSA test and digital rectal exam (DRE). The trial found that a PSA value of 
>4ng/ml has a selectivity of 93% and sensitivity of 24% in correct prostate cancer diagnosis (136, 
262). PSA exists in the blood either as free PSA (fPSA) or more commonly, bound to protease 
inhibitors, as complexed PSA (cPSA). The availability of epitopes on fPSA allows the quantification 
of fPSA and thus cPSA, in coordination with the normal PSA test that measures total PSA levels 
(136). The percentage of fPSA seems to be a more specific diagnostic factor than total PSA levels; 
<25% fPSA has a reported 95% selectivity and 20% sensitivity for correct prostate cancer diagnosis 
(263). 
However, PSA testing, like many biomarker diagnostic tools, does have problems in which false 
positives are detected and true positives missed.  PSA is detectable in other tissues including the 
lungs and salivary glands, (264) other disease states such as prostatitis can elevate circulating 
levels (71) and some men with cancer have normal (<4ng/ml) PSA levels, all of which complicate 
diagnosis (262). 
Several other diagnostic alternatives to PSA have been developed. The next generation urinary 
biomarkers for prostate cancer are PCA3 and TMPRSS2-ERG (265, 266). PCA3 is a non-coding 
transcript that is overexpressed, relative to normal tissue, in nearly all prostate cancers. There is 
significant data which suggests that PCA3 is more selective for prostate cancers than the PSA test 
(265, 267). This biomarker can also be utilised in combination with urinary TMPRSS2-ERG RNA – 
an extremely selective prostate cancer transcript, to stratify patient disease (266, 268). Currently, 
rapid detection colorimetric tests have been developed for TMPRSS2-ERG breakpoints that would 
allow assessment of fusion status from a post-DRE urine sample in less than two hours (269).  
Another powerful diagnostic platform is the Stockholm-3 (STHLM3) model developed by 
researchers in the Swedish capital (270). The diagnosis of clinically relevant cancers is based upon 
several plasma protein biomarkers, a genetic profile of 232 single nucleotide polymorphisms 
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(SNPs) and clinical variables of the individual patients. With the same sensitivity for cancer 
detection as the standard 3ng/ml PSA test; STHLM3 could reduce total biopsies taken by half and 
the number of unnecessary biopsies taken of benign disease by 76% (271).The model has recently 
been improved for the Swedish male cohort by inclusion of further SNPs, specifically a HOXB13 
variant and the removal of intact PSA as a serum biomarker, to further reduce unnecessary 
biopsies (272). 
Multi-parametric magnetic resonance imaging (mpMRI) can be used to direct single biopsies of 
prostate cancer foci through combination of several imaging techniques. These include; T2-
weighted imaging which can distinguish between the four tissue zones of the prostate and has 
high signal intensity in the PZ that is disrupted by tumours, diffusion weighted MRI which 
measures water movement parameters in tissue, particularly its restriction in tumours, and 
dynamic contrast enhanced MRI, in which a contrast agent is used to map tissue and tumour 
vasculature (273). mpMRI has been shown through several large cohort studies to be extremely 
accurate in detecting clinically significant prostate cancers, is far superior to standard transrectal 
ultrasound (TRUS) -guided biopsy (that takes 10-12 tissue cores) and is able to stratify disease that 
requires treatment or active surveillance (274-276).  
1.4.2 - The Gleason Grading System 
Detection of high circulating levels of PSA in a patient is followed by multiple prostate tissue 
biopsies to allow for disease stratification by the Gleason grading system (277). This system, 
based on tissue pathology, was reported in 1966 by Donald Gleason and remains the greatest tool 
of prognostic value in prostate cancer (278) over PSA levels, biomarkers and genetic profiling 
(128). It works by establishing and rating relative tumour architectural patterns that are scored 1-
5; one representing normal acinar morphology and five being anaplastic sheets of 
undifferentiated tissue. The two most commonly observed grade patterns present in the 
individual’s sample are added together to give a final score between two and ten that is then 
assigned to the cancer (Figure 10A). 
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FIGURE 10 - The Gleason grading system. 
A) The Gleason grading system chart of tissue pathology – 1 shows normal prostate acini and 5 
anaplastic undifferentiated sheets of tissue observed in advanced prostate cancer. Figure taken 
from Epstein 2005 (279). B) Clonal model of Gleason progression – divergent clones “stem” the 
Gleason 3 and 4 tissues. C) Transitional model of Gleason progression – the Gleason 3 cell incurs a 
molecular change that permits progression to the more advanced Gleason 4 tissue.  
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The system was revised in 2005, and again in 2014 by the International Society of Urological 
Pathology, with changes to protocol and additions to classification including; inclusion of cribiform 
cancer as grade 4, the reporting of negligible secondary lower grade cancer, final grade decision in 
the presence of tertiary pattern high grade cancer and the consideration of the benign nature of 
Gleason 3 tissue (279-282). 
The major problem that faces diagnosis of localised prostate cancer is that no current biomarker 
can distinguish between indolent and aggressive disease. This is particularly important when a 
patient presents with intermediate Gleason grade cancer (6-7); immediate treatment could be 
life-saving if the cancer is aggressive but over-treatment of indolent cancer has serious 
implications on the patient’s quality of life (128). 
There is a notable molecular difference between pattern 3 and 4 tissues, whereas Gleason scores 
of 4 and 5 are indistinguishable in gene expression studies (283). Gleason 6 and 7 transcriptomic 
differences were used to construct a gene signature with the ability to separate these tissues. 
Interestingly, inclusion of the Gleason 6 tumours in total analysis (comparing cancer to BPH) 
removed any previously observed separation of benign and cancerous tissue (66). Another similar 
study couldn’t produce such a divisive expressional signature; however this may have been due to 
domination of any underlying gene changes by the majority luminal cell cDNA input of the 
microarray (123). 
Detectable differences between the two tissues bearing separate Gleason grades opens another 
question facing both clinicians and scientists; do Gleason tissue patterns share a common or 
divergent ancestral clone? Namely, does the Gleason 3 cell progress into a pattern 4 cell, the 
transitional model, or are there separate clones for Gleason 3 and 4+ tissues, the clonal model? 
The most obvious way to conduct this research is to perform repeat biopsy on patient prostates 
to track if there is any progression or if development is stemmed from separate cancer clones. 
However, this approach is hampered by several factors, including; the heterogeneity of prostate 
tissue, the common multi-focal presentation of cancer and the inherent sampling error of needle 
biopsies (284-286). 
Clonal Model of Gleason Scores 
The widespread use of PSA testing has allowed earlier detection of tumours, in the natural history 
of the individual’s cancer, than before clinical adaptation of the biomarker. If Gleason grade 
progressed over time, this would mean that earlier detection would have reduced the number of 
higher grade tumours observed at diagnosis. A large study of over 1200 patients found that this 
wasn’t the case and that incidence of Gleason 7+ tumours has not changed post-PSA testing (286). 
Another piece of evidence supporting the clonal theory is the fact that Gleason 6 (3+3) patterns 
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rarely advance to lethal disease (287, 288) whereas presence of secondary, or even tertiary 
Gleason 4 tissue predicts cancer progression (289)(Figure 10B). 
Transitional Model of Gleason Scores 
Supporting a transitional advancement of Gleason grading, is the positive correlation of Gleason 
grade magnitude with age of detection; older men are diagnosed with increasingly aberrant tissue 
architecture (286). There is also extremely compelling molecular evidence in favour of the 
transitional model. Upon tumour tissue isolation, adjacent Gleason 3 and 4 patterns were 
separated by laser capture microdissection. The tissues were then processed and sequenced. This 
identified that a small population of the Gleason 3 pattern had stemmed the Gleason 4 tissue due 
to shared lineage of unique chromothriptic and TMPRSS2-ERG breakpoints (290). Either the 
tumour had progressed transitionally, or a common progenitor (containing the trunk 
chromothripsis and fusion genomic alterations) produced both the linked 3 and 4 patterns (Figure 
10C). 
1.4.3 – Treatment of Low Grade Prostate Cancer 
Treatment strategies for prostate cancer are very much dependent on the stage of disease. Low 
Gleason grade cancers are still differentiated and may require a more conservative approach such 
as active surveillance. Over-detection of cancers by PSA testing has resulted in treatment of some 
patients that would never have progressed to a clinically troubling disease. Protocols have been 
put in place to mark cancer progression rather than treat first, ask questions later. This applies to 
low Gleason grade tumours with a combined score no greater than 6. PSA is measured every 3 
months and biopsies are repeated annually over a 2 year period to monitor tumour status (291). 
The surgical approach towards advanced local disease, radical prostatectomy, can prove an 
effective treatment before local invasion and metastasis have occurred. The benefits of this 
surgery were observed in a clinical trial of patients that had T0-T2 stage disease, a negative bone 
scan and PSA <50ng/ml. After 10 years of follow up, deaths due to prostate cancer in the watchful 
waiting cohort were up 5.3% and incidence of distant metastasis increased by 10.2% over that of 
the radical prostatectomy arm of the trial (292). 
Focal Treatments 
Other options for the treatment of localised prostate cancer are focal therapies. This may be 
preferable to radical surgery in cases where progression of the cancer is low-risk. The chief aim of 
these therapies is to maximise cancer cell death whilst simultaneously minimising damage to the 
surrounding tissues (293). 
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High-Intensity Focused Ultrasound (HIFU) causes intensification of ultrasonic waves, allowing high 
energies to be delivered into a localised area whilst leaving the tissue along its path-length 
unaffected. This heats the target tissue rapidly to 80OC; denaturing their cellular protein content 
and facilitating necrotic cell death (294). HIFU is applied trans-rectally and is monitored carefully 
to ensure that the tumour is targeted for the entirety of treatment duration. This issue has been 
aided by the recent advances in real-time magnetic resonance imaging (295)(Figure 11A). 
Cryotherapy allows for rapid freezing and thawing of tissue to result in localised cellular necrosis 
and cell death, again by protein denaturation. Treatment of the tumour with either liquid nitrogen 
or argon gas is administered by transperineal cryoprobes under direction of TRUS (296). Freezing 
of surrounding tissue is monitored using temperature sensors and a warming catheter is applied 
to the urethra to limit any adverse damage (297)(Figure 11C). 
Radiotherapy (RT) delivers targeted ionising radiation to the tumour to cause DNA damage. 
Damage can occur indirectly; through formation of reactive oxygen species (ROS) that attack the 
genetic material, or directly; by inducing single or double strand breaks of the phosphodiester 
backbone. Extensive DNA damage leads to cell cycle arrest and apoptosis. The most common RT 
applied to prostate cancers is external beam radiotherapy (EBRT), where 5-7 beams are targeted 
to the tumour mass core. EBRT has recently been improved through use of Cyberknife, a 
technology that monitors movement of the prostate during treatment and corrects radiation 
targeting (of 150-200 beams) so that the focal point of radiation remains within a 2mm target 
area (298, 299)(Figure 11E). Brachytherapy is a variation on traditional RT. Here trans-perineal 
placement of radioactive seeds such as 103Pd, 125I and 131Cs into the prostate itself allow for 
localised administration of an internal radioactive dose. Both TRUS and MRI are used to achieve 
optimal placement (300)(Figure 11D). 
Photo-Dynamic Therapy (PDT) produces extremely localised tissue damage through photo-
activation of a targeted drug molecule. Energy provided by the light source is transferred to 
oxygen molecules resulting in formation of single delta oxygen (SDO). SDO creates a hypoxic 
environment surrounding the tumour and also cause apoptosis/necrosis of the cancer cells (301). 
Trans-perineal and trans-urethral insertions of fibres for photo-activation have been used in PDT 
treatment of prostate cancer (302)(Figure 11B). Recently, a Phase III clinical trial targeting low-
grade prostate cancers found PDT to be advantageous over active surveillance (303). 
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FIGURE 11 – Focal therapies of prostate cancer. 
A) High intensity focused ultrasound – heats cells to cause necrosis. B) Photodynamic therapy – 
activates targeted drug molecules using light to cause specific cancer cell death. C) Cryotherapy – 
rapidly freezes tissues to cause cell death by necrosis. D) Brachytherapy – planting of radioactive 
“seeds” in the prostate tumour to exert killing effect. E) Radiotherapy – targeted ionising radiation 
that causes extensive DNA damage and cell death F) Low Temperature Plasma – ionised gas 
injection that facilitates massive oxidative stress and cell death by necrosis and apoptosis. This 
focal therapy has not yet been tested in patients.  
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Pre-clinical studies in our laboratory have shown that application of Low Temperature Plasma 
(LTP) is also effective at killing primary prostate epithelial cells (304). Plasma is formed by the 
stripping of electrons from gas molecules, achieved by application of a high voltage across an 
oxygen-helium admixture. The background gases form the dominating species yet the accelerated 
free electrons drive a unique reactive environment that produces interconverting reactive oxygen 
and nitrogen species (RNS), UV radiation and charged particles (293). LTP treatment of primary 
prostate tumour cultures found that plasma reduced cell viability and induced DNA damage, 
leading to cellular necrosis (304, 305)(Figure 11F). Elucidating the mechanisms behind the killing 
effects of LTPs on tissues, considerations of safety, practical means of applying the plasma to the 
tumour site and the establishment an of optimal dose for individual patient treatments are all 
required before the devices can be implemented in a clinical setting. The full extent of LTP use as 
a potential anti-cancer strategy will be discussed further in Section 1.9.  
1.4.4 - Treatment of Advanced Prostate Cancer 
Cancers of higher Gleason grade have a less differentiated appearance, and this breakdown of the 
normal prostate structure hints at the invasive and metastatic potential of the cancer. In this 
event, the treatment is ADT. These therapies target the androgen signalling axis upon which the 
majority of prostate cancer cells are dependent (Figure 12). 
Androgens are produced mainly in the testes, where expression of testosterone is stimulated by 
luteinising hormone (LH). LH itself is released from the pituitary in response to hypothalamic 
luteinising-hormone releasing hormone (LHRH). Pharmacological castration can be achieved 
through use of LHRH antagonists such as Zoladex, which circumvents androgen production 
through restriction of circulating LH (306). 
Serum testosterone is further processed in prostate cells by the enzyme; 5α-reductase, into the 
more potent metabolite dihydrotestosterone (DHT) that directly binds AR. Inhibitors of 5α-
reductase testosterone metabolism such as finasteride (262) and dutasteride (307) are known to 
decrease intraprostatic DHT levels and subsequently reduce androgen signalling in the organ. 
ADT can also directly target AR through anti-androgens (molecules that act as AR antagonists). 
The anti-androgens hydroxyflutamide (308) and bicalutamide (309, 310) initially have similar 
efficacies to surgical castration (orchiectomy), showing the specificity these inhibitors have for AR 
upon first exposure. However, development of resistance to these drugs has prompted the 
production of second generation molecules.  
One such molecule, enzalutamide binds almost irreversibly to AR, reducing its ligand-dependent 
nuclear translocation and the receptor’s ability to bind androgen response elements to recruit 
coactivators and stimulate transcription (311). A phase 3 clinical trial observed that enzalutamide 
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increased survival in post-chemotherapy CRPC patients by 5.4 months over that of the placebo 
group. No direct comparisons with previously used anti-androgens were made, however 
enzalutamide extended median overall survival by 4.8 months (312). Androgens are produced in 
the testes, adrenal glands and, in some cases, the prostate by intra-tumoural expression of the 
CYP17 enzyme. Abiraterone is a selective inhibitor of CYP17 and blocks testosterone synthesis. 
The drug performed similarly to enzalutamide in post-chemotherapy CRPC patients, improving 
their overall survival by 3.9 months (313). These drugs represent the current forefront of prostate 
cancer treatment. Although a modest extension of expected lifespan is granted to these patients 
(312, 313) underlying tumoural resistance at the molecular level arises; with discovery of AR 
splice-variant (AR-V) upregulation (314, 315) and novel AR mutations in relapsed patients (316, 
317) which allow for promiscuous activation of AR, that can now bind hormones other than 
androgens (318). 
Cytotoxic therapies used in prostate cancer are palliative as they are restricted to the inevitably 
fatal metastatic patient cohort. The main chemotherapeutic agent used is docetaxel (319) which 
is utilised in a wide range of combination therapies (26). The drug has obvious toxicities as a 
microtubule stabiliser, yet resistance has developed through involvement of several proteins such 
as STAT1, (320) PIM-1 (321) and ABCB1 (322). 
Both ADT and chemotherapy assume that the tumour is a mass of homogenous cells that are 
respectively androgen-dependent and mitotically cycling. In this scenario the heterogeneity 
evident in prostate tumours is unaccounted for. This oversight is particularly relevant to the 
prostate CSC population, as they don’t express AR and are quiescent or at least extremely slow-
cycling. These cells have already been shown to be radio-resistant, (323) with other solid tumour 
CSCs noted to possess an efficient DNA damage response, (324) high levels of detoxifying 
enzymes (200) and drug efflux transporters, (325) making them extremely resilient targets (19). 
The most efficient possibility of targeting the CSC population is through use of differentiation 
therapies, discussed earlier in Section 1.3. In the case of prostate cancer this would deplete the 
stem cell pool through eventual production of more differentiated luminal cells that are then 
susceptible to ADT. Such differentiation therapies have been observed to work in gliobastoma 
(326), breast cancer (68, 327) and leukaemia (328). 
The targeting of the secretory luminal cells in prostate cancer by the ADT regimen is thought to 
select for the more advanced CRPC phenotype. This disease stage is irreconcilable and leads, 
eventually, to patient death. 
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FIGURE 12 – Androgen Deprivation Therapy 
The pharmacological targeting of the androgen axis in prostate cancer. The prevention of 
Luteinising Hormone Releasing Hormone (LHRH) stimulating Luteinising Hormone (LH) induced 
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production of testosterone in the testes, and the intraprostatic processing of testosterone to 
Dihydrotestosterone (DHT) by 5-alpha Reductase (5-αR), alongside antagonising DHT binding to 
the ligand binding domain (LBD) of AR all minimise the pro-proliferative effects of androgens on 
prostate cancers. 
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1.5 – The Genetic Background of Primary Prostate Cancer 
Current targeted treatments of prostate cancer focus on the androgen-axis, in part due to the 
work of Huggins (329) and the importance of AR in prostate development,(7) but also as relatively 
few other targetable defects have been identified through genetic studies. The profound 
heterogeneity between patient’s prognoses and corresponding genetic profiles of tumours has 
hampered progress (330, 331). Recent studies have attempted to define genetic subtypes that 
could be used to profile; cancer indolence/aggressiveness, Gleason scores and, in advanced 
cancers, separation of CRPC and neuroendocrine prostate cancer (NEPC) (27, 66, 283, 332, 333). 
The ultimate aim is to offer accurate prognosis to individual patients based on the genetic make-
up of their cancer. 
Prostate cancers differ from most solid tumours, as they rely almost entirely upon copy number 
variations, rather than specific mutation, to facilitate cellular transformation and disease 
progression (90, 133, 174, 175, 334, 335). With tumours of so-called “hypermutator” phenotype, 
regularly observed in primary cancers of other tissues, only presenting following advanced 
treatment (336, 337). Scrambling of the prostate cancer genome is achieved by chromoplexy; 
chained rearrangement events that are notably convergent between individual patient tumours. 
Temporally, it isn’t known when these patterned translocations and deletions occur in a cancer’s 
natural history. Due to clonality of founder or “trunk” events (fusion of TMPRSS2-ERG and NKX3.1 
deletion) and sub-clonality of further common genetic aberrations (PTEN and CDKN1B deletions) 
chromoplexy is presumably a staged event that occurs over a long time. Deletions of RB1 and 
TP53 are also linked to chromoplectic chains, yet only present in advanced prostate cancers (334, 
338). It is thought that defective DNA repair machinery, a common defect in prostate tumours, 
aids the chromoplectic re-shuffling of the genome. It is relevant that hallmark chromoplectic 
deletions and fusions are present in the prostate CSCs (66, 246, 247). 
As a hallmark of cancer, (148) genomic instability can both predispose and accelerate 
tumourigenesis, becoming particularly relevant to prostate cancer, in the light of common mass 
genomic rearrangement. Instability afforded by the reduction of telomere lengths and aberrations 
to DNA maintenance and damage response pathways in prostate cancer contribute towards a less 
favourable prognosis (339). 
Prostate cancer frequently presents with attenuated DNA damage response and repair networks 
(338, 340)(Figure 13). Studies of both familial and sporadic disease have identified predisposing 
genetic alterations in these pathways.  The well-known BRCA1 and 2 mutations most commonly 
associated with ovarian and breast cancers, also heighten risk of prostate cancer development in 
men (341, 342). Families with hereditary prostate cancer show an enrichment of Chk2 mutations; 
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with the defective enzyme unable to cause G1 arrest and prevent the accumulation of genetic 
aberration, upon detection of DNA damage (343). Risk alleles for DNA repair genes PARP1, ATM 
and XRCC1 have been identified by multiple independent population studies (344). Whilst these 
mutations and variants do increase risk of developing cancer, they typically present in less than 
5% of the total population. Observation of further recurrent ATM and p53 mutations in advanced 
prostate tumours show that DNA damage response is an important signalling axis in the initiation 
and progression of prostate cancers (27). These defects mainly affect the homologous 
recombination repair (HRR) pathway making prostate cancer cells more reliant on the error prone 
non-homologous end joining (NHEJ) pathway to fix double strand breaks (DSBs); a situation that 
lends itself to the production of chromoplexy. (Figure 13) 
FIGURE 13 – Defective DNA damage repair response in prostate cancer. 
The genes of all proteins depicted in the diagram are recurrently mutated or deleted in prostate 
tumours. Arrows depict phosphorylation (P) events that activate the recipient protein.  
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Replicative stress triggered by runaway oncogene activation also contributes towards genomic 
instability. In the prostate, ungated activation of AKT and the PI3K pathway; due to catalytic 
subunit mutations of PI3K (90, 133) and the more common PTEN deletion, (345) alongside 
proliferative signals supplied by dysregulated MYC increase the mitotic index and thus replicative 
stress of affected cells (346). AKT can promote the NHEJ DNA repair pathway, creating an 
environment more favourable for chromoplectic rearrangements (340). AR also has a role in DNA 
damage response as the nuclear receptor relies upon PARP1 to enforce its basal transcriptional 
program (347). Upon DNA damage; AR stimulates upregulation of DNA-PKCS, XRCC2 and XRCC3, 
proteins that have a role in the DSB repair pathways of homologous recombination repair and 
NHEJ (348). 
Tumours of the prostate that present with a mutator phenotype are attributed to genomic 
rearrangement and mutation of the mismatch repair pathway enzymes, specifically MSH2 and 
MSH6 (90, 133, 336, 337). Current evidence suggests that genetic insult to these enzymes, and 
thus tumour hypermutation, is created by the genotoxicity of cancer treatments. Therefore this 
phenotype is observed more prevalently in advanced disease; however mutation of MSH6 has 
been identified in primary prostate cancer (133, 337). 
Linkage studies relating ETS+ tumours to DNA repair gene variants have identified risk alleles 
encoding ESCO1, POLI1 and BRCA2 that form a genetic background inductive of fusion formation 
(349). In a culture environment of genotoxic stress, and a lineage-dependent manner; prostate 
cells form de novo TMPRSS2-ERG fusions, an event attributable to AR-mediated transcriptional 
proximity of involved loci (350). 
Distinct molecular subtypes of prostate cancer have now been assigned to tumours due to the 
frequent identification of genomic changes, in both primary and metastatic disease (334, 
335)(Figure 14). One classification paradigm is the ETS factor fusion status of the tumour. Now 
commonly and recurrently observed, ERG and ETV1 fusion events were discovered as prostate 
cancer specific aberrations in 2005 (351) and the TMPRSS2-ERG fusion has now been established 
by many large population cohort studies to occur in half of all primary tumours (90, 330, 331, 
334). These fusion positive tumours often have linked chromoplectic deletions of PTEN, TP53 and 
3p14 (a locus encompassing several tumour suppressor genes) (90, 133, 334). A divergent 
subclass of prostate tumours are those that harbour CHD1 deletions (133, 352). CHD1 is an ATP-
dependent chromatin remodelling factor that facilitates availability of transcriptionally active 
chromatin. CHD1 deletion is often mutually exclusive of ETS fusions, as loss of the remodelling 
protein results in an increase in condensed chromatin. The open chromatin structure usually 
observed at the fusion loci therefore no longer forms – meaning that there is a reduced chance of 
damage, inappropriate repair and thus fusion formation (353). SPOP mutation, the most 
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frequently observed mutation in primary cancers, (133, 330) co-segregates with CHD1 deletions 
to give an ETS- CHD1- SPOP- subclass. Through combining prostate cancer transcriptomes with 
matched genome data, detailed signatures can be used to stratify prostate tumours on prognosis 
and outcome using this advanced molecular data (90, 331, 338, 354, 355). 
The genetic heterogeneity of primary prostate cancer was highlighted by a study conducted by 
the Cancer Genome Atlas (TCGA) which extensively mapped over 300 primary prostate cancers 
and, using the comprehensive information gained by several sequencing platforms, was unable to 
group one in four of the tumours into a molecular signature. This genetic heterogeneity in the 
initial stages of localised cancer will impact the response to treatment of these tumours as well as 
their progression into more advanced and castrate disease (330). Another recent multi-centre 
sequencing study of prostate cancers identified novel coding and non-coding driving events in 
primary tumours that had remained undetected in previous datasets and their subsequent 
analysis (338). This highlights that there are still important molecular alterations which remain to 
be uncovered, aberrations that may play pivotal roles in the initiation and progression of select 
sub-groups of prostate cancer. 
FIGURE 14 – Common genetic alterations in primary and castrate resistant prostate cancer.  
Graph compiled using data from Taylor 2010 (90), Robinson 2015 (331) and TCGA 2015 (330). The 
scale represents the percentage of the sequencing cohort with genetic aberration in the labelled 
gene. 
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1.6 - Castrate Resistant Prostate Cancer (CRPC) 
1.6.1 - Androgen signalling in end-stage disease 
The first line of chemotherapy for advanced prostate cancer is ADT, which is achieved by chemical 
ablation of the androgen axis as discussed in Section 1.4. Specific targeting of the AR by anti-
androgens leads to the clonal expansion of cells that have AR aberrations. These cells can function 
in extremely low levels of androgen through dysregulation of the androgen signalling axis.  
Before the CRPC terminology, this end-stage of disease was referred to as androgen independent 
prostate cancer as the pharmaceutically imposed androgen blockade was thought to have 
nullified AR signalling. However in castrate conditions, tumours and metastases have been 
identified to possess residual, and augmented, androgen signalling. Here the cancer switches from 
androgen-dependent stromal paracrine signalling to a more autocrine pattern (356). The most 
common genetic alterations specific to CRPC, found in 50-60% of patients, are those that 
influence AR signalling and the receptor itself (331, 357, 358)(Figure 15). This is likely due to 
treatment-mediated selection of cellular subpopulations in which AR alteration confers survival 
advantages in castrate levels of androgen. Hormone naïve cancers rarely exhibit any detectable 
AR changes apart from a few exceptions, suggesting that the aggressive latter stage of disease 
may be induced by ADT (359, 360). Overexpression (361) (via possible autoregulation (362)) and 
transcription factor dysregulation (363-365), locus amplification (366, 367) and mutations that 
reduce ligand-specificity (368-373) of the receptor all manifest in CRPC tumours. A similar effect is 
seen in methotrexate resistance, where amplification or overexpression of dihydrofolate 
reductase is frequently observed in leukaemia (374). 
A recent study investigating patient-matched metastatic and non-metastatic tumours observed 
that AR amplification and mutation were; mutually exclusive, and absent in hormone-naïve 
cancers (27). It is now widely accepted that ADT profoundly alters prostate cancer genomes and 
transcriptomes (375). AR promotes a divergent transcriptional program in CRPC, to that of the 
nuclear receptor in localised disease, supporting cellular survival in castrate conditions (376). Thus 
AR maintains a role in the development of CRPC. 
Another ADT-circumvention mechanism upon which CRPC relies is the constituent action of AR 
splice variants (or AR-V). These divergent transcripts are created through aberrant splicing of 
cryptic exons early in the AR gene (377-380). The majority of the variants also exhibit absence of 
latter exons encoding the nuclear receptors’ hinge region and ligand-binding domain (LBD) (381) 
that allow for degradation (382) and activation of the receptor respectively. AR-Vs show 
constitutive nuclear localisation, that is not reliant upon canonical importation pathways (383, 
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384) and are able to activate transcription of the full-length AR gene portfolio independently of 
androgen binding, ablation therapy and indeed presence of the full-length transcript (315, 378, 
383, 384). 
FIGURE 15 – Androgen Receptor aberration in CRPC 
AR changes through splice variation, ligand binding domain mutation, overexpression and 
amplification in advanced castrate disease. Mutational plot highlighting clustering of LBD 
mutations was adapted from COSMIC website (385).  
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Variants activate gene transcription networks divergent from those of full-length AR such as 
STAT3, AP-1/Jun (384) and AKT (378). However not all studies are in agreement with this altered 
profile (315). As most anti-androgens including bicalutamide and next generation treatments such 
as enzalutamide target the LBD of AR (315), AR-Vs are not susceptibility to these therapies. 
Instead this innately conferred resistance allows the variants to proceed unaffected; directing the 
independent growth of cancer cells. They are observed to be upregulated and selected in castrate 
conditions both in culture (315, 381) and in tumours (378, 379). However, there is opposition to 
these findings that state the variants rely on full-length AR for effect, and this renders them 
sensitive to enzalutamide (381). In benign prostate tissues, presence of the splice variants in 
stromal and basal populations, but not in the luminal epithelia, may contribute towards the 
androgen independent growth of these cells (378). It is still unknown whether the epigenetic 
changes resulting in AR-V production are a driver of late stage disease or an adaptive change. 
Most studies interrogating the molecular workings of CRPC focus on AR. Whilst the nuclear 
receptor is an important driver, it does not completely account for the “efficacy” of end-stage 
disease. Indeed, recent studies have shown that small cellular populations of AR- neuroendocrine 
and AR independent basal cells are left untouched by hormonal treatment (241). Currently it is 
unknown whether CRPC is a natural progression of prostate cancer or if it is selected by ADT. 
Supporting evidence for CRPC as an inevitable stage of disease include; 10-20% patients have no 
biochemical response to ADT (386) and the identification of AR alterations prior to treatment 
(387). Castration selecting for CRPC has been suggested in the sudden appearance of androgen 
signalling defects in tumours and in studies in mice models (388). This selection could 
hypothetically be of a luminal cell that has already acquired therapy resistance attributes and/or 
of an androgen independent basal TIC.  
1.6.2 - Involvement of Basal Cancer Stem Cells in Metastatic disease 
Selection of the CSC pool is entirely plausible, as they are therapy resistant and would expand in 
response to the castration-induced apoptosis and growth arrest of the secretory luminal epithelia 
(232). Androgen-independent cells (existing at low frequencies; 1 in 105-106 cells) in a prostate 
cancer xenograft were able to re-initiate tumour growth by clonal expansion (389). These cells, 
although uncharacterised, were very probably the CSC population. 
In the recent generation of organoid cell lines which accurately represent metastatic prostate 
cancer, one of these models PCa6 presented with cytokeratin 5 and p63 expression and a genetic 
background of PTEN deletion and MLL2 mutation suggesting a metastatic outgrowth of basal cell 
origin (241). This is supported by another study which developed a comprehensive and congruent 
expression profile between primary basal stem cells and advanced neuroendocrine metastatic 
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cancer datasets from multiple studies – suggesting that the progenitors may be at the root of 
advanced disease (390). 
Dysregulation of micro RNAs (miRNAs), key post-transcriptional regulatory molecules dictating 
gene expression, in prostate cancer has been recognised for almost a decade (391-394) with 
implication of specific miRNA networks in castrate resistance (395-398). It has recently been 
shown that the miRNA profile of prostate CSCs is conserved between different disorders and 
tumour grades suggesting that miRNAs are critical in stem cell maintenance throughout disease 
progression. Forced expression of miR-548c-3p, upregulated in the progenitor population, 
reverted the CB cells to a more stem-like state, both phenotypically and functionally. 
Interestingly, the prostate CSC miRNA expression profile is closest to that of unfractionated CRPC 
cells (399) with the signature confirmed by other studies that noted miR-548c-3p elevation in 
advanced prostate cancers (400) and the overlap of EMT/CSC miRNA expression networks (401). 
CRPC is predominantly viewed as a progression of disease, yet a dedifferentiation phenotype is 
becoming more apparent. Whether this is an acquired plasticity of malignant cells or an expansion 
of the CSC pool is yet to be determined. There also exists the possibility that a subset of CSCs is 
more metastatic than others amongst the tumour initiating population, like that observed in 
pancreatic cancers (402). The reappearance of prostate CSC markers and molecular subtypes in 
advanced disease will hopefully be incorporated into the development of treatments which 
consider the difficulty of killing malignant stem cells. 
1.6.3 - Neuroendocrine Prostate Cancer 
The castrate levels of androgens also permit emergence of a distinct tumour phenotype. 
Anaplastic or NEPC is often seen focally in advanced prostate cancer and represents a truly 
androgen-independent form of disease as these cells do not express AR (27). NEPC correlates with 
a more aggressive clinical onset, progressing to death <6 months post-diagnosis (403-405). It is 
thought that neuroendocrine cell differentiation may be occurring during CRPC; thus cases of 
NEPC may benefit from docetaxel and carboplatin combination chemotherapy that would have 
obvious toxicity on the dividing cells (26). 
Neuroendocrine cells are found primarily in the PZ of the organ, scattered throughout the basal 
epithelium. They are terminally differentiated, canonically lack AR, release mitogenic compounds, 
and are classically identified through staining for chromogranin A (404). The functions of this cell 
type are unclear but it is thought that neuroendocrine cells assist prostate epithelial 
differentiation through secreted factors and may possibly affect the constitution of seminal fluid 
(396). Inflammatory stimuli also play a role in neuroendocrine differentiation; cooperativity 
between IL-6 and STAT3, like that reported in CSCs, has also been shown to cause neuroendocrine 
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differentiation in prostate cancer cell lines (406). Recent sequencing of cancers with 
neuroendocrine features identified upregulation of EZH2 and co-amplification of N-Myc and 
Aurora kinase. Molecular hallmarks that distinguish this disease stage over primary epithelial 
tumours (26). 
Neuroendocrine prostate cancer has clonal origins in prostatic adenocarcinoma as shown by a 
study investigating p53 mutation (407), a finding which is corroborated by exome sequencing 
efforts to disseminate the heterogeneity of advanced cancer. Postulation that the neuroendocrine 
phenotype may arise through divergent clonal evolution from the original adenocarcinoma 
following hormonal treatment rather than a linear progression into androgen independence (333, 
375) suggests that either an aberrant differentiation pathway or trans-differentiation may be 
promoted in castrate conditions. 
1.6.4 - Genetic heterogeneity in Castrate Resistant Prostate Cancer 
Considerable effort has been made to map the specific genomic landscape of CRPC (27, 335, 408-
410). Recurrent fusion of TMPRSS2-ERG, deletion of PTEN, NKX3.1 and BRCA2 with amplification 
of Myc are inherited from earlier stage tumours (27, 133, 174, 334, 335). Post-ADT tumours have 
additional AR mutation and amplification (not observed in hormone-naïve cancers), but also 
increased p53 mutation, RB1 loss and defects in DNA damage repair and response enzymes (27, 
335, 408, 409). SPOP mutation, although present, (27, 155, 331, 411) is not seen at the same level 
as observed in primary tumours, (133, 174) with mutation percentage dropping below 10% in 
advanced disease (330). 
Pathway analysis of CRPC also identified similar defects to these found in primary cancer, such as 
disruption of the PI3K signalling network, (90, 174, 335, 409), deregulation of ETS factors,(123, 
334, 335, 351) and AR cofactors including; NCOA2 (90, 409) and FOXA1 (334, 335). The Wnt/β-
catenin pathway is selectively activated in CRPC tissues over hormone-naïve cancers and is linked 
to a dedifferentiated phenotype in these castrate conditions (410). The Wnt and Glucocorticoid 
Receptor (GR) pathways are mutually exclusive in circulating tumour cell (CTC) subsets, suggesting 
that variant androgen-independence mechanisms develop side-by-side in metastatic cancers 
(411, 412). The shift in hormonal synthesis under low androgen conditions also creates an 
environment that selects for promiscuous AR mutant clones which can be activated by 
glucocorticoids (413). WNT5A, upregulated in CRPC, has also been shown to confer heightened 
cancer cell resistance to the anti-androgen enzalutamide (412) showing that these pathways not 
only allow more effective growth of cancer cells but also protect them from cell death. 
As discussed above, treatment of CRPC is palliative as no current drug combination can dissect the 
genetic heterogeneity of metastatic disease (reviewed in (414)). Heterogeneity regarding cell-
70 
 
type has again not been addressed to a sufficient level in these studies as most sequencing efforts 
employ, at best, epithelial cell mixtures from tissue microdissections or needle biopsies which also 
contain stromal and haematopoietic cells. However, the improved depth of sequencing does 
allow for visualisation of clonality – especially in metastatic polyclonal abundance (411, 412, 415). 
The mutation rate in non mutator phenotype tumours (331, 335-337) is very low in CRPC 
tumours, suggesting a non-obvious inductive aetiology. 
Alterations found in DNA repair and response genes are found in 20% of CRPCs. Loss of BRCA2, 
which also exhibits germline predisposition of prostate cancer, becomes apparent in castrate 
resistant over treatment naïve cancers (331). 
Targeting the androgen axis has proven to be effective in the short term, yet as resistance 
continually develops in response to next generation therapeutics, novel treatments that act upon 
other actionable defects in end-stage disease are required. Currently, the most promising among 
these is PARP inhibition (416-418). This utilises the defective DNA damage response and repair 
pathways against the cancer, and kills cells due to synthetic lethality. Synthetic lethality is where 
one mutational event has no effect as a variant bypass pathway can rescue the damage but a 
secondary event in (or inhibition of) said salvage pathway becomes lethal for the cell (340). 
PARP is involved in the repair of single-strand breaks with inhibition proving lethal to cells that 
have DSB processing defects – a common phenotype in advanced prostate cancer with recurrent 
identification of loss of or mutation to BRCA2 and ATM genes (331). Several studies have 
highlighted the potential of PARP inhibitors in cancer (416, 418). These insights have produced 
the TOPARP clinical trial of olaparib in prostate cancer patients which has confirmed the predicted 
enhanced response in patients that present with disrupted DNA response and repair (417). 
Aside from sequencing efforts to gain insight into how prostate cancer genomes are rearranged, 
studies have also identified dysregulation of multiple chromatin modifying enzymes that further 
impact upon the epigenetic state of tumours in advanced disease. These include alterations to the 
histone methyltransferases (HMTs) ; EZH2, (90, 123) MLL2, SMYD, (335) and demethylases; 
JMJD3, (419) KDM4C (420) and JARID1B to name a few. The epigenome of prostate cancer and 
indeed the significance of the alterations to both DNA and histones in the initiation, progression 
and prognosis of disease is only just beginning to be uncovered (421-423). 
1.6.5 - Prostate Cancer Invasion and Metastasis 
Metastasis is the process in which the primary cancer spreads to anatomically-distant secondary 
sites utilising body cavities or the circulatory and lymphatic systems. In prostate cancer, patient 
metastasis represents a terminal diagnosis. Only ~5% of patients initially present with metastases 
yet this percentage rises to 40% after treatment (26). Like other cancers, prostate metastases 
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have particular secondary tissue tropisms; - 90% of patients have bone metastases upon autopsy, 
highlighting the extreme bone tropism of prostate CTCs. Other common metastatic sites are the 
lungs (46%), liver (25%), pleural cavity (21%) and adrenal glands (13%) (424)(Figure 16A). 
The metastatic cascade is a series of steps that cancers must pass through to establish and form 
“successful” secondary cancers throughout the body, outlined in (Figure 16B).This process is 
extraordinarily inefficient, with estimates that fewer than 0.01% of CTCs actually form 
macrometastases (425). Certain steps such as final metastatic colonisation of the foreign tissue 
also have higher attrition rates than others (426). Most metastases have a clonal route from one 
locally confined cancer focus, showing a selection process of “successful” cancers. 
1. Local Invasion  
Breakdown of the BM by secreted proteases, such as matrix metallo-proteinases (MMPs), 
(427) releases extracellular matrix GF ligands that enhance an invasive phenotype. 
Destruction of the BM affords greater access to the reactive stroma that further 
contribute to invasion through heterotypic signalling (14). Here, EMT plays a critical role. 
Reduced E-cadherin expression through miRNA and transcription factor interplay causes 
dissolution of epithelial structures and allows cells to collectively invade local tissue. At 
the cellular level two distinct invasive programs have been identified; mesenchymal 
(protease, stress fibre and integrin dependent) and amoeboid (Rho/ROCK signalling 
dependent). Plasticity exists between these two states to optimise invasiveness in 
different microenvironments (164, 428). 
2. Intravasation  
Intravasation is the process by which tumour cells access the vasculature or lymph. The 
main route of metastasis is through the circulatory system with acquisition of traits that 
allow passage through the pericyte and endothelial cell layers which surround blood 
vessels. The vessels stimulated to grow within tumours however aren’t “normal”. 
Angiogenesis initiated by the hypoxic microenvironment creates an irregular neo-
vasculature. These vessels have incomplete pericyte coverage and are also prone to leaks 
due to weak endothelial cell interactions, both of which make intravasation a much easier 
process (429). 
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FIGURE 16 – Metastatic cascade of prostate cancer 
A) Common secondary sites for metastatic prostate cancer colonisation. B) The metastatic 
cascade of prostate cancer; 1. Invasion, 2. Intravasation, 3. Circulation, 4. Secondary site arrest, 5. 
Extravasation, 6. Survival in secondary site microenvironment, 7. Secondary site colonisation  
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3. Circulatory Survival 
CTCs are spread via venous and arterial blood flow to distant secondary sites. PSA 
expression has been used to detect prostate cancer CTCs in the peripheral circulation 
(430). CTC number has also been used in prognosis of castrate resistant disease. 
Identification of >5 cells in 7.5ml of blood correlated with a 10 month reduction in overall 
survival (431). These circulating cells have been characterised, showing the presence of 
TMPRSS2-ERG fusions with heterogeneous AR amplification and PTEN loss (432). As a 
survival requirement, these cells must suppress anoikis (apoptosis provoked by loss of 
anchorage to the substratum) mechanisms, (433) and assuage other problems, such as 
immune surveillance and shearing forces within the blood vessels. Expression of certain 
cell surface molecules allows the CTCs to complex with platelets and form metastatic 
emboli. These bodies can thus evade both fates through the binding of other circulatory 
cells (434). 
4. Arrest at Secondary site 
Cancer cells have preferable adhesion sites, evident in their individual tissue tropism 
profiles. It is thought that this process is dependent on both the physical restrictions of 
CTC passage through micro-vessels and differential expression of cellular adhesion 
molecules that allow selective attachment in certain capillary beds (164). 
5. Extravasation  
Upon vascular arrest, the cells move by the process of extravasation through the vessel 
walls. Extravasation is an exceedingly more difficult proposition than intravasation as 
secondary site vasculature is healthy and is likely to be of low permeability. This does 
have exceptions such as at the fenestrated sinusoids of the liver and bone (435). 
6. Survival in the Secondary site microenvironment 
Initial survival at the secondary site is obviously critical for metastasis formation. To 
achieve this, cells must adapt to the variant microenvironment that is composed of 
different stromal cell constitution, ECM ligands, GFs, cytokines and tissue architecture. 
There is evidence of preparation of secondary sites as pre-metastatic niches, with the aim 
to reduce the differences between the distant tissue and the primary tumour. This is 
thought to be achieved through tissue remodelling instigated by secreted systemic factors 
from the original tumour and would also explain cases of tissue tropism (436). This 
challenge also shows that cells involved in establishing secondary site metastases cannot 
be terminally differentiated, as some plasticity must be retained. In prostate cancer it has 
been shown that the β1 integrin is involved in interactions with bone stroma that enhance 
survival and colonisation (437). This includes α2β1, a surface marker of prostate CSC and 
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TA cell populations, (28) citing possible involvement of these progenitor cells in seeding 
metastases. 
7. Secondary site colonisation  
Survival at the secondary site is no guarantee of “successful” metastases, as the cells can 
remain viable but may not be able to produce any net gain in numbers due to either; 
entry into a quiescent state or simply a balance between proliferative and apoptotic 
indices. Tissue-specific tropism has been observed in divergent metastatic gene-sets 
identified in breast cancer for bone, lung, brain and liver colonisation (164). Success in 
sustaining prolonged growth however depends on the self-renewal capabilities of the 
cells establishing the secondary site, again implicating CSC involvement. 
An interesting study followed a single patient from diagnosis to death, tracking the genetic trail of 
the complete metastatic cascade. Sequencing of the patient’s multi-focal primary cancer and 
biopsied/autopsied metastases revealed a monoclonal origin with acquired genetic changes 
throughout staged progression (155). This approach has previously identified clonal origin of 
metastases in primary pancreatic tumours, (438) and indeed reflects the intra-tumoural 
heterogeneity of the primary cancer itself (439). 
 
75 
 
1.7 - Prostate Cancer Models 
1.7.1 - Cell Lines and Primary Cultures 
Cell lines are the primary model of studying prostate cancer as a disease. They are able to be 
easily manipulated and transfected over repeated passages and can be grown in varying culture 
conditions. There are now well established lines representative of normal tissue, benign, 
malignant and metastatic forms of disease. These cells also range across basal and luminal 
phenotypes to give a more complete picture of disease, in which the appropriate mode can be 
chosen for further study (Table 2). 
Cell lines are useful models in preliminary studies of the disease yet do not accurately represent 
prostate cancer in vivo. Long term culture of cells has been shown to cause divergence from the 
original phenotype and genotype of the once physiologically relevant disease at initial isolation 
(440). This includes chromosomal alterations, changes in gene expression (441) and promoter 
hypermethylation (442). There have also been cases of misrepresentation; due to cell line cross-
contamination (443) or laboratory introduction of an infectious agent (444). Current problems 
facing prostate cancer cell lines are; the relatively low number of them (which have been made 
widely available), their failure to recapitulate all of the molecular phenotypes of disease and the 
lack of lines produced from a current disease state, with the majority of cells having been isolated 
from tissue over 20 years ago (Table 2). Culturing of primary cells, taken with patient approval, 
provides a better disease model. Primary cells still have slight changes imposed upon them by 
culture conditions yet afford a close and relevant model of patient disease when kept at a low 
passage (445). These prostate cancer primary cultures display relevant molecular defects 
including TMPRSS2-ERG (66, 246) and PTEN deletion (247). Primary culture is not without its 
practical limitations. Cells are often slow growing and in some instances patient tissue doesn’t 
propagate in culture at all. The restriction of keeping cells at low passage also means that the high 
cell numbers required for some molecular techniques, and readily achievable through growth of 
cell lines, cannot be reached using primary cultures. 
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Cell line 
Tissue 
Derivation 
Immortalisation 
Method 
Phenotype 
Stage of 
Disease 
Disease 
Features 
Derivation 
Reference 
PNT2-C2 
Primary 
epithelial 
culture 
SV40 large T and 
small t antigen 
Luminal Normal Express CK19 
Berthon 1995 
(446) 
PNT1-A 
Primary 
epithelial 
culture 
SV40 large T and 
small t antigen 
Luminal Normal 
Luminal CK 
Expression 
Cusenot 1991 
(447) 
BPH-1 
TURP primary 
epithelial cell 
culture 
SV40 large T 
antigen 
Intermediate Benign 
Luminal CK 
expression, AR-
, PSA-, PAP- 
Hayward 
1995 (448) 
P4E6 
Primary 
epithelial 
culture 
HPV-16 E6 gene Intermediate Malignant 
Luminal and 
basal CK 
expression, 
CD44+, β1+, AR- 
Maitland 
2001 (449) 
Du145 
Brain 
metastasis 
/ Basal Metastatic 
Androgen 
insensitive 
Stone 1978 
(450) PTEN 
Heterozygous 
Deletion (451) 
PC3 
Bone 
metastasis 
/ Basal Metastatic 
Androgen 
insensitive 
Kaighn 1979 
(452) PTEN 
Homozygous 
deletion (453) 
22Rv1 
CWR22 
xenograft 
/ Luminal Metastatic 
Contains AR 
splice variants 
(454) 
Sramkoski 
1999 (455) 
LNCaP 
Lymph node 
metastasis 
/ Luminal Metastatic 
Mutant AR 
(456) 
Horoszewicz 
1980 (457) 
TMPRSS2-ETV1 
fusion (351) 
PTEN 
frameshift 
(453) 
VCaP 
Bone 
metastasis 
/ Luminal Metastatic 
TMPRSS2-ERG+ 
(458) 
Korenchuk 
2001 (459) 
TABLE 2 – Prostate cell lines 
Derivation, phenotype and molecular features of prostate epithelial cell lines.   
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Four years after characterisation of prostate epithelial stem cells in 2001, (41, 50) the same 
surface markers of CD44+ α2β1hi CD133+ were used to isolate the tumourigenic fraction from 
prostate cancers of varying Gleason grades. The selected population constituted ~0.1% of total 
tumour cells, exhibited self-renewal with high secondary colony forming efficiency, displayed 
enhanced proliferative potential over that of non-malignant prostate epithelial stem cells and 
were also extremely invasive (28). Selection of the tumour subpopulations is described in further 
detail in Figure 17 (50). 
There is also another problem that the current, and limited, repertoire of prostate cell lines 
doesn’t fully address; the genetic background of disease for both primary and advanced cancers. 
The metastatic cell lines, as indicated in Table 2, do have some common features of disease such 
as PTEN deletion, AR mutation and ETS factor fusions yet other subtypes of disease such as SPOP 
mutation, CHD1 deletion and SPINK1 overexpression aren’t represented (460). A study in 2014 
attempted to expand this cohort of lines by successfully generating seven fully-characterised 
organoid cultures (241). These cultures encapsulate the molecular phenotypes listed above as 
well as harbouring other common genetic alterations seen in advanced disease such as RB1 loss 
and TP53 mutation (335). These representative and more relevant models can hopefully be more 
widely distributed, to facilitate discovery of treatment strategies and further current 
understanding of the molecular underpinnings governing advanced prostate cancers. 
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FIGURE 17 - Generation of primary prostate epithelial cultures from tissue 
Tissue from patients is cultured using this process stream. Molecular markers can then be used to 
isolate individual cell populations from the heterogeneous epithelial cultures.  
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1.7.2 - Mouse Models; Xenograft and Transgenic lines 
For any theory or treatment option to be clinically accepted, results of in vitro studies must be 
validated in vivo. The greatest in vivo tool used in prostate cancer is the mouse. These are either 
generated as transgenic models or are recipients of human prostate cancer tissue xenografts 
(128). 
Studies using transgenic mice have been pivotal in uncovering the precise biology of many human 
diseases, however there are many anatomical differences between the prostates of mice and 
humans. Firstly, mouse prostate tissue atrophies with increasing age, a situation contrasted to the 
spontaneous neoplastic growth of both BPH and cancer in humans (461). Anatomical organisation 
also differs; the mouse organ comprises of four lobes surrounding the urethra whereas humans 
have an alobular prostate that envelopes the descending urethra (462). The glandular structure of 
the tissue is similarly divergent. Human acini are composed of distinct, yet contiguous, luminal 
and basal epithelial layers in comparison to the single mixed layer of epithelial cells of the mouse 
prostate (463)(Figure 18B).Tumours do not naturally initiate in the mouse prostate, meaning that 
any parallels drawn between cancer in the mouse to that in the human have to be carefully 
considered. The very act of promoting a non-naturally occurring scenario on a model system will 
produce artefacts, some of which may be open to misinterpretation. 
Since mice do not spontaneously develop prostate cancer, transgenic models have been 
generated to mimic disease development. The two classic transgenic lines are TRAMP and Lady, 
with other more specialised models subsequently generated to investigate gain or loss of specific 
proteins. Such mice include PTEN+/-, TMPRSS2-ERG+ and TMPRSS2-ERG+/PTEN+/- mice that have 
given useful insights into the process of carcinogenesis (464, 465)(Figure 18A). 
Xenografts can be established from cell lines or primary human tissue. Cell line xenografts have 
major limitations as they do not recapitulate the heterogeneity of prostate cancer. As previously 
mentioned, these cells have genetic and phenotypic changes induced by culture that aren’t 
representative of tumours. Grafting of human tissue provides a better model of true cancer yet 
proves even more challenging than primary tissue culture, with initial grafts only having a 0-20% 
“take” rate. Xenograft lines, established from successful primary tissue grafts, can be serially 
transferred between mice. In prostate cancer, these include the well-established LAPC and 
CWR22 lines. Again, the value of these models has been questioned due to lack of AR and PSA 
expression in most lines and the lack of physiological similarity due to tissue adaptation to the 
environment of the mouse. Efficacy of this process is dependent on the site of engraftment; 
subcutaneous, in the renal capsule or orthotopic. Each has relative survival advantages and 
mimicry of tumour microenvironment yet each is met with increasing procedural challenge. Other 
additional aids such as testosterone implant and mouse mesenchymal tissue recombination have 
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been shown to improve xenograft survival rates (466). Patient derived xenografts (PDX) are 
notoriously difficult to grow due to inefficient take rates and complication in that human T and B 
cell lymphocytic tumours spontaneously develop in the immune-deficient PDX models and mimic 
solid tissue derived cancer (467). Report of 21 novel and characterised PDXs, representative of 
metastatic prostate cancer, that both encapsulate the genetic heterogeneity of advanced disease 
and respond in similar fashion to conventional treatments (docetaxel and ADT), is promising news 
in the search for more efficacious CRPC therapies (468). 
Xenografting is performed in immunocompromised mice to stop the rejection of foreign tissue. 
The best emerging model are the NOD mice, these lack T and B cells and have NK cell and 
macrophages with impaired function. The addition of mutation-inactivated ILR2γ to these mice 
causes further depletion of NK cells and dendritic cell dysfunction. This augmentation to the 
original model has produced the NSG (NOD-SCID-ILR2γ-/-) and NRG (NOD-Rag1-/--ILR2γ-/-) mice 
which, due to lack of an effective immune response, allow for improved xenograft take efficiency 
(466)(Figure 18C). 
However, the lack of immune system in the mice can permit development of spontaneous human 
lymphomas in the mice from tumour-infiltrating immune cells with latent EBV infection. This is 
particularly common in prostate cancer PDXs which both decreases successful take rates and 
requires further diagnostic screening to remove these “false positives” (469, 470). 
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FIGURE 18 – Mouse models of prostate cancer 
A) Transgenic mouse models of prostate cancer, Lady and TRAMP represent early models and the 
latter highlighting the prostate specific expression (or lack) of known disease genes. B) Organ and 
gland anatomy of the mouse prostate. C) Xenograft mouse lines and engraftment sites for 
modelling prostate cancer  
82 
 
1.7.3 - Cancer Stem Cells in Mice 
Both basal (33, 238, 471) and luminal (239, 240) CSC models of disease are supported in the 
mouse prostate; a scenario that frustrates the search for the origin of an epithelial stem cell 
progenitor in human prostate cancer, adding more confusion than clarification. 
In terms of CSC dynamics during xenotransplantation, the niche in mouse tissue will not re-
capitulate that of the cell in culture or indeed that of epithelia in the human prostate. 
Hypothetically, xenografting of cancer cells may select for a previously non-dominant CSC clone 
that is better adapted in supporting tumour growth in the mouse (245). The stromal 
compartment is extremely important in prostate tumourigenesis; xenografting of cancer cells with 
human stroma enhances their tumourigenicity, implying that the CSC pool interacts with the 
stromal compartment to enhance intrinsic self-renewal and proliferative capabilities (472, 473). 
As discussed, mice are important in deciphering the development and mechanisms of prostate 
cancer. However, limitations are due to the physiological differences compared to the human 
prostate gland; both cellularly and anatomically (474, 475). The lack of immune response and 
non-endogenous heterotypic stromal interaction also adds further variables that must be 
accounted for in the modelling of disease (466). 
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1.8 - Alterations of Allelic expression in Prostate Cancer 
PTEN and SPOP are two tumour suppressor genes (TSGs) that are recurrently mutated, at modest 
frequencies, in primary prostate tumours. Genetic aberrations of both genes are typically 
heterozygous; meaning that a functional allele is still present in affected cells. Cancers may exploit 
this “opportunity” and silence the remaining gene copy epigenetically. The IDH-1 proto-oncogene 
is also observed to be heterozygously mutated in a small percentage of prostate tumours. The 
effects of mutation are pleiotropic in different cell backgrounds and thus the mutated allele may 
be silenced for reactivation in a more “favourable” setting by cancer cells to maximise the 
selective advantage of the enzyme’s neomorphic capabilities. 
Allelic regulation of gene expression has, over the last decade, been shown to affect many 
autosomal disease genes, a possible explanation for the variable penetrance of several 
neurodegenerative disorders, but hasn’t yet been interrogated in prostate cancer. Recent work 
conducted in the Maitland laboratory observed monoallelic expression of the TMPRSS2-ERG 
fusion gene in prostate CSCs. The finding highlights the importance of allelic perturbation in 
cancer and suggests that selection of ERG is beneficial for stem-like properties of these malignant 
progenitors. Identification of higher order regulatory mechanisms in allelic expression may allow 
therapeutic targeting of epigenetic insults in prostate cancer. 
1.8.1 - Classical monoallelic expression 
Mendelian genetics assumes that inherited alleles, paternal and maternal, are congruently 
expressed and contribute in equal parts to progeny phenotype. This is termed biallelic expression, 
where transcription of both alleles occurs in equivalent frequencies (476). However, for some 
gene sets; expression only occurs from a single allele. To date, there are three distinct examples 
of monoallelic expression; X chromosome inactivation (XCI), imprinting and random monoallelic 
expression (RME). 
X-inactivation is a mammalian female-specific dosage compensation event in which one of the X 
chromosomes is enveloped in heterochromatin and silenced. This creates cellular X monosomy, 
meaning that there is only one active copy of each X-linked gene present. The initial selection for 
silencing of the chromosome; XM (maternal) or XP (paternal) is random and propagates clonally, 
yielding a mosaic pattern of X inactivation across tissues (477). The mechanism of XCI is well 
studied and involves Xist (X-inactive silencing transcript), a long non-coding RNA (lncRNA) (478) 
produced from the X inactivation centre (XIC). Xist achieves this by recruiting the Polycomb 
repressive complex 2 (PRC2), containing EZH2, that directs trimethylation of H3K27 along the 
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chosen X chromosome (479). Silencing the majority of genes on a single X chromosome facilitates, 
by default, monoallelic expression of the partner alleles on the active X (Figure 19). 
 
FIGURE 19 - X chromosome inactivation 
1. RepA mRNA recruits PRC2 to the X inactivation centre (XIC) 
2. PRC2 directs trimethylation of H3K27 of XIC 
3. This activates Xist lncRNA expression that recruits PRC2 
4. Xist directs the repressive trimethylation of the whole X chromosome through PRC2  
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Imprinting is non-random monoallelic expression. Here, silencing is dictated by parent-of-origin-
dependent expression in gene clusters. This phenomenon accounts for observations that both 
paternal and maternal chromosomes are required in the development of viable progeny (480). 
These clusters all contain a regulatory element, or imprinting control region (ICR), that enforces 
the monoallelic expression of a local gene or genes. lncRNA genes also found at the loci further 
enforce silencing of one of the alleles.  
Gene imprinting has several models describing the regulation of allelic expression. Currently, 
these can be divided into insulator and lncRNA regulated imprinting. In the insulator mechanism; 
a protein coding and lncRNA gene (separated by a common ICR) share downstream enhancer 
sequences. The maternal allele ICR is bound to by a CTCF insulator protein which restricts access 
of the protein coding gene to the enhancer as they are now in disparate genomic 
neighbourhoods. At the paternal allele; the ICR is methylated thus CTCF cannot bind to the 
element. The paternal epigenetic alteration also seeds secondary methylation of the lncRNA gene 
resulting in paternal allele expression of the protein coding gene, as the enhancer regions are 
accessible and maternal-specific expression of the lncRNA. This is canonically observed at the Igf2 
– H19 locus (481)(Figure 20A). 
Currently the lncRNA model of imprinting has no definitive universal consensus, and indeed 
seems unique in both a cellular context and the nature of the individual lncRNA. There is evidence 
to show that the sense transcript may anneal to the antisense of the adjacent allele’s promoter 
causing, initially, transcriptional disruption followed by a proximal accumulation of repressive 
chromatin and DNA methylation, or loss of active histone marks (482). Another possibility is that 
the imprinting lncRNAs mimic Xist and package the other gene copy into repressive chromatin 
structures. Indeed, lncRNAs have been shown to interact with several epigenetic modifiers. These 
include; PRC2, the H3K9me3 HMT G9a, DNMT1 and KDM1B (H3K4 demethylase) offering 
plausible correlating evidence (481, 483, 484)(Figure 20B). 
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FIGURE 20 – Models of Imprinting 
A) Insulator mechanism of gene imprinting. B) The antisense and XCI mimic models of lncRNA 
mediated gene imprinting  
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1.8.2 - Random monoallelic expression; involvement in cancer? 
RME is unlike XCI and imprinting as it doesn’t occur at distinct loci but is observed to be 
widespread across autosomes (476, 485). It is established in development (486-488) and 
regulated through conserved epigenetic mechanisms (489, 490). There is an extremely high 
probability that RME is perturbed in cancer i.e. that pathogenic heterozygous mutation or 
deletion of a gene can trigger a switching of allelic expression at an epigenetic level that silences 
the remaining gene copy. In a cancer cell, this would cause complete removal of protein 
expression and, thus, tumour suppressor activity. Similarly, observation of epigenetic selection 
and activation of oncogenes remains plausible in this setting. 
Disease genes known to be affected by RME include those associated with neurodevelopmental 
disorders; (491) such as the amyloid precursor protein in Alzheimer’s (485) and α-synuclein in 
Parkinson’s (492). Death-associated protein kinase (DAPK1) in chronic lymphoblastic leukaemia 
(CLL), (485, 493) the Eya transcriptional co-factors implicated in brachio-otic/brachio-oto-renal 
syndromes (487) are other RME disease genes. The altering of expression occurs at a 
transcriptional level and typically reduces total transcriptional output although some genes do 
exhibit transcriptional compensation (487, 494). Haploinsufficiency and the variance produced by 
monoallelic expression produces intra-clonal diversity at the transcriptomic level in tissues. This is 
hypothesised to contribute towards the differing penetrance seen in many disease states (495). 
Some studies show that selective allelic expression can reduce the dosage of the mutant allele 
and presumably protect the cell from pathologic effects (496, 497). 
Cellular populations, due to stochastic choice upon development, will express an RME gene both 
monoallelically and biallelically. This generates a further layer of heterogeneity amongst 
genetically identical clones (485, 487, 494). In colorectal cancer xenografts, intra-clonal diversity 
has been observed to alter cellular proliferation and response to chemotherapy. Population 
variance couldn’t be attributed to genetic differences and therefore must be propagated by 
epigenetic alterations (including RME) and/or niche placement in the tumour microenvironment 
(498). Indeed, recent developments in single-cell transcriptomic sequencing (499, 500) has further 
revealed that both normal (501) and cancerous (502-504) cell clones vary greatly in their 
expression profiles and the levels of transcript expressed. The increased diversity allows tumour 
cells a wider field to enable survival upon tackling the selective pressures of microenvironmental 
changes and during treatment; meaning that they are more prepared, as a collective, for the 
adaptive changes required for progression into a “successful” cancer (212, 505). 
It has also been observed that most cells exhibit dynamic RME due to transcriptional bursting. 
This term is used to describe the temporally asynchronous production of mRNA transcript from 
paternal and maternal alleles. Dynamic RME is widespread across the human genome and affects 
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a significant percentage of transcribed loci (506). These episodic bursts complicate studies which 
evaluate stable monoallelic expression as most techniques, such as RNA-seq and RNA-FISH, only 
afford a snapshot of cellular mRNA expression at a single time-point. For a biallelically expressed 
gene, the alternate transient production of a single allele’s mRNA due to transcriptional bursting, 
as visualised by the aforementioned methods, will appear as stable monoallelic expression – 
resulting in a false positive result for allelic imbalance.  
This problem has been highlighted in an almost perfect case study. In 2012, a group reported 
monoallelic expression of the pluripotency factor nanog in the early stages of embryonic 
development using RNA-FISH (507). This allelic restriction however was shown to be due to 
transcriptional bursting by another study the following year. Fluorescent protein labelling was 
used to mark the two nanog alleles to show biallelic expression of the gene in real-time (508). It is 
therefore necessary to evaluate several time-points when looking at allelic expression, preferably 
using multiple analytic methods (486). 
This is both to prevent incorrect claims of stable monoallelic expression and also to reduce the 
number of false positives due to transcriptional bursts. Use of RNA-seq to determine allelic 
frequency ratios in mouse embryonic, liver and fibroblast cells detected global transcriptional 
bursting. This, as expected, gave a much higher than usual percentage of monoallelically 
expressed transcripts due to the dynamic nature of the bursting (509, 510). A follow-up study 
using single-cell RNA-seq that accounted for the clonal dynamics of cells, observed that the 
majority of cellular RME is due to transcriptional bursting with very few genes stably and clonally 
monoallelically expressed (511). 
RME genes differ between cellular lineages yet there appears to be a core group conserved across 
cell types. The observation at present is that the overlap is greater between biologically related 
and functionally similar cells (489, 510). This has impact on cancers, as, like their mutational 
content, they will most likely have variant monoallelically expressed gene-sets that may 
compromise important pathogenic alleles. However, as the field is in its infancy, the extent to 
which the phenomenon impacts upon the state of cancer is relatively unknown with only a select 
few “driving” genes having been linked to RME. The epigenetic regulatory mechanisms of 
monoallelic expression are known (489, 490) yet their timing, resolution and whether there are 
any key upstream players above the HMTs involved is still a mystery. All of the aforementioned 
may be perturbed in cancer leading to a state where allelic expression at a global level is affected. 
It is also worth noting that, although discovered in cell culture, RME has now been shown to exist 
in vivo by multiple studies and is not an artefact of the artificial growth environment (487, 489, 
511-513). 
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1.8.3 - Epigenetic regulation of random monoallelic expression and perturbation in cancer  
The regulation of allelic choice, in the majority of RME genes (487) is not controlled by correlative 
methylation of promoter CpG islands (246, 514, 515) as originally postulated. Strand-specific 
methylation could account for switching in active alleles at mitosis, however analysis of published 
ChIP-seq datasets implies that RME is defined by an asymmetric chromatin signature (516). 
Gene body histones of the active allele are tri-methylated at H3K36 and the nucleosomes of the 
silenced allele are trimethylated at H3K27 (489). This fingerprint has been shown to be predictive 
of monoallelic expression and is orthologically conserved in both mice (490) and chimpanzees 
(517) suggesting that the unknown upstream regulation of allelic expression is encoded into our 
DNA. The recent compilation of many transcriptional and ChIP-seq datasets has led to the 
creation of a monoallelic expression database that has both mouse and human cell and tissue 
records (518). In reference to the evolutionarily conserved nature of RME; Matthew Thayer’s 
laboratory have identified loci, found on chromosomes 6 and 15, which produce autosomal 
equivalents of the Xist lncRNA called ASARs (asynchronous replication and autosomal RNAs). 
These molecules direct monoallelic expression in cis along their chromosomes, placing ASARs in a 
possible higher order of regulatory mechanisms for RME. These regions may provide ICR activity 
as they act akin to the lncRNAs identified in imprinted gene clusters. It is likely there are other, as 
yet undiscovered, loci which dictate autosomal monoallelic expression (519, 520). 
The majority of genes encompassed by the characteristic RME chromatin structure are bivalently 
marked in embryonic stem cells (ESCs) (489). Bivalent or “poised” chromatin is formed by dual 
deposition of respective activating and repressive trimethylations, H3K4me3 and H3K27me3, on 
the same nucleosome (521-524), in gene promoter regions which, although antagonistic, 
maintains a low level of gene transcription. Removal of one of the marks by a specific histone 
demethylase (525) results in the rapid activation or repression upon stem cell differentiation 
(526)(Figure 21). Resolution of somatic stem cell bivalent marks into those observed in RME gene 
bodies is plausible theory (489, 527). It has been observed that promoter elements of RME genes 
are regulated by allelic accessibility in differentiated cells, and that this is pre-marked by 
deposition of H3K4me3, K27me3 and K9me3 in ESCs (528). Bivalent genes, like RME gene-sets, 
are lineage specific (529) and are perturbed in cancers of various tissues (530-537) including the 
prostate (423). The bivalent histone state of normal tissue and progenitor cell gene promoters has 
high predictive value for the subsequent methylation of these regions in tissue matched cancer 
cells (538, 539). These regions also exhibit microenvironmental plasticity and have been observed 
to respond to hypoxia (540). Breast cancer cells increase bivalent domains during EMT, to reduce 
transcript levels of epithelial identity genes, and resolve them during the reverse mesenchymal to 
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epithelial transition (MET) via expression of the H3K27me3 demethylase, JMJD3 (541). This 
permits successful secondary site seeding and the establishment of metastases. 
Sequencing has also identified an enrichment of events that dysregulate chromatin modifying 
enzymes involved in deposition of these trimethylations in prostate tumours. In advanced 
cancers, the H3K27 methyltransferase EZH2 is upregulated and its locus frequently amplified (90, 
123). EZH2 expression can be activated by ERG, a developmental transcription factor frequently 
dysregulated in prostate cancer, an interplay that promotes a de-differentiation program (542) by 
epigenetic silencing of critical genes such as NKX3.1 (543). H3K4 methyltransferases SMYD3 and 
MLL2 are also perturbed in prostate cancer. The first enzyme is seen to be frequently 
overexpressed in cancer tissues, (422) whilst MLL2, that interacts with and facilitates epigenetic 
transactivation of AR, is recurrently mutated (335). Interestingly these HMTs are involved in 
maintenance of bivalent chromatin;(526) that, in the prostate, marks a gene-set which becomes 
dysregulated during cancer development (423). Studies in prostate cancer cell lines have 
observed the alterations at bivalent loci from benign to cancerous states and also during EMT 
(421, 422) yet work of this nature needs to be undertaken in primary cells and tissues to ascertain 
closer to physiological correlations of these histone trimethylations. 
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FIGURE 21 - Resolution of bivalent chromatin to RME chromatin 
The original bivalent or poised state of the allele allows for rapid activation or silencing of the 
gene copy by promoter loss of a histone trimethylation and gene body gain of another.  
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Apart from obvious alterations to gene copy number by deletion and amplification, nucleotide 
changes that lead to an epigenetic switch of allelic expression have been identified in cancer. 
DAPK1 is a mediator of apoptosis that is monoallelically expressed in peripheral blood 
mononuclear cells (485). The gene promoter is recurrently hypermethylated in CLL, allowing the 
cells to become more resistant to apoptotic cell death. A rare germline mutation has also been 
discovered in a suppressor sequence of the gene that increases the binding affinity of the 
transcriptional repressor HOXB7, further reducing output of DAPK1 transcript from the mutant 
allele (493)(Figure 22A). 
In T-ALL, microinsertions upstream of the TAL1 oncogene disrupt normal deposition of silencing 
H3K27me3 and cause monoallelic reactivation of the gene that is usually silenced in the T-cell 
lineage. The nucleotide insertion was initially observed in the Jurkat cell line and has now been 
recurrently identified in primary samples – this monoallelic defect correlates with worse overall 
survival and higher blast counts in patients (544)(Figure 22B). 
Allele-specific upregulation of FGFR2 has been observed in breast cancers. Here a haplotype of 2 
specific minor SNPs confers abnormal binding of RUNX2 to the oncogenic allele – stimulating a 
disproportionate activation of FGFR2 expression in breast cancer cells. Allelic upregulation of the 
mitogenic receptor tyrosine kinase confers a growth advantage to cells which is exploited by the 
cancer (545, 546)(Figure 22C). 
TERT promoter mutations are always heterozygous, and have been observed in a number of 
cancers, but not in the prostate (547-549). This molecular defect can actually drive expression of 
telomerase more efficiently than the wild-type promoter (550). The mutant allele binds the 
GABPA ETS factor, causing a switch from the usual H3K27me3 to an active chromatin structure. 
The silent allele also becomes associated with repressive marks such as H3K27me3 and EZH2 
(551). This allele-specific binding event presumably allows for the deposition of H3K4me3 and the 
subsequent monoallelic expression of telomerase – granting replicative immortality to the cancer 
cell (552)(Figure 22D). 
The most comprehensive study of the proportion of mutated alleles expressed in cancer has come 
from multiple myeloma (497). Contrary to the assumptions of most genome sequencing studies 
that all mutations are expressed and affect protein; it was shown, through combination of 
matched patient RNA and DNA-seq datasets, that the majority of mutations in the cancer weren’t 
expressed. This phenomenon has also been previously observed in studies of breast, lung and 
brain cancers (553-555). 
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FIGURE 22 – Literature examples of normal to cancer allelic alterations 
Red circles – repressive epigenetic marks. Green circles – activating epigenetic marks. 
A) DAPK1 methylation in CLL. The gene is hypermethylated in chronic lymphoblastic leukaemia 
and a mutation upstream of the gene can provide a novel binding site for the HOX7B 
transcriptional repressor protein that further decreases transcriptional output. 
B) TAL1 chromatin changes in T cell lymphoma. Micro-insertions disrupt deposition of repressive 
histone modifications to cause allelic activation of the TAL1 oncogene. 
C) FGFR2 transcription factor binding in breast cancer. SNP variants create a RUNX2 binding site in 
an allele of FGRF2 and cause a hyperactivation of allelic transcription.   
D) TERT promoter mutation in several cancers. Promoter mutation produces a biding site for the 
GABPA ETS factor and a switch from silencing to active chromatin signature that permits 
telomerase expression from the single allele.  
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1.8.4 - Epigenetic modifiers as cancer treatments 
The switching on and off of allelic expression in disease can be related to dynamic chromatin 
restructuring. Prostate cancer itself has an enrichment of mutation and rearrangements in 
chromatin modifying enzymes such as CHD1, (174) MLL2 (335) and EZH2, among others (90). The 
polycomb group protein EZH2 is up-regulated by TMPRSS2-ERG, (542) and creates the chromatin 
structures seen to envelope bivalent and RME genes (489). Treating cancer cells that are 
epigenetically aberrant with small molecule inhibitors of specific DNA or histone modifying 
enzymes may cause a reversal of either the deposition or removal of the epigenetic mark – 
resulting in a regression of the cancer phenotype. 
CSCs of the prostate have heightened levels of heterochromatin that offers greater protection 
from radiotherapy. Co-application of an Histone Deacetylase (HDAC) inhibitor sensitised the stem 
cells to the radiation dose leading to formation of open chromatin structures and exposing DNA 
vulnerable to damage by the treatment (323). Promoter hypermethylation is another commonly 
observed epigenetic event in prostate cancer differentiation. Affected genes are first 
downregulated and then methylated to lock them in the repressed state. Interestingly these 
differentiation associated hypermethylated (DAH) genes were identified to have previously been 
associated with bivalent chromatin earlier in development. The DAH genes, in 3D cultured 
prostatic acini, showed a non-significant methylation increase with a significant decrease of the 
H3K4me3 mark throughout differentiation. Promoter H3K4 trimethylation permits the expression 
of the genes in the stem cells, yet this chromatin signature is lost upon development, causing 
gene downregulation and subsequent methylation (423). The identification of this gene-set in 
prostate cancer and its initial bivalent status suggest that RME may also play a genome-wide role 
in tumours through reduction of transcript levels and producing subsequent heterogeneity of 
gene expression during the aberrant differentiation of the prostate epithelia. 
Inhibition of DNA methyltransferases is used to facilitate epigenetic reactivation of TSGs. The 
reversible nature of methylation marks it as an attractive anti-cancer therapeutic target. 
Commonly used inhibitors are azacitidine and decitabine which have seen use in myeloid 
leukaemias with some effect (556). Azacitidine decreased PSA levels in correlation with reduced 
LINE methylation in pre-chemotherapy CRPC patients (557) suggesting possible application of the 
drug earlier in prostate cancer progression may reduce biochemical symptoms and slow 
progression of disease. In relation to RME, regular treatment of the Raji CLL cell line with 
decitabine caused a steady rise in DAPK1 expression while untreated cells had no response in 
expression levels as the tumour suppressor remained epigenetically silenced (493).  
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Targeting DNA methylation as a viable treatment option is possible yet it seems that in the case of 
prostate cancer, histone modifications are the more important regulators; advocating possible 
use of HDAC and HMT inhibitors in combination with other therapies. 
1.8.5 - PTEN and Prostate Cancer  
Phosphatase and tensin homologue deleted on chromosome ten (PTEN) is a dual-specificity 
protein tyrosine phosphatase (PTP) that has both lipid and protein targets (558). The enzyme 
itself was discovered due to frequent loss of heterozygosity (LOH) at chromosome 10q23 in 
prostate, breast and brain cancers; implicating the gene as a probable tumour suppressor (558). 
The major cellular role of PTEN is to antagonise PI3K phosphorylation at the 3’ position of PIP2 
(phosphatidylinositol 3,4 bisphosphate) and PIP3 (phosphatidylinositol 3,4,5 triphosphate) (559). 
Depletion of these specific phospholipid signalling molecules prevents binding of proteins with 
Pleckstrin homology (PH) domains, such as AKT; a central growth signalling kinase (560-562). 
In prostate cancer, PTEN deletion is among the most common genetic alterations in both primary 
and metastatic tumours. Deletion of the phosphatase is seen in ~40% of localised cancers with 
incidence rising to 70-80% in metastatic disease (345). This pattern suggests that PTEN plays a 
role in both initiation and progression of prostate cancers.  
Disruption of the phosphatase gene allows for unchecked AKT activity – sustained proliferative 
signalling, increased protein synthesis through MTORC1, enhanced cellular survival, angiogenesis 
and tumour progression (148, 563-565). PTEN also has caretaker functions as it promotes 
genomic stability, both through nuclear and cytosolic localisation, and aids the DNA damage 
response (565-568). The enzyme has protein targets, independent of its lipid phosphatase activity 
in the PI3K pathway. These include FAK (Focal Adhesion Kinase) (569) an enzyme involved in cell 
motility, the transcription factor CREB (570) and the non-receptor tyrosine kinase; Src (571). 
Alterations in the PI3K/AKT signalling pathway are a common occurrence in prostate cancer, with 
PI3K mutations and other regulators also being disrupted in the disease state (90, 174, 331, 345, 
572)(Figure 23). 
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FIGURE 23 – PTEN signalling and disturbances in Prostate Cancer 
Normal PTEN signalling and the molecular alterations to the gene frequently observed in prostate 
cancers. Mutational chart of exon 5 taken from COSMIC website (573).  
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The deletion of the 10q23 locus is commonly seen in TMPRSS2-ERG+ tumours (90) created by 
coordinated chromoplectic chain events (334). It has been shown that PTEN deletion also causes 
staged cancer progression; prostate specific homozygous deletion of the gene in transgenic mice 
causes accelerated development of PIN, adenocarcinoma and metastatic disease. The murine 
PTEN null tumours were hypersensitive to ADT, yet upon autopsy it was found that AR+ cells were 
still present. This suggests that if observation time had been extended, the PTEN-/- tumours may 
have advanced into a state of CRPC (574). The prevalence of genetic insults to the PTEN gene in 
prostate cancer has been used to map heterogeneity in tumours. Multifocal disease in the 
prostate is common and PTEN status at each focus varies, suggesting that loss of the phosphatase 
is a later sub-clonal event. Increased heterogeneity of PTEN deletion has also been shown to 
directly correlate with Gleason grade and thus cancer aggressiveness (345). 
Classically, for cancer to arise from mutated TSGs, inactivation of both alleles must occur 
according to Knudson’s two-hit hypothesis (575). The other PTEN allele in cancer has been 
observed to be deleted (homozygous removal of PTEN), mutated and epigenetically silenced 
(although promoter hypermethylation of the gene isn’t observed in prostate tumours) (174, 576, 
577). TMPRSS2-ERG+ tumours can also repress PTEN expression via ERG, highlighting that a 
convergent molecular outcome in prostate cancers is a reduction of PTEN protein (578). Thus the 
gene dosage of PTEN is critical in the prostate, as cancer can result from haploinsufficiency of the 
gene (579, 580). If RME affects the PTEN gene, then reduced dose through monoallelic expression 
in cancer will enhance tumourigenesis. 
The metastatic prostate cancer cell lines; PC3, LNCaP and Du145 represent the importance of 
PTEN aberrations in disease. PC3 cells completely lack PTEN due to homozygous deletion, Du145 
have heterozygous deletion and exon 5 point mutation to the remaining allele whilst LNCaPs have 
an exon 1 indel that creates a frameshift (451, 558). In prostate tumours it is observed that PTEN 
mutation typically targets the PTP domain of the enzyme (exon 5 of the gene), with the 
123HCKAGKGR130 catalytic loop being the most frequently mutated region of the phosphatase 
domain (565)(Tables 3 & 4). Although frequency varies between population studies; in prostate 
cancer, PTEN mutation is not a commonly observed event relative to deletions of the gene (133, 
330, 335, 558, 581-584). Recently, a recurrent inversion of the whole PTEN gene has been 
observed in hormone naïve localised prostate cancers that decreases PTEN mRNA production and, 
surprisingly, reduces pathway activity below that seen in cases of heterozygous deletion 
(332)(Figure 23). 
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Codon Nucleotide 
Change 
Amino Acid 
Change 
Location 
(Exon/Domain) Consequence Reference 
19G>C E7Q Exon 1 Missense Haffner 2013 (155) 
58G>T G20Stop Exon 1 Nonsense Dong 2001(585) 
70G>A D24N Exon 1 Missense COSMIC – UK (586) 
144C>A N48K Exon 2 Missense TCGA 2015 (330) 
163A>G R55G Exon 2 Missense Dong 2001 (585) 
202T>C Y68H Exon 3 Missense COSMIC – UK (586) 
259C>T Q87Stop Exon 5/PTPc Nonsense Vliestra 1998 (453) 
271G>C E91Q Exon 5/PTPc Missense Suzuki 1998 (584) 
276C>A D92E Exon 5/PTPc Missense COSMIC – UK (586) 
283C>T P95S Exon 5/PTPc Missense de Muga 2010 (581) 
302T>A I101N Exon 5/PTPc Missense Dong 2001 (585) 
328C>T Q110Stop Exon 5/PTPc Nonsense Dong 2001 (585) 
332G>A W111Stop Exon 5/PTPc Nonsense Kan 2010 (583) 
355G>T V119F Exon 5/PTPc Missense TCGA 2015 (330) 
384G>C K128N Exon 5/PTPc Missense Barbieri 2012 (66) 
385G>A G129R Exon 5/PTPc Missense Li 1997 (558) 
388C>T R130Stop Exon 5/PTPc Nonsense Vliestra 1998 (453) 
400A>T M134L Exon 5/PTPc Missense Li 1997 (558) 
401T>G M134R Exon 5/PTPc Missense COSMIC – UK (586) 
403A>G I135V Exon 5/PTPc Missense Dong 2001 (585) 
449A>G E150G Exon 5/PTPc Missense Dong 2001 (585) 
480C>T T160T Exon 5/PTPc Silent Dong 1998 (582) 
487A>T K163Stop Exon 5/PTPc Nonsense Grasso 2012 (335) 
517C>T R173C Exon 6 Missense COSMIC – UK (586) 
518G>A R173H Exon 6 Missense Barbieri 2012 (133) 
520T>A Y174N Exon 6 Missense Feilotter 1998 (587) 
638C>G P213R Exon 7/C2 Missense Grasso 2012 (335) 
697C>T R233Stop Exon 7/C2 Nonsense Barbieri 2012 (133) 
758T>A I253N Exon 7/C2 Missense COSMIC – UK (586) 
814C>T H272Y Exon 8/C2 Missense Dong 2001 (585) 
977A>G D326G Exon 8/C2 Missense TCGA 2015 (330) 
1008C>A Y336Stop Exon 8/C2 Nonsense Barbieri 2012 (133) 
1031A>G K344R Exon 9/C2 Missense Dong 2001 (585) 
1043C>T T348I Exon 9/C2 Missense Dong 2001 (585) 
1102T>G V369G Exon 9 Missense Dong 1998 (582) 
1144A>T T382S Exon 9 Missense Dong 2001 (585) 
TABLE 3 – All known PTEN mutations in prostate cancer  
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Exon 
Number 
mRNA/Protein Sequence 
1 
mRNA 
ATGACAGCCATCATCAAAGAGATCGTTAGCAGAAACAAAAGGAGATATCAAGAGGATGGATTCGAC
TTAGACTTGACCT 
Protein M T A I I K E I V S R N K R R Y Q E D G F D L D L T  
2 
mRNA 
ATATTTATCCAAACATTATTGCTATGGGATTTCCTGCAGAAAGACTTGAAGGCGTATACAGGAACAA
TATTGATGATGTAGTAA 
Protein Y I Y P N I I A M G F P A E R L E G V Y R N N I D D V V R  
3 
mRNA GGTTTTTGGATTCAAAGCATAAAAACCATTACAAGATATACAATCT 
Protein F L D S K H K N H Y K I Y N 
4 
mRNA TTGTGCTGAAAGACATTATGACACCGCCAAATTTAATTGCAGAG 
Protein L C A E R H Y D T A K F N C R 
5 
mRNA 
TTGCACAATATCCTTTTGAAGACCATAACCCACCACAGCTAGAACTTATCAAACCCTTTTGTGAAGAT
CTTGACCAATGGCTAAGTGAAGATGACAATCATGTTGCAGCAATTCACTGTAAAGCTGGAAAGGGA
CGAACTGGTGTAATGATATGTGCATATTTATTACATCGGGGCAAATTTTTAAAGGCACAAGAGGCCC
TAGATTTCTATGGGGAAGTAAGGACCAGAGACAAAAAG 
Protein 
V A Q Y P F E D H N P P Q L E L I K P F C E D L D Q W L S E D D N H V A A I H C K A G K G R T G 
V M I C A Y L L H R G K F L K A Q E A L D F Y G E V R T R D K K  
6 
mRNA 
GGAGTAACTATTCCCAGTCAGAGGCGCTATGTGTATTATTATAGCTACCTGTTAAAGAATCATCTGG
ATTATAGACCAGTGGCACTGTTGTTTCACAAGATGATGTTTGAAACTATTCCAATGTTCAGTGGCGG
AACTTG 
Protein G V T I P S Q R R Y V Y Y Y S Y L L K N H L D Y R P V A L L F H K M M F E T I P M F S G G T  
7 
mRNA 
CAATCCTCAGTTTGTGGTCTGCCAGCTAAAGGTGAAGATATATTCCTCCAATTCAGGACCCACACGAC
GGGAAGACAAGTTCATGTACTTTGAGTTCCCTCAGCCGTTACCTGTGTGTGGTGATATCAAAGTAGA
GTTCTTCCACAAACAGAACAAGATGCTAAAAAAG 
Protein 
C N P Q F V V C Q L K V K I Y S S N S G P T R R E D K F M Y F E F P Q P L P V C G D I K V E F F H K 
Q N K M L K K  
8 
mRNA 
GACAAAATGTTTCACTTTTGGGTAAATACATTCTTCATACCAGGACCAGAGGAAACCTCAGAAAAAG
TAGAAAATGGAAGTCTATGTGATCAAGAAATCGATAGCATTTGCAGTATAGAGCGTGCAGATAATG
ACAAGGAATATCTAGTACTTACTTTAACAAAAAATGATCTTGACAAAGCAAATAAAGACAAAGCCAA
CCGATACTTTTCTCCAAATTTTAAG 
Protein 
D K M F H F W V N T F F I P G P E E T S E K V E N G S L C D Q E I D S I C S I E R A D N D K E Y L V 
L T L T K N D L D K A N K D K A N R Y F S P N F K  
9 
mRNA 
GTGAAGCTGTACTTCACAAAAACAGTAGAGGAGCCGTCAAATCCAGAGGCTAGCAGTTCAACTTCT
GTAACACCAGATGTTAGTGACAATGAACCTGATCATTATAGATATTCTGACACCACTGACTCTGATCC
AGAGAATGAACCTTTTGATGAAGATCAGCATACACAAATTACAAAAGTCTG 
Protein 
V K L Y F T K T V E E P S N P E A S S S T S V T P D V S D N E P D H Y R Y S D T T D S D P E N E P F 
D E D Q H T Q I T K V Stop 
TABLE 4 – Location of prostate cancer associated mutations in the PTEN gene  
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1.8.6 - SPOP and Prostate Cancer  
The primary role of Speckled-type POZ protein (SPOP) is that of a substrate-specific adaptor 
protein for the Cullin3-RING E3 ligase (CRL3) (588, 589). SPOP owes its strange name to the 
roundabout way in which it was discovered. Application of autoimmune antibodies from a 
schleroderma patient onto COS7 cells created a confined speckled pattern in cell nuclei. Immuno-
screening of a HeLa library identified the epitope-containing protein that was found to contain a 
POZ (pox virus and zinc finger) domain by subsequent BLAST search. The protein was thus named 
speckled-type POZ protein (590).  
In complex with CRL3, SPOP marks a plethora of protein substrates for targeted proteasomal 
degradation by poly and multi-mono ubiquitination (591, 592). The adaptor protein is equipped 
for this function through MATH (meprin and TRAF homology) and BTB (Bric-a-
brac/Tramtrack/Broad, also known as POZ) domains. The MATH domain sequesters substrate 
protein whilst the BTB domain facilitates activation of SPOP-CRL3 dimerisation/oligomerisation, 
and the binding of the Cullin 3 complex, to bring the substrate into close proximity to the E3 
Ligase catalytic core (593-595). Substrate proteins contain an SPOP binding consensus (SBC) 
consisting of a 5 amino acid motif (595). SBCs are found in BMI1, macroH2A, Daxx, Gli2/3, DEK, 
TRIM24, AR, NCOA3, SETD2, BRD4 and ERG, to name a few of SPOP’s targets (382, 591, 592, 596-
603)(Figure 24A). Whilst this binding typically confers ubiquitin-mediated degradation, it has been 
shown to have other effects; such as aiding macroH2A deposition on the inactivated X 
chromosome (598) and antagonising INF2-mediated regulation of mitochondrial fission (604). 
SPOP also plays a role in the DNA damage response (605, 606) and in cellular senescence, 
suggestive of a caretaker role for the gene (607). The presence of SPOP in an E3 ligase complex, 
one of the largest human enzyme classes, opens the potential for dysregulation of widespread 
protein targets in cancer, some of which won’t have yet been identified as SPOP substrates. 
SPOP is the most commonly mutated gene in primary prostate cancer (settling at around 10%) 
(330-332, 608). Mutations of the gene have been identified in colorectal, (609, 610) 
hepatocellular, (611) thyroid (612) and endometrial (592) carcinomas. Allelic loss is also evident in 
breast cancer (613). SPOP can have an oncogenic role, inconsistent with its tumour supressing 
capabilities in several cancers. This is due to the fact that dysregulation of cellular ubiquitination is 
entirely context dependent. For example; in clear cell renal cell carcinoma, SPOP is seen to be 
consistently overexpressed. Here, SPOP upregulation shifts protein localisation to the cytosol, 
favouring the increased degradation of tumour suppressing CRL3 substrates – including PTEN 
(614, 615). The context dependent cancer promoting role for SPOP has led to the development of 
small-molecule inhibitors of SPOP-substrate interactions that promote renal cell death in vitro 
and in vivo (616). 
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FIGURE 24 – SPOP signalling in prostate cancer 
A) SPOP as a substrate binding adaptor protein of the Cullin3 E3 ligase – involved in the turnover 
of oncogenic proteins in the prostate – especially those involved in AR signalling. B)Mutational 
clustering in the substrate binding domain of SPOP (taken from COSMIC (617)) prevents substrate 
binding and degradation  
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Prostate cancer-associated SPOP mutations cluster exclusively in the MATH domain of the protein 
and affect amino acids required for substrate binding (382, 592, 596, 597, 605, 607). Currently, 17 
amino acid residues in the MATH domain (See Figure 24B, Tables 5 & 6)(133, 174, 330, 335, 583, 
593, 618-623) are affected by missense mutation in prostate cancer; with all tested point 
mutations abrogating the ability to bind substrate protein (596, 597, 605, 607, 624). Mutations in 
SPOP are mutually exclusive from ETS fusions and PI3K pathway alterations, yet correlate with 
CHD1 deletions in tumours and occur early in the cancer’s natural history (90, 330, 334, 605, 618). 
SPOP mutation has also been reported in hgPIN tissues adjacent to cancerous foci, marking it as a 
possible tumour-initiating event (133, 335). A study that tracked metastases, based on genetic 
alterations, back to their source in the prostate showed that SPOP mutation occurred early in 
progression of the cancer as the metastatic molecular signature could be linked to an originating 
sub-clonal focus within the primary tumour (155, 338). 
Disruption of SPOP-specific Cullin 3 substrate degradation in prostate cancer impacts the cellular 
ubiquitylome and causes inappropriate protein accumulation (592). Whilst in dimeric 
conformation with the wildtype protein, mutant SPOP is theorised to completely abrogate 
substrate protein ubiquitination – possibly explaining the complete effect of heterozygous 
mutation (592). This so-called dominant-negative effect was seen in prostate epithelial cells 
(hPREC, PC3 and LNCaP) to affect NCOA3 (625) (AR co-factor), TRIM24 (626) (androgen-
independent AR activator and degrades p53) and DEK (proto-oncogene) protein levels. Reduced 
degradation of these proteins that promote prostate epithelial cell growth and invasiveness 
correlated with increased tumourigenic potential of cells. SPOP’s regulation of androgen signalling 
is extensive as even the AR itself has an SBC located the hinge region of the protein. This has 
implications in CRPC as AR splice variants, for example; V7, lack this domain and therefore cannot 
be affected through wildtype SPOP-CRL3 ubiquitination, allowing the AR transcriptional program 
to be constitutively enforced (382). SPOP mediated degradation of AR is further supported by the 
fact that protein levels of closely related nuclear receptors; ERα (627) and PR (241) are also 
regulated by SPOP.  
The adaptor protein has also been observed to degrade ERG, through binding to an N-terminal 
SBC. Again mutation of the adaptor protein fails to cause degradation of the transcription factor 
and, depending on the location of the breakpoint, truncated ERG is partially or fully resistant to 
SPOP-mediated ubiquitination (596, 597). This means that in prostate cancer, the two dominant 
molecular subtypes; TMPRSS2-ERG fusion and SPOP mutation both achieve a congruent molecular 
endpoint; inappropriate accumulation of ERG. However, a recent study has observed that, in 
SPOP mutant prostate cancers; ERG is not expressed (628). This means that, although MATH 
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domain mutations can stabilise ERG, SPOP defects drive prostate cancer with a complete separate 
molecular aetiology from ERG-high prostate cancers. 
Recently, SPOP has been shown to aid degradation of PD-L1 which is involved in immune 
response suppression (629). Mutation of the adaptor protein in prostate cancers abrogates the 
proteasomal turnover of PD-L1, and is thus linked to high PD-L1 protein levels with reduced 
immune cell infiltration in tumours.  
SPOP has a wide repertoire of protein targets that are relevant to prostate cancer (382, 596, 597, 
614). This however isn’t complete and there is potential for important links to be made in future 
which broaden the effect of mutations to the E3 ligase adaptor protein. SPOP mutants cause 
activation of mTOR, PI3K and AR signalling in transgenic mice. Data that aligns with paired 
previously obtained DNA and RNA sequencing efforts of localised human prostate cancer, 
highlighting that the diverse range of SPOP targets influence critical growth pathways (630). If the 
SPOP gene is under regulation at an allelic level then there is the possibility that heterozygous 
mutation, with the functional allele silenced by histone trimethylations, can lead to complete loss 
of protein function as observed in multiple studies. 
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Codon Nucleotide 
Change 
Amino Acid 
Change 
Location (Exon; 
Domain) 
Consequence Reference 
248A>G Y83C Exon 6/MATH Missense Saar 2014 (620) 
259T>A Y87N Exon 6/MATH Missense Blattner 2014 (618) 
260A>G Y87C Exon 6/MATH Missense Barbieri 2012 (133) 
260A>C Y87S Exon 6/MATH Missense Grasso 2012 (335) 
304T>A F102I Exon 6/MATH Missense COSMIC – CA (621) 
304T>G F102V Exon 6/MATH Missense TCGA 2015 (330) 
305T>G F102C Exon 6/MATH Missense Barbieri 2012 (133) 
305T>C F102S Exon 6/MATH Missense Buckles 2014 (619) 
310T>G F104V Exon 6/MATH  Missense 
Garcia-Flores 2014 
(622) 
311T>C F104S Exon 6/MATH Missense TCGA 2015 (330) 
318C>T I106I Exon 6/MATH Silent Buckles 2014 (619) 
332G>A G111E Exon 6/MATH Missense Buckles 2014 (619) 
356G>A S119N Exon 7/MATH Missense Barbieri 2012 (133) 
358C>T Q120Stop Exon7/MATH  Nonsense 
Garcia-Flores 2014 
(622) 
373T>G F125V Exon 7/MATH Missense Kan 2010 (583) 
375T>A F125L Exon 7/MATH Missense Barbieri 2012 (133) 
385A>G K129E Exon 7/MATH Missense Barbieri 2012 (133) 
388G>A D130N Exon 7/MATH Missense 
Garcia-Flores 2014 
(622) 
391T>G W131G Exon 7/MATH Missense 
Garcia-Flores 2014 
(622) 
391T>C W131R Exon 7/MATH Missense TCGA 2015 (330) 
392G>C W131S Exon 7/MATH Missense TCGA 2015 (330) 
393G>C W131C Exon 7/MATH Missense TCGA 2015 (330) 
397T>G F133V Exon 7/MATH Missense Berger 2011 (174) 
398T>G F133C Exon 7/MATH Missense Barbieri 2012 (133) 
398T>C F133S Exon 7/MATH Missense Barbieri 2012 (133) 
399C>G F133L Exon 7/MATH Missense Barbieri 2012 (133) 
397T>A F133I Exon 7/MATH Missense TCGA 2015 (330) 
402G>C K134N Exon 7/MATH Missense Barbieri 2012 (133) 
N/A K135X Exon 7/MATH Missense Blattner 2014 (618) 
406T>C F136L Exon 7/MATH Missense COSMIC – UK (586) 
457G>A D153N  Exon 7/MATH Missense 
Garcia-Flores 2014 
(622) 
887A>T N296I Exon 11/BTB Missense Zuhlke 2014 (631) 
1103G>A R368H Exon 12 Missense TCGA 2015 (330) 
TABLE 5 – All known SPOP mutations in prostate cancer  
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Exon 
Number 
mRNA/
Protein 
Sequence 
1 
mRNA 
GGGGAGGAGGCCGCGCGGGGTGGGGTCTGGCGGTACGCGCTGGCTGCGTCGACGTGCTGACGCCATGA
CGCCCCGGCTGGTGTGTGTCGGTGTGTATGTGTGTGTGTGAGTGTGCGCGCTCCGAGTGTGTGTGTATTT
GTGTATCGGCGGTCCCGCAGGTCCCGGATGTTGCGGACAGTATGAGGCAAGCGCAGGGGGACGGGGAC
CAGCAGCTGTCGCCGCCGCTCTCAG Protein Non coding 
2 
mRNA 
ATCGAGTCTTGCTCTGTCACCCAGGCTGGAGTGCAGTGGCGCGATCTCAGCTCACTGCCACCTTTGCCTCC
TGGGTTCAAGCGATTCTTCTGCCTCAGCCTCCCGAGTAGCTGGGATTACAG Protein Non coding 
3 
mRNA GCTCTGGGAACCACCCTTCTACTTTCTGTCTCTAGGAATTTCACTACTCTAG Protein Non coding 
4 
mRNA 
GGTGAAGAGGGAACAGAAATCTTTGCCCCCTGACTTTGGAAATCTCGTTTAACCTTCAAACTGGCGATGTC
AAGGGTTCCAAGTCCTCCACCTCCGGCAGAAATGTCGAGTGGCCCCGTAGCTGAGAGTTGGTGCTACACA
CAG Protein M S R V P S P P P P A E M S S G P V A E S W C Y T Q 
5 
mRNA 
ATCAAGGTAGTGAAATTCTCCTACATGTGGACCATCAATAACTTTAGCTTTTGCCGGGAGGAAATGGGTGA
AGTCATTAAAAGTTCTACATTTTCATCAGGAGCAAATGATAAACTGAAATG Protein I K V V K F S Y M W T I N N F S F C R E E M G E V I K S S T F S S G A N D K L K 
6 
mRNA 
GTGTTTGCGAGTAAACCCCAAAGGGTTAGATGAAGAAAGCAAAGATTACCTGTCACTTTACCTGTTACTG
GTCAGCTGTCCAAAGAGTGAAGTTCGGGCAAAATTCAAATTCTCCATCCTGAATGCCAAGGGAGAAGAAA
CCAAAGCTATGG Protein W C L R V N P K G L D E E S K D Y L S L Y L L L V S C P K S E V R A K F K F S I L N A K G E E T K A M 
7 
mRNA 
AGAGTCAACGGGCATATAGGTTTGTGCAAGGCAAAGACTGGGGATTCAAGAAATTCATCCGTAGAGATTT
CTTTTGGATGAGGCCAACGGGCTTCTCCCTGATGACAAGCTTACCCTCTTCTGCGAG Protein E S Q R A Y R F V Q G K D W G F K K F I R R D F L L D E A N G L L P D D K L T L F C E 
8 
mRNA 
GTGAGTGTTGTGCAAGATTCTGTCAACATTTCTGGCCAGAATACCATGAACATGGTAAAGGTTCCTGAGTG
CCGGCTGGCAGATGAGTTAGGAGGACTGTGGGAGAATTCCCGGTTCACAGACTGCTGCTTGTGTGTTGCC
GGCCAGGAATTCCAGGCTCACAAGGCTATCTTAGCAG 
Protein 
V S V V Q D S V N I S G Q N T M N M V K V P E C R L A D E L G G L W E N S R F T D C C L C V A G Q E 
F Q A H K A I L A 
9 
mRNA CTCGTTCTCCGGTTTTTAGTGCCATGTTTGAACATGAAATGGAGGAGAGCAAAAAG Protein A R S P V F S A M F E H E M E E S K K 
10 
mRNA 
AATCGAGTTGAAATCAATGATGTGGAGCCTGAAGTTTTTAAGGAAATGATGTGCTTCATTTACACGGGAA
GGCTCCAAACCTCGACAAAATGGCTGATGATTTGCTGGCAGCTGCTGACAAG Protein N R V E I N D V E P E V F K E M M C F I Y T G K A P N L D K M A D D L L A A A D K 
11 
mRNA 
TATGCCCTGGAGCGCTTAAAGGTCATGTGTGAGGATGCCCTCTGCAGTAACCTGTCCGTGGAGAACGCTG
CAGAAATTCTCATCCTGGCCGACCTCCACAGTGCAGATCAGTTGAAAACTCAGGCAGTGGATTTCATCAAC
TA Protein Y A L E R L K V M C E D A L C S N L S V E N A A E I L I L A D L H S A D Q L K T Q A V D F I N 
12 
mRNA 
TCATGCTTCGGATGTCTTGGAGACCTCTGGGTGGAAGTCAATGGTGGTGTCACATCCCCACTTGGTGGCTG
AGGCATACCGCTCTCTGGCTTCAGCACAGTGCCCTTTTCTGGGACCCCCACGCAAACGCCTGAAGCAATCC
TAAGATCCTGCTTGTTGTAAGACTCCGTTTAATTTCCAGAAGCAGCAGCCACTGTTGCTGCCACTGAC Protein Y H A S D V L E T S G W K S M V V S H P H L V A E A Y R S L A S A Q C P F L G P P R K R L K Q S Stop 
TABLE 6 – Location of prostate cancer associated mutations in the SPOP gene  
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1.8.7 - Isocitrate Dehydrogenase-1 and Prostate Cancer  
IDH-1 is the cytoplasmic and peroxisomal isoform of Isocitrate Dehydrogenase, an enzyme that 
catalyses forward and reverse conversions of α-ketogluturate (α-KG) to iso-citrate. The 
mitochondrial IDH-2 supports the same reaction in the tricarboxylic acid cycle, a major pathway in 
aerobic respiration that fuels ATP production via oxidative phosphorylation. Besides aiding 
metabolism, the reaction which produces α-KG is one of the major contributors to the cellular 
NADPH pool. NADPH is a necessary reducing co-factor in redox regulation (both thioredoxin and 
glutathione require it) as well as being extensively utilised in several major biosynthetic pathways 
(632). 
Mutation of the IDH1 gene was first reported in glioblastoma, shortly followed by acute myeloid 
leukaemia. Whilst these cancers have the largest prevalence of IDH-1 mutation, the enzyme has 
now been found to be affected in many solid tumour types, albeit at much lower frequencies 
(633). Mutation of the IDH-1 enzyme is postulated to be an early or founder event, as noted in 
brain cancer sequencing studies that predict occurrence prior to cellular transformation (634, 
635). These mutations affect a key active site arginine residue, R132, to alter the reaction 
performed by the enzyme. Instead of producing isocitrate, mutant IDH-1 forms the 
oncometabolite 2-hydroxygluturate (2-HG) that, due to the mutation-induced imbalance in the 
molecule’s metabolism, builds to extraordinarily high intracellular concentrations (636). As 2-HG 
closely resembles α-KG, (the C2 carbonyl group of α-KG is replaced by a hydroxyl group) the 
molecule competitively inhibits α-KG-dependent dioxygenases, that rely on the molecule as an 
essential co-factor in catalysis. This is an extremely diverse enzyme class with over eighty 
members in human cells, thus the effects of inhibitory 2-HG concentrations are extensive. Instead 
of a single pathway being defective, the 2-HG mediated dysregulation of both metabolism and 
chromatin structure means that disease phenotype is pleiotropic between cell types, with the 
true pathological molecular origin difficult to pinpoint amidst other background alterations (632, 
637)(Figure 25A). 
Oxidative Stress 
The reaction facilitated by IDH-1 boosts the NAPDH pool to indirectly protect the cell from 
oxidative stress. However, in gaining the neomorphic ability to create 2-HG, mutant IDH-1 
depletes rather than increases cellular NADPH. In doing so the mutation promotes a redox 
environment with a decreased buffer from the harmful effects of ROS (632). As expected IDH-1 
mutation increases oxidative stress within glioma cells; a state, depending on the genetic 
background of the tumour, that may promote or inhibit cancer growth (638). 
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DNA Methylation 
DNA hypermethylation is a hallmark of IDH-1 mutant tumours. The ten-eleven translocase (TET) 
dioxygenases are a family of proteins that begin the process of DNA demethylation by converting 
5-methyl-cytosine moieties to 5-hydroxymethyl-cytosines. IDH-1 mutant gliomas present with this 
methylated phenotype due to TET2 inhibition by 2-HG (639). Aside from the expected gene 
silencing by promoter methylation,(640) reduced clearance of 5-methyl-cytosine has been 
observed to disrupt CTCF insulator binding sites across the genome. In particular, a restrictive 
boundary point between a super-enhancer element and the PDGFRA oncogene was shown to be 
defective in mutant IDH-1 patient gliomas; facilitating overexpression of the growth factor 
receptor and conferring subsequent proliferative advantage to mutant cells (641). This discovery 
highlights the effects of inappropriate hypermethylation, not just at promoter CpG islands but, at 
an epi-genomic level whilst also presenting a case that IDH-1 mutation may promote similar 
deregulatory effects in other cancers. 
Histone Methylation 
The Jumonji-C (JmjC) domain histone demethylase family are another class of α-KG-dependent 
dioxygenases affected in IDH-1 mutant cells. The JmjC domain has been crystallised with 2-HG in 
the active site pocket typically occupied by α-KG. This particular protein structure was further 
associated with increased global histone methylation (642). The complete effect and impact of 
IDH-1 mutation on chromatin organisation is only just beginning to be investigated. A recent study 
(643) using IDH-1 R132H knock-in mice, linked decreased protein expression of ATM in progenitor 
blood cells (but not in more differentiated progeny) to an increase of H3K9me3 at the gene’s 
promoter. ATM reduction increased HSC DNA damage that the authors suggested could initiate 
transformation of the myeloid lineage, yet investigation in a human system or patient samples is 
required to observe whether the same phenotype prevails. The above study (643) highlights the 
need for cellular heterogeneity to be taken into account, due to the pleiotropic effects of the 
mutation in cells with variant genetic backgrounds and differentiation states. 
Extracellular Matrix Composition 
Collagen synthesis through the critical hydroxylation of proline and lysine residues by α-KG 
dependent prolyl hydroxylase domain containing proteins (PHDs) (644, 645) is an anabolic process 
affected by IDH-1 mutation. This has been observed to cause basement membrane disruption and 
also promotes ER stress through accumulation of the immature collagen proteins in the organelle 
(646). Chondrosarcoma, the second most prevalent form of bone cancer, has an enrichment of 
IDH-1 mutations that are often combinatorial with aberrations to the COL2A1 cartilage collagen 
gene – suggesting that the molecular pathology of this cancer is to achieve disruption of collagen 
108 
 
synthesis (647). Breakdown of the ECM, a hallmark of prostate cancers, alters cellular adherence; 
with associated growth and cell death signalling subsequently changing – all of which may 
promote transformation or indeed invasion and metastasis. 
Hypoxia Inducible Factor Signalling 
PHDs also regulate the hydroxylation of HIF1 and 2 in normoxic conditions to allow for recognition 
and subsequent proteasomal degradation via the VHL ubiquitin ligase. IDH-1 mutation would 
therefore hypothetically increase HIF levels due to PHD inhibition. This has been observed in 
glioma cells both in vitro (642) and ex vivo (648, 649). However, regulation of HIF stability relies 
on several other factors, and HIF protein levels have been observed to be decreased (650) and 
subsequent signalling pathways inhibited (651) in the context of IDH mutation. HIF regulation by 
the EGLN prolyl-4 hydroxylases therefore classically marks the context dependence of IDH-1 
mutations between and even within cancers. 
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FIGURE 25 – IDH-1 mutation in prostate cancer 
A) IDH1 gains a neomorphic capability via R132 mutation to create 2-hydroxygluturate (2-HG). 2-
HG levels build in mutant cells and inhibit prolyl-hydroxylases (PHDs) and chromatin modifiers to 
disrupt critical cellular processes. B) Prostate cancer IDH-1 mutations taken from COSMIC (652).  
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A multi-tissue sequencing project led to discovery of low frequency IDH-1 R132 point mutations in 
prostate cancer (653). These mutations have now been recurrently identified in many cohorts of 
prostate cancer patients (330, 608, 654-656)(Figure 25B & Table 7). 
IDH-1 R132 mutant tumours appear to present in early-onset prostate cancers yet the mutation 
doesn’t appear to track linearly through cancer progression (330). Mutation of the enzyme isn’t 
detected in sequencing studies of metastatic disease meaning; i) IDH-1 mutation is at too low a 
frequency to observe transition to “successful” metastasis, ii) IDH-1 mutant tumours never 
progress to an advanced stage, or iii) a cancerous progenitor clone without IDH-1 mutation stems 
the aggressive lineage, after the growth of the primary IDH-1 mutant tumour has acted as a 
“gateway” event. The low percentage of IDH-1 mutation in the total patient population probably 
does mask progression of primary to metastatic cancer. To date a single study has observed IDH-1 
mutation in a lung metastases, but again there are too few known incidences of mutation to make 
a conclusion from current data (657). 
These prostate tumours also exhibit extensive hypermethylation of their genomes, to an extent 
greater than that previously documented in IDH mutant gliomas and leukaemias (330). As 
hypermethylation in IDH-1 mutant cells also presents in prostate cancers, it would be expected 
that there are similar disruptive effects on transcriptional neighbourhood organisation seen in 
gliomas that may play an active role in disease (641). Metabolic alterations would also be 
expected in these tumours, as observed in glioblastoma, however low incidence has hampered 
investigation into the mutation’s effects in prostate cancer. Disruption of collagen synthesis in 
IDH-1 mutants may have effects on the CSC population of the prostate that typically express high 
levels of collagen’s cognate integrin; α2β1. How this population is affected with regard to collagen 
anabolism and the hypothesised increase of stem cell symmetrical division observed in IDH-1 
mutant mice models are important future questions (632, 639, 658). The convergent nature of 
IDH-1 R132 mutations has allowed several selective inhibitors to be developed that reduce 2-HG 
levels and genome hypermethylation in mutant cells.  Interestingly allosteric inhibitors of the 
mutant enzyme have been observed to induce differentiation of leukaemic stem like cells and 
implementation of these inhibitors in the small patient cohort affected in prostate cancer is a 
realistic future exploitation of patient specific medicine (659, 660). 
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Codon 
Nucleotide 
Change 
Amino Acid 
Change 
Location 
(Exon/Domain) Consequence Reference 
59G>A R20Q 5 Missense COSMIC UK - 
COSU538 
356G>A R119Q 6 Missense Barbieri 2012 
(133)  
395G>A R132H 6 Missense Barbieri 2012 
(133)  
395G>T R132L 6 Missense Barnett 2014 
(655) 
394C>A R132S 6 Missense Barnett 2014 
(655) 
394C>T R132C 6 Missense Barnett 2014 
(655) 
394C>G R132G 6 Missense Barnett 2014 
(655) 
TABLE 7 – All known IDH-1 mutations in prostate cancer 
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1.8.8 - TMPRSS2-ERG; a defining rearrangement in Prostate Cancer 
In men, TMPRSS2 is almost exclusively expressed in prostate tissue under canonical activation of 
the AR (661) and in 2005 the gene was shown to be commonly fused to members of the ETS TF 
family in prostate cancers; establishing a novel role in carcinogenesis and the possibility that ETS 
factor expression is driven by androgen signalling (351). The most common of the ETS fusions; 
TMPRSS2-ERG, is consistently observed in ~50% of all prostate tumours (90, 330, 662). 
The ERG gene is located at 21q22.3, downstream of TMPRSS2 at 21q22.2 meaning that a fusion 
can be created as a result of a deletion event or through a series of translocations (174, 351). The 
chromosomal alteration places the 5’ untranslated region (UTR) of TMPRSS2 upstream of ERG, 
causing inappropriate expression of the transcription factor, now under control of an active 
promoter region. A recent study also found that ERG alters the global chromatin state in prostate 
cancer and creates super-enhancers; regions of high transcriptional activity characterised by 
elevated H3K27 acetylation (663). One of these regions extends through the TMPRSS2-ERG locus 
to further promote ERG expression. TMPRSS2-ERG fusions are unique to each patient’s tumour at 
a genomic nucleotide level and are thought to be generated through regions of micro-homology 
by NHEJ following DSB formation (664). Higher levels of the NHEJ master-regulator BRD4 
associate with fusion positive cancers and the BET (bromodomain and extraterminal) protein 
regulates formation of TMPRSS2-ERG (665). The transcriptional activity of TMPRSS2 and the 
accessibility of ERG intronic chromatin also determines fusion formation (666).  
Next generation sequencing can capitalise on the unique genomic nature of the fusion 
breakpoints; and employ them as highly specific trunk mutation clonal markers. TMPRSS2-ERG 
can thus be used to track cell population origin, development and location in prostate cancers 
(131, 667). The variety of fusion transcripts (and thus protein products) between and within 
samples are diverse, however the most commonly observed exon-exon fusions are those between 
TMPRSS2 exon 1 and ERG exons 4 (as seen classically in the VCaP cell line) and 5 (351, 596). 
Distinct fusions show focal heterogeneity in prostate tumour biopsy samples demonstrating that 
different fusions can exist side-by-side and are independently generated through separate 
initiating events within the same prostate (668). 
Fusions generated by deletion of the region between the two genes are heterogeneous within 
and between patients, with variant start sites leading to production of different fusions. The 
deletions, rather than the rearrangement events, can be correlated with cancers that have higher 
biochemical recurrence (PSA levels) after treatment (662). The deletion also removes ETS2, an ETS 
family member that is observed to be mutated in fusion negative prostate cancers (335, 662). This 
gene is a candidate tumour suppressor (669) and overexpression of ETS2 in VCaP decreased 
cellular proliferation, migration and invasion (335). Chromoplexy acts as a factory for 
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chromosomal rearrangements in prostate cancer and recurrently produces TMPRSS2-ERG fusions 
(334). TMPRSS2-ERG+ tumours have greater inter-chromosomal rearrangements than those that 
lack a fusion event suggesting that TMPRSS2-ERG-centred chromoplexy has wider carcinogenic 
effects on the genome; such as coordinated loss of tumour suppressing loci including PTEN and 
3p14; an area containing three potential TSGs (90, 334). Analysis of separate tumours found that 
different chromoplectic chains can still produce the necessary genetic rearrangements required 
for fusion formation. 
Creation of TMPRSS2-ERG involves interphase co-localisation of the genes and topoisomerase II 
recruitment (350, 670, 671). It has been hypothesised that androgen signalling is responsible for 
the close proximity of the loci and thus facilitates the chain of translocations leading to TMPRSS2-
ERG (174). Exposure of LNCaP to androgens does cause de novo fusion formation, an event that 
remains specific to cells of prostatic origin.  
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FIGURE 26 – Generation of the TMPRRS2-ERG fusion in prostate cancer. 
Transcriptional proximity of the loci and the addition of micro-environmental stressors produce 
the fusion either by deletion or translocation of the intervening genetic material. The fusions are 
always produced in intronic regions and align early TMPRSS2 exons with later ERG exons.    
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This effect is enhanced by the presence of inflammation, which itself, in absence of androgen, can 
generate de novo fusions as modelled by TNF-α exposure (666). Inflammation mediated by ROS 
has been observed to create fusions in LNCaP, both in vitro and in vivo. Interestingly, the in vivo 
study highlighted critical involvement of macrophage cytokines and the role of the innate immune 
system in TMPRSS2-ERG formation. As the supposed aetiology of human prostate cancer is rooted 
in inflammation of the organ, these findings give molecular evidence for the initial transformation 
of prostate cells. Repetition of these experiments in cells of a “normal” genetic background would 
add further and necessary weight to this theory (Figure 26). 
DNA repair gene variants, including BRCA2, ESCO1 and POLI, have been identified in population 
linkage studies to be significantly associated with fusion positive cancers, suggesting that they 
produce a genetic background conducive to TMPRSS2-ERG fusion production (349). Interestingly 
genotoxic stress – like androgen and TNF-α exposure – also causes creation of the fusion in 
prostate cells (350). 
Expression profiles of the precursor lesion PIN and prostate cancer itself are extremely similar. 
The transition of PIN into malignancy correlates with increased expression of ERG, ETV1 and ETV4, 
all known fusion partners; suggesting that TMPRSS2 rearrangements act as founder events in 
prostate cancer (123). ERG fusions are observed in hgPIN with incidence correlating with a faster 
rate of progression into prostate cancer over fusion negative PIN patients (132). As the fusion is 
assumed to be an early event in the development of prostate cancer, it can be used to trace 
metastases back to their focal origin in the primary tumour (662). TMPRSS2-ERG is present in the 
CSC fraction of the prostate, postulating a self-renewing root for widespread fusion presence in 
prostate tumours (246)  and, in a genetically manipulated mouse model of the prostate, the 
fusion has indeed been shown to increase the self-renewal and invasiveness of basal progenitor 
(Sca-1hi, EpCAM+) cells, (672)  again suggesting TMPRSS2-ERG  plays a role in maintenance of the 
CSC population and allows for the subsequent mutational accumulation. 
Transgenic TMPRSS2-ERG+ mice developed PIN with selective ERG overexpression at disease foci 
and not in benign glands, suggesting that enhanced protein levels induce a neoplastic phenotype 
rather than initiate the cancer. Further investigation using cell lines found that the fusion also 
facilitated an invasive phenotype through overexpression of MMPs and urokinase plasminogen 
activator (uPA). ERG knockdown in these cells raised expression of canonical luminal cell markers 
suggesting that overexpression of the ETS factor sequesters prostate epithelial cells in a 
dedifferentiated state (427). The invasive phenotype has also been noted in patient samples 
where fusion positivity co-segregated with an increase in TGF-β signalling, a hallmark of EMT (673, 
674). 
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ERG in this context has been shown to upregulate PIM1. This kinase is an oncogene overexpressed 
in both haematological and epithelial malignancies and is implicated in docetaxel resistance of 
prostate cancer. PIM1 increases cyclin B levels to cause destabilisation of the G2/M checkpoint, 
resulting in aneuploidy and genomic instability in pre-malignant prostate cells (675). ERG 
regulation by AR also creates a wider network of cross talk between the two important TFs. 
Overlap of AR and ERG binding sites in VCaP cells found that ERG is co-recruited to around half of 
all AR-bound loci. One of the most enriched sites, identified by ERG ChIP-seq, was the AR gene 
itself. siRNA targeting of ERG caused an increase in AR protein levels highlighting that ERG has 
repressive effects on the androgen signalling axis, a finding that may have wider implications in 
CRPC (542). 
The recent development of ERG inhibitory peptides that reduce transcriptional activity, increase 
degradation of the transcription factor and suppress cancer progression in vitro and in vivo marks 
a promising and novel treatment strategy for the 50% of patients that present with the fusion 
(676). 
In primary prostate epithelial cells, a SNP-based pyrosequencing strategy was utilised to show 
RME of TMPRSS2 in the basal cell populations of cancer and BPH samples. The strongest allelic 
restriction of TMPRSS2 was seen in the stem cells, yet in most cases this was relaxed or even 
switched to the other allele upon asymmetric division in clonal TA cells. However, in TMPRSS2-
ERG+ cancers the fusion is solely expressed in the stem cell population with no expression of 
TMPRSS2 from the unfused “wildtype” allele. This doesn’t follow the random pattern of 
expression in the fusion negative samples and implies that the fused allele is somehow selected 
for in the stem cell, the allelic expression of which wasn’t correlative with promoter 
hypermethylation (246). 
Identification of genetic defects in SPOP, PTEN, IDH-1 and presence of the TMPRSS2-ERG fusion 
gene in primary prostate epithelial cultures will allow for allelic expression analysis to observe; i) 
whether mutant alleles are expressed, and ii) if there is any non-random selection of allelic 
expression in prostate cancers. This will inform whether mutations are actionable and, if 
observed, will introduce another layer of heterogeneity needed to be addressed and accounted 
for in the diagnosis and treatment of prostate cancer. 
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1.9 - Low Temperature Plasma and Oxidative Stress 
1.9.1 - Low Temperature Plasma as an anticancer therapy 
Treatments of localised (293) and metastatic prostate cancer (26) have improved over recent 
years, yet there remains the problem of overtreatment during the early stages of disease due to a 
lack of clinical biomarkers that can determine indolent or aggressive cancer (283, 677). Current 
focal treatments of organ-confined disease such as radiotherapy have high rates of recurrence 
that can be attributed to sub-clonal cell populations in the prostate (323, 678). Novel therapies 
are required to maximise treatment-options, increase overall success and effectively ablate the 
tumour initiating cell pool as discussed in Section 1.4. 
The ability to generate plasma at ambient air temperatures has allowed biomedical 
implementation of LTP devices and subsequently, the technology has been postulated as an anti-
cancer therapy (293). Plasma is formed through application of a sufficiently high voltage across a 
gas-flow; causing removal and subsequent acceleration of gas molecule electrons into the 
surrounding atoms and molecules. A reactive cascade of interconverting neutral and charged 
species is created in the plasma effluent, alongside the emission of UV radiation. Mixing of LTP 
with gas molecules in the air is known to produce high concentrations of ROS and RNS (679-684) 
that can cause subsequent oxidative stress, DNA damage, protein oxidation and lipid peroxidation 
in living cells (685, 686). 
LTP based treatment has now been applied to a wide range of cell line models including those 
representative of; prostate cancer, (304, 305) cervical cancer, (687) melanoma, (688, 689) 
leukaemia, (690) ovarian cancer, (691) breast cancer, (692, 693) head and neck cancer, (679) 
glioblastoma, (694, 695) lung cancer, (696, 697) colorectal cancer (698) and liver cancer (699). 
1.9.2 - Oxidative Stress – Antioxidant and Transcriptional Response 
In vitro studies, including our own (304), have examined the effect of LTP upon cancer cell 
cultures and arrived at congruent conclusions; plasma is able to generate ROS and RNS in both the 
medium and the cells (304, 679, 687, 695-697, 699). This in turn causes oxidative damage of 
lipids, (699) proteins (692) and DNA (305, 679, 688, 689, 692, 695, 700) to ultimately produce loss 
of viability and cell death in cultures (304, 679, 687, 688, 692). 
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FIGURE 27 –Low Temperature Plasma and Reactive Oxygen Species. 
A) The basal antioxidant defence network of a cell. The cellular NADPH pool maintains the 
Glutathione and Thioredoxin cycles that redox enzymes require to mount an effective response to 
oxidative stress and damaged proteins. B) The induction of ROS by LTP causes varied molecular 
and cellular damage that impacts cell fate decisions.  
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Oxidative stress is defined by the imbalance of ROS and cellular antioxidants; a state induced by 
LTP treatment and experimentally demonstrated by skewing of reduced and oxidised forms of 
cellular antioxidants and co-factors such as glutathione (GSH) and NADPH (696, 701, 702). 
Antioxidants limit ROS induced damage and include both scavenging proteins and ROS-converting 
enzymes. Non-enzymatic antioxidants can donate electrons to neutralise ROS. GSH is the primary 
cellular antioxidant and can prevent damage caused by free radicals and peroxides. Enzymatic 
antioxidants include many well-studied proteins such as the superoxide dismutases (SOD), 
thioredoxins (TXN), glutathione peroxidases (GPX), haem oxygenases (HMOX) and peroxiredoxins 
(PRDX). Haem oxygenase 1 is an inducible enzyme that exerts an antioxidant effect by creation of 
biliverdin from haem. Biliverdin is subsequently entered into a cycle that scavenges and depletes 
cellular ROS (703). The peroxiredoxins are involved in removal of hydrogen peroxide from cells, 
with their native reduced state being regenerated by GSH, TXN and sulfiredoxin (SRXN) (704-
706)(Figure 27A). 
Whilst oxidative stress response occurs rapidly through alterations in enzymatic activities, 
transcriptional programs are also augmented, to give cells a survival advantage in prolonged 
exposure. Gene expression response to ROS is mediated by a plethora of transcription factors 
such as Nrf2, HIF, NF-kB and AP-1 (686, 707). 
Nrf2 is restricted to the cytosol by dimers of Keap1, an adaptor protein of the Cullin 3 E3 Ligase 
that facilitates constitutive degradation of the transcription factor in non-stress conditions. Keap1 
is redox sensitive at several cysteine residues and modification of these thiols by ROS causes 
dissociation from Nrf2. Nrf2 then translocates to the nucleus whereupon it forms heterodimers 
with small Maf proteins. These dimers act as transcriptional activators for genes downstream of 
Antioxidant Response Elements (AREs) including; glutathione reductase (GSR), PRDX, TXN, 
TXNRD1 (thioredoxin reductase 1), CAT, SOD1, HMOX1, NQO1 and GPXs (708-713). Nrf2 is also 
phosphorylated by kinases, such as PKC and ERK, during oxidative stress which is also thought to 
aid the transcription factor’s dissociation from Keap1 (686). Recent studies have indicated the 
involvement of Nrf2-mediated anti-oxidant signalling in the cellular response to plasma. 
Application of LTP, and even plasma activated media, is adequate to promote nuclear 
translocation, cause upregulation of target genes and enhance ARE binding of the transcription 
factor (714-716). 
Previous studies have also shown that LTP triggers MAPKs such as JNK, p38 and ERK (JNK and p38 
are also termed stress-activated protein kinases, SAPKs) through canonical phosphorylation of 
these proteins, allowing for activation of downstream apoptotic and response pathways (679, 
687, 715, 716). A microarray based approach in a lung cancer cell line identified increased 
expression of Jun and Fos transcription factors alongside increased activation of JNK in response 
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to LTP (717). Activator Protein 1 (AP-1) is a collection of several dimeric basic leucine zipper 
proteins belonging to the Jun, Fos, Maf and ATF families; although, classically, AP-1 is formed by 
Jun-Fos heterodimers. Transcriptional activity can be induced by ROS through phosphorylation of 
Jun by JNK and p38 (718). JNK phosphorylation can be induced by many upstream activators. 
Among these are ASK1, another kinase that is activated by hydrogen peroxide induced TXN 
oxidation, and the redox sensing GST(µ/π) to which JNK, and ASK1, are associated with in non-
stress conditions (414, 686, 719, 720). 
Activation of these TFs would allow cells to respond at a molecular level to the oxidative stress 
induced by LTP. Differential gene targets between normal and cancerous cells may have potential 
to be pharmacologically exploited to sensitise prostate cancers to plasma treatment over 
surrounding normal tissue. 
1.9.3 - Cell Fate in LTP induced Oxidative Stress 
Our own studies using primary prostate epithelial cells have shown that, instead of the usual 
apoptosis observed in cell line studies, the mechanism of cell death is necrosis (304). This can be 
interpreted as an abortive action when a cell has sustained a level of damage that cannot be 
salvaged. ROS excess switches cell death from apoptosis to necrosis as mitochondrial dysfunction 
reduces cellular ATP level, whilst ROS and RNS can inhibit caspases through oxidative modification 
or S-nitrosylation of the reactive thiol (721, 722).  
Oxidative stress can also lead to senescence through stalling of the cell cycle, which occurs as lipid 
peroxides prolong G1 phase, with aldehyde oxidation products also causing CDK and DNA 
polymerase inhibition. Oxidative DNA damage further contributes to stabilise p53 through JNK 
and p38 phosphorylations causing either restriction point stalling or apoptosis (414, 722). 
Interestingly we also noted an enhanced autophagy response – an increased level of mature LC3-
B - in the primary prostate cultures treated by LTP, suggesting that this salvage pathway may play 
a role in the survival of certain cells (304). Autophagy allows for absorption of defective 
organelles, such as mitochondria, and abnormal protein aggregates in stressed cells. This process 
relies on the double membrane formation of the autophagosome that degrades interred 
organelles or cellular bodies upon lysosomal fusion. Autophagy is induced by superoxide and 
hydrogen peroxide and is thought to be mediated through lipid peroxidation and specific Cys81 
thiol modification of Atg4, a key protein in autophagosome formation. Active Atg4 is critical in the 
formation of LC3-BII that coats the inner surface of the autophagosome whereupon it acts as a 
binding site for poly-ubiquitinated protein aggregates under the escort of the p62/SQSTM1 
chaperone protein (723, 724). Sequestosome 1 (SQSTM1) is an Nrf2, NF-kB and AP-1 target gene 
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(725, 726). Dysfunctional autophagy increases cellular oxidative stress as recycling of 
mitochondria, the major source of endogenous ROS, becomes defective (727)(Figure 27B). 
1.9.4 - Oxidative Stress in Prostate Cancer 
Cancer cells generally have a higher ROS threshold that allows them to dampen cell death signals 
normally induced by higher ROS concentrations and allows further aberrant signalling to be 
mediated by the oxygen species. For example, GSH levels are higher in some cancers to buffer the 
excess ROS and transcriptional changes seen in oxidative stress are enhanced, allowing for 
aberrant activation of these signalling pathways such as AKT-mediated apoptosis inhibition and 
cellular proliferation (702).  
Various cancers contain mutations in genes involved in ROS management and stress response. 
Antioxidant enzymes SOD2 and GPX are mutated in prostate and other cancers along with the 
oxidative DNA damage repair enzymes OGG1 and APE1 (686). The same is true of the 
transcription factor Nrf2 and its antagonising protein Keap1 (728). Epigenetic regulation of genes 
can also be disturbed by oxidative stress; ROS can increase DNMT expression leading to gene 
(BRCA1, RB1, MDM2, MLH1 and KEAP1) silencing and genome hypermethylation (702, 728). As 
mitochondria are the primary source of endogenous ROS, tumours can redirect their metabolic 
pathways into glycolysis, a change called the Warburg effect. This activates anaerobic hypoxic 
respiration, and also sets up a miniature Cori cycle with recruited cells. In oxidative stress, the 
process of oxidative phosphorylation becomes restricted, leading to pyruvate kinase inhibition 
and pentose phosphate pathway (G6PD) activation.  The resultant increased production of NADPH 
is able to maintain GSH in a reduced state, facilitating ROS scavenging (729, 730) and contributing 
to tumour cell ROS resistance. 
ROS resistance is enhanced in CSCs. The tumourigenic cell fraction in breast cancer was shown to 
have lower levels of ROS and higher levels of antioxidant proteins and enzymes. The importance 
of the antioxidant levels was demonstrated through the depletion of GSH which caused a 
significant reduction in colony forming efficiency of the CSCs (731). The majority of cancer 
treatments induce ROS; upregulation of the antioxidant network in the tumour initiating cells 
would aid their commonly observed radio- and chemoresistance. 
As part of the ROS-induced transcriptional response, mutations to KEAP1 that affect Nrf2 binding 
have been observed in prostate cancer cell lines and tumour samples; with epigenetic silencing, 
via DNA methylation of the gene, observed in Du145 cells (732). However, most studies 
investigating Nrf2 in prostate cancer report a reduction in levels of the TF, (733) with promoter 
methylation perhaps reducing transcript levels (734). Decreased Nrf2 presumably facilitates an 
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environment of oxidative stress to aid chromoplectic genome rearrangements and cellular 
transformation (734). 
AP-1 has context-dependent effects in prostate cancer due to its dual role in promoting both cell 
proliferation and apoptosis. Whilst the AP-1 axis isn’t notably affected by mutation or 
rearrangement, levels of the transcription factors in the various stages of disease appear to 
contribute towards clinical outcome.  
JUNB (cJun homologue) mRNA and protein levels decrease during cancer progression, where 
JUNB loss synergises with PTEN deletion mutants to promote invasive prostate cancer in 
transgenic mice (735). However, another study found PTEN loss caused JNK, and subsequent Jun, 
activation through PI3K. Positive correlation of pAKT and pJun levels in human prostate cancer 
tissue microarrays were then identified as a supposed result of common PTEN phosphatase 
deletion (736). AP-1 is elevated in more advanced prostate cancers with JNK driving disease 
progression from adenocarcinoma to metastatic disease in mouse models (737). Expression of 
both Fos and Jun increases throughout disease. Incidence peaks in metastases where significant 
co-expression is also observed. Activation of Jun, in particular, is predictive of decreased patient 
survival following relapse from ADT, suggesting that the AP-1 pathway may act as a driver of 
androgen independent disease (738, 739). 
By identifying the transcriptional networks activated following plasma treatment of primary 
prostate epithelial cultures, derived from multiple disease contexts, the upstream transcription 
factors can be identified. An increased understanding of how prostate epithelia react to LTP will 
afford insight to how resistant populations can survive the oxidative stress induced by treatment 
whist also informing on possible sensitising treatments for cancerous cells over that of adjacent 
normal tissue to maximise the killing effect of the focal therapy. 
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2. Thesis Aims 
AIM 1 
To identify if genes commonly altered in prostate cancer are monoallelically expressed 
and, if so, whether mutation of the gene affects allelic expression. 
Random monoallelic expression provides a source of expression heterogeneity. In the knowledge 
that allelic imbalances are molecular determinants of prostate cancers the phenomenon was thus 
investigated in primary prostate epithelial cultures. The study had two goals, to; 
• Determine if silent and expressed TMPPRSS2 alleles are marked by histone 
trimethylations associated with monoallelic expression in primary prostate epithelial 
subpopulations. Ascertain whether these also correlate with allele specific expression of 
TMPRSS2-ERG fusion in prostate cancer samples.  
 
• Analyse allelic expression of SPOP, PTEN and IDH1 and assess whether mutation of these 
commonly altered genes changes allelic expression. 
AIM 2 
To identify the molecular signalling events in prostate epithelia after Low Temperature 
Plasma exposure that are associated with the resistant population.  
LTP is a promising novel focal therapy for prostate cancer. Our previous work has identified a 
potent killing effect; however, a viable population of cells remained after treatment. This resistant 
population may cause regrowth and relapse of the tumour. By identifying the immediate 
signalling events that contribute to post-LTP survival it may be possible to sensitise the resistant 
population using combination therapy. The study had the following goals; 
• Identify whether oxidative stress response signalling was initiated by LTP. 
 
• Find altered signalling pathways after treatment using whole transcriptome analysis. 
 
• Identify active signalling intermediates and transcription factors upstream of gene 
expression. 
 
• Connect gene expression and transcription factor response to the resistant population. 
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3. Materials and Methods 
3.1 –Cell and Tissue Culture 
Primary Cell Culture 
Primary epithelial cells were dissociated from patient prostate tissue as previously described 
(Collins 2005)(28). For matched Gleason 7 and Normal cells, tissue was obtained through needle 
biopsy immediately following surgical removal of the prostate. Biopsy sites were informed by 
previous pathology, imaging and palpitation. BPH and Gleason 9 tissue were obtained through 
trans-urethral resection of the prostate. All tissues were transported in RPMI-1640 supplemented 
with 5% foetal calf serum (FCS) and 100U/ml antibiotic/anti-mycotic solution at 4oC and processed 
within 6 hours of surgery. All tissue was obtained with full ethical permission and consent of the 
patient through agreement with Hull Hospital - REC ref 07/H1304/121. Patient samples were 
anonymised before receipt at the York Cancer Research Unit.  
Primary cells were grown on Collagen I coated 10cm dishes (Corning) in 5ml stem cell media 
(SCM). This is based upon keratinocyte serum free media supplemented with  L-glutamine, stem 
cell factor, granulocyte macrophage colony stimulating factor, cholera toxin, bovine pituitary 
extract (Gibco), epidermal grown factor (Gibco) and leukaemia inhibitory factor, see Collins 2005 
(28). Primary cells were cultured in the presence of irradiated STO mouse feeder cells. No 
antibiotic/anti-mycotics were used to treat the cultures.  
STOs were grown in D10 media [DMEM (Gibco) supplemented with 10% FCS and L-glut]. Batches 
of STOs, for use as feeder cultures of primary cells, were irradiated (60Gy) and resuspended in 
KSFM to be used within 4-5 days and kept at 4oC. STOs were depleted by outgrowth of the 
epithelial cells before any plasma treatments so as to remove any mouse cell artefacts (19). 
Cell stocks were centrifuged to form pellets at 1500rpm for 5 minutes in the IEC CL30R centrifuge 
(Thermo Scientific). The pellet was then re-suspended in 1ml of filtered Freezing Media (7 parts 
RPMI 1640, 2 parts FCS and 1 part DMSO), transferred to a Cryo S cryovial (Greiner) and labelled. 
The sample was frozen in CoolCell LX foam freezing chamber (Biocision) from room temperature 
to -80oC and then transferred to liquid nitrogen dewars. Retrieving frozen stocks involved thawing 
the samples to 37oC, adding the sample to 2ml of its growth media in a 15ml falcon (Greiner) and 
then spinning down at 1500rpm for 5 minutes to pellet the cells. The pellet was re-suspended in 
the appropriate volume of growth media and the cells applied to tissue culture plastic. 
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Selection of Basal Epithelial Subpopulations 
Six Collagen I coated 10cm dishes (Corning) were blocked with 3ml PBS – 0.3% BSA (that had been 
heat treated at 80oC for 10 minutes followed by vacuum filtration) for 1 hour at 37oC. Whilst the 
plates were blocking, the whole population cultures (≥6x10cm confluent plates) were trypsinised, 
neutralised in R10 [RPMI-1640 (Gibco) supplemented with 1% L-glutamine (Gibco) and 10% FCS 
(Gibco)], spun down at 1500rpm for 5 minutes in the IEC CL30R centrifuge (Thermo Scientific) and 
then re-suspended in 9ml SCM. Blocked plates were removed after the elapsed time and washed 
in PBS. Blocked plates were then labelled; 3x SC/TA, 3x Intermediate. 3ml of cells were applied to 
each of the three SC/TA blocked plates and placed in the incubator for 5-10 minutes. The 
adherent cells after this time are the SC/TA population. Plates were removed from the incubator 
and the media containing non-adherent cells collected. Plates were then washed twice with 3ml 
PBS – that was also collected and placed into the media containing tube. The plates of adherent 
SC/TA cells were then trypsinised for 10 minutes. The cells in suspension were pelleted at 
1500rpm for 5 minutes and then re-suspended in 9ml SCM. 3 ml of the suspended cells were 
added to each of the three remaining blocked plates and incubated for 30 minutes. The 
trypsinised SC/TA cells were neutralised in R10 and spun down at 1500rpm for 5 minutes. If any 
adherent cells remained they were removed with 10X trypsin-EDTA. The SC/TA cells were then re-
suspended, in the amount of media required for the next assay, and counted. The second set of 
blocked plates were removed after 30 minutes and non-adherent CB cells collected, as before; 
removal of media and collection of two PBS washes. The adherent intermediate cells were 
trypisinised. CB cells were span down at 1500rpm for 5 minutes and counted. Intermediate cells 
were then collected in the same manner as the SC/TA population. SC/TA and CB populations were 
then either applied to plates or harvested immediately depending on the following treatment. 
For gDNA; intermediate cells were pelleted in the Accuspin Micro microcentrifuge (Fisher 
Scientific) – 2 minutes at 6500rpm. Pellets were washed in 1ml PBS, and spun down at the same 
speed and time. The PBS was aspirated and the pellet frozen at -80oC until gDNA extraction. 
For RNA; cells were grown in 12 well plates with 100,000 cells per well in 1ml SCM. They were left 
to adhere overnight before treatment and harvesting, or harvested immediately by spinning down 
at 6500rpm for 2 minutes in the Accuspin Micro microcentrifuge (Fisher Scientific), washed in PBS 
and re-pelleted. PBS was aspirated and the pellet frozen at -80oC until RNA extraction. 
For Protein; cells were grown in 6 well plates with 500,000 cells per well in 2ml SCM. They were 
left to adhere overnight before treatment and harvesting. Harvesting was either as cell pellets or 
protein lysate in 4X SDS protein buffer – See SDS-PAGE and Western Blotting section. 
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For Chromatin; cells were re-suspended in 2ml SCM and 54μl formaldehyde (36.5-38%)(Sigma 
Aldrich) was added. The sample was incubated in the formaldehyde for 15 minutes and flicked to 
prevent the cells settling on the bottom of the tube. After the allotted time the formaldehyde was 
neutralised with 1M glycine for 5 minutes. The sample was then centrifuged for 5 minutes at 
1000rpm at 4oC in the IEC CL30R centrifuge (Thermo Scientific). The pellet was rinsed twice in 4ml 
of ice cold PBS – both times the cells were spun down for 3 minutes at 2500rpm at 4oC. PBS was 
aspirated and the pellet frozen at -80oC before ChIP. 
Cell line culture 
See Table 2 in Section 1.7 for more details on prostate epithelial cell lines. 
• BPH-1 cells were grown in R5 [RPMI-1640 (Gibco) media supplemented with 5% FCS and 
1% L-glutamine (Gibco)]. 
• PNT1a cells were grown in R10 media. 
• PNT2-C2 cells were grown in R10 media. 
• P4E6 cells were grown in K2 [KSFM media (Gibco) supplemented with bovine pituitary 
extract, epidermal growth factor (Gibco), 2% FCS and 1% L-glutamine (Gibco)].  
• PC3 cells were grown in H7 [Hams F-12 media (Lonza) supplemented with 7% FCS and 1% 
L-glutamine (Gibco)]. 
• LNCaP cells were grown in R10 media. 
• Du145 cells were grown in R10 media. 
• VCaP cells were grown in R10 media on Corning Cell Bind T25 flasks (Corning). 
Cells were cultured in the absence of antibiotics and anti-mycotics on, unless specifically stated, 
standard tissue culture plastics supplied by Corning or Starstedt and incubated at 37oC with 5% 
CO2. 
3.2 – Molecular Analyses 
RNA extraction 
Cells were harvested by trypsinisation (1X Trypsin-EDTA (Gibco) and neutralised with equal 
volume of R10. They were then centrifuged for 5 minutes at 1500rpm in an IEC CL30R centrifuge 
(Thermo Scientific) then washed in 1ml PBS before final centrifugation at 6500rpm for 2 minutes 
to produce a cell pellet in an Accuspin Micro microcentrifuge (Fisher Scientific). RNA extractions 
were performed on fresh cell pellets, pellets previously stored at -80oC or by direct in-plate lysis 
(addition of complete RLT buffer followed by storage at -80oC overnight) using the RNeasy Micro 
Kit (Qiagen) following the manufacturer’s instructions for the animal cell protocol that proceeds 
as follows. 
127 
 
One part Β-mercaptoethanol (BioChemica) was added to one hundred parts RLT buffer, and 600μl 
of this mix was added to the cell pellet and mixed using a pipette. Lysates were then transferred 
into a QIAshredder column (Qiagen) in a 2ml collection tube and centrifuged for 2 minutes at 
13,000rpm in the Accuspin Micro microcentrifuge (Fisher Scientific). 600μl of 70% ethanol was 
added to the flow-through, mixed by pipette until homogenous and then aliquoted into an 
RNeasy Mini column in a 2ml collection tube. These were centrifuged at 8000rpm for 15 seconds 
(s) and flow-through discarded. Genomic DNA contamination was removed by on-column 
application of the RNase-free DNase Set (Qiagen) – this involved a wash step of 350μl Buffer RW1 
(8000rpm for 15s, flow-through discarded) before application of 70μl:10µl mix of Buffer 
RDD:DNase. Columns were left to stand at room temperature for 15 minutes before a second 
Buffer RW1 wash step as before. 500μl of Buffer RPE was then used to wash the column, 8000rpm 
for 15s and flow-through discarded. This step was repeated with a final 2-minute centrifugation. 
The column was transferred to a fresh collection tube and centrifuged at 13,000rpm for 1 minute. 
The collection tube and flow-through were discarded and the column placed in a 1.5ml labelled 
Eppendorf. RNA was eluted from the column with 30µl of PCR quality water (Sigma) directly 
pipetted onto the membrane and centrifuged for 1 minute at 8000rpm, this step was repeated for 
a total volume of 60µl RNA. Concentration was measured on the Nanodrop ND-1000 (Labtech) 
and either proceeded directly into cDNA synthesis or stored at -80oC. 
cDNA synthesis 
cDNA was synthesised directly from purified RNA using either the iScript cDNA synthesis kit 
(BioRad) or Superscript III or IV kits (Invitrogen), depending on availability in the laboratory. All 
mastermixes (MMs) were made up in the Mini V/PCR hood (Telstar) and the RNA added on bench. 
cDNA was stored at -20oC or used immediately in qRT-PCR assays or RT-PCR. 
iScript 
MM was made up of (for one reaction); 4μl iScript RT Supermix and 14μl of PCR quality water 
(Sigma). This was mixed with a pipette, pulse centrifuged and added to 2μl of template RNA 
(≤1μg). Reactions were then placed into the GeneAmp PCR System 9700 thermal cycler (Applied 
Biosystems) and entered into a program of; 25oC for 5 minutes, 46oC for 20 minutes and 95oC for 
1 minute. Sample cDNA concentration was assessed using the Nanodrop and diluted to stock and 
working concentrations in PCR quality water (Sigma). 
Superscript III 
All reagents marked with (*) are supplied in kit from Invitrogen and reactions carried out as per 
manufacturer’s instructions. MM1 for each reaction consisted of; 1μl Random Hexamer* (50g/μl), 
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1μl dNTP* (10mM). This was mixed using a pipette and added to 10μl sample RNA (≤5μg) and 
reactions placed in GeneAmp PCR System 9700 thermal cycler (Applied Biosystems) for 5 minutes 
at 65oC followed by 2 minutes on ice. At this point MM2 was made. Each reaction contained; 4μl 
First Strand Buffer*, 2μl DTT* (100mM), 1μl RNase OUT* (40U) and 1μl Superscript III Reverse 
Transcriptase* – mixed using a pipette and then pulse centrifuged. 8μl of MM2 was then added to 
each reaction before the tubes were again placed in the thermocycler; 25oC for 10 minutes, 42oC 
for 50 minutes, 15 minutes at 72oC, hold at 4oC. cDNA was then isolated using the QIAquick PCR 
Clean up kit (Qiagen) as described in PCR Product Purification. Following clean up, sample cDNA 
concentration was assessed using the Nanodrop and diluted to working concentrations in PCR 
quality water (Sigma). 
Superscript IV 
All reagents marked with (*) are supplied in kit from Invitrogen and reactions carried out as per 
manufacturer’s instructions. MM1 for each reaction consisted of; 1μl Random Primers* (50μM), 
1μl dNTPs* (10mM), 2μl PCR quality water (Sigma). MM1 was mixed using a pipette, pulse 
centrifuged and 4μl added to 1.5μl of template RNA (≤5μg) in PCR tube. Tubes were placed in 
GeneAmp PCR System 9700 thermal cycler (Applied Biosystems) for 5 minutes at 65oC followed by 
1 minute on ice. At this point MM2 was made. Each reaction was made up of; 4µl of 5X SSIV 
Buffer* (after vortexing and pulse centrifugation), 1µl DTT* (100mM), 1µl RNase OUT* (40U) and 
1µl Superscipt IV Reverse Transcriptase*. MM2 was mixed using a pipette, pulse centrifuged and 
7µl added to the MM1 + RNA on ice. The reactions were again placed in the thermal cycler on the 
following program; 23oC for 10 minutes, 50oC for 10 minutes and 80oC for 10 minutes. Each 
sample then had 1μl RNase H* added and placed back in the thermal cycler for 20 minutes at 
37oC. cDNA concentration was measured on the Nanodrop and diluted in PCR quality water 
(Sigma) to appropriate working stock concentrations. 
Quantitative Real Time PCR (qRT-PCR)  
qRT-PCR was performed in FrameStar 96 qRT-PCR plates (4titude). Input cDNA was standardised 
at 30ng per well and biological samples averaged from technical triplicate measurements. MM 
was constituted in the Mini V/PCR hood (Telstar) and was added 7μl per well (giving a total 
volume of 10μl) before the wells were protected by a clear adhesive cover and the plate 
centrifuged at 1000rpm for 2 minutes in the Heraeus Megafuge 1.0R centrifuge (Thermo Fisher). 
TaqMan probes were purchased from Thermo Fisher and BioRad, and are listed in Table 8. qRT-
PCR was performed using the C1000 Thermal Cycler and CFX96 Real-Time System (BioRad) under 
the following protocol for all applications; 95oC – 2 minutes, 39 cycles; 95oC for 5s, 60oC for 30s, 
4oC Hold. When using TaqMan Fast Universal Master Mix (Applied Biosystems) the following PCR 
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was used; 95oC – 10 minutes, 39 cycles; 95oC for 15s, 60oC for 60s, 4oC Hold.  Machine reader 
heads were configured to WHITE-ALL CHANNELS (Thermo Fisher Taqman & BioRad Taqman), or 
WHITE-FAM ONLY (Thermo Fisher Taqman) dependent on Taqman probes used. Data was 
annotated using the CFX Manager 2.0 (BioRad) and analysed using the 2-ΔΔCt method in Microsoft 
Excel (740).  
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Gene Target Probe Company Code 
HMOX1 FAM BioRad qHsaCIP0033307 
HSPA1A FAM BioRad aHsaCEP0040036 
JUN FAM BioRad qHsaCEP0032009 
GAPDH TexRed BioRad qHsaCEP0041396 
SOD2 FAM Thermo Fisher Hs00167309_m1  
GPX2 FAM Thermo Fisher Hs01591589_m1  
NOS2 FAM Thermo Fisher Hs01075529_m1 
RPLP0 FAM Thermo Fisher Hs99999902_m1 
NRARP FAM Thermo Fisher Hs04183811_s1  
HES1 FAM Thermo Fisher Hs00172878_m1  
SOX9 FAM Thermo Fisher Hs00165814_m1  
IL6R FAM Thermo Fisher Hs01075664_m1  
NR4A1 FAM Thermo Fisher Hs00374226_m1  
NR4A2 FAM Thermo Fisher Hs01117527_g1  
NR4A3 FAM Thermo Fisher Hs00545009_g1  
FOSB FAM Thermo Fisher Hs00171851_m1  
DUSP10 FAM Thermo Fisher Hs00200527_m1  
SQSTM1 FAM Thermo Fisher Hs01061917_g1  
JUN FAM Thermo Fisher Hs01103582_s1  
HMOX1 FAM Thermo Fisher Hs01110250_m1  
18S VIC Thermo Fisher Hs99999901_s1 
TABLE 8 – TaqMan probes used in study.  
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SDS-PAGE and Western Blotting 
Cell lysates were either prepared from frozen pellets or cells were directly lysed in 6-well plates 
following plasma treatment. Each individual protein lysate sample required 5x105 cells. 
Cell pellet lysates were prepared by resuspension in 80μL CytoBusterTM Protein Extraction 
Reagent (Novagen) with PhosStop phosphatase inhibitors (Roche), cell debris removed by 
centrifugation in the Accuspin Micro microcentrifuge (Fisher Scientific) (13,000rpm, 5 minutes) 
and protein content measured by PierceTM BCA Protein Assay Kit (Thermo Fisher Scientific). BCA 
Assays were performed according to manufacturer’s instruction in a 96 well plate (Starstedt). A 
2mg/ml stock of Bovine Serum Albumin (Sigma) was prepared in CytoBusterTM Protein Extraction 
Reagent, this was then serially diluted in triplicate across the wells (10μl/well) of the 96 well plate 
to produce standards. 10μl of protein sample, unknown concentration, was then pipetted into 
separate wells before addition of 190µl of BCA reagent (1 part Reagent B to 50 parts Reagent A). 
The plate was incubated at 37oC for 30 minutes before absorbance at 562nm was measured using 
the POLARstar OPTIMA plate reader (BMG Labtech). Data collected by the FluoSTAR OPTIMA 
program and protein concentration of the unknown samples calculated using Microsoft Excel.  
20µg of protein with the appropriate amount of 4X SDS protein sample buffer (40% glycerol, 
240mM Tris-HCl pH 6.8, 8% SDS, 0.04% bromophenol blue, 15% beta-mercaptoethanol) was 
incubated at 95oC for 5 minutes before loading onto an acrylamide gel. 
In-plate cell lysates were prepared by direct application of 200μL/well 4X SDS protein sample 
buffer followed by cell scraping. Samples were then sonicated for 3x 10s using the Soniprep 150 
(MSE Sanyo) and incubated at 950C for 5 minutes on a heatblock (Grant BT3). 40μL of lysate was 
loaded per well. 
Protein samples were resolved on 10% acrylamide gels for 2 hours at 110V with 10μl Precision 
Plus Kaleidoscope Prestained Protein Standards (BioRad). Proteins were transferred onto PVDF 
Immobilon P membranes (Merck Millipore) for 1 hour at 100V, with ice-pack. The membrane was 
blocked for 1 hour in 5% milk-TBS at room temperature before primary antibody was applied in 
1% milk-TBS overnight at 4oC. After overnight incubation the membrane was washed 3x 5 minutes 
in TBS-Tween and secondary antibody applied; either anti-mouse or anti-rabbit HRP, at 1:10,000 
in 1% milk-TBS. The membrane was washed 3x 5 minutes in TBS-Tween and then developed, using 
BM Chemi-luminescence Western Blotting Substrate (POD)(Roche), and viewed on the 
GeneGnome XRQ (Syngene). For all primary and secondary antibodies used, see Table 9. 
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Target Species Dilution Used Code Company 
Nrf2 Rabbit polyclonal 1:500WB/1:100IF ab137550 Abcam 
Keap1 Mouse monoclonal 1;500 ab119403 Abcam 
Keap1 (IF) Rabbit monoclonal 1:100 D6B12 #8047 Cell Signalling 
Technologies 
Phospho-SAPK/JNK 
(Thr183/Tyr185) 
Rabbit monoclonal 1:500 81E11, 
#4668  
Cell Signalling 
Technologies 
SAPK/JNK Rabbit monoclonal 1:500 #9252  Cell Signalling 
Technologies 
Phospho-cJun (Ser63) Rabbit monoclonal 1:500 54B3, #2361  Cell Signalling 
Technologies 
Phospho-cJun (Ser73) 
(IF) 
Rabbit monoclonal 1:100 #9164   Cell Signalling 
Technologies 
cJun Rabbit monoclonal 1:500 60A8, #9165  Cell Signalling 
Technologies 
Cleaved Notch1 
(Val1744) 
Rabbit monoclonal 1:500 D3B8 #4147 Cell Signalling 
Technologies 
NOTCH1 Rabbit polyclonal 1:500WB/1:100IF ab27526 Abcam 
NF-kB (p65) Rabbit monoclonal 1:500 D14E12 
#8242 
Cell Signalling 
Technologies 
NF-kB (p65) (IF) Rabbit monoclonal 1:400 D14E12 
#8242 
Cell Signalling 
Technologies 
IkBα Rabbit monoclonal 1:500 [E130] 
ab32518-100 
Abcam 
Phospho-IkBα (Ser32) Rabbit monoclonal 1:500 14D4 #2859 Cell Signalling 
Technologies 
CD49b-FITC (IF) Mouse polyclonal 1:800 MCA743F Serotec 
NIK Rabbit polyclonal 1:500 #4994 Cell Signalling 
Technologies 
Actin Rabbit monoclonal 1:10,000 04-1040, 
clone EP184E 
Merck-Millipore 
GAPDH Rabbit polyclonal 1:10,000 ab9485 Abcam 
Anti-Mouse HRP Goat 1:10,000 115-035-003 Affinipure 
Anti-Rabbit HRP Goat 1:10,000 7074P2 Cell Signalling 
Technologies 
Anti-Rabbit 
AlexaFluor 568 (IF) 
Goat 1:1000 A11036 Life 
Technologies 
Anti-Mouse 
AlexaFluor 568 (IF) 
Goat 1:1000 A11031 Invitrogen 
TABLE 9 – Antibodies used in study.  
IF – Immunofluorescence, WB – Western blot. Antibodies that have no notation after their name 
were used in western blotting experiments.  
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Densitometry Analysis 
All western blot images were edited on GIMP 2.8 (GNU Image Manipulation Program) prior to 
densitometry analysis. In GIMP, the image colour output levels were reduced to avoid saturating 
the image analyser in the next step. Densitometry acquisition was performed using Image Studio 
Lite 5.2 (Licor). Using the analysis tools, a box was drawn around the band and the box copied (to 
not allow for any change in area affecting densitometry analysis) and pasted to surround adjacent 
bands. The readout from the densitometry then allowed results to be analysed using Excel 2010 
(Microsoft). 
In Excel, house-keeping gene normalisation as a loading control formed the first step of analysis. 
The lowest densitometry score for a house-keeping band was used to normalise the other house-
keeping gene bands (division of the band score by the lowest score) – so that the lowest score 
was 1 and the other bands scored ≥1. The other protein bands in the lane were then divided by 
this score, for example proteins in the same lane as the lowest house-keeping gene band 
densitometry scores went unchanged as they were just divided by 1. Treatment induced changes 
in the levels of protein were then determined by dividing the normalised score of treated 
densitometry by the normalised untreated densitometry. This allowed for absolute protein level 
changes to be calculated but not phosphorylation of cleavage events. 
Phosphorylation events were calculated from the house-keeping normalised scores in the 
following equation;  
[
𝑝ℎ𝑜𝑠𝑝ℎ𝑜𝑃𝑟𝑜𝑡𝑒𝑖𝑛𝑇𝑟𝑒𝑎𝑡𝑒𝑑 
𝑝ℎ𝑜𝑠𝑝ℎ𝑜𝑃𝑟𝑜𝑡𝑒𝑖𝑛𝑈𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑
]
[
𝑇𝑜𝑡𝑎𝑙 𝑃𝑟𝑜𝑡𝑒𝑖𝑛𝑇𝑟𝑒𝑎𝑡𝑒𝑑 
𝑇𝑜𝑡𝑎𝑙 𝑃𝑟𝑜𝑡𝑒𝑖𝑛𝑈𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑
]
 
This allowed for changes in the total level of the protein to be taken into account as this could 
affect the level of phosphorylation seen by Western Blot. The same equation was applied to 
calculate Notch activation – here cleaved protein substituted phosphoprotein. 
Statistical Analysis of Data 
All analyses were performed using the statistical analysis platform on Prism 7 (GraphPad). 
Unpaired t tests (one-tailed) were performed on biological triplicate measurements of epithelial 
subpopulation gene expression data. All statistical tests, error bar parameters and biological 
repeats (n values) are included in the figure or figure legend.  
Genomic DNA extraction  
Genomic DNA was extracted from frozen cell pellets using the Qiagen DNeasy Blood and Tissue Kit 
protocol for cultured cells, detailed below. 
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Cell pellets were allowed to thaw on ice. Pellets were loosened by gentle flicking of the tube. 
220μl of a solution constituted by 200μl PBS and 20μl Proteinase K (20mg/ml)(Qiagen) was used 
to break up the pellet – mixed using the pipette. 4μl of RNase A (100mg/ml) (Sigma) was added 
and each sample incubated at room temperature for 2 minutes. 200μl of ATL buffer was applied 
and mixed by pipette until the solution was homogeneous. The sample was then incubated at 
56oC for 10 minutes in a water bath. 200μl of ethanol (96-100%) was then added and again mixed 
to a homogeneous solution before being transferred to the DNeasy Mini spin column in a 2ml 
collection tube. The sample was then centrifuged in the Accuspin Micro microcentrifuge (Fisher 
Scientific) at 8000rpm for 1 minute with flow-through and collection tube discarded after the spin.  
The column was then placed into a new collection tube and 500μl of AW1 buffer was added 
before being centrifuged again for 1 minute at 8000rpm. Flow-through and collection tube were 
discarded again and the column placed in a fresh collection tube. 500μl of AW2 buffer was added 
and the sample centrifuged for 3 minutes at 13,000rpm. Again both flow-through and collection 
tube were discarded and the column placed in a 1.5ml Eppendorf tube. 50μl of PCR quality water 
(Sigma) was pipetted directly onto the membrane in the column and allowed to stand for 1 
minute. The sample was then centrifuged for 1 minute at 8000rpm. The elution step was repeated 
so that genomic DNA was in a final total volume of 100μl – sample concentration was determined 
on the Nanodrop ND-1000 (Labtech) and gDNA stored at -20oC. 
Polymerase Chain Reaction 
PCR product was amplified using two different polymerase systems, GoTaq Flexi G2 (Promega) 
and Phusion (NEB). All reactions were performed in the GeneAmp PCR System 9700 thermal 
cycler (Applied Biosystems). Reactions had 50ng total of gDNA or cDNA as template material 
(typically as 5µl at 10ng/µl). For negative reactions (no template controls) this was replaced by 5μl 
of PCR quality water (Sigma Aldrich). Before separation, products were combined with 6X Purple 
Loading Dye (NEB). Products were separated on a 1-3% agarose 1X TAE gel containing 1:20,000 
GelRed Nucleic Acid Gel Stain (Biotium) alongside, unless stated, Quick-Load Purple 2log DNA 
Ladder (NEB). Gels were immersed in 1X TAE buffer and electrophoresed for 90 minutes at 90V, 
unless stated. Products were visualised under UV using the PXi Touch (Syngene). 
GoTaq Flexi G2 
All reagents marked with (*) are supplied in kit from Promega and reactions carried out as per 
manufacturer’s instructions. 
The MM was made up on ice in the Mini V/PCR hood (Telstar). For a single PCR tube; 10µl 5X Clear 
Flexi Buffer*, 6µl MgCl2* (25mM), 2µl dNTP mix (10mM) (Invitrogen), 1µl forward primer, 1µl 
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reverse primer, 0.5µl GoTaq G2 Polymerase*, 26.5µl PCR quality water (Sigma). 45µl of the MM 
was added to 0.2ml PCR tubes followed by 5µl of DNA (10ng/µl). 
The reactions were added to the thermocycler and ran; 94oC – 2 minutes, 35 cycles [94oC – 30 sec, 
(variable annealing temperature, see Table 10)– 30 sec, 72oC – 30 sec], 72oC – 5 minutes, 4oC – 
hold. 
Phusion 
All reagents marked with (*) are supplied in kit from NEB and reactions carried out as per 
manufacturer’s instructions. 
Phusion requires two MMs, both of which were made up on ice in the Mini V/PCR hood (Telstar). 
For a single PCR tube, MM1 contained; 28.75µl PCR quality water (Sigma), 1µl dNTP mix* (10mM), 
2.5µl forward primer and 2.5µl reverse primer. 34.25µl of MM1 was added to the tubes in hood. 
MM2 was then made up of 0.25μl Phusion Polymerase* and 10µl HF Buffer*.  
Tubes were taken out of the hood and 50ng of DNA was added to each sample on bench. The 
thermocycler was heated to 98oC and then paused before 10.25µl of MM2 was added to each 
tube and mixed. The reaction was placed directly into the thermocycler on the following program; 
98oC – 30 sec, 35 cycles [98oC – 10 sec, (variable annealing temperature)– 30 sec, 72oC – 20 sec], 
72oC – 5 minutes, 4oC – hold. 
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Target Primer Sequence 
Annealing 
Temperature 
(OC) 
Product 
Size (bp) 
Template 
material 
SPOP exon 6 & 
7 
FP: TTCTATGGGGCCTGCATTT 
62 (Phusion) 429 gDNA 
RP: CTCCACTTGGGGCTTTTTCT 
IDH1 exon 6 
FP: ATATTCTGGGTGGCACGGTC 
62 (Phusion) 456 gDNA 
RP: TGCAGCCAGTGTTGAAAACC 
PTEN exon 5 
FP: ACCTGTTAAGTTTGTATGCAAC 
56 (Phusion) 385 gDNA 
RP: TCCAGGAAGAGGAAAGGAAA 
PTEN intron 8 
FP: CATTCTTCATACCAGGACCAG 
60 (GoTaq) 354 gDNA 
RP: TCATGTTACTGCTACGTAAAC 
TMPRSS2 
exon 6 
FP: CTGTTACTGTCACTCGGCGG 
60 (GoTaq) 174 gDNA 
RP: CTCGTGCAGTTCGCCTCTAC 
TMPRSS2-ERG 
Outer 
FP: CGCGAGCTAAGCAGGAGGC 
70 (Phusion) Variable cDNA 
RP: GGCGTTGTAGCTGGGGGTGAG 
TMPRSS2-ERG 
Inner 
FP: GGAGCGCCGCCTGGAG 
71 (Phusion) Variable cDNA 
RP: CCATATTCTTTCACCGCCCACTCC 
GAPDH 
FP: GCTCTCTGCTCCTCCTGTTC 
63 (Phusion) 357 cDNA 
RP: AAATGAGCCCCAGCCTTCTC 
TABLE 10 – PCR information 
FP – forward primer, RP – reverse primer, bp – base pairs. 
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PCR Product Purification 
PCR products were purified for sequencing using an on-column method, extraction from gel 
fragments or DNA precipitation. Standard on-column purification was used for bulk PCR reactions. 
Gel extraction was used to separate unknown DNA fragments for sequencing and BLAST 
identification. DNA precipitation was used as an alternate method to on-column purification to 
confirm PCR product sequences. 
On-column Purification 
All reagents marked with (*) are supplied in the QIAquick PCR Purfication kit (Qiagen) and the 
purification carried out as per manufacturer’s instructions. 200µl of Buffer PB* was added to the 
40μl of remaining PCR product (10μl had been previously ran on a gel) and mixed by pipette. If 
the colour of the solution had turned from the yellow of Buffer PB* to an orange or violet then 
10µl of 3M sodium acetate (pH 5.0) was added and mixed by pipette. The solution was then 
transferred to a QIAquick column* in 2ml collection tube and centrifuged at 13,000rpm for 1 
minute in the Accuspin Micro microcentrifuge (Fisher Scientific). Flow-through was discarded and 
750μl Buffer PE* applied to the column. The column was centrifuged at 13,000rpm for 1 minute 
and flow-through discarded. The tube was then centrifuged again for 1 minute at 13,000rpm to 
remove any residual buffer. The collection tube was discarded and the column placed in a clean 
1.5ml tube. 30μl of PCR quality water (Sigma) was added to the membrane of the column and left 
to stand for 1 minute before being centrifuged at 13,000rpm. The elution step was repeated, 
making the final volume of gDNA; 60µl. The sample concentrations were measured on the 
Nanodrop ND-1000 (Labtech) and then stored at -20oC. 
Gel Extraction 
All reagents marked with (*) are supplied in the QIAquick Gel Extraction kit (Qiagen) and the 
purification carried out as per manufacturer’s instructions. The entire PCR reaction was loaded 
onto a 1% agarose TAE gel with 1:10,000 SYBRsafe DNA gel stain (Invitrogen) and ran at 90V for 90 
minutes. Following this the gel was placed on the Safe ImagerTM (Invitrogen) and the band of 
interest excised using a scalpel. The gel fragment was then placed in a colourless 1.5ml tube and 
weighed on the Sartorius LE244S balance. 3 volumes of Buffer QG* was added to the single 
volume of gel, where 100mg of gel is a single volume of 100µl QG*. The gel in buffer was then 
incubated at 50oC in a heatblock (Grant BT3) for 10 minutes and the tube vortexed briefly every 3 
minutes to aid the dissolving of the gel fragment. If the colour of the solution had turned from the 
yellow of Buffer QG* to an orange or violet then 10µl of 3M sodium acetate (pH 5.0) was added 
and mixed by pipette. A single gel volume of isopropanol was then added to the solution and 
mixed. The gel solution was then transferred to the QIAquick spin column* in a 2ml collection 
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tube and centrifuged for 1 minute at 13,000rpm in the Accuspin Micro microcentrifuge (Fisher 
Scientific). 500μl of Buffer QG* was added to the column which was then centrifuged at 
13,000rpm for 1 minute. Flow-through was discarded and 750μl Buffer PE* applied to the column 
which was centrifuged again at 13,000rpm for 1 minute. Flow-through was discarded and the 
column centrifuged at 13,000rpm to remove residual buffer from the membrane. The collection 
tube was discarded and the column placed in a 1.5ml tube. 30μl of PCR quality water (Sigma) was 
added to the membrane of the column and left to stand for 1 minute before being centrifuged at 
13,000rpm. The elution step was repeated, making the final volume of gDNA; 60µl. The samples 
concentration was measured on the Nanodrop ND-1000 (Labtech) and then stored at -20oC.    
DNA Precipitation 
Protocol adapted from Collas 2011 (741). 
400µl of PCR quality water (Sigma) was added to the 50μl PCR reaction in a 2ml tube. 44µl of 
sodium acetate (3M, pH5.2), 5μl linear acrylamide carrier (Ambion) and 1ml of 96% ethanol at -
20oC was added to the DNA and the solution mixed thoroughly. The tube was then incubated at -
80oC overnight. The next day, the tube was thawed and centrifuged at 14,000rpm for 15 minutes 
at 4oC in the Mikro 220R (Hettich). The supernatant was removed using a pipette and 1ml of 70% 
ethanol at -20oC was added. The tube was, again, centrifuged at 14,000rpm for 15 minutes at 4oC 
in the Mikro 220R (Hettich) and supernatant removed. The pellet was dried using the 
Concentrator 5301 (Eppendorf) at 30oC for 10 minutes with brake on. The DNA pellet was 
dissolved in 30µl PCR quality water (Sigma) and the concentration measured on the Nanodrop 
ND-1000 (Labtech). 
PCR Product Sequencing 
PCR products were Sanger sequenced in the departmental technology facility by a staff member. 
Each reaction was submitted as 5µl at 5ng/μl – making 25ng of DNA in total – sequencing primer 
or forward primer was supplied at a concentration of 3.2µM - 1μl per reaction. Trace files were 
analysed using the MegAlign and SeqMan II analysis software (DNA Star). 
3.3 - Low Temperature Plasma Treatments 
Dielectric Barrier Discharge LTP Jet Setup and Cell Treatments 
The LTP jet consisted of a quartz glass tube of inner/outer diameter 4/6mm, with two copper tape 
electrodes 20mm apart. One electrode was powered (6kV sinusoidal voltage at 30kHz) and the 
other grounded. Helium, the carrier gas, flowed at 2 standard litres per minute and was fed with 
0.3% molecular oxygen admixture. 1-5x105 cells were used for each treatment condition, cell 
number varied, dependent upon assay used. Cells were exposed to the LTP jet at a distance of 
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15mm from the end of the bottom electrode for 180s in 1.5ml centrifuge tubes, suspended in 
1.5ml of respective media or directly in 6-well (cells in 2ml SCM) or 12-well (cells in 1ml SCM) 
plates (Corning or Sarstedt). The distance between the end of the glass tube and the media 
surface was ~2mm. Treatment times up to 600s did not raise the surface temperature of culture 
media above 36.5oC, measured using a thermocouple. The temperature and relative humidity of 
the laboratory were ~20oC and ~25% respectively.  
RT2-PCR Oxidative Stress Profiler Arrays 
Oxidative stress arrays (Qiagen) are 96 well plates consisting of 84 wells containing gene-specific 
primers to transcripts responsive to oxidative stress, 5 wells for house-keeping genes (HPRT1, 
GAPDH, B2M, RPLP0, B-ACT) for relative fold change quantification, PCR control wells in triplicate, 
reverse transcription control wells in triplicate and a single genomic DNA contamination control 
well. 1µg of RNA (8µl of 125ng/µl) was used as input for reverse transcription to cDNA with the 
RT2 First Strand Synthesis kit (Qiagen). The cDNA was combined with SYBR Safe Mastermix 
(Qiagen) and aliquoted across the array plate. All array plate qRT-PCR was performed using the 
C1000 Thermal Cycler and CFX96 Real-Time System (BioRad) under the RT2 Array qRT-PCR 
protocol; 95oC – 10 minutes, 39 cycles of 95oC for 10s, 60oC for 1 minute (Qiagen). Data was 
assimilated using the CFX Manager 2.0 (BioRad) and analysed using the Qiagen’s online Data 
Analysis Center (http://www.qiagen.com/gb/shop/genes-and-pathways/data-analysis-center-
overview-page/)(742). Gene expression scatterplots generated in the software were of the Log10 
2-ΔΔCt values plotted against each other (treated/untreated), upregulation was marked as ≥2 fold 
change in expression. 
Clariom D Affymetrix Microarray 
Microarray analysis was outsourced and performed by Eurofins on RNA harvested from six 
primary samples before (untreated) and 2 hours (treated) after LTP treatment. 
Meta-analysis of All Samples Treated against Untreated 
Initial microarray analysis was performed using the Transcriptome Analysis Console ver3 
(Affymetrix) set up with the Clariom_D_Human.na36.hg38.probeset. All samples were grouped 
Untreated against Treated and that dataset was used for all subsequent analysis. 
LIMMA (Linear Models for Microarray and RNA-seq Data), GO (Gene Ontology) enrichment and 
KEGG pathway analysis were performed by Dr Alistair Droop. LIMMA Analysis Pre-processed data 
were analysed using the LIMMA (743) within the R numerical environment (744). Cell of origin 
and treatment type was modelled in the design matrix. Significant results after empirical Bayes 
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smoothing of the standard errors were extracted using a false discovery rate threshold of 0.025. 
No log fold change threshold was applied. 
Results were also analysed using gene set enrichment. The topGO package (745) was used. GO 
testing was performed using the "weight01" algorithm with Fisher's statistics. A threshold of 0.05 
was used to select significant results. 
Pathway analysis was performed against the KEGG (746) pathways. Significant results from the 
LIMMA analysis were analysed with a p-value threshold of 0.05. 
Immunofluorescence  
Cultured primary cells were trypsinised into chamber slides. These were BioCoat Collagen I 8-well 
plates (Corning) – 10,000 cells per well, or 2-well Nunc Lab-Tek chamber slides (Sigma Aldrich) – 
300,000 cells per well. 
Cells were left overnight before being treated in-well by plasma. A plasma dose of 1.5-minutes 
was used for 8 well chamber slides and 3-minutes for 2 well chamber slides. Following treatment, 
cells were fixed at either 0.5 hours or 2 hours post-treatment using 4% PFA (Paraformaldehyde) - 
100µl for 8 well and 500μl for 2 well. Wells were then washed 3x for 5 minutes in PBS (equivalent 
to the volume of PFA). Chamberslides were then stored at 4oC with the equivalent volume of PBS 
in well or carried forward into permeabilisation. 
Cells were permeabilised for 10 minutes in 0.5% Triton X-100 (Sigma) in PBS (at a volume 
equivalent to that used for PFA). Triton X-100 was tipped off and cells washed in PBS 3x 5 
minutes. Cells were then blocked in 10% goat serum (Sigma) in PBS for 1 hour. Goat serum was 
then removed and primary antibody applied. See Table 9 for more information. Primary antibody 
was diluted in 10% goat serum in PBS. The chamber slides were left in the fridge overnight (~16 
hours) at 4oC on orbital shaker (Stuart SSM3) at 50rpm. 
After overnight incubation the primary antibody (Table 9) was removed and cells washed 3x 5 
minutes in PBS. The secondary Alexafluor 568 antibody (Table 9) diluted in 10% goat serum was 
then applied for 1 hour at room temperature. This incubation step was performed beneath a 
plastic box lid to prevent loss of Alexafluor signal. Secondary antibody was removed and cells 
washed 3x 5 minutes in PBS. 
The chamber of the slides was now removed. For the BioCoat 8-well slides, the tool accompanying 
the slides was used, for the 2 well Nunc Lab-Tek slides the chamber was lifted off and the 
adhesive removed using forceps. 4 drops of Vectashield with DAPI (Vector, H-1200) was applied to 
the slide and a coverslip added on top. Excess Vectashield was wiped away and any air bubbles 
were removed before being sealed with nail varnish and left to dry for 15 minutes in the dark. 
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Slides were either stored at 4oC in the dark or imaged immediately on the DM IL LED Microscope 
(Leica) with the DFC365 FX Camera (Leica), equipped with DAPI and Cy3 filter blocks. Images were 
viewed and stored using the LAS X program (Leica). 
SmartFlares 
SmartFlares were prepared from lyophilised stock by addition of 50µl Nuclease Free Water 
(Merck-Millipore). This was mixed by pipette and then vortexed to assure that there was no 
biphasic separation of the probes. The SmartFlares were then stored at room temperature away 
from light.  
SmartFlare (Merck Millipore) experiments were attempted in two variations, with treatment 
before and following SmartFlare addition. SmartFlares used in the experiment were; Uptake-Cy3, 
Scrambled-Cy5 and HMOX1-Cy3 (discontinued). 
LTP Treatment Before Application of SmartFlares 
5x105 cells suspended in 1.5ml growth media were treated with LTP. The cells were then added to 
a 48 well plate - 40,000 cells per well in 500µl media. SmartFlares were diluted 1:20 in PBS and 4µl 
added to each well. Plates were monitored and pictures taken 24 hours after addition of 
SmartFlare on DM IL LED Microscope (Leica) with the DFC365 FX Camera (Leica). Images were 
viewed and stored using the LAS X program (Leica). 
LTP Treatment After Application of SmartFlares 
100,000 cells were aliquoted across a 24 well plate and left to adhere for 6 hours in 1ml of media. 
SmartFlares were diluted 1:20 in PBS and 10µl added to each well. Cells were then treated with 
the appropriate plasma dose and pictures taken 24 hours after LTP treatment with the DM IL LED 
Microscope (Leica) uing the DFC365 FX Camera (Leica). Images were viewed and stored on the 
LAS X program (Leica). 
Arsenite Treatments of Cell Lines 
Sodium meta-arsenite 0.05M (Merck Millipore) was diluted to the appropriate concentration in 
K2 or R10 medium directly before treatment. Cells were exposed to arsenite-containing media for 
the allotted time, up until harvesting. Following treatment, cells were washed twice with PBS to 
maximise the removal of arsenite and pelleted.  
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3.4 - Allelic Expression Experiments 
SURVEYOR 
The SURVEYOR system detects mutation or SNPs by first forming heteroduplexes of wildtype and 
variant strands before the SURVEYOR nuclease is added. This enzyme can recognise regions of 
mismatch or ≤12bp indels and upon recognition; cleaves the duplex. This allows the fragments to 
then be separated by gel electrophoresis. Reagents marked with a (*) were supplied in the 
Integrated DNA Technologies kit. 
Each reaction contained; 200-300ng purified PCR product (>10ng/μl), 2μl 0.5M KCl and PCR 
quality water (Sigma) to a final consistent volume between 20-30μl. The reactions were placed in 
a thermocycler (Applied Biosystems) on the following program to allow for heteroduplex 
formation; 95oC – 10 minutes, 85oC – 1 minute, 75oC – 1 minute, 65oC – 1 minute, 55oC – 1 
minute, 45oC – 1 minute, 35oC – 1 minute, 25oC – 1 minute, 4oC – hold. 
SURVEYOR nuclease was then added to these reactions in the following MM. For one reaction; 
2.5μl 0.15M MgCl2*, 1μl SURVEYOR nuclease*, 1μl ENHANCER*. 4.5μl was added to each reaction, 
mixed by pipette and incubated at 42oC for 1 hour in a thermocycler (Applied Biosystems). After 
incubation 2.5μl of STOP solution* was added. 
The entire reaction was then loaded onto a 2% agarose 1X TAE gel with 1:20,000 GelRed and 
electrophoresed at 80V for 100 minutes. Bands were visualised under UV on the PXi Touch 
(Syngene) 
PTEN Intron 8 LOH HincII Restriction Digests 
The solution used for restriction digest was constituted of; 0.4μl of HincII (NEB), 2.5μl 3.1 
restriction buffer (NEB) and 17.1μl of PCR quality water (Sigma). Following PCR of the intronic 
region, 20μl of HincII MM was added to 30μl of un-purified PCR product. Reactions were 
incubated at 37oC for 30 minutes and then at 65oC for 25 minutes in separate water baths. 
Reactions were combined with 10μl of 6X DNA loading dye and then 20μl loaded onto a 3% 
agarose 1X TAE gel alongside 10μl of undigested PCR product. Gels were ran at 100V for 1 hour 
and products visualised on the PXi Touch (Syngene). 
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4. Results – Determination if common tumourigenic alterations to genes in 
prostate cancers alters their allelic expression 
Large scale genome sequencing studies often assume mutations to be expressed. Yet evidence of 
said expression is rarely provided through use of matched transcriptomic or proteomic data. (330, 
497) This assumption is naïve in the common knowledge that many pre- and post-transcriptional 
mechanisms exist in cells, above the level of genetic alterations, that can significantly impact final 
and functional protein expression (or lack thereof) which affects the cancer phenotype. These 
include epigenetic modifications, which can promote or silence transcription, and nonsense 
mediated decay; that acts as a mRNA quality control mechanism. Most mutations and 
chromosomal alterations are heterozygous and cells retain a functional wildtype allele that, unless 
levels of the protein are critical and haploinsufficiency results, should be able to rescue the usual 
loss-of-function effects that such genomic alterations result in. Changes in the expression of 
disease or wildtype alleles therefore may have measurable molecular and cell fate outcomes in 
prostate cancer. The flowcharts, provided in Figures 28 & 34, show the plan of study progression 
in determining the effects on allelic expression made by gene alterations in prostate cancer. 
4.1 – Heterozygosity in TMPRSS2 is common in primary prostate epithelial cultures 
TMPRSS2 is monoallelically expressed in human tissues, including that of the prostate (246, 518). 
The prostate cancer unique TMPRSS2-ERG fusion is also selectively expressed at an allelic level in 
CSCs (246). To reproduce previous work, and show monoallelic expression in primary prostate 
cultures, heterozygosity had to be established so that the expression of each TMPRSS2 allele 
could be measured. Patient culture information on TMPRSS2 heterozygotes from previous work 
was compiled in Table 11. This data allowed for the selection of known heterozygous primary 
samples alongside the testing of recently harvested genomic DNA stocks for heterozygosity at SNP 
rs12329760, located in exon 6 of the TMPRSS2 gene (Figure 29A). In total, thirty-six primary 
cultures (from thirty-four patients) were tested and nine rs12329760 heterozygotes were 
identified, at a minor allele frequency (MAF) of 0.125 (9/72) half of the expected global MAF 0.25 
(Figure 29B + 30). Sequence traces for all samples can be found in the Appendix – 9.1. From these 
findings, fourteen patient samples were grown from liquid nitrogen stocks and the cultures 
subsequently fractionated into epithelial subpopulations (Figure 31) where RNA, genomic DNA 
(gDNA) and chromatin were harvested. After this, the rs12329760 state of the freshly grown 
samples was confirmed by PCR (Figure 32A) and Sanger sequencing of the product (Figure 32B). 
The second round of sequencing identified that YO47/09 and H329/13 LB were not A (minor 
allele) homozygotes, as was previously identified. 
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4.2 – The TMPRSS2-ERG fusion is expressed in primary prostate epithelial cultures 
The advantage of fusion positive samples is that monoallelic expression can be established by RT-
PCR. The fused and unfused TMPRSS2 alleles are inequivalent therefore expression of both can be 
assessed independently. Analysis of fusion expression in the primary cultures was achieved using 
a nested RT-PCR method (previously developed by Polson 2013 (246)) where outer and inner 
forward primers were located in TMPRSS2 exon 1 and the reverse primers in ERG exon 6, allowing 
for the amplification of all major fusion mRNA products (596). Product from PCR 1, using the 
outer primers, was immediately entered into PCR 2, using the inner primers, to achieve specificity 
and minimise off target amplification of any other cDNAs (Figure 33A). The strategy was 
confirmed to work using VCaP, a prostate cancer cell line with a confirmed TMPRSS2-ERG fusion, 
(351) to produce a PCR product that was identified as fusion mRNA by BLAST (Figure 33B). A total 
of seventeen patients, with various whole population and subpopulation cultures, were tested for 
presence of the fusion. Three patient prostate cancer cultures; H434/14 RM, H116/11 RA and 
H050/11 RA, were TMPRSS2-ERG+ (Figure 33C). Assessment of the unfused TMPRSS2 allele in the 
TMPRSS2-ERG+ cultures wasn’t carried out at this stage as the cellular heterogeneity present in 
the primary cultures would prevent determination of monoallelic fusion transcript expression 
(246). 
From the combined work on TMPRSS2 heterozygosity and fusion status of the primary samples, 
twelve cultures were fractionated into epithelial subpopulations, and RNA, gDNA and chromatin 
were collected (Table 12). These samples were to be analysed for allelic asymmetry in TMPRSS2 
expression and promoter/gene body histone trimethylations. 
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FIGURE 28 – Allelic expression of TMPRSS2 study structure and the primary cultures assessed for 
heterozygosity of the gene. 
Flowchart detailing the workflow for the determination of allelic expression and assessment of 
the factors governing the expression of TMPRSS2 in primary prostate basal epithelial cultures. 
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Patient Pathology SNP rs12329760 
Y023/09 BPH G 
Y006/09 BPH G/A 
Y012/09 BPH G 
Y013/09 BPH G 
Y025/09 BPH G/A 
YO29/09 BPH G 
YO30/09 BPH G 
YO40/10 BPH G/A 
YO47/09 BPH A 
YO26/09 BPH G 
PE667 Gleason 6 (3+3) G 
YO08/06 Gleason 6 (3+3) G/A 
H016/09 Gleason 7  G 
PE665 Gleason 7 (3+4) G/A 
PE671 Gleason 7 (3+4) G 
PE659 Gleason 8 (4+4) G 
PE434 Gleason 8/9 G 
YO46/09 CRPC  G 
YO11/09 Gleason 8 (3+5) G 
YO21/09 Gleason 9 (4+5) G 
TABLE 11 – Primary samples with known rs12329760 status.  
Data was compiled from (Polson 2013) (246) and lab books. 
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FIGURE 29 – Analysis of TMPRSS2 exon 6 DNA from primary prostate cultures for the SNP 
rs12329760. 
A) TMPRSS2 exon 6 PCR products from primary prostate epithelial cultures. B) The coding SNP - 
rs12329760 C/T. Taken from the NCBI SNP database (747).  
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FIGURE 30 - Sanger sequencing traces of rs12329760 heterozygotes in TMPRSS2 exon 6 of primary 
cultures. 
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FIGURE 31 – Selection of prostate basal epithelial subpopulations by collagen I adhesion.  
Diagrammatic representation of whole population (WP) primary culture fractionation protocol 
used to isolate; stem and transit amplifying (SC & TA), intermediate (Int.) and committed basal 
(CB) cell subpopulations in the TMPRSS2 allelic expression study. 
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FIGURE 32 – Confirmation of rs12329760 SNP status in fractionated primary culture samples.  
A) PCR products of TMPRSS2 exon 6 in chosen samples. B) Sanger sequence traces of rs12329760 
in the fractionated samples, grouped as hetero- or homozygotes. 
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FIGURE 33 – Identification of TMPRSS2-ERG fusion expression in primary prostate cultures. 
A) Nested PCR strategy for analysing TMPRSS2-ERG expression in primary sample cDNA. The 
analysis allowed detection of the most common fusion products; TMPRSS2 exon 1 to ERG exons 2, 
4 and 5. B) i) VCaP TMPRSS2-ERG RT-PCR product amplified by the nested PCR strategy, ii) Small 
and large products isolated from the bright band in i. iii) Top BLAST result from the Sanger 
sequence consensus derived from both large and small products. C) TMPRSS2-ERG expression in 
primary prostate cultures. 
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Sample Pathology SNP 
rs12329760 
Fusion 
status Passage 
H001/08 Gleason 6 
(3+3) G/A -ve 3 
H434/14 RM Gleason 7 
(4+3) G/A +ve 3 
H209/12 LA Normal G/A -ve WP -
RNA/gDNA 
H329/13 LB Gleason 7 
(3+4) G/A -ve 
WP -
RNA/gDNA 
Y047/09 BPH G/A -ve 5 
H048/11 RB Gleason 6 
(3+3) G/A -ve 3 
H052/11 LB Gleason 7 
(3+4)  G/A +ve 2 
H052/11 RA Gleason 7 
(3+4) G/A -ve 2 
YO60/10 BPH G/A -ve 3 
Y025/09  BPH G/A -ve Didn’t Grow 
H054/11 RB  Gleason 7 
(3+4) G/A -ve 3 
H056/11 RB Gleason 7 
(4+3) G -ve 4 
H050/11 RA Gleason 7 
(3+4) G +ve 3 
H116/11 RA Gleason 7 
(4+3) G +ve 4 
H233/12 RA Gleason 8 
(4+4) G -ve 3 
TABLE 12 - Primary samples selected for further study of TMPRSS2 allelic expression in fractionated 
populations. 
Samples were grouped on rs12329760 heterozygote status. TMPRSS2-ERG fusion status of 
samples is included. Passage number was that of the sample at harvest of RNA, gDNA and 
chromatin. 
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FIGURE 34 – Study plan - Does point mutation in prostate cancer genes affect allelic expression? 
Flow chart of experiments to determine if and how mutation could affect allelic expression in 
prostate cancer. 
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FIGURE 35 – SPOP, PTEN and IDH-1 aren’t mutated in prostate cell lines.  
A) PCR products of SPOP exon 6+7, PTEN exon 5 and IDH-1 exon 6 in prostate cell lines. B) 
Alignment of cell line SPOP exon 6+7 PCR product Sanger sequences and traces highlighting 
presence of the SNP; rs2066747 in the BPH-1 and Du145 cell lines. C) Alignment of cell line PTEN 
exon 5 PCR product Sanger sequences. D) Alignment of cell line IDH1 exon 6 PCR product Sanger 
sequences.  
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4.3 – Mutations observed in primary prostate cancers aren’t represented in current cell 
lines 
Mutational “hotspots” in the three genes chosen for allelic analysis; SPOP exon 6+7, PTEN exon 5 
and IDH1 exon 6, were amplified in seven prostate cell lines (Figure 35A). No mutations were 
observed in the SPOP amplicon yet two of the cell lines; BPH-1 and Du145, had an intronic SNP – 
rs2066747 (Figure 35B). Both PTEN and IDH1 in the cell lines were wildtype (Figure 35C+D). PC3 
cells showed no PCR product for PTEN exon 5 as the cell line has a homozygous deletion of the 
gene (451). 
4.4 – PTEN heterozygous deletion is represented in primary prostate cancer cultures 
Deletion of PTEN is a common event in primary prostate cancers (345). To ascertain the effect of 
mutation on the allelic expression of PTEN, the gene needs to have both alleles intact. 
Heterozygous deletion would produce a situation that mimics monoallelic expression, therefore 
establishing that relevant samples had both alleles of PTEN was necessary in this study. Loss of 
heterozygosity (LOH) was determined in primary cancer cultures using a SNP (rs555895) in intron 
8 of PTEN, the T allele of which provides a restriction site for the HincII enzyme. G/T 
heterozygotes produce a three-band pattern detectable by electrophoresis (Figure 36A). Twenty-
two patient lymphocyte (normal, with both alleles) and matched tumour samples were tested for 
LOH in the cancer PTEN gene. In four of the tested tumours, the uncut PTEN allele was deleted 
(Figure 36B). In this small sample cohort, the LOH was 18% with a MAF of 0.45. A frequency 
comparable to the European MAF of 0.37 (Figure 36C). Differences in banding intensities between 
tumour and lymphocyte DNA is due to there being more starting material in the lymphocyte PCR. 
4.5 – Mutations observed in primary tumours aren’t observed in primary prostate cancer 
cultures 
The mutational status of 55 primary prostate cultures, taken from 49 patients, including 5 PDXs, 
was assessed. SPOP, PTEN and IDH1 were amplified in all cancer samples (Figure 37). Some of the 
samples appeared under-represented in the SPOP and PTEN PCR products, however this was 
deemed to be technical variation upon repeat and not reflective of LOH status. After PCR, 
mutation of the genes was analysed either using the SURVEYOR nuclease assay or by Sanger 
sequencing.  
The SURVEYOR assay allows mutations to be easily visualised by firstly denaturing and then re-
annealing heterozygous PCR products to form heteroduplexes. The SURVEYOR nuclease is then 
applied to the products that can recognise and cut at the mismatched sites in formed 
heteroduplexes, allowing the different sized fragments to be separated by gel electrophoresis 
(Figure 38A). The assay was first optimised by increasing the PCR product input over that of the 
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manufacturer’s recommendation (Figure 38B) before being tested on the primary samples. SPOP 
heterozygotes were detected in tumour DNA by SURVEYOR, however the allelic difference was 
not due to mutation rather a germline SNP (rs2066747) as shown by the identical banding pattern 
produced by SPOP SURVEYOR in patient matched lymphocyte DNA (Figure 38C). 
PTEN and SPOP intronic heterozygotes were found, however no allelic differences were detected 
in IDH1. No tumour culture samples were mutated in the three chosen genes. SPOP Sanger 
sequence traces of all heterozygote samples are provided in Figure 39, PTEN in Figure 40 and 
IDH1 (examples of homozygotes) in Figure 41. Sequence traces for all samples can be found in the 
Appendix – 9.1. 
The goal of the study was to establish whether heterozygous mutation in prostate cancer altered 
the allelic expression of the affected gene and its wildtype copy. As no mutations of SPOP, PTEN 
or IDH1 were detected in either cell line or primary prostate cancer culture this goal could not be 
met. The models used in the study and that are currently available to researchers do not 
represent the full spectrum of disease that falls under the umbrella heading of prostate cancer. 
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FIGURE 36 – Detection of PTEN Loss of Heterozygosity in prostate cancer primary cultures. 
A) LOH of PTEN using the rs555895 SNP located in intron 8 of the gene that can act as a restriction 
site for HincII. B) LOH of primary prostate culture PTEN using HincII digests of patient matched 
tumour and lymphocyte DNA. LOH samples are highlighted. C) LOH percentages of primary 
samples with matching lymphocyte DNA. Minor allele frequency (MAF) of SNP in the tested 
samples compared to publicly available (NCBI SNP database (747)) MAF of European samples. 
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FIGURE 37 – Primary prostate culture SPOP exon 6+7, PTEN exon 5 and IDH1 exon 6 PCR products. 
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FIGURE 38 – SURVEYOR detection of primary prostate culture SPOP heterozygotes.  
A) Diagrammatic process of the SURVEYOR nuclease assay. i) PCR is performed on the 
heterozygous amplicon to produce a mixture of allelic PCR products with variance at 
heterozygous nucleotide position/s, ii) products are denatured and then re-annealed allowing 
heteroduplexes (and homoduplexes) to form between heterozygous products, iii) SURVEYOR 
nuclease recognises mismatches (and indels of ≤12bp) and cleaves dsDNA to leave different sized 
fragments, iv) gel electrophoresis allows separation of the variant SURVEYOR cleavage products to 
detect heterozygosity. B) Optimisation of SURVEYOR assay with varying amounts of SPOP PCR 
product. C) Identification of germline SNP in SPOP prostate tumour and patient lymphocyte gDNA 
using SURVEYOR. 
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FIGURE 39 – SPOP Sanger sequence traces of heterozygote primary prostate cancer cultures.  
SNP detected in the PCR product is rs2066747. 
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FIGURE 40 – PTEN Sanger sequence traces of heterozygote primary prostate cancer cultures. 
SNP detected in the PCR product is rs398123319. 
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FIGURE 41- IDH1 Sanger sequence traces of primary prostate cancer cultures.  
Examples of sequence traces taken from six primary prostate culture samples with wildtype IDH1. 
The traces show the location of the most frequent mutation (R132H) in the IDH1 gene.  
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5. Results– Oxidative stress response signalling in LTP treated primary 
prostate basal epithelial cells 
5.1 – Optimisation of plasma dose and post-treatment assessment of gene expression 
To investigate the immediate signalling events following LTP treatment of prostate basal epithelial 
cells (Table 13), optimisation of both plasma dose and the post-treatment time-point at which 
gene expression changes became apparent were required. 
The intention was to profile the antioxidant response of primary cells using the Qiagen Oxidative 
Stress Profiler Arrays which can simultaneously assess the expression of 84 genes. Genes common 
to the array plates were chosen for initial qRT-PCR analysis to establish both the time-point at 
which responsive gene expression was assessed and the time period of plasma treatment. Firstly, 
four prostate cell lines were assessed for their expression of the mitochondrial ROS scavenging 
enzyme SOD2 at 2, 4, 6 and 8 hours after a 10-minute plasma dose (post-treatment time-points 
and LTP dose were informed by previous work (304)) (Figure 42). PC3 and PNT2 lines weren’t 
responsive in their SOD2 expression, whereas both BPH-1 and LNCaP showed an increase in the 
transcript over the time-course.  
From this initial data, 4 and 6 hour time-points were chosen and the number of array genes 
assessed was expanded. Expression of SOD2, GPX2 (peroxide scavenging enzyme) and NOS2 
(reactive nitrogen species generating enzyme) was analysed in three primary cultures (Figure 43). 
This experiment also included a 3-minute plasma dose and a 1mM hydrogen peroxide treatment. 
The peroxide treatment had previously been used as a positive control for both oxidative damage 
effects and cell fate responses in prostate primary cultures (304), its inclusion in gene expression 
analysis was to provide the same positive inductive effect on cellular antioxidant response 
networks. The 3-minute plasma dose was the most effective in raising gene expression. SOD2 
expression was marginally upregulated in cultures at the 4 hour time-point. GPX2 expression was 
largely unchanged by plasma and NOS2 also didn’t appear to have a patterned upregulation in the 
cultures assessed. 
As the primary cells didn’t respond to plasma like the cell lines, post treatment time-points were 
tested directly on the Qiagen Oxidative Stress Response Profiler arrays. This included 0.5 and 2 
hour time-points to monitor rapid response and the later snapshots of 4 and 8 hours to observe 
prolonged transcriptional change (Figure 44). We observed, across multiple cultures, that the 2 
hour post-LTP time-point was optimal for monitoring primary cell transcriptional response and 
that very few changes in gene expression were observed at 4 and 8 hours. The 3-minute plasma 
dose was chosen for the study as it produced a wider expressional response than the longer 
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treatment of 10 minutes (Figure 45A). An H2O2 treatment also produced a robust induction of 
oxidative stress response genes, including catalase, at the 2 hour time-point. The peroxide 
response was similar to that of the 3-minute LTP dose in the H209/12 LA culture (Figure 45C). 
5.2 – A central oxidative stress response is triggered by LTP in cultures, regardless of 
pathology 
Oxidative stress transcriptional response was assessed with Qiagen Oxidative Stress Profiler Array 
qRT-PCR plates. These monitored 84 literature-defined genes linked to oxidative stress, 5 house-
keeping genes for normalisation and internal reverse transcriptase, PCR and genomic DNA 
contamination controls. All RNA samples used passed these internal quality controls. To see 
whether LTP response was determined by tissue pathology, three separate patient cultures from 
four different disease states were used; normal, BPH, Gleason 7 and Gleason 9 (Table 14). For 
added comparative power, the normal and Gleason 7 tissues came from the same patient – a 
Patient Matched Pair – allowing a true comparison of normal and cancer that doesn’t require 
adjustment for known inter-patient heterogeneity (304). 
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 Sample Identifier Tissue Type 
Biopsy Core 
Positivity 
Tumour 
palpable? 
Operation 
Age of 
Patient 
 YO68/09 BPH / / TURP N/A 
 H221/12  BPH / / TURP 77 
 H229/12 BPH / / TURP 69 
 H249/12 BPH / / TURP 83 
 
 
H209/12 LA Normal 0/5 No  
LRP 
64 
H209/12 RA Gleason 7 (4+3) 4/5 Yes 
H329/13 LB Gleason 7 (3+4) 3/5 Yes  
ORP 
53 
H329/13 R Normal 0/5 No 
H341/13 LB Gleason 7 (3+4) 3/5 Yes 
LRP 52 
H341/13 R Normal 0/5 No 
H434/14 LM Normal 0/6 No  
ORP 
68 
H434/14 RM Gleason 7 (4+3) 4/4 Yes 
H523/13 LM Normal 0/5 No  
LRP 
66 
H523/13 RM Gleason 7(4+3) 4/5 Yes 
H641/17 L Normal 0/5 No  
RRP 
64 
H641/17 R Gleason 9(4+5) 4/7 Yes 
H643/17 LM Normal No cores No  
RRP 
78 
H643/17 RM Gleason 7(3+4) 5/5 No 
H646/17 LM Gleason 7(3+4) 8/8 No  
RRP 
67 
H646/17 RM Normal 0/5 No 
 
 H594/17 L Gleason 7(3+4) 8/5 Yes RRP 61 
 H637/17 L Gleason 7(3+4) 7/14 Yes RRP 52 
 H652/17b R Gleason 7(3+4) 4/4 Yes RRP 57 
 H306/13 Gleason 9 (5+4) 6/6 NA chTURP 60 
 H460/14 Gleason 9 (4+5) No cores NA chTURP 76 
 H545/15 RM Gleason 9 (4+5) 4/5 Yes ORP 69 
TABLE 13 – Sample information of all patient cultures used in LTP study.  
The letters after the anonymous patient identifier inform on the biopsy site of the originating 
tissue. L – left, R – right, A – apex, M – mid and B – base. Operations included Robotic Radical 
Prostatectomy (RRP), Open Radical Prostatectomy (ORP), Laparascopic Radical Prostatectomy 
(LRP) and channel (ch)/TURP – Transurethral Resection of the Prostate. 
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FIGURE 42 – Prostate cell line expression of SOD2 in response to LTP is varied. 
Expression of SOD2 was measured at 2, 4, 6 and 8 hour time-points following application of a 10-
minute LTP dose in four prostate cell lines. Note that y axis scales are different. Graph error bars 
represent the standard error of the mean (SEM) of the biological triplicates. 
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FIGURE 43 - Primary culture stress response gene expression following oxidative treatment. 
Expression of SOD2, GPX2 and NOS2 was measured at 4 and 6 hour time-points following an LTP 
dose of 3 or 10-minutes and 1mM H2O2 treatment. Note that y axis scales are different. Graph 
error bars represent the SEM of the biological triplicates. 
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FIGURE 44 - Oxidative stress response array time-point optimisation using the H329/13 LB primary 
culture. 
Gene expression analysis using the Oxidative Stress Profiler Arrays shows the upregulation of 
genes 2 hours after LTP dose. Black solid line denotes “no change” between untreated and 
treated gene expression, the dashed line (above and below the black solid line) signifies a 2-fold 
change in gene expression. Upregulated genes are red dots, unchanged genes are black dots and 
downregulated genes are green dots. Scatterplots prepared using Qiagen’s online data analysis 
tool (742). 
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FIGURE 45 - Oxidative stress response array dose optimisation using the H209/12 LA primary culture. 
Gene expression at 2 hours post LTP using the treatments of A) 3-minutes LTP, B) 10-minutes LTP 
and C) 1mM H2O2. Black solid line denotes “no change” between untreated and treated gene 
expression, the dashed line (above and below the black solid line) signifies a 2-fold change in gene 
expression. Upregulated genes are red dots, unchanged genes are black dots and downregulated 
genes are green dots.  
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Tissue Sample Treatment Time-point (hr) 
BPH 
H221/12 
Untreated 0 
3 min LTP 
0.5 
2 
H229/12 
Untreated 0 
3 min LTP 
0.5 
2 
H249/12 
Untreated 0 
3 min LTP 
0.5 
2 
Normal 
H209/12 LA 
Untreated 0 
3 min LTP 
0.5 
2 
2 (repeat) 
10 min LTP 
0.5 
2 
H2O2 2 
H329/13 R 
Untreated 0 
3 min LTP 
0.5 
2 
H434/14 LM 
Untreated 0 
3 min LTP 
0.5 
2 
Gleason 7 Cancer 
H209/12 RA 
Untreated 0 
3 min LTP 
0.5 
2 
H329/13 LB 
Untreated 0 
3 min LTP 
0.5 
2 
4 
8 
10 min LTP 
4 
8 
H434/14 RM 
Untreated 0 
3 min LTP 
0.5 
2 
Gleason 9 Cancer 
H306/13 
Untreated 0 
3 min LTP 
0.5 
2 
H460/14 
Untreated 0 
3 min LTP 
0.5 
2 
H545/15  
Untreated 0 
3 min LTP 
0.5 
2    TOTAL – 44 Arrays 
 
TABLE 14 – Summary of conditions and samples used for Oxidative Stress Profiler Arrays   
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The H434/14 normal culture rapidly responded to plasma treatment with an increase in the 
number of genes upregulated at the 2 hour mark. The Gleason 7 of the patient matched pair was 
muted in its response at 0.5 hours and had only a few upregulated genes at the later time-point 
(Figure 46). Both cultures of the H329/13 patient matched pair showed an initial downregulation 
of genes followed by an upregulation of multiple genes at 2 hours, here the cancer had a greater 
number of responsive genes than the normal culture (Figure 47). The H209/12 normal culture 
showed the usual response of initial gene downregulation and upregulation at the later time-
point yet the cancer culture had a greatly reduced output at 2 hours with upregulation of only 
three genes (Figure 48). Through averaging the responses of the three patient matched pairs it 
was possible to identify common genes that were either up or downregulated across patients. At 
the earlier time-point of 0.5 hours, the Gleason 7 cultures downregulated a number of genes, a 
response that wasn’t observed in the other tissue pathologies (Figure 49A). At 2 hours, the 
patient matched pair cultures had a very similar expression profile; sharing upregulation of 
HMOX1, TXNRD1, HSPA1A and SQSTM1, with the normal epithelia additionally expressing SRXN1 
and DUSP1 – which were both recurrently upregulated by LTP in the other pathologies (Figure 
50A+B). 
The patient matched pairs also afforded the ability to explore whether or not the cancer cultures 
expressed oxidative stress genes to a greater extent over normal counterparts with no treatment. 
Each patient’s cancer varied in the composition of genes that were over or under-expressed in the 
disease state, yet the mean expression response highlighted that a few genes were consistently 
upregulated in Gleason 7 disease over normal epithelia, including HMOX1 and HSPA1A (Figure 
51).  
BPH cultures, with the exception of H249/12, were the most responsive of the tissue types half an 
hour after treatment and showed a similar expression signature to the other pathologies at the 
later time-point (Figure 52). The average expression profile of BPH showed the upregulation of 
HMOX1, HSPA1A and DUSP1 at 2 hours, similar to normal prostate epithelia (Figure 50C). 
The Gleason 9 samples also showed marked variability between patients that was observed 
amongst the other tissue pathologies. All cultures had a minimal response at 0.5 hours followed 
by a pronounced upregulation of genes at the 2 hour time-point. H306/13 showed huge 
upregulation of DUOX1 and GPX4 at both time-points in response to plasma (Figure 53). The 
pathology average for the Gleason 9 patients showed upregulation of HMOX1, HSPA1A and 
SRXN1, with DUOX1 and GPX4 included due to the magnitude of both gene’s expression in 
response to LTP in H306/13 (Figure 50D). 
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Validation of the results obtained using the arrays was carried out by TaqMan qRT-PCR. The 
expression of four genes (SOD2, GPX2, HMOX1 and HSPA1A) was tested using this method across 
the four tissue pathologies; H229/12 – BPH, H329/13 R – normal, H329/13 LB – Gleason 7 and 
H545/15 – Gleason 9, with both SYBR green and TaqMan qRT-PCR producing similar results 
(Figure 54A). Melt curve analysis of the array plates following the PCR showed that the array 
primers were specific as the PCR product generated in each well was a single species (Figure 54B). 
Assessment of real-time upregulation of the top hit from the arrays; HMOX1, was attempted 
using SmartFlares. These are gold nanoparticles coated in oligonucleotides specific to the mRNA 
of interest which are taken up indiscriminately by cells. Bound to these oligonucleotides are 
complementary fluorescent probes which are quenched when in close proximity to the gold 
particle. When the target mRNA increases it specifically displaces the probes on the gold particle 
and thus fluorescence increases (Figure 55A). SmartFlares were chosen as they would permit 
simultaneous observation of close to real time increases in mRNA transcript and allow for 
assessment of cell population transcriptional heterogeneity. However, no change in HMOX1 
fluorescence was observed in response to treatment in the PC3 cell line (Figure 55B) or primary 
cells (Figure 55C). HMOX1 expression, as measured by the SmartFlares, did not match the 
accompanying qRT-PCR data. 
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FIGURE 46 - Oxidative stress gene response in the H434/14 patient matched pair.  
Oxidative stress transcriptional response in normal and Gleason 7 cultures from patient H434/14. 
Expression was assessed 0.5 and 2 hours after a 3-minute LTP dose. Black solid line denotes “no 
change” between untreated and treated gene expression, the dashed line (above and below the 
black solid line) signifies a 2-fold change in gene expression. Upregulated genes are red dots, 
unchanged genes are black dots and downregulated genes are green dots  
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FIGURE 47 - Oxidative stress gene response in the H329/13 patient matched pair. 
Oxidative stress transcriptional response in normal and Gleason 7 cultures from patient H329/13. 
Expression was assessed 0.5 and 2 hours after a 3-minute LTP dose. Black solid line denotes “no 
change” between untreated and treated gene expression, the dashed line (above and below the 
black solid line) signifies a 2-fold change in gene expression. Upregulated genes are red dots, 
unchanged genes are black dots and downregulated genes are green dots.  
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FIGURE 48 - Oxidative stress gene response in the H209/12 patient matched pair. 
Oxidative stress transcriptional response in normal and Gleason 7 cultures from patient H209/12. 
Expression was assessed 0.5 and 2 hours after a 3-minute LTP dose. Black solid line denotes “no 
change” between untreated and treated gene expression, the dashed line (above and below the 
black solid line) signifies a 2-fold change in gene expression. Upregulated genes are red dots, 
unchanged genes are black dots and downregulated genes are green dots.  
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FIGURE 49 - Tissue pathology average of oxidative stress response gene expression at 0.5 hours post-
LTP. 
Average gene expression taken from the three cultures of A) Normal prostate, B) Gleason 7 
cancer, C) Benign prostatic hyperplasia and D) Gleason 9 cancer, at 0.5 hours after a 3-minute LTP 
dose. Black solid line denotes “no change” between untreated and treated gene expression, the 
dashed line (above and below the black solid line) signifies a 2-fold change in gene expression. 
Upregulated genes are red dots, unchanged genes are black dots and downregulated genes are 
green dots.  
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FIGURE 50 - Tissue pathology average of oxidative stress response gene expression at 2 hours post-
LTP. 
Average gene expression taken from the three cultures of A) Normal prostate, B) Gleason 7 
cancer, C) Benign prostatic hyperplasia and D) Gleason 9 cancer, at 2 hours after a 3-minute LTP 
dose. Black solid line denotes “no change” between untreated and treated gene expression, the 
dashed line (above and below the black solid line) signifies a 2-fold change in gene expression. 
Upregulated genes are red dots, unchanged genes are black dots and downregulated genes are 
green dots.  
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FIGURE 51 - Oxidative stress response genes are expressed at higher basal levels in Gleason 7 
cultures of patient matched pairs. 
Patient matched pair cancer and normal gene expression from untreated cultures were 
compared. The patient is marked on each scatterplot, the lower right panel shows the average 
expression of the three patients. Black solid line denotes “no change” between untreated and 
treated gene expression, the dashed line (above and below the black solid line) signifies a 2-fold 
change in gene expression. Upregulated genes are red dots, unchanged genes are black dots and 
downregulated genes are green dots.  
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FIGURE 52 - Oxidative stress gene response in three BPH primary cultures. 
Oxidative stress transcriptional response in cultures from patients H221/12, H229/12 and 
H249/12. Expression was assessed 0.5 and 2 hours after a 3-minute LTP dose. Black solid line 
denotes “no change” between untreated and treated gene expression, the dashed line (above 
and below the black solid line) signifies a 2-fold change in gene expression. Upregulated genes are 
red dots, unchanged genes are black dots and downregulated genes are green dots.  
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FIGURE 53 - Oxidative stress gene response in three Gleason 9 primary cultures. 
Oxidative stress transcriptional response in cultures from patients H306/13, H460/14 and 
H545/15. Expression was assessed 0.5 and 2 hours after a 3-minute LTP dose. Black solid line 
denotes “no change” between untreated and treated gene expression, the dashed line (above 
and below the black solid line) signifies a 2-fold change in gene expression. Upregulated genes are 
red dots, unchanged genes are black dots and downregulated genes are green dots.  
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FIGURE 54 - Oxidative stress gene expression qRT-PCR array data was reproducible and robust. 
A) Primary culture expression of four genes included on the arrays was measured using TaqMan 
qRT-PCR 2 hours after LTP treatment. Error bars of qRT-PCR measurements represent SEM of 
biological triplicates. B) Melt curve analysis of recurrently upregulated gene products on the array 
plates reveals amplification of a single product.  
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FIGURE 55 - SmartFlares do not accurately represent transcriptional changes in HMOX1 gene 
expression. 
A) Diagrammatic depiction of how mRNA changes can be assessed in real time by fluorescence 
using SmartFlare gold particles. B) HMOX1 SmartFlare fluorescence in the PC3 cell line and 
comparison to transcript levels detected by TaqMan qRT-PCR. Error bars are representative of the 
SEM of biological triplicate measurements. C) SmartFlare fluorescence in the H434/14 patient 
matched pair with comparison to HMOX1 mRNA levels detected by Array qRT-PCR. Note different 
y axis scales in the HMOX1 expression graphs. Black scale bars are 75µm.   
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5.3 – LTP stimulated the respective activation and accumulation of AP-1 and Nrf2 
transcription factors in prostate epithelial cells 
The recurrent upregulation of several antioxidant genes by LTP across several tissue pathologies 
suggested involvement of a common upstream transcription factor/s. Literature supported the 
involvement of Nrf2 and AP-1 (709-712, 726, 748), both canonical oxidative stress responders, in 
the induction of gene expression. The activation of both transcription factors following LTP 
exposure was assessed in patient matched pair cultures. Following 3-minute plasma treatment, 
the oxidative stress transcription factor Nrf2 accumulated in primary cultures (Figure 56A+B). This 
effect, determined by densitometry, was more pronounced in the normal tissues of the patient 
matched pairs, compared to the accumulation of the transcription factor in the Gleason 7 cultures 
(Figure 56C+D). Levels of Keap1, the protein responsible for Nrf2 turnover in non-stressed cells, 
were unchanged by treatment (Figure 56). The AP-1 factor Jun was potently activated half an 
hour after plasma treatment, shown by the phosphorylation (pJun) in treated cells across all 
cultures of the three patient matched pairs. Activation of the AP-1 signalling axis was further 
confirmed by congruent activation (by phosphorylation) of Jun’s upstream kinase; JNK, by LTP 
(Figure 56A+B).  
Attempts to view Nrf2 translocation from the cytoplasm to the nucleus after LTP treatment were 
hampered by the discovery that the transcription factor was located in the nucleus of untreated 
cultures, at least in the two patient matched pairs that were used. Only H209/12 RA showed 
expected cytosolic staining for Nrf2 in non-stress conditions (Figure 57A). However, upon testing 
if treatment altered Nrf2 localisation, the initial result could not be reproduced and, in untreated 
cells, Nrf2 was nuclear as for the other cultures (Figure 57B). 
Jun phosphorylation was increased by LTP treatment in all cultures, with typical nuclear 
localisation of the transcription factor observed (Figure 58A). The same was true of the active 
transcription factor in the basal epithelial subpopulations (SC/TA and CB). For several cultures 
(H594/17, H643/17 RM, H646/17 RM) pJun staining after treatment was more intense in the 
progenitor SC/TA fraction than in the more differentiated CB cells (Figure 58B). 
5.4 – Development of a cell line model of primary LTP stress response 
Primary prostate cultures can rarely be grown to cell numbers adequate for assessment of 
transcription factor-response element binding by ChIP. As IF had failed to establish Nrf2-ARE 
binding after plasma treatment, a cell line model of primary prostate cancer was required to 
establish whether LTP altered both Nrf2 and Jun response element occupancy and whether this 
binding to chromatin caused transactivation of genes. 
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Two cell lines; P4E6 (cancer) and PNT1a (normal) were treated with the stress inducing chemical; 
sodium meta-arsenite (arsenite). P4E6 cells were more sensitive to the arsenite, with cell death 
obvious at 10µm dose and, using HMOX1 transcription as a readout, maximum gene expression 
reached levels four times those observed in the PNT1a cells (Figure 59A). PNT1a also appeared 
more resistant in cellular morphology, with no obvious increase in cell death, even at the higher 
doses (Figure 59B). 
To map the timing of transcriptional stress response in the cell lines, HMOX1 was used. Following 
arsenite treatment, P4E6 showed a gradual production of transcript whereas LTP produced a 
delayed, but, peaked response (Figure 60A). The PNT1a cell line showed the opposite response, 
with a peaked arsenite response and gradual HMOX1 expression after plasma treatment. The cell 
line was also much more sensitive to arsenite than plasma (Figure 60C). Transcriptional output of 
HMOX1 reached greater levels than in the dose-response experiment (Figure 59B). JUN 
transcription was also assessed in treated P4E6 cells. mRNA levels of the AP-1 factor reacted 
much quicker than that of HMOX1 and displayed a wave-like curve in response to both 
treatments (Figure 60B).  
LTP was shown to induce a robust and recurrent oxidative stress transcriptional response in 
primary prostate epithelial cultures which was confirmed by upstream involvement of classical 
stress-activated transcription factors Nrf2 and AP-1. Cell lines also responded to plasma yet had a 
longer refractory period than the patient cultures to the reactive species, something which may 
be attributable to “culture shock”(reviewed in (749)) where the demands of adapting to the 
plastic environment have increased capacity to scavenge damaging ROS. As this focused approach 
had shown that primary cells responded to LTP, global transcriptional changes in treated cells 
were assessed using a micro-array based approach. 
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FIGURE 56 -LTP caused accumulation of Nrf2 and activation of AP-1 within 0.5 hours of treatment. 
A) Oxidative stress response pathway protein analysis at 0.5 and 2 hours after a 3-minute plasma 
dose in three patient matched pairs. B) Densitometry analysis of LTP induced protein changes in 
all six cultures (n=6). Each sample’s LTP induced fold change is plotted as a single pink circle 
(0.5hrs) and green triangle (2hrs) on the boxplot. Mean of measurements is plotted as a small (+) 
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in the boxplots. C) Densitometry analysis of LTP induced protein changes in the three normal 
prostate cultures (n=3) D) Densitometry analysis of LTP induced protein changes in the three 
Gleason 7 cultures (n=3). Note that y axis scales of densitometry boxplots are different.   
187 
 
FIGURE 57 - Nrf2 is located in the nucleus of primary prostate basal epithelial cultures. 
A) Assessment of Nrf2 and Keap1 localisation in the H209/12 and H434/14 patient matched pairs. 
B) Repeat assessment of Nrf2 and Keap1 localisation in the H209/12 RA culture before and 30-
minutes after 3-minute LTP treatment. All white scale bars are 100µm.  
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FIGURE 58 - pJun is nuclear in primary prostate cultures and phosphorylation was increased by LTP 
treatment. 
A) Assessment of pJun localisation in three patient’s primary prostate cultures 30-minutes after 
LTP treatment. B) Assessment of pJun localisation in the basal epithelial subpopulations of five 
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patient cultures 30-minutes after LTP. CD49b (α2 integrin) levels indicates a successful separation 
of SC/TA (high CD49b) and CB (low CD49b) populations. All white scale bars are 100µm.   
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FIGURE 59 - Arsenite dose response in P4E6 and PNT1a prostate cell lines. 
A) P4E6 morphology and HMOX1 transcription at increasing doses of sodium meta-arsenite. B) 
PNT1a morphology and HMOX1 transcription at increasing doses of sodium meta-arsenite. All 
white scale bars are 200µm. Note different y axis scales of the HMOX1 expression graphs. The 
error bars represent SEM of biological triplicates.  
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FIGURE 60 – HMOX1 and JUN transcript levels in Arsenite and Plasma treated P4E6 and PNT1a 
prostate cell lines. 
A) P4E6 8 hour time-course of HMOX1 mRNA abundance following treatment with either 3-
minute LTP dose or 0.8µM arsenite. B) P4E6 8 hour time-course of JUN mRNA amount following 
treatment with either 3-minute LTP dose or 0.8µM arsenite. C) PNT1a 8 hour time-course of 
HMOX1 mRNA following treatment with either 3-minute LTP dose or 2µM arsenite. The graph is 
split as LTP-induced expression wouldn’t be visible if included with arsenite-induced HMOX1 
expression. Note different y axis scales of expression graphs. Error bars of all graphs are 
representative of the SEM of the biological triplicates.  
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6. Results– Microarray analysis revealed rapid activation of Notch and AP-1 by 
LTP 
6.1 – Microarray data identified activation of multiple signalling pathways by LTP in 
prostate primary cultures 
As the qRT-PCR Profiler arrays had identified that LTP elicited a recurrent gene expression 
response in the primary prostate cultures, whole transcriptome analysis of LTP-treated cells was 
performed to gain a complete picture of the transcriptional changes caused by the treatment. 
RNA was harvested from six untreated and treated primary prostate cultures 2 hours after a 3-
minute plasma dose. The RNA was taken from two patient matched pairs and two Gleason 9 
cancers. Quality of all RNA samples was excellent; with each sample earning a perfect RIN score of 
10 and showing strong 28S and 18S rRNA banding in the accompanying electrophoresis images 
(Figure 61A). Multidimensional scaling (MDS) using the Euclidean distance of each point of 
transcript expression was able to successfully separate the primary epithelial culture 
transcriptomes from those of two prostate cell lines; BPH-1 and PC3, that were also submitted for 
analysis in a separate experiment (Figure 61B). Comparison of treated against untreated samples 
observed that LTP treatment altered the expression of 645, out of a total 540,000, transcripts on 
the Clariom D microarray. 544 were upregulated and 101 were downregulated 2 hours after a 3-
minute plasma dose (Figure 61C). 
Focusing on the upregulated transcripts, it was immediately apparent that genes involved in NF-
kB (NR4A1-3, RIPK1+4, IL6R, TNFS13B, TNFAIP3, IRAK2, SQSTM1, NFKBIA, REL, NFKB2), AP-1 (JUN, 
JUND, FOSB, FOSL1, DUSP5, DUSP10, MAP3K8, MAP2K3) and Notch signalling (NRARP, HES1, 
HEY1, SOX9, ID2, ID3) were activated by the plasma alongside upregulation of many transcription 
factor genes. (ATF3, EGR2+3, KLF4,9+10) (Figure 62). LIMMA analysis, which accounts for inherent 
biological variability in gene expression and removes genes that have a wide range of 
transcriptional variability in untreated samples from further analysis, (743) was applied to the 544 
LTP-upregulated transcripts and returned 89 upregulated probe-sets, of which 42 were annotated 
genes (Figure 63). This further confirmed involvement of Notch and AP-1 with a responsive 
expression of several previously identified transcription factors. 
Expression of twelve genes in four independent primary cultures following LTP was assessed by 
qRT-PCR to validate the signalling pathways implicated in microarray analysis. NRARP was the only 
tested gene of those chosen to represent Notch signalling to pass validation (Figure 64). The two 
AP-1 factors JUN and FOSB were expressed consistently following plasma treatment whereas the 
negative regulator DUSP10 was not (Figure 64). IL6R also failed to pass validation. SQSTM1 and 
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HMOX1 were upregulated 2 hours post-LTP across the four samples, as were the three NR4A 
isoforms (Figure 64). 
6.2 – Upstream transcription factors Notch1 and Jun are activated by plasma 
The transcription factors indicated to be initiating the transcriptional response to LTP in the 
primary cultures; Notch, NF-kB and AP-1, were assessed in two patient matched pairs over a 2 
hour time-course. Nrf2 was also included (Figure 65 & 66A). 
Canonical NF-kB signalling was not universally activated by the plasma. IkBα levels remained 
stable and phosphorylation of the inhibitory protein only occurred in the Gleason 7 cultures of the 
patient matched pairs (Figure 65 & 66B). Non-canonical NF-kB signalling however, was activated. 
Following LTP treatment, NIK protein accumulated over the time-course, an effect most obvious 
in the H646/17 LM culture (Figure 65 & 66C).  
Notch signalling was activated in the primary cultures after plasma treatment, which caused a 
release of the Notch1 intracellular domain (NICD). This cleavage event was most clearly observed 
in patient H646/17 (Figure 65). Cleavage of Notch1 was initiated almost immediately by LTP and 
mean levels of the transcription factor peaked 1 hour after plasma dose (Figure 66D). 
AP-1 signalling was activated in all of the patient matched pairs (Figure 65). The maximum 
intensity of Jun phosphorylation occurred, like Notch activation, 1 hour after LTP treatment 
(Figure 66E). Nrf2 was present at high basal levels in the patient matched pair cultures, and no 
change in the amount of the transcription factor or its negative regulator, Keap1, was observed 
across the time-course, with the exception of Keap1 in the H643/17 RM culture (Figure 65 & 66A). 
Further analysis of canonical NF-kB signalling found that plasma treatment resulted in no change 
in the localisation of NF-kB p65, which remained cytosolic; in both whole population (WP) culture 
(Figure 67A) and in the basal epithelial subpopulations (Figure 67B). Western blot data also 
showed no alteration in NF-kB p65 levels by LTP across four primary cultures. IkBα 
phosphorylation remained unchanged, yet total protein was reduced by treatment after 2 hours 
in the H523/15 matched pair – suggesting activation of the transcription factor in this patient 
(Figure 67C). 
Notch signalling was further assessed in three patients, 0.5 hours and 2 hours after LTP. In the 
majority of these cultures, Notch1 proteolytic activation was increased 0.5 hours after treatment 
(Figure 68A+B). 
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FIGURE 61 - Microarray RNA sample integrity and initial microarray data showed that LTP treatment 
alters gene expression. 
A) Agilent electrophoretic image shows the intact ribosomal RNA in all samples sent for 
microarray analysis. All samples achieved a perfect RNA integrity score of 10. B) Multi-
dimensional scaling of all transcripts expressed in the samples, as detected by microarray analysis, 
was able to separate two prostate cell lines and the primary cultures (top right) into three distinct 
clusters. C) Volcano plot showing significant fold changes in transcript expression at 2 hours post 
3-minutes LTP dose in primary prostate epithelial cultures. All samples (2x normal, 2x Gleason 7 
and 2x Gleason 9) were grouped and treated was compared to untreated. In total 645 transcripts 
were altered by LTP; 544 upregulated and 101 downregulated.   
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FIGURE 62 - Heatmap of annotated gene expression changes following LTP treatment. 
Expression intensity in untreated and LTP-treated samples for genes of interest in the six primary 
prostate cultures. The heatmap was constructed on Affymetrix Transcriptome Analysis Console 3 
and the genes chosen due to relation to activation of related pathways and magnitude of 
significant expression change.  
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FIGURE 63 - Linear Models for Microarray Data (LIMMA) analysis found 89 transcripts were 
significantly altered by LTP in primary prostate cultures. 
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Each sample’s expression of the transcript is plotted as a single dot, mean of total population 
(n=6) expression is represented by the vertical line. Green dots represent untreated, and blue are 
the treated samples.  
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FIGURE 64 - Validation of 12 genes from initial analysis confirmed robustness of the microarray 
dataset. 
Genes were chosen from the Notch (NRARP, HES1, SOX9), AP-1 (JUN, FOSB, DUSP10) Stress 
response (HMOX1, SQSTM1) and NF-kB (NR4A1-3, IL6R) signalling pathways. The blue boxplot 
shows gene expression of the six microarray samples, the green boxplot shows average gene 
expression of the four validation samples, with the individual biological replicates of the validation 
samples also plotted. 2-fold upregulation is marked by the solid red line across the gene 
expression data. Mean of sample box plots is indicated by (+). Note that y axis scales of gene 
expression boxplots are different.  
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FIGURE 65 - LTP activated Notch and AP-1 signalling in primary prostate epithelial cultures. 
Western blot time-course analysis of NF-kB, Notch, AP-1 and Nrf2 signalling in two LTP-treated 
patient matched pairs.   
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FIGURE 66 - Densitometry analysis of LTP treatment time-course showed activation of Notch, AP-1 
and non-canonical NF-kB signalling. 
Total protein and activation densitometry analysis of Figure 65 Western Blots. A) Nrf2 and Keap1, 
B) Total IkBα and phospho-IkBα, C) NIK, D) Notch1 and Cleaved Notch1, and E) Total Jun and 
phospho-Jun. Each sample’s fold change is plotted with the group mean represented by a + within 
the boxplot. Note that y axis scales of the densitometry boxplots are different.  
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6.3 – Stem and transit amplifying cells are the plasma-responsive fraction in primary 
cultures 
As all previous analysis had been conducted in heterogeneous cultures where epithelial 
subpopulations may have contributed differently to the LTP response, WP cells were separated on 
their expression of α2β1 integrin. This yielded an α2β1hi population consisting of prostate 
progenitors (SC/TA) and an α2β1lo population of differentiated CB cells. The SC/TA population were 
the most responsive to LTP (Figure 69). Mean upregulation of the NR4A isoforms in the 
progenitor population was higher than in both WP and CB cells, with only two exceptions (NR4A3 
in H643/17 LM WP & NR4A1 in H594/17 WP). LTP upregulated NR4A1 and 3 in the progenitors to 
a significantly higher level than that observed in the more differentiated CB cell population. 
AP-1 was also more readily activated by plasma in SC/TA cells (Figure 70A). Average Jun 
phosphorylation in the SC/TA pool was three times that observed in the more differentiated CB 
cells (Figure 70B). JUN mRNA was increased in all populations by LTP but there was no significant 
difference in upregulation of the gene between the SC/TA and CB epithelial subpopulations 
(Figure 70C). 
Notch1 signalling was constitutively active in the H646/17 patient matched pair and responsive to 
LTP in H652b/17 SC/TA. Densitometry analysis revealed that NICD release after plasma treatment 
was also greatest in the SC/TA pool (Figure 70E). The progenitor subpopulation also had higher 
levels of the Notch1 receptor than CB cells (Figure 70D). Significant upregulation of NRARP was 
seen 2 hours after LTP treatment in SC/TA cells but not CB cells from the same patients (Figure 
70F). Notch1 staining of plasma treated epithelial subpopulations revealed changes to cellular 
morphology and contact; some cells rounded up after LTP was administered and most treated 
cell-sheets were disrupted by the treatment (Figure 71A). LTP altered Notch localisation in four of 
the five primary prostate cultures treated. Nuclear foci of Notch1 were observed exclusively in the 
LTP-treated SC/TA subpopulation, 30 minutes after plasma dose (Figure 71B). 
The microarray highlighted the diverse molecular response produced by LTP in the primary 
prostate cultures which was further characterised by validation of the upstream protein 
components. Activation of stress response pathways of AP-1 and NF-kB was expected, the global 
approach highlighted the involvement of Notch, a signalling network critical to epithelial 
differentiation and the human prostate stem cell population (53). Separation of the basal cell 
populations revealed a heterogeneous response in both the transduction of the signal and the 
transcriptional output of primary prostate cells following plasma treatment. The activation of 
Notch and non-canonical NF-kB may prove to be hallmarks of the LTP-resistant population, 
something which requires further investigation.   
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FIGURE 67 - Canonical NF-kB signalling in primary prostate cultures is unaffected by LTP. 
A) Immunofluorescence of NF-kB p65 30-minutes post-LTP in treated and untreated cultures. B) 
Immunofluorescence of NF-kB p65 30-minutes post-LTP in H594/17 L epithelial subpopulations. 
CD49b (α2 integrin) levels indicate a successful separation of SC/TA (high CD49b) and CB (low 
CD49b) populations. White scale bar is 100µm. C) Canonical NF-kB activation protein analysis in 
four primary prostate cultures.  
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FIGURE 68 - Notch1 is activated by LTP in primary prostate epithelial cultures. 
A) Assessment of LTP induced changes to Notch1 receptor total amount and its activation by 
proteolysis to produce the NICD 0.5 and 2 hours after a 3-minute LTP dose. B) Densitometry 
analysis of Notch1 receptor changes following LTP treatment. Each sample’s LTP induced fold 
change is plotted and the mean is represented by the + inside the boxplot.  
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FIGURE 69 - NR4A isoform upregulation by LTP was more potent in the SC/TA subpopulation of 
primary prostate cultures. 
NR4A1, 2 & 3 gene expression in the epithelial subpopulations from three primary prostate 
epithelial cultures. Individual biological replicates are plotted. The red lines highlight the 2-fold 
increase required for the gene to be designated “upregulated”. The mean of biological triplicates 
is represented by a (+) Note that y axis scales of the gene expression boxplots are different. 
Unpaired t-tests were performed between subpopulation gene expression – significant 
differences are shown in the figure.   
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FIGURE 70 - Epithelial subpopulation analysis of LTP-induced AP-1 and Notch signalling. 
 
A) Protein analysis of Jun activation 30-minutes post 3-minute LTP dose in the epithelial 
subpopulations of three primary cultures. B) Densitometry analysis of change in Jun activation in 
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LTP treated prostate epithelial subpopulations. Individual samples are plotted. Mean of the 
samples is represented by +. C) JUN expression 2 hours post 3-minute LTP dose in the epithelial 
subpopulations of three primary cultures. Individual biological replicates are plotted. 2-fold 
upregulation is marked by a solid red line. Mean of biological triplicates is represented as a (+). 
Note that y axis scales are different. Unpaired t-tests were performed between subpopulation 
gene expression – significant differences are shown in the figure. D) Protein analysis of Notch1 
activation 30-minutes post 3-minute LTP dose in three primary cultures subpopulations. E) 
Densitometry analysis of Notch1 cleavage in LTP treated prostate epithelial subpopulations. 
Individual samples are plotted. Mean of the samples is represented by +. F) NRARP expression 2 
hours post 3-minute LTP dose in the epithelial subpopulations of three primary cultures. 
Individual biological replicates are plotted. 2-fold upregulation is marked by a solid red line. Mean 
of biological triplicates is represented as a (+). Note that y axis scales are different between the 
patients. Unpaired t-tests were performed between subpopulation gene expression – significant 
differences are shown in the figure.   
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FIGURE 71 - Notch1 was nuclear in LTP-treated SC/TA cells. 
A) Immunofluorescence of Notch1 in epithelial subpopulations of five primary prostate cultures. 
CD49b (α2 integrin) panel indicates a successful separation of SC/TA and CB populations. B) Larger 
images of Notch1 nuclear foci in SC/TA cells of four cultures. White scale bar is 100µm in all 
images.  
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7.1 Discussion – Alterations in allelic expression of genes involved in the 
molecular pathogenesis of prostate cancer 
7.1 – Do current cell lines and the primary prostate basal epithelial cultures adequately 
represent modern prostate cancers? 
Mutation is an infrequent event in prostate cancer with most genomic changes achieved by 
chromosomal rearrangements such as fusions of TMPRSS2 and ERG, and deletions in the PTEN 
gene (90). AR is the most commonly mutated gene in prostate cancer, yet this molecular 
aberration only occurs in advanced disease and is selected for by hormonal treatments (73). In 
primary prostate cancer, SPOP is the most commonly affected gene with publications citing 
mutation frequencies between of 5-15% in patient tumours. PTEN and IDH1 mutation are even 
less frequent, observed in ~1% of all tumours (330, 618). In a recent global study of prostate 
cancer genomes, SPOP and IDH1 mutation defined subclasses of prostate cancers and therefore 
will have independent disease features and treatment susceptibilities. In order to recapitulate the 
heterogeneity of prostate cancer we must have models of these disease variants rather than 
project an all-encompassing conclusion of a treatment outcome or molecular aberration on a 
single model of disease. Especially now we have knowledge that a significant proportion of 
patient disease does not readily fall into a single category of prostate cancer or, even with the 
combined power of whole genomic, transcriptomic and epigenetic data-sets, is able to be 
grouped at all (330). 
7.1.1 - Cell lines 
Current commercially available prostate cell lines are limited and most represent the advanced 
stage of disease with VCaP, Du145, LNCaP and PC3 having all been isolated from metastatic tissue. 
Whilst common molecular defects such as the TMPRSS2-ERG fusion (VCaP) and PTEN aberration 
(LNCaP, PTEN, Du145) are represented in cell lines, mutation of SPOP, PTEN or IDH-1 wasn’t 
detected in the panel of seven lines (351, 451, 453)(Figure 35). 
SPOP mutation has only been documented in a single cell line isolated in 2014 (241). However, 
the model hasn’t been widely distributed. There is no documented production of an IDH1 mutant 
prostate cancer cell line, probably due to the low frequency of this mutation in tumours. 
7.1.2 - Primary basal epithelial cultures 
The primary basal cultures are grown from tissue biopsies isolated from radical prostatectomies. 
Cancerous tissue biopsies are informed by palpation (feeling the tumour in the organ at time of 
removal) and assessment of tissue pathology. Palpable tumours with a high rate of Gleason grade 
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positivity give the greatest chance of growing cultures that originate from cancerous cells. Biopsy 
cores, harvested with this criteria, typically contain >70% cancer cells (Unpublished data from 
1996). 
The data collected from the primary prostate cancer cultures show that they mirror population 
diversity well in regards to minor allele frequency of SNPs and that molecular changes attributed 
to prostate cancer are present, such as LOH in the PTEN gene (Figure 36) and expression of the 
highly prostate cancer specific TMPRSS2-ERG fusion (Figure 33). 
The lack of observable IDH1 and PTEN mutation in the patient population assessed is reasonable 
due to the expected low frequency of both mutations identified in much larger studies (330). 
However, not a single SPOP mutation was found in the 55 cancer cultures tested (Figure 39). 
Although this isn’t a large patient group it would be expected that, even at the lower end of 
mutational frequency (~5%); 2-3 patients would harbour point mutations. There are several other 
groups that have reported a lack of SPOP mutants in patient cohorts, including that of Guido 
Jenster in Rotterdam. 
Aside from the possibility that SPOP mutations are entirely absent in the tumours from which we 
have grown the primary cultures used in this study, there are several other possibilities as to why 
no SPOP point mutants were detected.  
Genomic differences between prostate cancers of variant racial/ethnic groups. 
Genomic disparities exist between prostate cancers diagnosed in patient cohorts of different 
races (750). For example, prostate cancers in Chinese men have low frequencies of TMPRSS2-ERG 
fusions (~6%) and divergent driver chromosomal alterations such as PCDH9 deletions (32%) and 
amplification of PLXNA1 (23%) (751). The mortality and diagnostic figures based on geography 
show that different populations of men vary greatly in their disease outcomes (73). Geographical 
environmental factors also play a significant role in disease outcome, and perhaps molecular 
pathology (144). The first major SPOP mutation studies (133) were conducted in New 
York/Boston, cities that have far greater racial and ethnic diversity than North Yorkshire where my 
laboratory sources it’s samples from. However this may not be such a decisive factor as a previous 
study has found that SPOP mutation varied little across ethnically diverse patient cohorts (618). 
Outgrowth of normal epithelia. 
Although unlikely, it is a possibility that some samples may have had an outgrowth of normal 
prostate epithelia. Methods are in place to reduce the percentage of normal tissue included in the 
cancer biopsies, yet in all cases it is impossible to completely remove normal prostate epithelia 
from the biopsy. Biopsy core cancer positivity is monitored by tissue pathology and most tumour 
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biopsy sites are palpable through the prostate capsule. The harvesting of sample DNA at low 
passage limited the chance that normal outgrowth may have occurred and simultaneously will 
have retained cancer cells in which mutation would be detectable by a sensitive molecular 
technique such as PCR. Normal cells may out-compete cancerous epithelia in some patient 
samples, as adaptation to culture is determined on a patient-by-patient basis. Some samples 
don’t grow at all. Therefore it is possible, although highly unlikely due to the presence of PTEN 
deletion and TMPRSS2-ERG expression in the same cultures, that primary “cancer” cultures may 
be normal epithelia and thus SPOP mutation wasn’t detected.  
Mutation is cell type dependent. 
SPOP mutations have been detected by studies that process whole-prostate tissue sections (133, 
175). This identifies that a mutation is present in the prostate, yet not which cell type it occurs in. 
Some efforts have been made to identify cell-type using laser capture microdissection. However, 
due to the skewed epithelial proportions in cancer, this is likely to be a signature dominated by 
the luminal cells of the tumour (133). A less likely hypothesis is that the mutation is exclusive to 
stromal cells. Stromal mutations are known to occur in epithelial cancers and aberrant signatures 
assigned to cancers have later been determined to be stromal, highlighting the difficulties of 
dissecting information provided by whole-tissue processing (752). The more plausible scenario, as 
our cultures are grown from prostate basal epithelia, is that the SPOP mutation is in the luminal 
cells of tumours which do not grow in the culture environment. This would be interesting as it 
would imply that a separate lineage incurs the SPOP mutation that is then carried into advanced 
metastatic disease (73). 
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7.2 Discussion - Stress signalling in LTP treated primary prostate basal 
epithelial cells 
7.2.1 - Primary cultures respond more rapidly to plasma treatment than prostate cell lines 
All of the cell lines tested (Figure 42) exhibited a delayed transcriptional response to LTP over that 
seen in the primary cultures. The genomic, transcriptomic and proteomic separation of cell line 
and primary cultures is well documented (753, 754). Currently, the metastatic stage of disease is 
over-represented in prostate cancer cell lines (450, 452, 455, 457, 459) whereas our primary 
cultures have been taken and grown from organ confined tumours, the disease state for which 
LTP if successful, could provide a future treatment. The stark separation of the primary culture 
transcriptome from that of two basal prostate cell lines in Euclidean analysis of the samples used 
in this study gives further evidence of the distance from which cell lines can accurately re-
capitulate disease, or even “normal”, pathologies (Figure 63B). The transcriptional response of 
the cell lines, peaking 4-8 hours after treatment, was misleading with respect to the primary 
culture experiments. Some cultures responded within half an hour of treatment (H221/12, 
H229/12 and H306/13) (Figure 52 & 53) with widespread reactionary transcription observed at 
the 2 hour time-point (Figure 50). 
7.2.2 - Oxidative stress is initiated by LTP in prostate primary cultures 
Previous work has observed that ROS are generated in primary culture growth medium by low 
temperature plasma (304) with characteristic DNA damage following the induction of the reactive 
species. This work identified a robust gene expression response is triggered by the plasma, which 
is very similar to that generated by hydrogen peroxide treatment – implying that this particular 
species may be a major contributor to the damage initiated by LTP (Figure 45C). 
All cultures tested (with the exception of H249/12) robustly express genes involved in oxidative 
stress response. From the averaged expression data based on tissue type, six genes were 
highlighted as a core plasma response; HMOX1, HSPA1A, TXNRD1, SRXN1, DUSP1 and SQSTM1 
(Figure 50). 
HMOX1 and HSPA1A are present in the mean expression data of all four pathologies (Figure 50). 
HMOX1 translates as the inducible Haem Oxygenase 1 enzyme that permits intracellular ROS 
scavenging via catalysis of haem metabolism reactions (755) and HSPA1A (Heat Shock Protein 
A1A); a protein folding chaperone (autophagy and ER stress) (756, 757) that also has a negative 
feedback role in NF-kB signalling (758). 
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SQSTM1 was upregulated in normal and Gleason 7 tissue averages and appears in individual BPH 
and Gleason 9 samples (Figure 50). The gene encodes an autophagy chaperone protein called 
Sequestosome 1 or p62. SQSTM1 escorts misfolded protein aggregates to the autophagosome 
(724, 759). Autophagy is activated in plasma treated prostate basal epithelial cells, so an increase 
in the molecular effectors of this response was not unexpected (304). The activation of 
autophagic processes in LTP-response was further confirmed by pathway analysis highlighting 
enrichment in unfolded protein and ER stress signalling responses in treated cells (Table 16). The 
misfolding and subsequent aggregation of proteins alongside potential oxidative damage to 
organelles would initiate autophagy in cells attempting to survive LTP. 
Like SQSTM1, DUSP1 upregulation was observed in all tissue pathologies and appeared in the 
mean expression plots of normal and BPH patient cultures (Figure 9). This gene encodes Dual 
Specificity Phosphatase 1, a MAPK phosphatase that acts as a pan-specific negative regulator of 
p38, JNK and ERK activation (760). DUSP1 is classically upregulated in response to stress stimuli 
(761) and functions as an “off-switch” for AP-1 signalling.  
SRXN1 was upregulated in all tissue types by LTP and appeared in the mean expression data of 
both the normal and Gleason 9 samples (Figure 50). Sulfiredoxin 1 acts as a redox regulator in 
oxidative stress by recycling peroxiredoxins (762, 763). The peroxiredoxins, in their recycled form 
are responsible for the detoxification of hydrogen peroxide, (764) thus a rise in SRXN levels allows 
cells to buffer an increase in H2O2 and ROS. This again suggested, alongside the H2O2 treatment 
data (Figure 45C)(304) that peroxide is a major active species induced within cells by the plasma. 
Although TXNRD1 (thioredoxin reductase 1) wasn’t upregulated in BPH cultures, (Figure 52) the 
enzyme was expressed in response to plasma in the other pathologies and was consistently 
expressed in the patient matched pair cultures (Figure 50). The TXN system is a major cellular 
anti-oxidant defence which resolves inappropriate disulphide bridges in proteins that have 
sustained oxidative damage and restores them to native and functional state. However, in the 
process TXN itself becomes reduced with its active form being regained through enzymatic action 
of TXNRD1 (765). Upregulation of this redox regulator suggests that cells enter a state of oxidative 
stress following LTP treatment and require a larger turnover of active TXN.  
The upregulation of the above genes after LTP treatment indicates a state of oxidative stress was 
produced in primary prostate cultures. Activation of genes involved in protein misfolding, 
autophagy and ROS scavenging suggests that cells sustain oxidative damage and attempt to 
respond via a transcriptional response. 
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7.2.3 - Gleason 7 cultures have elevated expression of oxidative stress genes over their 
normal counterparts 
The relative expression change of genes in response to plasma was measured using treated and 
untreated cells. Through comparison of both untreated normal and cancerous gene expression 
from the patient matched pairs it was, firstly, obvious that patient cultures had a divergent 
expression signature from one another and, secondly, that the Gleason 7 cultures had an elevated 
expression of several important oxidative stress response genes. For example, the Gleason 7 
culture of patient H209/12 shows elevated expression HMOX1, HSPA1A, SQSTM1 and TXNRD1 
over its corresponding normal epithelia (Figure 51). By combining the data from the three 
patients, the prostate cancers again show a heightened expression of several well-known 
antioxidant genes, including; HMOX1, HSPA1A, GPX2 and SOD3. Prostate cancers do have an 
inflammatory aetiology that relies upon the control of oxidative species to promote hallmark 
genomic rearrangements in prostate cells (72, 73, 666). 
Metabolic changes in cancer cells are well studied and tumours are known to utilise different 
energy systems to normal tissues (766). Indeed some cancers have hallmark defects in response 
to oxidative stress, with allelic variants or mutational expression pre-disposing carcinogenesis 
(767, 768) and transcriptional profiles indicating a higher expression of antioxidant genes (769). 
Mutation or epigenetic changes in antioxidant transcription factors are also common in cancers, 
such as those observed for Nrf2 and the transcription factor’s associated regulatory network 
which typically increase baseline levels of Nrf2 in cancer cells to increase their innate ROS 
scavenging capacity (770). The pathology-dependent transcriptional separation identified in the 
base expression of the patient matched pairs agrees with previously published differential 
expression of antioxidant response genes in primary prostate cancer and normal cultures (771). 
7.2.4 - The HMOX1 SmartFlare fluorescence doesn’t match transcript levels of its target 
From the expression data of HMOX1, the gene was upregulated over 20-fold in some cultures 
after plasma treatment and was the obvious candidate for real-time monitoring of mRNA 
increases in cells. However, there was no change in SmartFlare fluorescence post LTP, relative to 
untreated cultures. This was surprising as HMOX1 is an inducible enzyme and therefore its 
basal/non-stress levels in the cell are low. The generation of ROS by LTP stimulates HMOX1 
production in treated cells, as shown by the matched qRT-PCR data, and thus SmartFlare 
fluorescence should increase (Figure 55B+C). A lack of response was also observed with the other 
SmartFlare probe being used in our laboratory at the same time. The ineffectiveness of the probes 
was further confirmed by a recent publication (772). The paper observed that fluorescence 
variations produced by the HMOX1 SmartFlare were dependent on cellular uptake of the gold 
particles and not the amount of target transcript in cells. Testing of four other gene probes 
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achieved the same result; changes in fluorescence didn’t match that of true transcript levels. 
SmartFlares therefore, fundamentally do not work and/or the quality control applied by the 
distributor, Merck-Millipore, was inadequate. Indeed, the number of commercially available 
SmartFlares in their inventory has dropped from ~1700 target transcripts to just 6 at present. 
7.2.5 - The transcription factors Nrf2 and AP-1 are activated by Low Temperature Plasma in 
patient cultures 
Due to the consistent transcriptional response of the recurrently upregulated genes across the 
primary cultures it was reasonable to assume that a common upstream regulator/s was activated 
by the plasma. The involvement of HMOX1 in the response, suggested a role for the redox active 
transcription factor Nrf2. In fact, upon further literature analysis, all six identified genes had Nrf2 
consensus AREs in their promoters (709-712, 726, 748). Nrf2 is activated by LTP in colorectal 
cancer, keratinocyte and fibroblast cell lines whereupon it aids cell survival (715, 716) through 
transactivation of a cytoprotective expression response initiated by binding to upstream AREs 
(714)(Figure 72A). 
Following plasma treatment, Nrf2 protein levels rose as expected (Figure 56A+B). This was a rapid 
response, with a snapshot at half an hour post-treatment showing an obvious increase that was 
then reduced by the 2 hour time-point. This suggests that in the prostate epithelia, LTP induces 
oxidative stress that facilitates Nrf2 accumulation by redox alteration of Nrf2-bound Keap1. The 
constant levels of Keap1 in all cultures mean that the observed increase of Nrf2 protein is due to 
oxidative stress and not a decrease in its negative regulator (Figure 56A+B). The transcription 
factor is then free to activate gene expression observed at the 2 hour time-point following LTP. 
The reduction in oxidative stress caused by the gene expression response causes the degradation 
of the transcription factor, as Keap1 is no longer modified by ROS and can be recycled to its 
reduced form, facilitating direction of Nrf2 to the proteasome, as is normal in non-stress 
conditions (Figure 56). 
The activation of Nrf2 is more pronounced in normal prostate epithelia than in the cancer cultures 
as shown by the densitometry analysis (Figure 56C+D). This may imply that normal cultures can 
respond to oxidative stress better than their corresponding Gleason 7 cancers, however follow up 
work tracking the outcome and cellular fate of this antioxidant signalling is required before any 
conclusion can be drawn from this data. Basal levels of Nrf2 protein are higher in the cancer 
cultures (H209/12 RA and H523/15 RM) thus a less potent activation is expected. This observation 
also highlights that prostate cancers do have alterations in their base antioxidant levels and 
activities, also shown in the elevated expression of oxidative stress response genes in Gleason 7 
cultures (See Section 1.9 & Figure 51). 
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FIGURE 72 – Stress induced Nrf2 and AP-1 Signalling.  
A) In non-stress conditions, binding of Keap1 to Nrf2 promotes the proteasomal degradation of 
the transcription factor. In oxidative stress, ROS modify key cysteine sulphydryl groups on Keap1 
causing a conformational change in the protein. This prevents Keap1 binding of Nrf2 and frees the 
transcription factor. Nrf2 translocates to the nucleus and affects antioxidant gene expression to 
promote cell survival. B) The stress activated protein kinases, including JNK, are activated by ROS. 
JNK then activates the AP-1 transcription factor Jun, by phosphorylation, to promote gene 
expression. AP-1 signalling can affect multiple cell fate outcomes.  
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It was hypothesised that LTP treatment would cause translocation of Nrf2 from the cytosol into 
the nucleus of cells. However, the immunofluorescence data showed that Nrf2 is already localised 
in the nucleus in untreated cultures (Figure 57A) with perhaps a slight increase in nuclear 
intensity upon plasma treatment (Figure 57B). Nuclear localisation does not necessarily 
determine functionality. It is entirely possible that nuclear Nrf2 in untreated cells is not bound to 
AREs, with a switch being made upon LTP treatment. To test this directly using chromatin 
immunoprecipitation (ChIP) however is extremely challenging due to the low cell numbers of 
primary cultures. Native ChIP, that is primarily used for detection of histone tri-methylations (and 
a limited repertoire of transcription factors), has been reported, for whole genome analyses, at 
cell counts of <1000 (741, 773). X-ChIP a method that crosslinks the DNA to transiently bound 
transcription factors however requires an input of much larger cell numbers. The protocol 
attempted in our laboratory needed ~20x106 cells (774) and current leading techniques require 
100,000 cells (775). Adaptation of new techniques will require optimisation in the primary cells 
but, in future, should remove the limitations of working with low amounts of cellular material. 
Although Nrf2 represented the most obvious transcription factor to be activated by plasma in the 
primary cultures from the gene expression analysis, recurrent DUSP1 upregulation was a major 
clue to AP-1 activation (Figure 50). The DUSP1 gene is responsive to oxidative stress and the 
protein product; dual specificity phosphatase 1, a MAPK phosphatase, acts as a negative regulator 
of p38 and JNK, the stress-activated protein kinases (776). Effectively, DUSP1 is an “off-switch” for 
AP-1 signalling (Figure 72B). 
AP-1 factors and upstream kinases, like the Nrf2 response, have previously been observed to be 
affected by LTP. Cell line studies have reported phosphorylation of JNK, p38 and ERK in response 
to plasma, (679, 687, 716, 777) with an increase in the protein expression of Jun and Fos also 
resulting from the treatment (717). 
The AP-1 axis of prostate epithelial cells is activated by plasma, with rapid phosphorylation of the 
DUSP1 substrate; JNK, followed by phospho-activation of the AP-1 factor Jun (Figure 56A+B & 
72B). The pJun immunofluorescence confirmed the AP-1 activation observed by Western blot. 
Nuclear localisation of the active transcription factor was observed only after treatment in whole 
cultures (Figure 58A). This study is the first to establish Jun phosphorylation as an outcome of 
plasma treatment. The response is conserved across the patient matched pairs where the 
activation of Jun is amplified by active JNK in the signal transduction process (Figure 56B). This 
signal amplification appears to be larger in the cancer cultures, which is attributable to the high 
base levels of pJNK in the H209/12 and H434/14 Gleason 7 cultures (Figure 56 A,C+D). Elevated 
pJNK is a requirement for some cancers that rely on Jun for oncogenesis and growth (778). A high 
base tumoural level of active JNK or Jun may be a hallmark of that patient’s disease. 
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7.2.6 - Interpatient heterogeneity, and not tissue pathology, is the main generator of 
variability between the oxidative stress transcriptional response in primary cultures 
There exists in the field of LTP treatment of cancer, a contentious theory; that cancerous cells 
have an increased sensitivity to LTP compared to their normal counterparts (779). There are now 
many papers dedicated to this phenomenon; however all of them probably include some 
misinterpretations. Some studies use, for comparison, a normal cell line derived from a separate 
organ site (696, 780-782) or use cultures derived from separate lineages (such as epithelial and 
mesenchymal cells) (715). Inter-patient heterogeneity is also neglected as a determining factor in 
treatment response when cell lines from the same organ and cell type are compared (777). 
There is a possibility that the selective effect does exist, as some cancers do have recurrent and 
hallmarked defects in antioxidant defences (783) and plasmas may exploit this Achilles heel in 
localised treatments. However, no study has provided sufficient evidence to make such a bold 
claim. Obvious variables in cell studies have not been accounted for and other alterations in cell 
culture biology such as the imposed immortalisation of “normal” cell lines aren’t acknowledged. 
Differences in culture medium constitution also impose further artefacts upon conclusions drawn 
from these studies. 
In this study of LTP response in normal and cancerous prostate epithelia, the heterogeneity 
evident in the gene composition, timing of response and in the magnitude of individual gene 
expression meant that individual patients, regardless of disease pathology, couldn’t provide a 
divisive signature. The experiment was designed to include four states of prostate tissue; normal, 
BPH, Gleason 7 and Gleason 9 cancer to discern if there was a difference in how they responded 
to the same plasma dose. However, in the primary prostate basal epithelial cultures, there was no 
clear divergence of gene expression response at the 2 hour time-point. Instead a core group of six 
LTP-induced genes was identified across the four tissue pathologies (Figure 50). No great variance 
in the LTP-response transcriptional profile was expected between disease states as previous work 
showed little difference in downstream damage and salvage pathways initiated by the treatment 
in patient matched pair cultures (304). 
This work represents a true normal/cancer comparison with the patient matched pairs supplying 
tissue isolated from the same individual yet with different disease pathology. There is extensive 
work detailing prostate cancer associated genomic and transcriptomic differences between 
normal and cancer primary cultures (66, 246, 323, 771). Cultures were grown in the same medium 
and were not immortalised. There are no differences apparent between normal and cancer in 
cellular viability or colony forming efficiency (304) after an LTP dose. The same is true at the 
molecular level of gene expression (Figure 50) and protein response, (Figure 46 & 65) where no 
218 
 
recurrent differences can distinguish between the tissue pathology. The main generator of 
variance appears to be the biology of each individual patient’s prostate.  
If tissue pathology was unknown for the individual patient 2 hours post-LTP scatterplots, any 
attempt to sort the patients (on the basis of gene expression response) into the four separate 
tissue pathologies using the average gene expression profiles (Figure 50) would be completely 
unsuccessful. No divisive signature in the gene expression response is apparent across the 
individual scatterplots (Figure 46, 47, 48, 52 & 53). The only near match of an individual patient to 
any of the tissue pathology 2 hour average gene expression signatures produced by LTP is 
H545/15 (Gleason 9), which would be identified as a normal prostate epithelial culture (Figure 
53). 
The protein data draws the same conclusion; that cancer and normal cannot be separated based 
upon their LTP response, with slight differences only evident between individual patients. The 
stress signalling of Nrf2 and AP-1 are interchangeable between disease state and to a degree, 
between patients (Figure 56). Notch signalling is also extremely variable between normal and 
cancer and seems to be determined by the patient of origin. For example, in the time-course 
Western blots, NICD activation is more similar between the cultures from the same patient than 
the disease state of normal or Gleason 7 (Figure 65). This implies that a patient’s background 
biology, rather than that of the disease seems to be driving the heterogeneity observed in 
transcription factor responses. 
7.2.7 - A model of a model; using P4E6 to map LTP induced stress responses in the 
prostate 
Primary cultures are a useful model of patient disease, which they mimic more closely than cell 
lines can achieve, however they are slow growing, difficult to transfect and have a limited life-
span in culture. This hampers analysis using methods that require high cell numbers or those that 
alter cell biology using plasmids. As Nrf2 localisation in cells post LTP treatment was ambiguous in 
the primary cells, testing of Nrf2 occupancy and activation of AREs following plasma was 
attempted using ChIP and reporter luciferase assays in the P4E6 cell line. The same experiments 
were chosen to assess Jun activity in the prostate cancer cell line following plasma treatment. 
P4E6 are a cell line which models localised prostate cancer that was generated from a primary 
culture grown in my laboratory. Immortalisation was achieved using the HPV 16 E6 protein (449). 
The cell line has a basal morphology and behave extremely similarly to the primary epithelial 
cultures. Current work using ptychographic live cell imaging has given insight into the 
morphology, migration, size and other cellular variables of primary and cell line cultures (784). Of 
the cell lines used, P4E6 is the closest representation of primary prostate epithelial cells. By using 
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P4E6 the limitations of the primary cultures can be avoided, whilst utilising a cell line model that 
resembles patient disease. PNT1a were chosen simply as they could be used as a “normal” cell 
line control to the induced stress responses of the study.  
As the oxidative stress produced by LTP in the primary cultures was transduced through Nrf2 and 
AP-1 transcription factors; arsenite was selected as a chemical inducer that could generate a 
similar stress response in prostate cells. This chemical has been used previously to activate both 
Jun (785, 786) and Nrf2 (710). In cell line studies of oxidative stress, arsenite could be used to 
stimulate a like-response in P4E6 and PNT1a cells. From initial dose curve analysis, it was 
immediately apparent that P4E6 were much more sensitive to arsenite than PNT1a cells. This was 
visible both in cellular morphology (appearance of vacuoles and abnormal processes in all arsenite 
concentrations) and apoptosis evident from ≥1µM, and in HMOX1 expression, with 1000-fold 
upregulation at higher doses (Figure 59A). In comparison PNT1a cells were resistant to arsenite, 
with no obvious increase in cell death in culture and a, still potent, yet greatly reduced HMOX1 
transcriptional response (Figure 59B). 
From this experiment, (Figure 59) a dose of 0.8µM for P4E6 and 2µM for PNT1a were chosen for 
ChIP and luciferase assays as they produced a ~50-fold upregulation in HMOX1 in each cell type, 
according to the dose curve, a response comparable to the 20-fold change following plasma in the 
primary cultures.  
The timing of both plasma and arsenite responses was measured over an 8 hour time-course to 
find the optimum window to conduct Nrf2 and AP-1 ChIP analysis. Nrf2 timing was estimated by 
using HMOX1 transcription as a readout of activity. In P4E6, the cumulative response of gene 
expression produced over the 8 hours by arsenite was expected due to the cells constant 
exposure to the dose over the treatment course (Figure 60A). HMOX1 transcript levels reached 
those previously observed in the dose response experiment (Figure 59A). The HMOX1 response to 
plasma also proceeded as expected and the single “hit” treatment produced a peak of gene 
expression at 6 hours (Figure 60A). This again shows that even for the P4E6 cell line, which has 
been generated from a primary culture, the speed of transcriptional response is much slower than 
that observed in primary cells. For the PNT1a cell line, the results were quite puzzling. HMOX1 
transcriptional levels reached much higher magnitude than was observed in the dose response 
experiment and the cumulative and peaked curves were reversed. The intensity of response 
between arsenite and plasma treatments were also very different, with the PNT1a appearing to 
be resistant to the 3-minute plasma dose (Figure 60C). This may be due to particular antioxidant 
levels in the cell line that are able to buffer the effects of the arsenite whilst the plethora of 
reactive species induced by plasma treatment caused damage that wasn’t able to be reconciled 
over the frame of the time-course. It also serves to highlight that the complexities of a cell-wide 
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and context dependent response cannot be equated to the transcriptional readout of a single 
gene. AP-1 response was also measured in reaction to both arsenite and plasma in the P4E6 cell 
line using JUN transcription. The transcription factor is known to trigger an autoregulatory 
feedback loop once activated (787) and produces a wave-like pattern suggestive of JUN positive 
feedback in the P4E6 cells (Figure 60B). The response is also much more rapid than that resulting 
in HMOX1 transcription, citing that AP-1 acts as a very quick responder in P4E6 – and by 
projection; prostate epithelia (Figure 65). 
Initial work developing the P4E6 cell line into a model of stress response for LTP was promising, 
however unforeseen complications in the transfection of the cell line and time pressure meant 
that the work is incomplete. Finishing the designed experiments, alongside additional protein 
work to determine transcription factor localisation using IF and the activation/accumulation of 
Jun and Nrf2 respectively by Western blot would provide a robust characterisation of the cell 
line’s response to LTP. Development of this model is discussed further in the Appendix – 9.2. As 
the cell line is easier to handle and grow than primary cultures any preliminary work could then 
be optimised using P4E6. Obviously, results would have to be extrapolated carefully into working 
with primaries for this approach to be successful, yet in doing so this would save time and avoid 
wasting the valuable, and finite, resource of the primary cells. 
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7.3 Discussion - Microarray analysis reveals rapid activation of Notch and AP-1 
by LTP 
7.3.1 - Microarray analysis reveals that Low Temperature Plasma significantly alters the 
expression of multiple genes involved in stress response and cellular fate 
The microarray data of six prostate primary culture samples revealed that a large number of 
genes were central in the response to plasma, with significant alteration of over 600 transcripts 
following treatment (Figure 61C). These fold-changes were consistently observed across all 
samples and the three chosen tissue pathologies; normal, Gleason 7 and Gleason 9 cancer. Genes 
could be grouped into functional pathways and it was apparent that plasma altered several 
signalling networks, the most obvious being Notch, NF-kB and AP-1 (Figure 62). These pathways 
are very much context-dependent and can determine cell death, growth and differentiation state, 
the fluctuation of which will be occurring simultaneously amongst treated culture cell 
populations. The activation of transcription does, simply and as expected, infer that cells survive 
treatment and that cell death isn’t an instant response – an attempt to recover from LTP-induced 
stress is initiated by primary cultures. 
Similar global gene expression signatures were obtained in studies that manipulated Notch (788) 
and HIF1α expression (789). The second group also observed comparable transcriptomic changes 
in cells exposed to the Na+/K+ ATPase inhibitor, ouabain. LTP may alter the transcriptional profiles 
of these transcription factors and influence membrane polarisation in prostate epithelial cells. 
This may be through the oxidative modification of cell surface proteins or be produced by 
electroporative effects associated with some plasma devices (790, 791). 
As interpatient heterogeneity is common in the primary patient cultures, this presented a 
limitation in the analysis of a single snapshot of gene expression.  The time-point of 2 hours post-
treatment was well considered and optimised across a range of primary cultures (Figure 44 + 45) 
isolated from a variety of tissue pathologies. However, the lack of gene expression changes 
observed in some cultures in response to LTP, combined with huge variance in upregulated genes 
at both 0.5 hour and 2 hour post-treatment highlights that transcription was induced as a peak by 
the “single-hit” therapy. Due to differences in cellular adaptation to culture and also epi/genetic 
and patient-based biological variance between cultures, response timing varied around the 
chosen time-point and peak expression in some instances may have been missed altogether by 
analysis. Whilst peripheral response genes may have been “missed” due to patient-patient 
heterogeneity, it strengthens the positive identification of the six central response genes in the 
oxidative stress arrays (Figure 50) and the 545 transcripts in the microarray that, even with 
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variables of interpatient variance in gene expression, were still recurrently and robustly 
upregulated by LTP across the six patient samples. 
Whilst primary cultures are more physiologically relevant and representative of modern prostate 
cancers than cell lines, (Figure 61B) the plastic environment and growth medium change of cell 
culture still shifts the transcriptomes of primary cultures away from that of in-situ populations 
(445). Acknowledgement of these differences in model systems must be made by studies before 
extrapolation of therapeutic results into clinical application – whilst the majority of upregulation 
observed in the prostate cultures by LTP is probably accurate of epithelial tissue response there 
will be a cohort of genes that are altered due to the cellular adaptation to culture environment. 
7.3.2 – Low Temperature Plasma activates Notch-directed gene expression in primary 
prostate cultures 
Notch signalling in the prostate  
Notch signalling regulates cell fate decisions (249), through establishment of asymmetrical 
division (792), cell patterning events such as lateral inhibition (793, 794) and the maintenance of 
stem cell pools by enhancing the self-renewal capabilities of progenitor populations (248, 795, 
796)(Figure 73). As Notch signalling can achieve these functional outcomes, the pathway is often 
misappropriated by tumour initiating cells, such as in breast cancer (797, 798) and glioma (799). 
Notch activation by mutation is classically observed in over half of all T cell acute lymphoblastic 
leukaemias (ALLs) (800). 
The receptor family also plays a regulatory role in the prostate. Notch signalling directs the 
development, and differentiation of the gland as well as formation of the organ itself (801). Notch 
can repress AR dependent gene expression (802) and regulate the PI3K/AKT signalling axis 
through modulation of PTEN levels (803, 804). Both of these signalling networks are important for 
development and differentiation of the normal prostate and in cancer progression. 
Immunohistochemical and gene expression analyses of patient tumour tissue found that Notch 
signalling components are increased in higher Gleason grade cancers, (805, 806) showing that 
Notch signalling plays a role in advancing disease and possibly reverts cancer cells to a favourable 
dedifferentiated state (807, 808).The Notch receptors are direct transcriptional targets of ERG and 
the signalling pathway becomes critical to the survival of fusion positive prostate cancers (663, 
809). 
Some members of the Notch signalling pathway (NOTCH1, HES1) are enriched in prostate 
epithelial SCs over their more differentiated progeny (66)(Figure 74). The pathway appears to be 
critical to the identity of multipotent basal progenitors in the human prostate (53). Notch 
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receptors and ligands are also expressed at the protein level in primary prostate cultures, where a 
reduction of signalling molecules was observed following treatment with gamma secretase 
inhibitors (GSI) (Adamson unpublished data, Figure 75A). Inhibition of Notch, using GSIs, reduced 
prostate epithelial stem cell self-renewal capabilities in colony forming efficiency assays, both 
alone and in synergy with ionising radiation (Figure 75B). GSI treatment of patient-derived 
prostate cancer xenograft cells found that Notch inhibition slowed tumour growth and could, at 
lower inoculation numbers, ablate tumour formation/initiation altogether (Figure 75C). After 
removal from mice that had been treated with GSIs, basal cells from human prostate cancers 
expressed PAP, a protein marker of luminal differentiation (Figure 75D). This suggests that 
inhibition of Notch signalling in the basal epithelia of the prostate pushes cells towards a luminal 
and terminally differentiated state where they are more susceptible to radiation (Figure 75C+D). 
A similar killing effect is observed by targeting Notch in conjunction with radiation in glioma stem 
cells (810). In future, use of antibodies specific to the tumour-associated Notch receptor isoform 
in treatments rather than non-specific GSIs could reduce toxicity towards other somatic stem cell 
pools, allowing for a more targeted treatment in cancers that misappropriate the signalling 
pathway (811, 812). 
Activation of Notch signalling in plasma treated cells, as indicated by initial findings of the 
microarray, (Figure 62) was surprising. Notch signalling has not been implicated in any previous 
work utilising LTP treatment of cells. This study therefore documented the first observed 
activation of the pathway by LTP. Transcriptional responders such as NF-kB and AP-1 were 
anticipated, in relation to the ROS induced stress, but the inclusion of a pathway linked heavily to 
stem cell function and epithelial cell fate determination in the microarray was unexpected The top 
hit of transcriptional and subsequent LIMMA analysis was the NRARP gene; a direct negative 
regulator of the NICD (813). Interestingly, the constitutive expression of Notch1 in ESCs identified 
a similar transcriptional signature to that which was observed in the LTP treated prostate 
epithelial cells. Convergent hits included the ID proteins, NRARP, HEY1, HES1, BTG2, GADD45B, 
SOX9, RHOV, EFNA1, HBEGF (814), ITPKC, RIPK4, ATF3 and the EGR proteins (788). This implicates 
that Notch directly, by causing transactivation of the expressed gene, or indirectly, through 
augmentation of other transcription factor activities, may alter the expression of these genes in 
prostate epithelial cells following plasma treatment. 
Notch is responsive to oxidative stress (815). Hydrogen peroxide activates Notch1 and initiates 
downstream gene expression in mesenchymal stem cells whilst the NICD can inhibit apoptosis 
induction upstream of SAPK activation to promote cell survival (816). ROS, induced by application 
of the plasma, may therefore be the initiating factor of the Notch pathway in the primary prostate 
epithelial cultures. 
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FIGURE 73 - Notch signalling  
A) Canonical Notch signalling. Notch receptors are stimulated by binding of ligand receptor; 
Jagged or Delta. This initiates a series of proteolytic events that releases the Notch Intracellular 
Domain (NICD) into the cell. Here the NICD acts as a transcription factor and increases canonical 
gene expression of Hes1 and Hes1 transcriptional repressors that suppress differentiation by 
silencing lineage defining transcriptional programs. B) Bi-directional Notch signalling. The Notch 
ligand receptors Jagged and Delta are also internalised following receptor-receptor binding and 
the ICDs can also initiate gene expression changes. Delta ICD can synergise with SMAD proteins 
and inhibit AP-1 transcription, whilst Jagged ICD can promote AP-1 mediated gene expression. 
  
225 
 
FIGURE 74 – Notch signalling molecule mRNA expression in prostate basal epithelial subpopulations. 
Notch signalling elements are elevated in prostate basal epithelial stem cells over their more 
differentiated progeny; committed basal cells. Figure produced from microarray data in Birnie 
2008 (66). 
   
226 
 
 
 
 
227 
 
FIGURE 75 - Inhibition of Notch signalling in primary prostate cultures promoted epithelial 
differentiation.  
A) Protein analysis showed that gamma secretase inhibitors DBZ and RO4929097 decreased levels 
of Notch signalling members in primary cultures. B) Gamma secretase inhibitor RO4929097 (and 
radiation - 2Gy) decreased prostate stem cell colony forming efficiency. C) Gamma secretase 
inhibitor RO4929097 decreased tumour formation in prostate cancer xenografts. D) Extracted 
xenograft tumour cells treated with RO4929097 were positive for the Prostatic Acid Phosphatase 
(PAP) differentiation marker. White scale bar - 15μm. Images were adapted from unpublished 
work completed by Rachel Adamson.   
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Gene H434/14 
LM 
H434/14 
RM 
H329/13 
LB H329/13 R H460/14 H545/15 
Average 
Fold 
Change 
ANOVA p-
value 
Notch 
NRARP 105.6 86.73 265.23 111.49 54.78 197.11 126.92 3.04E-09 
SOX9 8.66 5.11 2.78 3.45 3.47 8.3 4.67 0.000321 
ID1 1.6 1.89 3.05 2.18 4.63 4.05 2.53 0.213964 
ID2 3.95 5.51 3.22 2.06 4.55 2.15 4 0.044476 
ID3 1.54 3.94 18.44 9.14 9.29 2.97 5.8 0.00132 
HES1 4.1 6.56 2.06 1.12 6.93 1.19 2.99 0.00924 
HEY1 6.95 3.67 3.57 3.13 2.77 2.93 3.52 0.000006 
AP-1 
DUSP1 4.2 3.84 1.26 1.46 2.87 5.93 1.82 0.02892 
DUSP5 2.76 4.14 5.67 2.51 1.08 7.83 2.81 0.023169 
DUSP6 2.71 1.23 1.74 1.88 -4.23 2.28 2.55 0.56087 
DUSP10 12.59 10.47 1.58 1.88 9.56 6.91 7.75 0.000669 
FOSB 38.67 106.39 49.13 5.56 7.28 9.45 29.86 0.000557 
FOSL1 7.48 4.16 6.98 4.24 1.23 5.23 4.8 0.002221 
FOS 2.13 4.54 -2.4 -6.24 1.26 -1.19 -1.16 0.927986 
JUNB 2.1 4.22 1.88 1.31 1.19 1.81 1.27 0.160081 
JUN 6.5 17.24 4.23 2.23 10.78 4.07 5.62 0.000081 
JUND 3.77 5.08 4.56 1.95 4.24 1.27 4.07 0.012237 
NF-kB 
REL 2.23 2.49 4.03 3.89 3.3 2.18 2.38 0.004957 
NFKB1 1.46 1.59 4.08 3.11 -1.26 1.79 1.87 0.038902 
NFKB2 1.6 1.72 2.54 2.31 1.42 1.67 2.12 0.00357 
NFKBIA 3.16 3.42 7.58 6.05 1.46 3.85 4.84 0.001085 
NR4A1 53.43 47.41 59.06 24.55 2.18 14.15 40.94 0.000172 
NR4A2 25.53 16.39 48.97 11.12 7.77 9.68 14.99 0.000001 
NR4A3 63.63 34.45 188.37 53.5 9.47 7.95 39.07 0.000014 
HSPA1A 7.94 17.59 6.56 12.88 9.92 6.95 9.47 0.000249 
HSPA1B 12.35 12.09 11.42 12.4 8.47 9.96 11.02 0.000094 
RIPK1 3.36 3.89 2.84 2.17 2.39 2.73 2.84 0.001091 
RIPK4 5.63 15.84 55.83 18.33 7.39 7.37 14.71 0.000561 
TNFAIP3 5.13 4.1 6.35 5.3 1.47 3.36 3.89 0.000026 
MAP3K8 22.25 25.75 45.19 19.55 4.48 7.81 15.64 0.000039 
Cytokine 
IL1B 1.98 2.16 4.32 2.94 -1.25 2.53 2.05 0.041643 
IRAK2 2.86 3.72 7.64 2.93 2.06 1.52 4.1 0.027495 
IL6 4.09 5.35 22.22 7.32 -1.72 2.27 5.24 0.268214 
IL6R 13.9 13.84 5.1 7.69 3.71 4.12 10.35 0.000594 
Stress 
SQSTM1 4.37 9.01 2.94 2.04 4.99 3.7 3.13 0.000354 
HMOX1 2.25 2.71 2.02 2.51 4.24 1.61 2.56 0.00031 
TABLE 15 – Signalling Pathway upregulated genes indicated by initial microarray analysis.   
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Validation of Notch target genes upregulated by LTP in microarray analysis 
See Table 15. 
NRARP 
The top upregulated transcript in plasma treated cells was Notch Regulated Ankyrin Repeat 
Protein (126.92-fold, p=3.04x10-9). NRARP is directly induced by Notch (813) and provides a 
negative feedback loop which causes loss of the NICD (817, 818). The gene is recurrently 
overexpressed in breast, liver and thyroid cancers and is required for the maintenance of liver CSC 
stemness (819-821). NRARP was an obvious choice in the validation of microarray results and 
plasma activation of the gene’s expression passed the cut-off of a two-fold increase in three of the 
four samples chosen for qRT-PCR (Figure 64). Upregulation in a further patient matched pair 
highlights that NRARP is recurrently expressed in response to LTP in prostate basal epithelia 
(Figure 70F). 
HES1 and HEY1 
These canonical Notch targets are basic-helix-loop-helix (bHLH) transcriptional repressor proteins 
that maintain cells in a dedifferentiated state through silencing of multiple targets – many of 
which haven’t yet been characterised (822). They co-ordinately repress lineage transcription 
factors and other genes that can trigger differentiation, to assert Notch’s control on stem cell fate 
dynamics (823). Both were upregulated across the six treated samples; HEY1 - 3.52-fold (p=6x10-6) 
and HES1 – 2.99-fold (p=0.00924). Associated transcriptional co-repressors TLE3 (2.11-fold, 
p=0.0005) and TLE4 (2.01-fold, p=0.0011) were also upregulated by LTP, these proteins aid the 
silencing of developmental genes by associating with Hes1 and Hey1 (824, 825). 
Hes1 is a negative regulator of PTEN, (803) Wnt3, Wnt4 (826) and the CDK inhibitors; p21 and p57 
(827). Expression of the protein is also inducible by oxidative stress (828). HES1 was selected for 
validation as it’s mRNA is differentially expressed at higher levels in prostate epithelial stem cells 
over more differentiated progeny (66)(Figure 74) and it is a Notch specific gene. It failed to pass 
validation cut-offs, with only mild upregulation observed in H594/17 (Figure 64). However, HES1 
is commonly subject to transcriptional oscillation, therefore peak expression may be missed by 
the single snapshot of gene expression afforded by qRT-PCR. Further time-points of analysis 
would be required to definitively rule out HES1 as a LTP responsive gene (829). 
HEY1 negatively regulates ID1 (830) and AR, (802) which is particularly relevant in prostate 
epithelial progenitors. Interestingly, Hey1 can be, in certain cellular contexts, upregulated by Jun 
(831) which is also activated and upregulated by plasma (Figure 46 & 64). HEY1 was confirmed by 
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LIMMA analysis as a LTP responsive gene. Expression should be validated in future work, along 
with changes in protein levels of both Notch signalling effectors (Figure 63). 
 
ID2 and ID3 
The ID (inhibitors of differentiation) proteins are also associated with stem-like cells and belong to 
the same family of bHLH transcriptional repressors as HES1 and HEY1 (832). Like HES1 and HEY1, 
the ID proteins maintain a primitive cellular state with aberrancy in regulation and expression also 
defining CSC pools (reviewed in (822)). These genes, depending upon cellular context, can be 
directly upregulated by the NICD (788, 833-835). Both ID2 (4.00-fold, p=0.044) and ID3 (5.8-fold, 
p=0.0013) are significantly increased by plasma treatment in the six sample group, with ID1 also 
observed to be upregulated in individual samples (2.53-fold, p=0.214).  
SOX9 
Another Notch interacting gene, upregulated by LTP (4.67-fold, p=3.21x10-4), is Sox9; a member of 
the SRY box family of transcription factors that classically maintain stemness by inhibiting 
differentiation. Interplay of Sox9 and Notch has been observed in pancreatic progenitor cells 
(836). Notch causes parallel HES1 and SOX9 expression in these pancreatic ductal cells, showing 
that the Sox9 transcription factor is a target of the NICD, either directly or through secondary 
effectors – an observation supported by other studies (788, 837-839). SOX9 was selected for 
further validation as, like HES1, it was elevated in prostate stem cells (Figure 74) and was an 
intriguing Notch target gene. Even though some biological replicates showed upregulation of the 
transcription factor, the gene failed validation as a plasma responsive gene (Figure 64). 
The failure of some Notch signalling components in the validation process may be due to 
variable/unfavourable relative percentages of progenitor and CB cell populations in the patient 
cultures used. As shown for the NR4A isoforms and NRARP, the more differentiated cells can mask 
responsive expression of the gene in the SC/TA cells, (Figure 69 & 70F) especially if the LTP-
induced upregulation of the gene is subtle. 
Bi-directional Notch signalling; a lesser studied phenomenon 
Although much study has been directed at canonical Notch receptor signalling, little research has 
focused on the activation of signalling by the reciprocal ligand receptors; Jagged and Delta-like. 
Jagged and Delta both release intracellular domains (JICD & DICD) that subsequently localise to 
the nucleus after binding Notch (840-842). The ligand receptor ICDs can physically interact with 
the NICD and prevent formation of the active Notch ternary complex. The JICD can also stimulate 
proteasomal degradation of the Notch transcription factor (843, 844). 
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Delta ICD can promote growth arrest in cells, independent of nuclear localisation of the protein 
(845). The intracellular fragment can also bind to transcription factors which mediate gene 
expression through protein-protein interaction. DICD binding to Smad proteins can promote 
neural differentiation by augmentation of TGFβ signalling (846). A similar interaction with Jun 
causes inhibition of AP-1 dependent transcription in endothelial cells (847). 
The reverse is observed for the JICD, which can increase AP-1 transcriptional activity. Again, the 
downstream signalling initiated by the active ligand receptor is not wholly dependent on nuclear 
localisation and could be nullified by the NICD (841). Jagged overexpression can transform cells, 
an outcome attributable to a PDZ (PSD-95/Dlg/Zo1) ligand sequence in the JICD. This facilitates 
protein-protein binding to alter cellular gene expression and promote oncogenesis (848). 
There may be functionally relevant bidirectional Notch signalling occurring in the LTP treated 
samples, however the cellular context for this is yet to be determined (Figure 73). Further work 
would need to establish which Notch and ligand receptor isoforms were present in the signalling 
cascades initiated by LTP exposure in prostate epithelia. Whilst it is an attractive prospect that the 
JICD plays a role in the Jun signalling observed in plasma treated prostate epithelia, upstream 
SAPK signalling is likely to be the main contributor to AP-1 activation (Figure 56). Indeed, other 
functional signalling pathways may be downstream targets of ligand receptor ICDs in the prostate 
lineage, yet no prior studies exist that have investigated signalling of the Notch ligands in this 
cellular context. Bi-directional Notch signalling is not apparent in every cellular situation, hinting 
again at a context dependency of this pathway (849). 
Upstream protein analysis shows Notch1 activation in prostate basal epithelia by LTP 
Although only one of the three genes chosen for validation of activated Notch signalling by 
plasma passed the criteria, analysis of protein lysates treated with LTP were assessed for presence 
of the Notch1 receptor and the activate NICD (Figure 65 & 68). 
Cleavage of the Notch1 receptor, due to LTP treatment, to release the active NICD (distinguished 
in Western blot analysis by the proteolytically revealed Val1744 epitope) was observed in seven 
cultures taken from five separate patients, with densitometry analysis confirming the activation 
apparent in qualitative blotting images (Figure 65 & 68). Time course analysis showed a rapid and 
incremental increase of the NICD in both the normal and cancer cultures of H646/17. Release of 
the intracellular fragment was also apparent at 30 minutes post treatment in H643/17 RM (Figure 
65). This body of evidence indicates that Notch activation by LTP is a conserved event in prostate 
basal epithelial cells. The context of the signalling and the cellular background make it very 
difficult to hypothesise the outcome of NICD release, but the answer may lie in the differential 
activation of Notch in the epithelial subpopulations, discussed further in Section 7.3.8. 
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7.3.3 - Further evidence of AP-1 signalling in plasma treated primary cultures 
AP-1 target genes were noticeably altered in the microarray data. Upregulation was observed of 
the factors themselves, negative feedback regulators and genes involved in upstream kinase 
signalling nodes. 
The microarray highlighted the autoregulatory effects of the AP-1 transcription factors (787, 850) 
that had been observed for Jun in the P4E6 cell line (Figure 60B). Application of plasma caused 
significant upregulation of four AP-1 factors; FOSB (29.86-fold, p=5.57x10-4), FOSL1 (4.8-fold, 
p=2.22x10-3), JUN (5.62-fold, p=8.1x10-5), and JUND (4.07-fold, p=0.012) (Table 15). FOSB was 
included in the gene-set approved by the more stringent LIMMA analysis (Figure 63) and both 
FOSB and JUN passed qRT-PCR validation with consistent upregulation at levels similar to that 
observed in the microarray (Figure 64).  
DUSP1 was identified, by the targeted oxidative stress response gene arrays, as a plasma 
upregulated negative controller of MAPK activation (Figure 50). The microarray approach found 
other DUSP family phosphatases to be expressed in response to LTP, presumably to further 
attenuate AP-1 activation. 
DUSP5 expression was elevated modestly by plasma (2.81- fold, p=0.023). This phosphatase is a 
direct transcriptional target of Jun (851) and, like DUSP1, has pan-selectivity for p38, ERK and JNK 
(852). Other DUSP isoforms were upregulated across individual samples, showing that negative 
regulation of AP-1 signalling was an important pathway induced by plasma (Table 15). The highest 
upregulation observed for a MAPK phosphatase following LTP was that of the DUSP10 gene (7.75-
fold, p=6.69x10-4). This phosphatase has specificity for the SAPKs; JNK and p38, (853, 854) which 
have previously been identified to be activated by LTP (679, 717) (including JNK in prostate 
epithelia) (Figure 56). Although upregulation of DUSP10 by plasma was expected as it provides 
negative feedback for stress activated AP-1 signalling, the gene did not pass the validation criteria 
in any of the four treated primary cultures (Figure 64). 
The use of more frequent intervals in the time-course experiment allowed a more accurate 
assessment of AP-1 activation timing (Figure 65). For the two normal samples of the patient 
matched pairs Jun phosphorylation was delayed in comparison to the Gleason 7 cultures, taking 
an hour to be activated following LTP. More samples would need to be tested over this time 
frame to ascertain if this was common to all prostate cancers as H209/12, H434/14 and H545/15 
normal cultures do show an activation of Jun at 30 minutes post-LTP (Figure 56). 
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Activation of AP-1 directed gene expression and the phosphorylation of transcription factor 
proteins are a common denominator in plasma treated prostate cells, of both benign and 
cancerous origin. However, like Notch signalling, the problem of context-dependent signalling is, 
as yet, unresolved. Activated Jun could be promoting cell death in cultures or it may be 
coordinating an oxidative stress survival response. To ascertain the functionality of pJun in the 
setting of plasma treatment, future work is required in the monitoring of primary culture cell 
death and survival following LTP exposure with additional molecular dissection of the AP-1 
response with small molecule inhibitors, such as JNK inhibition (855) and si/shRNAs (short-
interfering/short-hairpin RNAs) to individual proteins. This would tease out the consequences of 
AP-1 activation from the complex milieu of signalling presented in the microarray analysis, 
discussed further in Section 8.2. 
7.3.4 - Activation of NF-kB is not consistently observed in plasma treated cultures  
NF-kB Signalling 
The importance NF-kB signalling in primary prostate cultures is well established, with survival and 
malignancy of the prostate epithelial CSC population reliant upon the transcription factor (66). 
Appearance of the pathway in the microarray data was expected due to its combined involvement 
in stress-response signalling and in the maintenance of prostate epithelial cell populations. 
The NF-kB family is made up of two separate classes of proteins; Rel (c-Rel, RelA and RelB) and 
NF-KB (NFKB1 p50/p105 and NFKB2 p52/p100) that form homo (with the exception of RelB) or 
heterodimers to affect transcription. In the canonical signalling pathway; NF-kB complexes are 
held inactive in the cytosol by IkB proteins (α, β, γ, ε and ζ isoforms). Upon activation of upstream 
signalling, the sequestering IkB protein is phosphorylated, (signalling for its ubiquitination and 
degradation) permitting NF-kB dissociation and nuclear translocation (Figure 76A). The upstream 
effectors are typically cell surface receptors, such as the tumour necrosis factor receptor (TNFR). 
Receptor activation then permits recruitment of TRAF and RIP proteins that subsequently activate 
the IKK complex responsible for IkB phosphorylation (856). 
NF-kB triggered gene expression can also occur through a non-canonical route. Here, activation 
relies upon signals passing through NIK (MAP3K14) or NF-kB-inducing kinase (Figure 76B). NIK is 
constitutively degraded in unstimulated cells by a ubiquitin ligase complex containing TRAF3. 
Upon cell surface receptor activation, the TRAF proteins are recruited and degraded in-complex 
by the cognate E3 ligase; allowing NIK protein levels to rise.  The kinase is then able to activate 
IKKα by phosphorylation and subsequently permit the processing of NF-kB p100, to its active 
form; p52. The increase in p52 is dependent thereupon the transcription and translation of the 
NFKB2 gene that encodes p100 and takes place over hours rather than minutes (857). 
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The importance of the NF-kB proteins as master regulators of cellular stress and inflammation 
response is reliant upon complex modulating factors in every situation, which dictate the 
multifaceted and context dependent outcome of NF-kB signalling. 
FIGURE 76 – Canonical and Non-canonical NF-kB signalling elements. 
A) Canonical signalling. Cellular stress activates the IKK complex (IKKα:IKKβ:NEMO). IKK then 
phosphorylates IkBα, which sequesters NF-kB factors in the cytosol, stimulating the subsequent 
ubiquitination and degradation of the protein. The NF-kB proteins (RELA:p105) can then be 
processed, translocate to the nucleus and effect gene expression. B) Non-canonical signalling. 
Oxidative stress inhibits the constitutive degradation of NIK (NF-kB inducing kinase). Stabilised NIK 
activates the IKKα complex by phosphorylation which permits processing of p100 to active p52. 
p52 heterodimerises with RELB to promote the transcription of NF-kB genes  
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Validation of NF-kB genes upregulated by LTP in microarray analysis 
See Table 15. 
Direct NF-kB genes – NFKB2, REL, NFKBIA 
Two subunits of NF-kB were upregulated by plasma treatment; c-Rel (2.38-fold, p=0.005) and 
NFKB2 (2.12-fold, p=0.0036). The seemingly modest upregulation of these genes was significant as 
they were already expressed at mid to high levels in untreated epithelial cultures (Figure 62). The 
NFKBIA gene that encodes the IkBα inhibitory protein was also upregulated (4.84-fold, p=0.001) in 
plasma treated cultures.  
NR4A isoforms 
The orphan nuclear receptor 4A (NR4A) family is comprised of three members NR4A1 (Nur77), 
NR4A2 (Nurr1) and NR4A3 (Nor-1). All were upregulated by LTP treatment in the prostate 
epithelial cultures; NR4A1 (40.9-fold, p=1.7x10-4), NR4A2 (14.99-fold, p=1x10-6) and NR4A3 (39.07-
fold, p=1.4x10-5) (Figure 64 & Table 15). The transcription factors are constitutively active, with 
control of function being achieved through a variety of mechanisms including the subcellular 
localisation and post-translational modification (PTM) of the receptors (858). The role of the 
receptors is cell- and tissue dependent. They have a multitude of functions from pro-apoptotic 
signalling to DNA repair (859). NR4A proteins have a large interactome and are modulated by a 
diverse range of proteins and transcription factors including NF-kB, AP-1 and Notch (860). NR4A1 
can be phosphorylated by active JNK to promote apoptosis (861), whilst Notch is able to both 
inhibit NR4A1 transcription (862) and to physically inhibit (863) the receptor, preventing the 
initiation of apoptotic signalling. In the myeloid lineage, NR4As are upregulated by NF-kB and 
feedback to have effects on the transactivation of the transcription factor itself (864, 865). 
The receptors can act as negative regulators of the NF-kB network; NR4A1 and NR4A3 deficient 
cells have increased NF-kB target gene expression and phosphorylation of the p65 NF-kB subunit 
(864, 866, 867). Depletion of NR4A2 results in the same phenotype, as the receptor acts as a NF-
kB inhibitor through accrued PTMs,(868) NR4A3 can act on multiple levels of NF-kB signalling by 
limiting initial activation, translocation of the factor to the nucleus and downstream gene 
expression of NF-kB (869). 
The effect of the NR4A receptors however is entirely context dependent and synergistic activation 
of NF-kB gene expression has also been reported (865, 870, 871). The orphan receptors can 
simultaneously attenuate and promote NF-kB signalling in the same cell type, (872) highlighting 
the dynamic and diverse signal modulation of this response network, probably to fine tune the 
potent NF-kB response in plasma treated prostate epithelial cells.  
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The three isoforms were chosen for further validation as they were all highly upregulated in the 
microarray data and they held an intriguing possibility of NF-kB modulatory differences between 
epithelial subpopulations, (discussed in Section 7.3.7) where one receptor may promote a certain 
cell fate that is abrogated by another. All NR4A genes were recurrently upregulated by LTP in the 
validation samples to similar fold changes observed on the array (Figure 64). NR4A3 showed high 
biological variability due to transcript levels being almost undetectable in untreated prostate 
basal epithelia. 
Upstream effectors of NF-kB signalling 
Expression levels of receptor interacting serine/threonine protein kinases (RIPK) 1 and 4 were 
responsive to plasma treatment; RIPK1 (2.84-fold, p=0.001) and RIPK4 (14.71-fold, p=5.61x10-4). 
RIPK1 associates with upstream cell surface receptors to activate the IKK complex. The formation 
of these receptor signalling-complexes is facilitated by ubiquitin chains, linked through variant 
lysine residues, regulated by ubiquitin editing enzymes. One such editing ligase is TNFAIP3. This 
protein acts as a negative regulator of NF-kB, that can simultaneously disrupt the ubiquitin 
scaffold and target RIPK for proteasomal degradation (873). TNFAIP3 (3.89-fold, p=2.6x10-5) was 
also upregulated in treated primary cultures by LTP. This suggests that immediate transduction of 
NF-kB signals into the cell is important following exposure to LTP. Response applied to this point 
in the cascade would provide an immediate opportunity to either, completely abrogate the signal 
through disruption of the signalling scaffolds, or amplify it by upregulation of the RIP kinases.  
In activation of NF-kB; RIPK1 can interact with SQSTM1 (implicated in the qRT-PCR arrays and also 
upregulated in the microarray data; 3.13-fold, p=4x10-4) to facilitate atypical PKC activation of the 
IKK complex (874). RIPK1 is also required for activation of MAP3K8, a kinase that functions as an 
upstream hub of MAPK and NF-kB signalling, (875) and was also responsive to plasma treatment 
(15.64-fold, p=3.9x10-5) implying that this node of signal transduction may be important in LTP-
treated cells. 
RIPK1 is also a regulator of both apoptosis and necroptosis (programmed necrosis following 
caspase inhibition) (876). Necrosis is the dominant cell death response observed in our primary 
cultures treated with LTP, (304) the implication that this response may be regulated by RIPK1 
could warrant further investigation in future experiments which can assign cell fate consequences 
to the signalling pathways activated. 
RIPK4, like RIPK1, can activate NF-kB signalling (877) and interacts with PKC (878). It is a 
downstream target gene of NF-kB, MAPK (879) and p63, (880) a classical marker of prostate basal 
epithelia. 
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SQSTM1 and HMOX1 were chosen as genes for further validation to confirm previous 
identification as plasma-responsive genes in qRT-PCR arrays and the microarray (HMOX1, 2.16-
fold, p=0.0003). Both genes passed stipulated cut-offs yet there was significant biological and 
intra-patient variability in plasma responsive expression (Figure 64). 
Interleukin receptor signalling was also triggered by plasma treatment. Upregulation of the 
agonist, IL1B (2.05-fold, p=0.042) and signal transducer; IRAK2 (4.1-fold, p=0.027), a protein that 
can activate both NF-KB and JNK, was observed (881). Plasma also enhances gene expression of 
IL6 signalling proteins – this pathway is particularly important in maintenance of the CSC 
population of the prostate though JAK-STAT signalling (253). The cytokine itself was upregulated 
in the cultures but not to significant levels (IL6, 5.24-fold, p=0.29) whilst its cognate receptor IL6R 
(10.35-fold, p=5.9x10-4) was differentially expressed in treated cells. 
IL6R was a gene of interest due to previous association with prostate CSCs and its upregulation by 
plasma on the microarray (66, 253). The gene was included by LIMMA analysis (Figure 63) yet did 
not pass validation, (Figure 64) appearing to be almost unresponsive to LTP treatment in four 
primary cultures. 
LIMMA analysis and protein data conflict with initial microarray findings 
From the initial microarray data, discussed above, NF-kB activation by LTP in the primary cultures 
appeared to be certain, with both intrinsic proteins and modulating regulators upregulated 
following treatment with the plasma. However, LIMMA analysis (Figure 63 & Table 16) removed 
most NF-kB transcripts (apart from RIPK4, MAP3K8 and the NR4A genes) suggesting that the high 
background of cyclic NF-kB signalling present in the cultures may have been picked up in 
microarray analysis rather than LTP enforcing a functional activation of the transcription factor 
(66). 
Assessing the upstream activation of NF-kB proteins returned results that also suggested a lack of 
pathway activation by plasma. The time-course experiment showed that IkBα protein content was 
not changed in treated cells with phosphorylation of the inhibitory protein only observed in the 
Gleason 7 cultures of the patient matched pairs (Figure 65 & 66B). This cancer-specific 
phosphorylation of IkBα was only seen in patients H643/17 and H646/17. The signalling event was 
also observed to occur in normal cultures and was absent in some Gleason 7 samples following 
LTP treatment (Figure 67C). This again highlights that interpatient heterogeneity and not the 
tissue pathology of the primary prostate cultures is the variable that determines molecular 
response to LTP. 
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If canonical activation was observed, there would have been a rapid phosphorylation of IkBα 
followed by loss of total protein, which would permit liberation of the NF-kB transcription factor. 
Phosphorylation without the expected decrease in NF-kB-bound inhibitor suggests that NF-kB 
remains inactive in LTP-treated primary prostate cultures. This was confirmed by the lack of 
nuclear translocation of the NF-kB factor; p65, in whole and subpopulation cultures, (Figure 
67A+B) further evidence of cytosolic sequestration by IkBα. Patient H523/15 cultures were the 
only samples to respond to LTP, with a loss of IkBα at 2 hours post-treatment (Figure 67C). 
Phosphorylation of the protein wasn’t observed at the earlier time-point yet may still have 
occurred after this snapshot of cellular protein levels was taken. In any case, NF-kB activation 
doesn’t appear to be a widespread consequence of LTP in primary prostate epithelial cultures.  
The slight increase in NFKB2 gene (which encodes NF-kB p100/p52) expression following 
treatment with LTP implied that non-canonical signalling may be activated in LTP-treated prostate 
epithelium. The rise in NIK levels following treatment (Figure 65 & 66C) would suggest a role for 
this signalling in LTP response. Extension of the time course to assess the processing of NF-kB 
p100 to p52 would be required to confirm that the non-canonical signalling arm was truly having 
an effect in treated cells. The outcome of the signalling is again unknown but would be expected 
to be present in surviving cells as the stimulation of NF-kB processing requires time. Fresh protein 
synthesis of the NF-kB p100 protein has to occur for the effects of non-canonical signalling to take 
place, a process which is longer than the latency period of cell death mechanisms. 
Initial impressions from the microarray data was that NF-kB must react rapidly via the canonical 
arm of signalling. However, activation of the slower non-canonical pathway may be an initial 
indicator of signalling in surviving cells as the full outcome of NIK accumulation and downstream 
signalling would take longer than the cell death mechanisms that would remove ROS damaged 
cells. Implying that cells which accumulate NIK may form an LTP-resistant population. Further 
investigation into how and if activation of non-canonical NF-kB associates with LTP-resistance is 
required. 
7.3.5 – Gene Ontology and KEGG metadata confirms pathway activation and highlights the 
unfolded protein response, ER stress and a balancing of apoptotic signalling processes in 
LTP treated prostate epithelia 
See Table 17 for all GO and KEGG terms enriched in LTP-treated primary prostate basal epithelial 
cells. 
Gene ontology (GO) and KEGG analysis are useful analytical tools as they provide a broad stroke 
picture of gene expression and activated pathways. However sole use of these tools without 
validation of individual gene and protein changes can detract from informing upon the finer 
239 
 
workings of molecular responses as unfocused background noise can be assigned to the gene 
signatures by numerous irrelevant annotations on genes, particularly as the collection of publicly 
available microarray datasets grows. To this end, the metadata from the LTP treated microarrays 
is discussed here, following the validation of both gene upregulation and signal pathway 
activation indicated by the patterns of individual annotated transcripts in the initially generated 
dataset and by LIMMA analysis.  
Firstly, an LTP-induced state of oxidative stress was implied in the treated prostate primary cells 
by inclusion of GO terms; cellular response to oxidative stress (p=0.0002) and cellular response to 
hydrogen peroxide (p=0.0003), a reactive species known to be important in the cocktail of 
molecules activated by LTP (Figure 45). There was also negative regulation of the cell cycle 
(p=0.003) which would be expected in cells that encounter LTP-induced DNA damage observed in 
the primary cultures following treatment (304). 
Other known signalling pathways were enriched in the GO and KEGG terms, expanding upon the 
immediately obvious gene regulation from initial array data (Figure 64 & Table 15). NF-kB 
signalling appeared throughout the GO terms, including; positive regulation of tumour necrosis 
factor mediated signalling pathway (p=7.2x10-5) and NF-kB transcription factor activity (p=0.003). 
There was also extensive sequence-specific transcription factor (activator and repressor) and 
coactivator binding terms. Selective terms for AP-1 signalling were also apparent; MAPK3 activity 
(p=0.048) and MAPK signalling pathway (p=0.01). IL-6 signalling was also observed to be 
significantly activated in the microarray data; interleukin-6 binding (p=0.004), receptor activity 
(p=0.004) and receptor binding (p=0.015). 
Primary prostate cultures don’t undergo apoptosis following LTP treatment and instead die via 
necrosis (304). However the cells appeared to orchestrate a wide array of apoptotic signalling 
processes, apparent in the metadata generated from the microarray. The KEGG pathway hit of; 
Apoptosis – multiple species (p=0.006), was reinforced by multiple GO terms suggesting apoptotic 
cell death was occurring, including; positive regulation of cytochrome c from mitochondria 
(p=3.5x10-5) and positive regulation of protein insertion into mitochondrial membrane involved in 
apoptotic signalling pathway (p=0.002). However, there were a significant amount of negative 
regulatory processes involved in apoptosis also enriched in the GO terms (negative regulation of 
mitochondrial outer membrane permeabilisation involved in apoptotic signalling pathway, 
p=0.0001, and negative regulation of extrinsic apoptotic signalling pathway in absence of ligand, 
p=0.002). This suggested that LTP may initiate an apoptotic response in primary cells which is then 
aborted by activation of reciprocal signalling pathway or that the heterogeneous cell populations 
in the primary cultures have variant apoptotic signalling responses to LTP. 
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Probably the major finding from the metadata was the initiation of an unfolded protein response 
and ER stress by LTP. Both processes were heavily enriched throughout the GO term processes 
and KEGG analysis. ER stress is linked directly to the unfolded protein response. This was observed 
in the upregulation of genes such as the heat shock proteins HSPA1A (9.47-fold, p=2.49x10-4) and 
HSPA1B (11.02-fold, p=9.4x10-5) that are stress responsive and act as protein folding chaperones 
and characteristic upregulation of ATF4 in four of the six samples. In conditions of ER stress, the 
ER transmembrane protein PERK phosphorylates the translation initiation factor, eIF2α. Phospho-
eIF2α then causes upregulation of ATF4 to aid cellular anti-oxidant response and alleviation of ER 
stress (reviewed in (882)). The accumulation of unfolded proteins after LTP-induced oxidative 
damage upsets ER homeostasis and can initiate a diverse range of molecular responses such as 
JNK activation, NF-kB signalling, Nrf2 accumulation and autophagy (883). All of which are 
implicated in the LTP response of prostate epithelia (Figure 46)(304). The ER is also involved in 
Ca2+ homeostasis that affects a multitude of signalling pathways if disrupted. In relation to the 
microarray data; NR4A isoforms are upregulated by Ca2+ changes (884) and ITPKC is a modulator 
of extracellular signal-initiated calcium response (885). 
Another finding that was specific enough to warrant further analysis was the GO term enrichment 
in steroid hormone receptor activity (p=0.0003), highlighting glucocorticoid (p=0.0004) and 
retinoid X receptor binding (p=0.03) in treated cells. The signalling initiated by the hormone 
receptors will be context dependent in prostate epithelia but may be indicators of renewal 
processes following LTP treatment. 
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Symbol Gene Fold 
Change 
ANOVA 
p-value 
LIMMA 
p-value 
NRARP Notch regulated ankyrin repeat protein 126.92 3.04E-09 5.0759E-10 
HSPA1A Heat shock protein A1A 9.47 0.000249 1.25377E-08 
HSPA1B Heat shock protein A1B 11.02 0.000094 1.50624E-08 
EFNA1 Ephrin A1 9.98 0.000078 2.2241E-08 
HBEGF Heparin binding EGF like growth factor 22.22 0.000002 5.72194E-08 
RHOV Ras homologue family member V 20.72 0.000044 8.03929E-08 
NR4A2 Nuclear receptor 4A2 14.99 0.000001 2.03093E-07 
CYP1A1 Cytochrome P450 family 1 subfamily A member 1 20.3 0.000099 2.32924E-07 
MAP3K8 Mitogen activated protein kinase kinase kinase 8 15.64 0.000039 2.86501E-07 
ATF3 Activating transcription factor 3 37.37 0.000015 3.38407E-07 
BTG2 BTG anti-proliferation factor 2 12.74 0.000029 4.3246E-07 
RHOB Ras homology family member V 6.39 0.00001 5.36957E-07 
NR4A3 Nuclear receptor 4A3 39.07 0.000014 6.76664E-07 
RIPK4 Receptor interacting protein kinase 4 14.71 0.000561 8.20509E-07 
OVOL1 Ovo like transcriptional repressor 1 8.74 0.000855 9.05974E-07 
ARL5B ADP ribosylation factor like GTPase 5B 4.95 0.000037 1.03334E-06 
PPIF Peptidylprolyl isomerase F 7.14 0.000211 1.32265E-06 
PMAIP1 Phorbol-12-myristate-13-acetate-induced protein 1 11.66 0.000416 1.54963E-06 
ITPKC Inositol-triphosphate3-kinase C 26.33 0.000019 1.79006E-06 
IL6R Interleukin 6 receptor 10.35 0.000594 1.81086E-06 
DAPP1 Dual adaptor of phosphotyrosine and 3-
phosphoinositides 1 4.91 0.000019 2.51189E-06 
CYP1B1 Cytochrome P450 family 1 subfamily B member 1 19.78 0.000108 2.90671E-06 
RNU12 RNA, U12 small nuclear 6.92 0.000098 4.28598E-06 
THBD Thrombomodulin 3.08 0.005813 5.29702E-06 
NR4A1 Nuclear receptor 4A1 40.94 0.000172 5.55242E-06 
PPP1R15A Protein phosphatase 1 regulatory subunit 15A 5.16 0.000269 6.54149E-06 
HEY1 Hes related family bHLH transcription factor with 
YRPW motif 1 3.52 0.000006 6.73261E-06 
INSIG1 Insulin induced gene 1 3.25 0.002229 7.11905E-06 
LHFPL3-
AS2 LHFPL3 antisense RNA 2 2.67 0.000037 8.16209E-06 
RNU4-1 RNA, U4 small nuclear 1 5.6 0.021446 9.17945E-06 
RNF122 Ring finger protein 122 5.45 0.000034 9.61055E-06 
BCL2L11 BCL2 like 11 2.51 0.000865 1.55846E-05 
TABLE 16 – LIMMA-specified and range-separated LTP-upregulated genes 
Table includes the annotated transcripts identified as upregulated by LTP treatment. These all 
passed LIMMA analysis and the further constraint that expression ranges in the untreated and 
treated samples had no overlap. Genes are ranked by LIMMA p values, the most significant at the 
top.  
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GO - Biological Process 
GO ID Term Annotated Significant Expected score 
GO:1904722 positive regulation of mRNA endonucleolytic cleavage involved in unfolded protein 
response 
2 2 0 4.80E-06 
GO:0090200 positive regulation of release of cytochrome c from mitochondria 29 3 0.06 3.50E-05 
GO:0000122 negative regulation of transcription from RNA polymerase II promoter 752 13 1.67 5.70E-05 
GO:1903265 positive regulation of tumor necrosis factor-mediated signaling pathway 6 2 0.01 7.20E-05 
GO:1901029 negative regulation of mitochondrial outer membrane permeabilization involved in 
apoptotic signaling pathway 
8 2 0.02 0.00013 
GO:1902237 positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling 
pathway 
10 2 0.02 0.00021 
GO:0034599 cellular response to oxidative stress 248 7 0.55 0.00023 
GO:0070301 cellular response to hydrogen peroxide 82 4 0.18 0.00025 
GO:0042026 protein refolding 24 3 0.05 0.0006 
GO:0051131 chaperone-mediated protein complex assembly 19 2 0.04 0.0008 
GO:1902236 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic 
signaling pathway 
20 2 0.04 0.00089 
GO:1900740 positive regulation of protein insertion into mitochondrial membrane involved in 
apoptotic signaling pathway 
29 2 0.06 0.00187 
GO:1903917 positive regulation of endoplasmic reticulum stress-induced eIF2 alpha 
dephosphorylation 
1 1 0 0.00222 
GO:2001240 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand 33 2 0.07 0.00242 
GO:0045786 negative regulation of cell cycle 586 5 1.3 0.00275 
GO:0051092 positive regulation of NF-kappaB transcription factor activity 134 3 0.3 0.00323 
GO:0060734 regulation of endoplasmic reticulum stress-induced eIF2 alpha phosphorylation 2 1 0 0.00443 
GO:0061394 regulation of transcription from RNA polymerase II promoter in response to arsenic-
containing substance 
2 1 0 0.00443 
GO - Molecular Function 
GO ID Term Annotated Significant Expected score 
GO:0031249 denatured protein binding 2 2 0 4.50E-06 
GO:0001106 RNA polymerase II transcription corepressor activity 28 3 0.06 2.90E-05 
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region 
sequence-specific binding 
257 5 0.55 0.00021 
GO:0003707 steroid hormone receptor activity 59 3 0.13 0.00028 
GO:0035259 glucocorticoid receptor binding 13 2 0.03 0.00035 
GO:0070330 aromatase activity 23 2 0.05 0.00111 
GO:0044183 protein binding involved in protein folding 27 2 0.06 0.00153 
GO:0051082 unfolded protein binding 108 3 0.23 0.00161 
GO:0001078 transcriptional repressor activity, RNA polymerase II core promoter proximal region 
sequence-specific binding 
117 3 0.25 0.00202 
GO:0097718 disordered domain specific binding 32 2 0.07 0.00215 
GO:0004879 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA 
binding 
48 3 0.1 0.00333 
GO:0019981 interleukin-6 binding 2 1 0 0.00431 
GO:0004915 interleukin-6 receptor activity 2 1 0 0.00431 
GO:0019825 oxygen binding 47 2 0.1 0.0046 
GO:0001046 core promoter sequence-specific DNA binding 112 3 0.24 0.00534 
GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding 332 4 0.72 0.00548 
GO:0047844 deoxycytidine deaminase activity 3 1 0.01 0.00646 
GO:0031072 heat shock protein binding 96 3 0.21 0.00726 
GO:0005138 interleukin-6 receptor binding 7 1 0.02 0.015 
GO:0072542 protein phosphatase activator activity 8 1 0.02 0.01713 
GO:0000988 transcription factor activity, protein binding 602 6 1.3 0.0172 
GO:0046982 protein heterodimerization activity 468 4 1.01 0.01769 
GO:0016679 oxidoreductase activity, acting on diphenols and related substances as donors 9 1 0.02 0.01925 
GO:0004126 cytidine deaminase activity 9 1 0.02 0.01925 
GO:0042826 histone deacetylase binding 103 2 0.22 0.02073 
GO:0008440 inositol-1,4,5-trisphosphate 3-kinase activity 10 1 0.02 0.02137 
GO:0020037 heme binding 127 2 0.27 0.03058 
GO:0004115 3',5'-cyclic-AMP phosphodiesterase activity 15 1 0.03 0.03188 
GO:0046965 retinoid X receptor binding 15 1 0.03 0.03188 
GO:0008157 protein phosphatase 1 binding 18 1 0.04 0.03814 
GO:0001223 transcription coactivator binding 19 1 0.04 0.04022 
GO:0005525 GTP binding 371 3 0.8 0.04531 
GO:0005506 iron ion binding 158 2 0.34 0.04548 
GO:0000983 transcription factor activity, RNA polymerase II core promoter sequence-specific 22 1 0.05 0.04642 
GO:0004709 MAP kinase kinase kinase activity 23 1 0.05 0.04848 
KEGG Pathway analysis   
Pathway n.pathway n.seen p.value  
path:hsa04141 Protein processing in endoplasmic reticulum 166 4 0.00227184  
path:hsa04215 Apoptosis - multiple species 33 2 0.00560536  
path:hsa04010 MAPK signaling pathway 255 4 0.01042539  
path:hsa00980 Metabolism of xenobiotics by cytochrome P450 74 2 0.02631755  
path:hsa04151 PI3K-Akt signaling pathway 342 4 0.02774234  
path:hsa05204 Chemical carcinogenesis 82 2 0.03182386  
TABLE 17 – Gene Ontology and KEGG Pathway annotations of microarray data  
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7.3.6 - Plasma responsive genes of biological interest highlighted by LIMMA analysis 
LIMMA analysis reduced the initial data-set of 645 differentially expressed transcripts in treated 
cells to 89 (Figure 63). Only 42 of the 89 transcripts were annotated genes, which were then 
further concentrated by excluding transcripts that had any point of overlap in expression range 
between LTP treated and untreated cohorts. This yielded 32 genes that were; i) significantly 
upregulated in LTP treated cells when accounting for the transcript’s inherent expressional 
variability and ii) completely separated on terms of expression between untreated and treated 
groups across all six samples (Table 16). 
Although no further investigation was directed for the majority of the genes included by this 
analysis, several of the transcripts with high scoring p-values such as ATF3, EFNA1, RHOV and 
HBEGF could be followed up with further study of context specific function in the prostate 
epithelia and the role that they play in LTP-induced stress response. If they are able to distinguish 
between resistant and susceptible populations, they may also have future significance if utilised 
as biomarkers of LTP response through tests of pre and post-treatment urinary RNA levels. Whilst 
the LIMMA analysis is a powerful tool in determining possible functionally significance of gene 
expression differences in the LTP treated cells, it is not infallible. IL6R signalling was highlighted in 
the GO terms (Table 17) and was already noted by previous work done in our laboratory as a gene 
important in the signalling of prostate basal epithelial cells (253). However, IL6R didn’t pass the 
validation criteria in qRT-PCR testing of LTP treated cultures (Figure 64). This means that all genes 
that passed stringent LIMMA analysis would still have to be independently verified to confirm 
whether they are critical in the transcriptional response to LTP. 
7.3.7 - Basal epithelial subpopulations differ in their molecular responses to plasma 
Heterogeneity in primary prostate cultures is well documented. Previous studies have observed 
both differential gene expression (66) and treatment response (323, 771) among the basal 
subpopulations. Therefore, differences in how SC/TA and CB cells responded to plasma were 
expected. 
NF-kB signalling plays a significant role in primary culture cell survival, (66) therefore changes in 
signal modulation in epithelial subpopulations following LTP treatment could impact cell fate 
dramatically. The NR4A orphan receptors are known to both attenuate and promote NF-kB 
signalling, and can do so simultaneously in cells (872). The end consequence of their upregulation 
in LTP treated prostate cells is unknown, yet the progenitor SC/TA population consistently 
responds with greater upregulation of each NR4A isoform than that observed in CB cells (Figure 
69). This correlates with the increased requirement of NF-kB signalling in the stem cells over their 
more differentiated progeny (66) and may be because modulation of the pathway requires a 
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greater degree of control here, than in the CB cells; where upregulation of isoform expression is 
observed, just at more modest levels. The context-dependence of the NR4A receptors means that 
further work is required to discern their exact function in LTP response. Firstly, the background 
context of NR4A protein expression and localisation in the primary basal epithelial cells should be 
deduced to properly assess the changes impacted upon the receptor isoforms by LTP. Previously 
observed protein interactions such as those between NR4A1 and the NICD, (863) and whether the 
receptors are targets of JNK phosphorylation (861) warrant further investigation, alongside wider 
cell fate processes such as apoptosis and DNA damage repair (859) – both of which LTP induces 
(304) and the NR4A receptors are involved in. 
The pattern provided by the expression of the NR4A receptors (Figure 69) and NRARP (Figure 70F) 
in the prostate epithelial subpopulations also highlights one of the limitations of the WP array. 
This data suggests that the LTP response is mainly elicited by the SC/TA cells, however this 
population constitutes 25-50% of the whole culture population (with the remainder of cells being 
CB cells). This means that the transcriptional response coordinated in the progenitor population is 
diluted by the more differentiated cells and the expression signature is masked. The effect is seen 
clearly in the NRARP and NR4A1 expression of both cultures from patient H643/17 where WP 
expression has just passed the threshold of 2-fold upregulation, matching that of the less-
responsive CB fraction, yet the transcript is robustly expressed in the SC/TA population (Figure 69 
& 70F). Responsiveness of the progenitor population in the primary cultures allowed the effects 
of LTP to be observed in the whole culture microarray, however genes that may still be 
upregulated in a single subpopulation yet to a lesser extent (than observed for NRARP and NR4A 
isoforms) will be lost in the dominant non-responsive signature. To assess these “lost” genes, 
microarray analysis of individual subpopulation responses to plasma would have to be carried out 
where cultures are first separated into SC/TA and CB cells, treated with plasma and then gene 
expression assessed. The reduction of heterogeneity would afford a clearer view into the effects 
of LTP on the individual subpopulations and may allow true differences to be more readily 
established between the response of normal and cancerous prostate epithelium. 
Similar to members of the Notch signalling pathway, Jun mRNA is consistently expressed at a 
higher level in prostate epithelial stem cells than in the CB population, (66)(Figure 77A) with my 
own data confirming that the transcription factor’s base expression was higher in the progenitors 
(Figure 77B). The protein levels of Jun were also elevated in the SC/TA population of H643/17 LM 
and H652b/17 cultures, (Figure 70A) and the activation of the transcription factor was also more 
potent in the progenitors (Figure 70B). With an increased amount of active Jun, the progenitor 
population would be expected to have a higher upregulation of JUN, through the transcription 
factor’s autoregulatory effects (787). However, no significant difference was observed between 
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SC/TA and CB upregulation of the AP-1 factor gene (Figure 70C). AP-1 signalling is entirely context 
dependent, with activation initiating signalling cascades for both cell death and survival in 
alternate circumstances. The downstream functionality of LTP-stimulated phospho-Jun in the 
progenitor population of the primary cultures is unknown. LTP affects the colony forming 
efficiency of primary prostate cells, reasoning that the oxidative stress induced by the treatment 
must abrogate stem cell function, possibly by killing this population. Whilst previous studies could 
find no apoptotic cell death in primary cultures after LTP (304) the enrichment of apoptotic 
pathways in GO terms (Table 17) and active AP-1 suggests that this mode of cell death may also 
occur in some cells. 
From the transcriptional data alone it is difficult to ascertain what cell populations are resistant 
and which are susceptible to LTP. For example; are the CB cells dying (or becoming senescent? 
(688)) and therefore have a reduced transcriptional output or just non-responsive as LTP-
stimulated ROS simply aren’t affecting critical cellular processes. The final consequences of AP-1 
cell fate determination will only be discernible after further study. Assessment of cell viability and 
death after plasma treatment in conjunction with pathway inhibitors will reveal if Jun 
phosphorylation is a LTP-resistance mechanism or a harbinger of cell death. Through the 
monitoring of these cell fate dynamics in both SC/TA and CB populations, the differential 
transcriptional responses may be linked to a functional outcome; the death or survival of a 
particular subpopulation.  
7.3.8 - Stem and transit amplifying cells selectively activate Notch signalling in response to 
plasma treatment 
As discussed previously in Section 7.3.2; Notch signalling is enriched in prostate epithelial stem 
cells and is important for maintenance of their dedifferentiated state (Figure 73). This data was 
confirmed by assessment of Notch signalling following LTP in fractionated prostate epithelial 
subpopulations (Figure 70 D-F). The Notch1 receptor was more highly expressed in the SC/TA 
fraction than in the CB cells (Figure 72D & 74) and, although Notch signalling was active to some 
degree in all patient cultures, densitometry analysis showed that the progenitor population 
activated Notch1 receptor cleavage more readily than the more differentiated CB cells (Figure 
70E). The significance of this selective activation was further increased by discovery that the 
receptor was internalised and translocated to the nucleus only in LTP-treated SC/TA cells (Figure 
71). The nuclear foci of the Notch1 receptor were not observed in treated CB cells nor in the 
untreated cells of either population. This suggests that LTP initiates a rapid response in the 
progenitor population Notch signalling network, a conclusion supported by the exclusive 
upregulation of the negative regulator NRARP ~10-fold caused by LTP in the SC/TA cells; whilst 
transcription of the Notch target gene is unchanged in the CB population (Figure 70F). The Notch1 
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antibody used in the study is polyclonal and has been approved for ChIP meaning that it can 
detect both the receptor and it’s intracellular fragment. 
Notch signalling is classically activated to retain cellular identity and a dedifferentiated state (249, 
823). This poses three questions; i) could LTP-induced ROS provide a differentiation-promoting 
stimulus to the prostate epithelial stem cell population? ii) do the progenitors trigger Notch 
signalling in attempt to retain their stemness? And, iii) is the activation in Notch signalling critical 
in LTP resistance and regeneration of the epithelial hierarchy following treatment? 
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FIGURE 77 – Prostate epithelial progenitors express JUN to greater levels than differentiated 
committed basal cells. 
A) Microarray data from comparison of SC and CB JUN expression. Across all four gene probes, 
JUN expression is significantly higher in the stem cells. Produced from data gathered in Birnie 
2008 (66). B) qRT-PCR data taken from fractionated epithelial cultures shows that the SC/TA 
population express equal or higher levels of the JUN transcription factor mRNA.   
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FIGURE 78 – Model of Notch signalling and the balance of prostate epithelial stem cell decision. 
High ROS levels can promote a cellular environment favourable to stem cell depletion through 
symmetric division and forced differentiation. Activation of Notch signalling can aid ROS 
scavenging and promote self-renewal of the stem cell pool to give LTP resistance whilst also 
repairing the prostate epithelial hierarchy, allowing for relapse. 
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ROS are observed to stimulate differentiation in human ESCs (886) and glioma CSCs (887) through 
SAPK activation. The same process also occurs in prostate stromal cells (888). Notch is known to 
maintain low ROS levels in cells and is activated, in some contexts, by elevated ROS (815, 816). In 
Drosophila, Notch signalling is activated to prevent lammellocyte stem cell differentiation in high 
ROS concentrations to prevent loss of niche integrity (889). Airway basal stem cells activate Notch 
through Nrf2 in high levels of ROS to enhance self-renewal and allow for the repair of the 
epithelial hierarchy, whilst Nrf2 antioxidant signalling protected the stem cell pool from oxidative 
damage and differentiation (890). The same situation has been observed in LTP-treated prostate 
epithelial cells where active SAPKs, Nrf2 and Notch have all been observed (Figure 56 & 65). 
It is therefore possible that prostate epithelial stem cells (in both normal and cancer cultures) 
initiate Notch signalling to both prevent depletion of the progenitor population, through high ROS 
promoting symmetrical division of the stem cells and subsequent differentiation; and replace 
dead cells further down the epithelial hierarchy by increasing self-renewal capabilities 
(asymmetrical divisions) (Figure 78). If reactive species stimulated by LTP are promoting 
differentiation of the epithelial cultures this could be monitored through tracking loss and gain of 
epithelial differentiation markers – appearance of PSA, PAP, CK8 and CK18, with loss of CD133, 
α2β1 integrin, CK5 and CK14 – following treatment. The colony forming efficiency of prostate basal 
epithelial cells is diminished by LTP (304) suggesting that self-renewal is impaired, and 
combination of LTP treatment with Notch inhibition, using GSIs or Notch receptor antibodies, may 
reveal the true importance of the Notch pathway to the surviving fraction of cells. Differentiation 
therapy, the pushing of stem cells into cycle to promote depletion of the progenitor population 
whilst increasing the number of therapeutically targetable differentiated cells, has already been 
discussed with respect to prostate cancer (236). 
There remains the problem that Notch activation by LTP is not exclusive to cancer cells as normal 
epithelia rely on the same signalling pathway to, presumably, retain stem cell numbers. This may 
also be an epithelial tissue regeneration response in the prostate, initiated by therapeutic insult 
(891). Off-target inhibition of Notch in the prostate epithelial stem cell niche of normal tissue 
would be detrimental to acinar integrity (892). Multiple Notch receptors and ligands are 
expressed in primary prostate cultures (Figure 74 & 75A). However, only the LTP-response of 
Notch1 was examined. Further work is required to discern the full repertoire of Notch receptors 
and ligand-receptors in both normal and cancerous epithelia (including subpopulations) and how 
different isoforms respond to treatment. Any differences in cancer cell Notch signalling that can 
be targeted using receptor isoform specific antibodies in conjunction with LTP treatments could 
provide an enhanced killing effect in the tumour over surrounding normal tissue. This result 
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would be a significant advance towards the clinical implementation of the plasma-device as a 
possible focal therapy option in the treatment of localised prostate cancers. 
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8. Future work 
8.1 – Determination of allelic expression changes in prostate cancer 
This study attempted to assess any allelic expression changes produced by mutations in the SPOP, 
PTEN and IDH1 genes. There is a common assumption by cancer genome studies that detected 
heterozygous mutations are always expressed; biallelic expression would thus produce a mix of 
wildtype and non-functional or neomorphic protein product that enforces the molecular 
pathology of the tumour. Studies that have combined genomic and transcriptomic data have 
observed that some cancers do not express the mutated allele (497, 553, 555). Combined 
datasets have been acquired from prostate cancers, (330) however the appropriate analysis of the 
data to the level of allelic expression hasn’t been conducted. 
One of the main purposes of the study was to determine whether the presence of a mutated 
allele affected the expression of the gene. Would the allele be continually expressed, or would it 
be silenced? There are several functional implications of heterozygous mutation in the context of 
allelic expression due to the plastic nature of epigenetic control. For example; 
• The disease allele may be silenced and not expressed at all as it is simply disadvantageous 
to the cancer. 
• The disease allele may be silenced to be later expressed. This may be due to a shift in 
microenvironmental stimuli, a permissive mutation/s is accrued that allows the silenced 
allele to be expressed without killing the cell, or possibly a differentiation stimulus, 
followed by a change in transcription factor regimens permits disease allele expression.  
• The disease allele may be expressed biallelically alongside the wildtype. 
• The disease allele may be selectively expressed whilst wildtype is silenced to give a 
population of affected protein that can cause carcinogenesis without the effect being 
“diluted” by wildtype protein. 
Due to the heterogeneity in primary prostate cultures, any of the above hypotheticals could be 
occurring exclusively or simultaneously in different epithelial subpopulations. This was observed 
to be the case for the allelic expression of TMPRSS2-ERG. The fused allele was selectively 
expressed in the stem cell fraction of the prostate tumour epithelia and the “choice” of allele then 
relaxed throughout differentiation. The unit of heterozygosity between the alleles needed to be a 
relevant point mutation, a SNP wouldn’t create a “disease” allele and therefore it would be 
assumed to have no bearing upon allelic gene expression. SNPs would have been used to 
determine true biallelic expression of SPOP, PTEN and IDH1 in wildtype cultures as reading the 
pyrosequencing trace of the mutated nucleotide position in a wildtype homozygous cDNA sample 
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would always show a 100% distribution of the nucleotide, without informing on the different 
contributions of the two wildtype alleles to that nucleotide position’s 100% total. However, only 
IDH1 has a suitable coding synonymous SNP; rs11554137 that occurs at a population frequency of 
~6%.  A more laborious way to ascertain allelic expression of the genes would be to use single 
molecule FISH techniques that can detect intronic SNP expression in nascent mRNA (893, 894). 
SPOP (rs6504618 in intron 8), PTEN (rs555895 in intron 8) and IDH1 (rs1437410 in intron 4) would 
be the appropriate heterozygous markers. 
The primary aim of the study was to determine if the allelic restriction of TMPRSS2 and that of the 
TMPRSS2-ERG fusion observed in primary prostate cultures was imposed by either gene body or 
promoter deposition of asymmetrical activating and silencing histone trimethylations (489, 526). 
This was due to the switching of allelic expression through differentiation. Fluctuations that were 
unable to be associated to promoter methylation status in the various epithelial subpopulations 
(246). Although understanding of epigenetics has increased significantly over the last 20 years, it 
is still difficult to ascertain whether histone modifications determine the transcriptional state of 
associated chromatin or are deposited for transcriptional memory to mark a neighbourhood that 
is silent or active (895). For example, RNA Polymerase II associated Set1 and 2 enzymes methylate 
histones as the polymerase transcribes the gene – these particular methylations are a 
consequence of transcription (896, 897). Until recently the simplest way to alter histone 
modifications would be the application of an inhibitor targeting the enzyme responsible for 
deposition and removal of the marks. This changes the global chromatin state, therefore any 
alteration in gene expression associated could be due to a number of factors other than the single 
histone mark deemed to have been removed or deposited at the locus of interest. These include 
activation or repression of master regulator transcription factors that can alter the global 
transcriptome and the alteration of genomic neighbourhood structuring which can repress of 
activate genes depending on the re-ordering of long and short-range chromatin loops. 
The development of CRISPR-Cas9 technology now affords researchers the opportunity to position 
Cas9 anywhere in the genome. The sequence-specific targeting of Cas9 has allowed precise 
modification of the cellular epigenome. Catalytically deactivated Cas9 (dCas9) has been fused to 
p300 H3K27acetyltransferase (898), LSD1 histone demethylase (899), Tet1 DNA demethylase and 
Dnmt3a DNA methyltransferase (900). These studies have shown that removal or deposition of 
epigenetic marks at key loci can activate or silence protein expression which then impacts cellular 
identity. This can be solely attributed to the placement of the dCas9 construct and not any off-
target effects associated with enzyme inhibition. Use of these (and future) dCas9 systems 
alongside techniques that allow unbiased identification of proteins at specific genomic loci (901-
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903) will further identification of protein factors and post-translational modifications that 
determine the transcriptional state of genes. 
Unlike previously reported RME, (487) expression of the TMPRSS2 allele wasn’t held to initial 
choice in the stem cell; allelic expression was switched during epithelial differentiation. This 
finding has implications in our understanding of the complexity of cancer heterogeneity, which is 
rooted in genomic studies rather than mRNA and protein expression variability, and could also act 
as a gateway for emergent expression of a previously silenced fusion allele in a more 
differentiated cell type whereupon tumourigenesis can occur alongside accumulation of other 
epigenetic and genetic defects. Promoter and gene body histone trimethylation status would 
have also been ascertained if SPOP, IDH1 and PTEN allelic expression had been identified. 
Through the TMPRSS2-ERG work, fourteen primary samples were fractionated in to SC/TA and CB 
subpopulations from which RNA and chromatin were isolated. This material is sufficient for 
further study of histone modifications and the impact that they may have upon allelic expression 
in prostate cancers. 
Transcriptional bursting would have to be accounted for in further studies and remains a blight on 
otherwise powerful transcriptional datasets produced by microarrays and RNA-seq (486). Due to 
the temporally asynchronous production of mRNA product, techniques that rely on a single 
snapshot in analysis are incapable of determining stable RME in the absence of other 
methodologies or repeated time-points. Transcriptional bursting of TMPRSS2 is unlikely as ERG 
protein levels and localisation were assessed in fusion positive cells by IF (246). Subpopulations 
that expressed only the fused allele expressed the ERG protein and in cultures that exclusively 
expressed unfused TMPRSS2 mRNA, the transcription factor protein was absent. ERG half-life in 
prostate cells is longer than typical bursts of allelic transcription (904) yet this may vary in the 
primary cultures meaning that, either ERG protein turnover is rapid (in this microenvironmental 
context) or there is a stability in allelic expression of the gene beyond that of transcriptional 
bursting in the epithelial subpopulations of primary prostate epithelial cells.  
The impact of selective allelic expression in cancer is vast as it allows flexible expression of disease 
genes in varying contexts of differentiation and carcinogenesis. To gain further knowledge into 
the pervasiveness of this phenomenon would only serve to deepen our understanding of the 
disease and inform future treatment choices as clinicians progress towards the ultimate goal of 
personalised prostate cancer medicine; tailored treatment of each and every man’s cancer at an 
individual level. 
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8.2 – LTP induced signalling and cell fate outcomes in prostate epithelial subpopulations 
Investigation of the transcriptional response to LTP treatment in the primary culture system 
revealed induction of stress signalling and activation of multiple pathways that can impact cell 
fate decisions. Analysis of how individual cell populations contribute to whole culture response 
and how cell fate outcomes are reached by the signalling networks initiated by plasma are 
required to ascertain pathways that are treatment-actionable. 
To confirm that the reactive species created by LTP were the primary agent in the induction of 
cellular transcriptional response, experiments using ROS scavengers, such as the vitamin E 
analogue trolox or N-actelycysteine (905, 906) would allow rescue of signal transduction through 
AP-1 and cleavage of the Notch receptor if reactive species were responsible. There is also the 
possibility that the electroporative effects of LTP (790, 791) may cause mechanical release of the 
NICD by disrupting the cell membrane. Use of the scavenging molecules should ascertain if Notch 
cleavage is a ROS-independent event or whether reactive species are responsible for the 
upregulation of Notch target genes. 
As previously discussed, the mixing of progenitor and more differentiated cells can dilute the 
transcriptional signature produced by either cell pool if the other in non-responsive. To fully 
appreciate the differences between the cell populations in which resistance may either be 
inherent or develop following LTP, signatures (both transcriptional and in signalling intermediates) 
from separate epithelial subpopulations need to be established. WP cultures fractionated into 
SC/TA and CB cells would be treated with LTP and the subpopulation response measured using 
microarray and protein analysis. The reduction in cellular heterogeneity should allow 
transcriptional signatures to be viewed more clearly – such as Notch signalling in the SC/TA cells. 
From the knowledge of varying responses in the subpopulations, indicators of the different 
signalling pathways activated (AP-1, Nrf2, Notch, NF-kB) would be chosen. Ideally this would be in 
conjunction with live cell imaging to map changes in responsive cell populations over a longer 
time-course – ie. does the pJun population die after 24 hours? Monitoring protein 
levels/subcellular localisation of the responsive mRNA transcripts such as the NR4A isoforms and 
those of the Notch signalling pathway; NRARP, HES1 and HEY1, could be useful here and would 
allow the initiated transcriptional response to be resolved in cells. The appropriate marking of 
positive Notch response, positive Jun response and positive Nrf2 response would allow tracking of 
populations of cells, from initial signalling to final cell fate outcome. To this end, SmartFlares 
would have been the ideal experimental tool as they would allow real time activation of specific 
signalling pathways to be viewed due to gene expression changes following LTP treatment. In the 
failure to mark signalling intermediates, specific si/shRNA or small molecule inhibition of 
individual pathways, up- and downstream of transactivation, will be sufficient to tease apart the 
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pathways critical in LTP resistance and survival, from those that direct cell death or are completely 
inconsequential in the determination of cell fate. In the case of Notch signalling, particular 
monitoring of differentiation antigens before and after plasma exposure (with and without Notch 
receptor inhibition) would be interesting in validating whether LTP-induced ROS impact balances 
within the epithelial hierarchy of the prostate. 
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Appendices 
A.1 – Complete Sanger sequence traces of all samples; TMPRSS2, SPOP, PTEN & IDH1 
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FIGURE 79 – TMPRSS2 exon 6 Sanger sequence traces. 
Heterozygosity at the rs12329760 position detected in the PCR product is displayed in, and 
marked above traces.  
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FIGURE 80 – SPOP exon 6 and 7 Sanger sequence traces of all samples. 
The rs2066747 SNP status of the sample is displayed in, and marked above traces. 
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FIGURE 81 – PTEN exon 5 Sanger sequence traces of all samples. 
The rs398123319 SNP status of the sample is displayed in, and marked above traces. 
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FIGURE 82 – IDH1 exon 6 Sanger sequence traces of all samples. 
Traces show the location of the most frequent IDH1 mutation; R132H. 
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A.2 - Development of P4E6 as a stress signalling model of prostate cancer 
Primary cultures have limitations in biological research as they are difficult to transfect and also 
don’t grow to cell numbers large enough for some analytical techniques. Access to an easy-to-use 
model of LTP induced stress signalling would be advantageous in discerning some of the 
molecular details in the response. 
Luciferase assays allow an accurate assessment of stress pathway transcriptional activation by 
measuring luminescence initiated by reporter Luciferase expression. In this context, the Luciferase 
gene has been placed downstream of a series of transcription factor elements on a plasmid. 
Promega supply a number of stress-reporter luciferase constructs. AP-1 and ARE (Nrf2) stress-
reporter Firefly luciferase plasmids were acquired alongside constitutive Thymidine Kinase (TK) 
and CMV Renilla luciferase constructs. The constitutive reporters allow transfection efficiency to 
be estimated and normalised between conditions. The CMV promoter was used to optimise initial 
transfection of the cell lines and the TK for use in the stress reporter dual luciferase assay as CMV 
promoters can be transactivated by SAPKs such as JNK (907). Vectors were prepared in competent 
bacteria and their identity confirmed by double restriction digest using the publicly available 
vector sequences provided by Promega (Figure 83A). Optimising the transfection of the BPH-1 
and P4E6 cell lines was attempted using a GFP plasmid. BPH-1 cells are usually easy to transfect 
however, using the XtremeGene reagent and varying seeding densities, transfection efficiency 
didn’t exceed 30% (Figure 83B). As the XtremeGene system was unsuccessful, Lonza 
Nucleofection – which had previously been used in my laboratory to achieve ~70% transfection 
efficiency in the P4E6 line – was used instead. However, even with varying input plasmid amount 
and seeding density transfection efficiency was poor (Figure 83C). As a result of this and the 
prioritisation of other experiments, the luciferase reporter work was left incomplete. Inclusion of 
Notch reporter luciferase plasmids in future study would ascertain whether P4E6 also show an 
activation of the pathway by LTP. 
P4E6 grow more quickly than primary cultures and have higher replicative longevity meaning that 
the cell numbers needed for transcription factor ChIP could be reached. 20x106 cells were to be 
used for each condition; untreated, arsenite and LTP treated. Sonication cycles were tested on 
P4E6 chromatin. A program of 45 cycles was used to concentrate fragments between 200-1000bp 
(Figure 84). Post-treatment time-points for the cross-linking of chromatin in treated P4E6 cells 
was determined using the HMOX1 and JUN expression time-courses, (Figure 60A+B) 0.5 hours 
following treatment was chosen for Jun and the 4 hour time-point for Nrf2 – as the transcription 
factors would be expected to be bound to promoter elements here to cause the rise in target 
gene expression.  Unfortunately, due to prioritisation of other work, the ChIP experiments, like 
the luciferase work was unable to be completed. 
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A continuation of both streams of study and adaptation of new ChIP techniques to reduce cell 
number requirements is required to characterise LTP stress signalling in the P4E6 cell line and 
determine whether it is a faithful representation of primary cell LTP response. 
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FIGURE 83 - Stress-reporter Luciferase vector preparation and optimisation of P4E6 transfection. 
A) Double restriction digest of stress and constitutive reporter Firefly (F) and Renilla (R) Luciferase 
(Luc) plasmids to confirm construct identity. B) Transfection of the BPH-1 cell line, seeded at 
increasing densities, with GFP using the XtremeGene reagent. Black scale bar is 25µm. C) 
Transfection of the P4E6 cell line with GFP by Nucleofection. Cells were seeded at increasing 
densities and amount of input plasmid was either 1 or 2µg. Black scale bar is 100µm.  
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FIGURE 84 - Optimisation of P4E6 chromatin sonication. 
Increasing sonication cycle number produce fragmentation of the chromatin until an enrichment 
of fragments less than 1000bp was produced at 45 sonication cycles.  
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List of Abbreviations used 
2-HG – 2-hydroxygluturate 
ADT – Androgen Deprivation Therapy 
ALL – Acute Lymphoblastic Leukaemia 
AML – Acute Myeloid Leukaemia 
AP-1 – Activator Protein 1 
AR – Androgen Receptor 
ARE – Antioxidant Response Element 
AR-V – Androgen Receptor splice variant 
ASAR – Asynchronous Replication and Autosomal RNAs 
AZ – Anterior Zone 
BCA -Bicinchoninic Acid  
BET – Bromodomain and Extraterminal 
bHLH – basic Helix-Loop-Helix 
BLAST – Basic Local Alignment Search Tool 
BM – Basement Membrane 
bp – base pair 
BPH -Benign Prostatic Hyperplasia 
BSA – Bovine Serum Albumin 
BTB – Bric-a-brac/Tramtrack/Broad 
CB – Committed Basal cell 
CDK – Cyclin Dependent Kinase 
ChIP – Chromatin Immunoprecipitation 
CK - Cytokeratin 
CLL – Chronic Lymphoblastic Leukaemia 
CMV – Cytomegalo Virus 
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COSMIC – Catalogue Of Somatic Mutation In Cancer 
COX – Cytochrome c Oxidase 
CRISPR – Clustered Regularly Interspaced Palindromic Repeats 
CRL3 - Cullin3-RING E3 ligase 
CRPC – Castrate Resistant Prostate Cancer 
CRUK – Cancer Research United Kingdom 
CSC – Cancer Stem Cell 
Ct – Threshold Cycle value 
CTC – Circulating Tumour Cell 
CZ – Central Zone 
DAH – Differentiation Associated Hypermethylated 
DAPK1 – Death Associated Protein Kinase 1 
DBD – DNA Binding Domain 
dCas9 – deactivated Cas9 
DHT – Dihydrotestosterone 
DICD – Delta Intracellular Domain 
DLL- Delta-Like 
DNA – Deoxyribo Nucleic Acid // c (prefix) – copy // g (prefix) - genomic 
DNMT – DNA Methyltransferase 
DRE – Digital Rectal Exam 
DSB – Double Strand Break 
DTT – Dithiothreiotol 
DUSP1 – Dual Specificity Phosphatase 1 
EBV - Epstein-Barr Virus 
EGF – Epidermal Growth Factor 
EMT – Epithelial to Mesenchymal Transition 
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ER – Endoplasmic Reticulum 
ER – Estrogen Receptor 
ESC – Embryonic Stem Cell 
FAK – Focal Adhesion Kinase 
FC – Field Cancerisation 
FCS – Foetal Calf Serum 
FGF – Fibroblast Growth Factor 
FISH – Fluorescent In Situ Hybridisation 
FP – Forward Primer 
G – (prefix to a number) Gleason 
GF – Growth Factor 
GO – Gene Ontology 
GPX – Glutathione Peroxidase 
GR – Glucocorticoid Receptor 
GSH – Glutathione 
GSI – Gamma Secretase Inhibitor 
GSR – Glutathione Reductase 
H – followed by 1,2,3 or 4 – Histone 
HCA – Heterocyclic Amines 
HDAC – Histone Deacetylase 
HIFU – High Intensity Focused Ultrasound 
HMOX - Haem Oxygenase 
HMT – Histone Methyltransferase 
HPV – Human Papillomavirus 
hr – hour/s 
HRR – Homologous Recombination Repair 
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HSC – Haematopoietic Stem Cell 
HSPA1A – Heat Shock Protein A1A 
ICR – Imprinting Control Region 
ID – Inhibitors of Differentiation 
IDH1 – Isocitrate Dehydrogenase 1 
IF – Immunofluorescence 
IGF – Insulin-like Growth Factor 
IL – Interleukin 
JAG – Jagged 
JICD – Jagged Intracellular Domain 
LA – Left Apex 
LB – Left Base 
LBD – Ligand Binding Domain 
LH – Luteinising Hormone 
LHRH – Luteinising Hormone Releasing Hormone 
LIMMA - Linear Models for Microarray and RNA-seq Data 
LM – Left Mid 
LOH – Loss of Heterozygosity 
LRP – Laparascopic Radical Prostatectomy 
LTP – Low Temperature Plasma 
MAF – Minor Allele Frequency 
MAPK – Mitogen Activated Protein Kinase 
MATH – Meprin and TRAF homology 
MDS – Multidimensional Scaling 
MET – Mesenchymal to Epithelial Transition 
min – minute/s 
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MM – Master Mix 
MMP – Matrix Metalloproteinase 
mpMRI – multi-parametric Magnetic Resonance Imaging 
NEPC – Neuroendocrine Prostate Cancer 
NHEJ – Non -homologous End Joining 
NICD – Notch Intracellular Domain 
NIK – NF-kB Inducing Kinase 
NK – Natural Killer cells 
NR4A – Nuclear Receptor 4 A 
NRARP - Notch Regulated Ankyrin Repeat Protein 
NRG - NOD-Rag1-/--ILR2γ-/- 
NSG – NOD-SCID-ILR2 γ-/- 
NTC – No Template Control 
NTD – N Terminal Domain 
ORP – Open Radical Prostatectomy 
p – (prefix to number) passage 
p – (prefix to protein) phoshpho- 
PAP – Prostatic Acid Phosphatase 
PBS – Phosphate Buffered Saline 
PCR – Polymerase Chain Reaction // q (prefix) – quantitative // RT (prefix) – reverse transcriptase 
PDGF – Platelet Derived Growth Factor 
PDT – Photodynamic Therapy 
PDX – Patient Derived Xenografts 
PDZ - PSD-95/Dlg/Zo1 
PFA – Paraformaldehyde 
PHD – Prolyl Hydroxylase Domain containing protein 
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PhIP - 2-amino 1-methyl-6-phenylimidazo[4,5-b]pyridine 
PIA – Prostatic Inflammatory Atrophy 
PIN – Prostatic Intraepithelial Neoplasia // hg (prefix) – High Grade 
PIP – Phosphatidylinositol phosphate 
PLB – Passive Lysis Buffer 
POZ - Pox virus and Zinc finger 
PR – Progesterone Receptor 
PRC2 – Polycomb Repressive Complex 2 
PRDX – Peroxiredoxin 
PSA – Prostate Specific Antigen // f (prefix) – Free // c (prefix) - Complexed 
PTEN - Phosphatase and tensin homologue deleted on chromosome ten 
PTM – Post Translational Modification 
PTP – Protein Tyrosine Phosphatase 
PZ - Peripheral Zone 
RA – Right Apex 
RAR/RXR – Retinoic Acid Receptor 
RB – Right Base 
RIPK - Receptor Interacting serine/threonine Protein Kinase 
RM – Right Mid 
RME – Random Monoallelic Expression 
RNA – Ribo Nucleic Acid // m (prefix) – messenger // lnc (prefix) long non-coding // mi (prefix) – 
micro // si (prefix) - short-interfering // sh (prefix) - short-hairpin 
RNS – Reactive Nitrogen Species 
ROS – Reactive Oxygen Species 
RP - Reverse Primer 
RRP – Robotic Radical Prostatectomy 
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RT – Radiotherapy // EB (prefix) – External Beam 
RT – Reverse Transcriptase or Room Temperature or Radiotherapy 
SAPK – Stress Activated Protein Kinase 
SBC – SPOP Binding Consensus 
SC – Stem Cell 
SCM – Stem Cell Media 
SDO – Single Delta Oxygen 
SDS – Sodium Dodecyl Sulphate 
SEM – Standard Error of the Mean 
SHH – Sonic Hedgehog 
SNP – Single Nucleotide Polymorphism 
SOD – Superoxide Dismutase 
SOX9 – SRY box 9 
SPOP - Speckled-type POZ protein 
SQSTM1 – Sequestosome 1 
SRXN – Sulfiredoxin 
SSB – Single Strand Break 
STHLM3 – Stockholm 3 
STI – Sexually Transmitted Infection 
T – Treated 
TA – Transit Amplifying cell 
TAE – Tris-Acetate-EDTA 
TBS – Tris Buffered Saline 
TCGA – The Cancer Genome Atlas 
TERT – Telomerase Reverse Transcriptase 
TET – Ten Eleven Translocase 
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TIC – Tumour Initiating Cell 
TK – Thymidine Kinase 
TNFR – Tumour Necrosis Factor Receptor 
TNM – Tumour, Nodes, Metastases 
TRUS – Transperineal Ultrasound 
TSG – Tumour Suppressor Gene 
TURP – Transurethral Resection of the Prostate // ch (prefix) – channel 
TXN – Thioredoxin 
TXNRD1 – Thioredoxin Reductase 1 
TZ – Transitional Zone 
U – Untreated 
UGE – Urogenital Epithelia 
UGM – Urogenital Mesenchyme 
UGS – Urogenital Sinus 
uPA – urokinase Plasminogen Activator 
UTR – Untranslated Region 
V - Volts 
VEGF – Vascular Endothelial Growth Factor 
WP – Whole Population 
XCI – X Chromosome Inactivation 
XIC – X chromosome Inactivation Centre 
αKG – α-ketogluturate 
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